





 EXPLORATION OF STRONTIUM UPTAKE BY BONE AND SOFT TISSUES  






















EXPLORATION OF STRONTIUM UPTAKE BY BONE AND SOFT TISSUES  

















NUS GRADUATE SCHOOL FOR INTEGRATIVE 
SCIENCES AND ENGINEERING 











I hereby declare that the thesis is my original 
work and it has been written by me in its 
entirety. I have duly acknowledged all the 





The thesis has also not been submitted for any 















The works presented in this thesis are resulted from a number of collaborations. It has 
been an inspiring and wonderful experience for me to work with these passionate and 
insightful scientists. 
My first word of thanks must go to my supervisor, Assoc. Prof. Thomas Walczyk. 
His positive influences over the course of my graduate study cannot be overstated. Most of 
all, his enthusiasm and great ideas serve as a constant motivation for me to strive for 
perfection. 
I am grateful to my committee members, Assoc. Prof. Michael Raghunath and Asst. 
Prof. Lee Taeyong, for their time and consideration. Their inputs and support have helped me 
through the important milestones of this work. I would also like to thank our collaborators 
that have contributed to these works in one way or another, especially Prof. Hans-Arno Synal, 
Prof. Annette Liesegang, Assoc. Prof. Thomas Prohaska, Asst. Prof. Lee Taeyong and Assoc. 
Prof. Thomas Osipowicz for their time, brilliant ideas and resources, without which many 
parts of this project would not have been possible. 
I am also equally grateful to my fellow PhD candidates and research assistant in 
Assoc. Prof. Thomas Walczyk’s research group, especially Ms. Chew Chin Na Gina, Mr. Bay 
Lian Jie, Ms. Chen Jiehua, Ms. Nadia Nur Singh and Ms. Ren Yao. Their intellectual 
contributions and moral supports for the past couple of years have been countless and very 
valuable.  
I feel fortunate to have the opportunities to work closely with Mr. Tim Schulze-
König, Ms. Johanna Irrgeher, Ms. Ren Minqin, Ms. Yang Xiao, Ms. Tay Hui Huang, Mr. Goh 
Kar Hui Edmund, Ms. Yeoh Chooi Syn, Ms. Steffiana Yuliani Wijaya, Ms. Lim Sze Wee 
Zoeraine, Ms. Gan Yuan Ying, Dr. Andreas Zitek, Ms. Chan Wai Kam, Mrs. Joanna Schmid 
and Dr. Patrick Reilly. Their intellectual contributions and technical supports have made the 
completion of this project possible. 
v 
 
I am also thankful to the other members and former members of Assoc. Prof. Thomas 
Walczyk’s research group (Dr. Patrick Galler, Dr. Monika Inkret, Mr. Ji Xiang, Mr. Li Bin, 
Mr. Dong Xiao, Ms. Soumiya Srinivasan and many others), Assoc. Prof. Thomas Prohaska’s 
research group (Ms. Monika Horsky, Ms. Stefanie Kappel and many others) and Asst. Prof. 
Lee Taeyong’s research group (Ms. Jeeva Lavanya Lakshmi, Ms. Chen Xiuli and many 
others) for creating not only an intellectually stimulating and research-conducive 
environment, but also a supportive and friendly atmosphere.  
I would like to acknowledge NUS Graduate School for Integrative Sciences and 
Engineering (NGS) for the financial support of my graduate education and the Virtual 
Institute for the Science of Ageing (VISA) for the support and funding given for this project. 
In addition, my research efforts have been greatly aided by administrative and logistical 
supports from the NGS office (Ms. Irene Chuan, Ms. Rahayu Aziz, Ms. Vivien Li and Ms. 
Ivy Wee).  
Last, I would like to express my greatest gratitude to my family, especially my 
parents (Mr. Budiyanto Muliohardjo and Ms. Farida Astuti Anaf), my husband (Mr. Petrus 
Alfredo Jakub) and my siblings (Ms. Anastasia Irawati and Mr. Christian Tricahyono) for 




TABLE OF CONTENTS 
 
Cover ..........................................................................................................................................i  
Title Page ................................................................................................................................. ii 
Declaration ............................................................................................................................. iii  
Acknowledgments ...................................................................................................................iv  
Table of Contents .................................................................................................................... vi 
Summary ................................................................................................................................ xii  
List of Tables ......................................................................................................................... xiv  
List of Figures ....................................................................................................................... xvi  
List of Symbols ...................................................................................................................... xix  
List of Abbreviations ............................................................................................................ xxi 
 
Part A – Literature Review and Methodology ...................................................................... 1 
Chapter 1: Introduction .......................................................................................................... 2 
Chapter 2: Bone ....................................................................................................................... 5 
2.1. Bone Structure ........................................................................................................... 5 
2.2. Bone Composition ..................................................................................................... 6 
2.3. Bone Growth, Modeling and Remodeling ................................................................. 7 
2.4. Bone Mass Cycle  ...................................................................................................... 8 
2.5. Factors Influencing Bone Mineral Deposition ........................................................ 10 
2.5.1. Diet ................................................................................................................ 10 
2.5.2. Lifestyle ......................................................................................................... 16 
Chapter 3: Osteoporosis ........................................................................................................ 18 
3.1. Types and Impact of Osteoporosis .......................................................................... 18 
3.2. Pathophysiology ...................................................................................................... 19 
3.3. Osteoporosis Treatments ......................................................................................... 21 
3.3.1. Antiresorptive Agents .................................................................................... 21 
vii 
 
3.3.2. Anabolic Agents ............................................................................................ 22 
3.3.3. Double-Acting Agents ................................................................................... 23 
Chapter 4: Methods to Study Bone Metabolism and Bone Health ................................... 25 
4.1. Clinical Techniques ................................................................................................. 25 
4.1.1. Bone Mineral Density .................................................................................... 26 
4.1.2. Biochemical Markers ..................................................................................... 28 
4.1.2.1. Bone Formation Markers .................................................................. 28 
4.1.2.2. Bone Resorption Markers ................................................................. 30 
4.2. Tracer Techniques ................................................................................................... 31 
4.2.1. Stable and Radioisotopes to Study Mineral and Trace Element 
Metabolism .................................................................................................... 31 
4.2.2. Short-term Kinetics ........................................................................................ 34 
4.2.2.1. Plasma or Serum Isotope Appearance .............................................. 34 
4.2.2.2. Fecal Excretion ................................................................................. 34 
4.2.2.3. Urinary Excretion ............................................................................. 35 
4.2.2.4. Compartmental Analysis................................................................... 36 
4.2.3. Long-term Kinetics ........................................................................................ 38 
4.2.3.1. 41Ca Studies ....................................................................................... 38 
4.2.3.2. Non-compartmental Analysis ........................................................... 44 
Chapter 5: Strontium Metabolism ....................................................................................... 45 
5.1. Physiological Functions ........................................................................................... 45 
5.2. Skeletal Deposition and Release .............................................................................. 48 
5.3. Absorption ............................................................................................................... 51 
5.3.1. Dietary Factors Enhancing Absorption .......................................................... 52 
5.3.2. Dietary Factors Inhibiting Absorption ........................................................... 54 
5.4. Excretion .................................................................................................................. 54 




Chapter 6: Strontium and Bone Health ............................................................................... 60 
6.1. Diagnostic Applications .......................................................................................... 60 
6.1.1. Use of Strontium as a Surrogate Marker or Tracer for Calcium .................... 60 
6.1.2. Use of Strontium to Study Bone Metabolism ................................................ 62 
6.2. Therapeutic Applications ......................................................................................... 65 
6.2.1. Strontium Ranelate ........................................................................................ 66 
6.2.2. Other Types of Strontium .............................................................................. 68 
6.2.2.1. Citrate ............................................................................................... 68 
6.2.2.2. Chloride ............................................................................................ 69 
6.2.2.3. Gluconate .......................................................................................... 69 
6.2.2.4. Lactate............................................................................................... 70 
6.3. Toxicity .................................................................................................................... 70 
6.4. Strontium as an Essential Element? ......................................................................... 73 
Chapter 7: Methodology ........................................................................................................ 75 
7.1. Mass Spectrometry .................................................................................................. 75 
7.1.1. Thermal Ionization Mass Spectrometry ......................................................... 76 
7.1.2. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) .......................... 79 
7.1.3. Accelerator Mass Spectrometry (AMS) ......................................................... 83 
7.1.4. Isotope Dilution Mass Spectrometry (IDMS) ................................................ 84 
7.2. Statistical Approaches .............................................................................................. 85 
7.2.1. One-Way Analysis of Variance (ANOVA).................................................... 85 
7.2.2. Mann-Whitney U-test and Kruskal Wallis-H-test .......................................... 87 
7.2.3. Monte-Carlo Simulation for Estimation for Measurement Uncertainty ......... 89 






Part B - Exploration of Strontium Uptake by Bone and Soft Tissues Using Stable 
Isotope Techniques .......................................................................................... 93 
Chapter 1: Isotopic Labeling of Bone for Assessment of Changes in Bone Calcium 
Balance: A Comparative Study in Sheep Using 41Ca and 86Sr .................... 94 
1.1. Introduction ............................................................................................................. 94 
1.2. Materials and Methods ............................................................................................ 97 
1.2.1. Test Animal ................................................................................................... 97 
1.2.2. Tracer Preparation and Administration .......................................................... 97 
1.2.3. Urine Sampling and Sample Preparation ....................................................... 98 
1.2.4. Bone Sampling and Sample Preparation ...................................................... 100 
1.2.5. Calcium and Strontium Elemental Analysis by AAS .................................. 100 
1.2.6. 41Ca Isotopic Analysis by AMS ................................................................... 101 
1.2.7. 86Sr Isotopic Analysis by TIMS ................................................................... 102 
1.2.8. Data Analysis ............................................................................................... 103 
1.3. Results ................................................................................................................... 103 
8.3.1. Urinary Tracer Excretion ............................................................................. 104 
8.3.2. Skeletal Tracer Deposition ........................................................................... 107 
1.4. Discussion .............................................................................................................. 111 
1.5. Conclusion ............................................................................................................. 116 
Chapter 2: Isotopic Labeling of Bone for the Assessment of Changes in Bone 
Mineral Balance: Evaluation of Spatial Tracer Distribution (86Sr) in 
Mineralized Tissues ....................................................................................... 118 
2.1. Introduction ........................................................................................................... 118 
2.2. Materials and Methods .......................................................................................... 120 
2.2.1. Animal Study ............................................................................................... 120 
2.2.2. Bone Sampling and Sample Preparation ...................................................... 121 
2.2.3. 86Sr Isotopic Analysis by LA-ICP-MS ......................................................... 121 
2.2.4. 86Sr Isotopic Analysis by TIMS ................................................................... 123 
x 
 
2.3. Results ................................................................................................................... 123 
2.4. Discussion .............................................................................................................. 128 
2.5. Conclusion ............................................................................................................. 132 
Chapter 3: Uptake and Deposition of Strontium in Bone and Soft Tissues: A Dose-
Response Study in Rats ................................................................................. 134 
3.1. Introduction ........................................................................................................... 134 
3.2. Materials and Methods .......................................................................................... 137 
3.2.1. Test Animals and Sampling Procedures ................................................... 137 
3.2.2. Calcium and Strontium Concentration in Tissue Samples ....................... 138 
3.2.3. Calcium and Strontium Distribution in Bone Samples ............................. 139 
3.2.4. Mechanical Testing................................................................................... 140 
3.2.5. Biomarkers of Bone Turnover .................................................................. 141 
3.3. Results ................................................................................................................... 141 
3.3.1. Treatment Tolerability .............................................................................. 141 
3.3.2. Strontium Uptake ...................................................................................... 142 
3.3.3. Strontium Effects on Bone Mechanical Properties ................................... 145 
3.3.4. Strontium Effects on Bone Biomarkers .................................................... 148 
3.4. Discussion .............................................................................................................. 152 
3.5. Conclusion ............................................................................................................. 158 
Chapter 4: Age-Dependent Differences in Calcium and Magnesium Intake in 
Singaporean Chinese Women ...................................................................... 161 
4.1. Introduction ........................................................................................................... 161 
4.2. Methods ................................................................................................................. 162 
4.2.1. Subjects..................................................................................................... 162 
4.2.2. In-house Calcium and Magnesium Database ........................................... 163 
4.2.3. Assessment of Mineral Intake .................................................................. 164 
4.2.4. Sample Analysis ....................................................................................... 165 
4.2.5. Statistical Analysis ................................................................................... 166 
xi 
 
4.3. Results ................................................................................................................... 167 
4.3.1. Subject Characteristics ............................................................................. 167 
4.3.2. Method Validation .................................................................................... 169 
4.3.3. Survey ....................................................................................................... 169 
4.4. Discussion .............................................................................................................. 172 
 
Part C – Conclusion ............................................................................................................. 183 
 
References ............................................................................................................................. 189 
 
Appendix I ............................................................................................................................ 227 
Appendix II ........................................................................................................................... 241 




Due to their similar chemical properties, strontium shares similar physiological 
pathways as calcium. Both elements are mainly located in bones. Although skeletal 
deposition of radio-strontium (90Sr) from nuclear accidents was the main concern in the past, 
interest in strontium has increased recently with the use of stable strontium as an osteoporosis 
drug. At high doses, strontium can positively affect bone quality and reduce fracture risk. 
However, concerns have been raised regarding its safety, which resulted in the European 
Medicines Agency’s (EMA’s) recommendation on its restrictions. 
In the first part of the thesis, similarities and differences in bone deposition and 
urinary discharge between calcium and strontium were explored. In the first ever long-term 
study of its kind, a stable strontium isotope (86Sr) has been administered together with 41Ca to 
an adult sheep. Urinary tracer excretion was monitored over 6 months using Accelerator Mass 
Spectrometry (AMS) and Thermal Ionization Mass Spectrometry (TIMS). Discrimination 
between both tracers was strong at the beginning. Subsequently, 86Sr followed 41Ca excretion 
closely. A stronger response of the 86Sr signal due to an unexpected change in bone mineral 
balance indicates that strontium is a more sensitive tool. Laser Ablation Mass Spectrometry 
(LA-ICP-MS) of bone samples revealed that tracer was deposited preferentially in areas of 
bone growth and high remodeling activity. Isotopic labeling of the skeleton with the long-
living radiotracer 41Ca has been suggested as an ultra-sensitive technique to assess changes in 
bone calcium balance. However, its analysis is technically demanding and limited to a dozen 
research laboratories worldwide. Findings suggest that strontium isotopes are a convenient 
alternative to 41Ca for assessing changes in bone calcium balance qualitatively but not 
quantitatively. 
In the second part, we investigated the possible risks associated with high strontium 
intakes, particularly in soft tissues, and their effect on bone turnover and biomechanical 
properties. Rats were kept on two strontium levels for 3 months.  Strontium and calcium 
concentrations in bones and soft tissues were determined by isotope dilution mass 
xiii 
 
spectrometry (IDMS). Spatial distribution of calcium and strontium in bone was studied by 
Particle Induced X-Ray Emission (PIXE) analysis. An improvement in bone quality was 
observed in the lower dose group, which exhibited serum strontium levels comparable to 
patients undergoing strontium therapy. For the higher dose group, strontium had a negative 
impact on bone quality. A threshold level may exist beyond which strontium and possibly 
calcium is taken up less efficiently by bone and deposited increasingly in soft tissues. 
Calcification/strontification of soft tissues and blood vessels has been suggested as a 
mechanism leading to cardiovascular disease. 
Lastly, we assessed strontium intake from diet in a group of Singaporean Chinese 
women. Strontium intake was found to be lower by two orders of magnitude than the 
therapeutic dose. Dietary strontium intake should therefore have a negligible effect on bone 
and soft tissues. In the same study we found that most women did not meet estimated dietary 
requirements for calcium and magnesium. Older women were at lower risk of insufficient 
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CHAPTER 1: INTRODUCTION 
 
Mean life expectancy has increased linearly over the last two centuries and the 
upward trend is likely to continue (1). In the older population, age-related diseases, including 
osteoporosis, have become more common. Osteoporosis is a skeletal disease characterized by 
low bone mass and micro-architectural deterioration, leading to an increase in bone fragility 
and susceptibility to fracture (2). Due to the potentially devastating outcomes (3) and high 
risk of fractures (4), it has become an important public health issue. With continued ageing of 
the population, the annual number of fractures is likely to grow significantly. Assuming that 
age-adjusted incidence rates remain constant, the estimated hip fracture incidences will 
increase from 1.7 million in 1990 to 6.3 million in 2050 worldwide. Moreover, fracture rates 
seem to be rising. With the assumption that age-adjusted rates will rise by only 1% per 
annum, the hip fracture prevalence could be as high as 8.2 million by 2050 (5). Osteoporotic 
fractures also inflict a major economic burden on the health-care systems. Conservatively, the 
annual costs of hip fractures was estimated to be US$131.5 billion worldwide in 1997 (6). In 
2002, the annual costs of all osteoporotic fractures were estimated to be US$20 and US$30 
billion in the USA and Europe, respectively (3). 
Hip fractures are also a major public health problem in Asia, including Singapore. It 
has been projected that 50% of all hip fractures in the world will occur in Asia by 2050 (7). In 
Hong Kong, the incidence of hip fracture have increased by more than two-fold in the last few 
decades (8). In 1995, six out of 1 000 women and three out of 1 000 men, who were 70–79 
years-old, fractured their hip. A similar increase in hip fracture incidence has also been 
observed in Singapore during the same period (9). However, the incidence rates in Mainland 
China remained much lower than in Hong Kong and Singapore. Compared to the Hong Kong 
rates, the age-adjusted incidence in men and women in Beijing was only 50% and 25%, 
respectively (10). In Japan, the age-adjusted incidence of hip fracture was also found to be 
lower than in Hong Kong, 132 per 100 000 in men and 285 per 100 000 in women (11). 




Overall, the statistic shows that suitable osteoporosis prevention and treatment 
strategies are clearly required. The main challenge in recognizing effective strategies to 
preserve bone health is the absence of techniques that are sensitive enough to evaluate the 
skeletal response to interventions. At the moment, dual energy X-ray absorptiometry (DXA) 
is the most widely used technique to assess changes in bone mineral density (BMD). 
However, it is not sensitive enough to evaluate subtle effects of softer interventions, such as 
diet and lifestyle changes, on bone health. Bone turnover can also be monitored with 
biochemical markers of bone metabolism. Nonetheless, biomarkers show strong intra-
individual variations, which greatly limit their sensitivity (12, 13). 
On the other hand, isotopic labeling is an ultra-sensitive tool, which allows the 
assessment of short-term and soft interventions. Theoretically, both stable and radioisotopes 
of calcium can be used for isotopic labeling. However, due to health concerns, conventional 
radiotracers are rarely used. Although stable isotopes are safe, the doses required, and 
consequently the costs involved, would simply be high and uneconomical. Alternatively, 
there is a very long-living radiotracer (
41
Ca, half-life ≈ 105 years), that is also safe to use for 
isotopic labeling while the doses required in this application is minute. However, its 
technically challenging and expensive analysis has hindered its use in routine applications or 
clinical settings. Similar chemical behaviors between strontium and calcium have pointed to 
the possibility of using strontium stable isotopes as a surrogate marker for calcium in bone 
metabolism studies. Strontium, like calcium, is a bone seeking element as 98-99% of 
strontium in the human body is stored in bones. It has similar chemical properties and 
passively follows calcium in the body (14). However, its isotopic analysis requires much less 
sophisticated instrumentation.  
Similar to calcium, strontium is also present in a regular diet, but in a much lower 
amount compared to calcium (14). In a higher amount, strontium has played a role as a 
therapeutic agent for osteoporosis prevention and treatment. Since 1950s, strontium has been 
suggested to be useful in osteoporosis treatment (15). A few decades later, strontium ranelate 
was finally approved as an osteoporotic drug. However, a recent data evaluation from clinical 




studies by the European Medicines Agency’s Committee for Medicinal Products for Human 
Use showed a higher risk of heart attack in strontium ranelate group than with placebo, with 
no observed increase in mortality risk (16). This may be consistent with the facts that 
strontium is similar to calcium. Excessive calcium intakes have been shown to be harmful in 
the long-term as they may cause soft tissue calcification, leading to kidney stones and 
cardiovascular diseases (17). 
The aims of this thesis were to explore the use of stable isotope strontium (
86
Sr) as a 
diagnostic tool to study bone mineral metabolism; to investigate its role as a therapeutic 
substance to improve bone health, together with its side effects on soft tissues; and to assess 
the intake of strontium, as a prospective essential nutrient present in the diet, in a group of 
Singaporean Chinese. Hence, this thesis would cover the roles of stable strontium isotopes as 
a diagnostic tool, a therapeutic agent and a potential nutrient. 




CHAPTER 2: BONE 
 
2.1. Bone Structure 
Typically, a long bone consists of an epiphysis at each end, a diaphysis at the center 
and a metaphysis connecting them. The epiphysis is composed of a trabecular network 
surrounded by a thin peripheral cortical shell and a subchondral bony top. A growth plate 
complex exists underneath the epiphysis. After skeletal maturity, this growth plate will be 
replaced with a thin layer of bone. The metaphysis is composed of a sponge-like network of 
interconnected trabecular structures. The cortical shell is progressively thickened from the 
upper metaphysis toward the diaphysis, while the trabecular network becomes increasingly 
thin and eventually disappears. The diaphysis is composed of mainly cortical bone and 
contains a marrow space at the center. The skeletal joint is responsible for transferring the 
load from one bone to the other. In order to minimize friction between the bony ends during 
movement, the joint is covered by articular cartilage that is supported by subchondral bone 
(18, 19).  
Cortical bone is a semi-solid shell that covers the entire bone, while trabecular or 
cancellous bone is a sponge-like network structure that fills the interior of the epiphysis and 
metaphysis. In adult, cortical bone contributes 80% of the total skeletal mass and only 30% of 
the total bone surface, resulting in a low turnover rate. It provides biomechanical support and 
protection. In contrast, trabecular bone contributes only 20% of the total bone mass and 70% 
of the total surface of the skeletal system, resulting in a high turnover rate. The main function 
of the trabecular bone is to provide biomechanical support and to fulfill homeostatic demands 
(18). Figure A-1 depicts the structure of a typical long bone. 
  





Figure A-1: (a) Schematic view of a femur showing the gross profile of a typical long bone 
(longitudinal cut), (b) diaphysis section and (c) schematic view of histological details of 
cortical bone. A typical long bone consists of an epiphysis at each end, a diaphysis at the 
center and a metaphysis connecting them. A growth plate complex exists underneath the 
epiphysis. Cortical bone contains Haversian canals, Volkmann's canals and resorption 
cavities, containing mainly blood vessels and nervous tissue, which allows nutrition, nerve 
signals and metabolites to be exchanged between cortical bone and its surrounding. Haversian 
canals are interconnected with Volkmann's canals, which run horizontally from periosteal to 
endocortical surface. As such, a network of canals exists throughout the entire cortical bone. 
During remodeling process, one or more existing osteons/Haversian systems are partially 
removed to create space for the new osteons (18, 19). Figures are adapted from Servier 
website. 
 
2.2. Bone Composition 
Bone is composed of organic matrix (20-40%), inorganic mineral (50-70%), cellular 
elements (5-10%) and lipids (3%). The organic bone matrix consists mainly of type I collagen 
(19). Several collagen molecules, known as tropocollagens, are bundled together forming 
collagen fibers. Interfibrillar cross-links are formed between the ends of tropocollagens to 
stabilize the matrix. Tropocollagens are aligned with numerous gap regions, into which 
hydroxyapatite crystals are incorporated during mineralization. A lamella sheet is made of 




collagen fiber aligned parallel to each other. Hydroxyapatite, the primary molecule of bone 
mineral, is a naturally occurring mineral form of calcium apatite, usually denoted as 
Ca10(PO4)6(OH)2. It provides load bearing capacity and mechanical rigidity for the bone. It 
contains impurities, like magnesium, fluoride and strontium, which can be incorporated into 
the crystal lattice or absorbed onto the surface. Imperfect crystals are more soluble, enabling 
bone to be resolubilized and releasing these ions into the extracellular fluid as needed to meet 
homeostatic requirements of the whole body. Homeostatic needs can also be met by the 
minerals absorbed onto the surface. Other non-collagenous proteins, which make up 10% of 
the total organic matrix, play important roles in the calcification process, fixation of the 
hydroxyapatite crystals to the collagen, and regulation of osteoblastic and osteoclastic 
metabolism. Osteocalcin, osteonectin, osteopontin and bone sialoprotein are the most 
abundant among these proteins. During the breakdown of bone matrix, some proteins, 
including hydroxyproline and collagen cross-links, are released into the circulation. 
Therefore, evaluating the levels of these proteins in urine, plasma or serum is useful to 
monitor the bone turnover status as well as to diagnose, assess progression and determine the 
efficacy of treatments for skeletal disorders (20, 21). 
 
2.3. Bone Growth, Modeling and Remodeling 
The growth plate complex, which is responsible for longitudinal growth, is composed 
of a large number of chondrocytes and hyaline cartilage matrix. The hyaline cartilage consists 
of columns with multiple shelves that stack chondrocytes together. In each column, the 
chondrocyte develops from a flat precursor to a mature cell by proliferating to maximize its 
volume and producing a large numbers of cartilage matrix, which subsequently become 
calcified cartilage. Finally, chondrocytes experience cellular apoptosis, which gives way to 
the concurrent osteoclastic resorption and vascular ingrowth, which is followed by bone 
formation by osteoblast, resulting in a densely connected trabecular network. During bone 
elongation, the old cancellous bone at the diaphseal end is removed and a new metaphyseal 
region is added at the epiphyseal end, which consequently increases bone length. As the bone 




becomes longer, radial growth proportionally enlarges its cross-sectional area. During growth, 
increased mechanical demands stimulate the periosteum, activating the bone modeling and 
eventually resulting in radial growth and enlarged cross-sectional area of the bone (19). 
Bone modeling activities includes osteoblastic bone formation and osteoclastic bone 
resorption. Although these processes are triggered and carried out separately on different bone 
sites, they are synchronized in order to enlarge and alter the shape of the bone as needed. 
Throughout the growing period, these processes are going continuously. After skeletal 
maturity, the formation drift is limited on the periosteal surface while the resorption drift 
seems to cease (22, 23).  
Bone adapts to mechanical and non-mechanical stimuli through bone remodeling. 
During childhood, the remodeling process is mostly responsible for substituting immature 
woven bone with more metabolically and biomechanically competent lamellar bone. During 
growth, the remodeling process enables bone elongation. During adulthood, the remodeling 
process replaces damaged or mechanically unfit bones in order to maintain the mechanical 
capacity. All cortical bone is remodeled completely every twenty years while all trabecular 
bone is completely remodeled every one to four years. Figure A-2 shows the remodeling 
process in both trabecular and cortical bones. The coupling between bone formation and 
resorption usually becomes unsynchronized after age 30. Consequently, a negative bone 
balance is created in each cycle for all remodeling bone multi-cellular units (BMUs) leading 
to an age-related bone loss (see Figure A-3). 
 
2.4. Bone Mass Cycle 
Bone mineral accretion continues even though growth has ceased. Depending on the 
skeleton site, peak bone mass (PBM) can be reached as early as the late adolescent years or as 
late as the mid-thirties (see Figure A-3) (24). Once PBM has been reached, bone mass will 
remain relatively constant until age-related bone loss takes place, resulting in the drastic drop 
in bone mass. PBM varies among individuals and is regulated mainly by genetic factors 
(approximately 80%) (25). Other factors, such as gender and environment, account for about 




20%. PBM is a determining factor for osteoporotic risk fracture. Ten percent increase in PBM 
can result in 50% fracture risk reduction (26). 
 
Figure A-2: Bone remodeling in trabecular and cortical bone. The remodeling cycle is 
composed of activation, resorption, reversal and formation. During activation, mononuclear 
monocyte-macrophage osteoclast precursors are recruited and activated. The lining cells were 
lifted off the bone surface and multiple mononuclear cells fuse to form multinucleated 
preosteoclasts. Osteoclast-mediated bone resorption takes only about two to four weeks. After 
bone resorption is completed, preosteoblasts recruited to begin new bone formation. The 
reversal phase is a transition from bone resorption to formation. Bone formation completes in 
approximately four to six month (18). Figure is taken from Bartl and Frisch, 2009 (27). 
 
Regardless of the PBM, both males and females will eventually experience age-
related changes in their bone, which result in bone mineral loss caused by increased trabecular 
resorption, endocortical thinning and increased cortical porosity (28). Both males and females 
experience trabecular bone loss to about the same extent. However, cortical bone loss is less 
in males than females, which is believed to be a result of greater periosteal bone formation in 
men (28). The gender-difference in bone strength persists during old age, due to greater 
overall bone loss in women than men (29). However, the gender-difference in bone strength is 
not limited to BMD, the skeletal structure (dimensions, cortical thickness), biomechanical 




responses, bone turnover, as well as trabecular microstructure are also affected (30). The 
decrease in bone strength is more evident in women compared with men, particularly after 

















Figure A-3: Typical changes in bone mass over a lifetime. This diagram highlights the 
difference between the bone mass changes in men (grey) and women (blue) and in individuals 
who reach their full genetic potential for skeletal mass (top curve) and in those who do not 
(bottom curve). Once the age-related bone loss sets in, fracture risks would be higher in those 
individuals who do not reach their full genetic potential. The rapid decline of estrogen levels 
in females after menopause accelerates this bone loss process. Figure is taken from Bartl and 
Frisch, 2009 (27). 
 
2.5. Factors Influencing Bone Mineral Deposition 
2.5.1. Diet 
Calcium is the most abundant cation in the human body, 99% of which exists in the 
skeleton as hydroxyapatite crystals, while the rest is found in the extracellular fluid, blood and 
soft tissues. Calcium deposition into the organic matrix of bone contributes to its strength and 
rigidity. At the same time, bone functions as a reservoir of calcium, making it readily 
available for its roles in multiple physiological and biochemical processes including 
neuromuscular functioning, coagulation, cell permeability, enzyme activation, hormone 
secretion and functioning (32). The calcium required for the non-osseous functions is satisfied 




primarily by intracellular calcium. Since a small fraction of bone contains more calcium than 
the entire extracellular fluid space, the requirement of the body’s cellular functions will never 
deplete the bone’s calcium reservoir (33). Nevertheless, extended periods of inadequate 
calcium intake require enhanced resorption of bone to meet extracellular calcium needs, 
resulting in bone deterioration. Hence, suboptimal intakes are unlikely to lead to maximum 
genetically determined bone mass (34). On the other hand, calcium intakes above the 
threshold will not add appreciably to skeletal retention.  
Although calcium supplements are commonly administered as a part of osteoporosis 
prevention and treatment, they have been associated with a higher risk of cardiovascular 
events (33). In the Women’s Health Initiative Calcium/Vitamin D (WHI CaD) study, it has 
been observed that calcium and vitamin D supplements increased the risk of cardiovascular 
events (35). An earlier study, the Kuopio Osteoporosis Risk Factor and Prevention Study, has 
also observed a higher morbidity and mortality rate caused by coronary heart disease among 
subjects receiving calcium supplements (36). More recently, in the Swedish mammography 
cohort, intake of calcium above 1400 mg/day was associated with a higher mortality rate, 
including from cardiovascular events. Without supplement consumption, the increase was 
modest. However, the combination of high calcium intake from the diet and supplement 
resulted in a more significant rise in mortality (37). In agreement to this, Xiao et al. (38) 
showed that high intake of supplemental calcium, but not from dietary sources, is associated 
with an excess risk of death from cardiovascular disease in men but not in women. In the 
Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study 
(EPIC-Heidelberg), Li et al. (39) also showed that while increase in dietary calcium intake 
might not have a substantial effect on cardiovascular health, calcium supplements should be 
taken with caution, since they might elevate myocardial infarction risk. 
Nevertheless, some studies showed that there was no increase in adverse cardiovascular 
effects associated with calcium supplementation. Bhakta et al. (40) observed no significant 
increase in progression of aortic valve or coronary artery calcification in women taking oral 
calcium supplementation. Hsia et al. (41) also observed no difference in the rates of stroke or 




coronary events in female participants receiving calcium supplementation or placebo. A more 
recent study by Lewis et al. (42) also supported these findings. Nevertheless, it needs to be 
highlighted that calcium intakes beyond the current recommendation has little or no value. 
Besides an increase in cardiovascular events, high dietary consumption of foods rich 
in calcium and oxalate may cause kidney stone formation (calcium oxalate) and crystalluria 
(43). On the other hand, decreased availability of free gastrointestinal (GI) calcium to bind 
oxalate may also result in an increase in oxalate absorption and urinary oxalate excretion, 
which plays a greater role than calcium in the development of kidney stones. Thus, daily 
calcium intake within a certain range (1000–1500 mg/day) may help to bind oxalate, 
preventing its absorption and decreasing the formation of calcium oxalate stones (43). 
However, there is not enough evidence to support a correlation between renolithiasis risk and 
calcium intakes at the level expected to be consumed by postmenopausal women, either from 
diet or supplement (44). In response to growing concerns regarding the potential negative side 
effects caused by excessive calcium intakes, some adjustments had been made to the Dietary 
Reference Intake (DRI) for calcium in certain subject groups (45). As such, the 
Recommended Dietary Allowance (RDA) was lowered from 1,200 mg to 1,000 mg for adults 
51 -70 years old and the Tolerable Upper Level of Intake (UL) was lowered from 2,500 mg to 
2,000 mg per day for adults older than 51 years. 
Vitamin D is produced from previtamin D3 and partially obtained from dietary 
sources. Previtamin D3 is generated from the vitamin D3 precursor, 7-dehydrocholesterol (7-
DHC), in the skin after exposure to sunlight or specifically UV B (46-48), and is then readily 
converted to vitamin D3. In the liver, vitamin D3 is hydroxylated to form 25-hydroxyvitamin 
D (25(OH)D), which will be further hydroxylated in the kidney to 1,25-dihydroxyvitamin D3 
(1,25(OH)2D, calcitriol), the active form (49). Once formed, calcitriol will be bound to 
vitamin D binding protein and enters the circulation to target tissues that regulate calcium and 
phosphorus metabolism. In the intestine, calcitriol interacts with its vitamin D receptor (VDR) 
to improve the expression of an epithelial calcium channel and increases the expression of a 
calcium binding protein (calbindin) which results in the improved transport of calcium from 




the intestinal lumen into the circulation (50, 51). In the skeleton, calcitriol interacts with its 
VDR in the osteoblast to enhance the expression of receptor activator of NFκB ligand 
(RANKL) (52). Monocytic preosteoclasts possess the receptor RANK which interacts with 
RANKL resulting in signal transduction leading to the formation of multi-nucleated 
osteoclasts to destroy the bone matrix releasing calcium into the circulation. In the kidneys, 
calcitriol increases tubular reabsorption of calcium. Calcitriol interacts with its VDR in the 
parathyroid glands and regulates parathyroid hormone (PTH) production (50, 53). The major 
roles of vitamin D are to maintain serum calcium in physiologically acceptable range to 
support metabolic functions and to secure the mineralization of the skeleton. Besides that, 
vitamin D supplementation has been shown to enhance muscle strength (54), which 
eventually reduces fall incidence (55), one of the major causes of fracture. As the VDR is 
expressed in both skeletal muscle (56) and myoblast cells (57), this association is expected. In 
vitro, vitamin D has been demonstrated to increase protein synthesis and cellular growth in 
muscle cells with an increase in size and number of type 2 muscle fibers (58) which are the 
first muscle fibers recruited when falling (59). 
Phosphorus is essential to the structural integrity of the cell and for metabolites’ 
passage. It regulates a great number of enzymes and manages the storage and transformation 
of the body’s energy. It plays a fundamental role in providing oxygen to the tissues through 
2,3-diphosphoglycerate and adenosine triphosphate (ATP) in the erythrocytes, forming part of 
the buffer systems of urine and blood, and its presence is critical to the body’s defense against 
infection (60). In bone, calcium and phosphate metabolism work together with osteoblasts, 
osteocytes, and extracellular matrix proteins to mineralize osteoid as it is deposited (61). On 
the contrary, in non-skeletal tissues, a regulatory system inhibits the deposition of calcium-
phosphate complexes in soft tissues (62, 63).  
Vitamin K is necessary for the biological activity of several coagulation factors (64). 
It functions as a cofactor for the vitamin K–dependent carboxylase that assists the post-
translational conversion of glutamyl to γ-carboxyglutamyl residues (65). Besides the hepatic 
tissue, γ-carboxyglutamyl–containing proteins are abundantly available in bone tissue (66). 




Osteocalcin accounts for up to 80% of the total γ-carboxyglutamyl content of mature bone 
(64). γ-Carboxyglutamyl residues are responsible for a highly specific affinity to the calcium 
ion of the hydroxyapatite molecule (67). Although the exact role remains to be clarified, the 
available findings indicate a regulatory function of osteocalcin in bone mineral maturation 
(68, 69). Some in vitro and in vivo data also suggest that vitamins K and D work 
synergistically on bone metabolism (70, 71). There is also evidence that calcium balance is 
positively influenced by vitamin K, including increasing calcium retention (72).  
Phytoestrogens are naturally occurring plant compounds that function like estrogen 
agonist–antagonists. There are three major forms of phytoestrogens: isoflavones (genistein, 
daidzein, glycitein), lignans (enterolactone and enterodiol) and coumestans (coumestrol). 
Different types of phytoestrogens have different affinities towards estrogen receptor alpha 
(ERa) versus beta (ERb), which alter their effects on the skeleton and other tissues (73). As 
has been reported for estrogens, phytoestrogens can modulate calcium metabolism and 
produce bone sparing effect (74). Studies have shown that phytoestrogens can: 1) directly 
modulate gene expression, including calciotropic receptor, cytokines, and growth factors (75, 
76); 2) increase alkaline phosphatase activity, enhance bone mineralization (77) and 
stimulates osteoblast differentiation (78); 3) inhibit bone resorption by decreasing osteoclast 
differentiation, increasing osteoclast apoptosis or interfering with signalling pathways (79); 4) 
interact with enzymes and receptors (80). Through ERa-dependent mechanisms, 
phytoestrogens are able to increase osteoblastic osteoprotegerin production and 
simultaneously suppress receptor activator of NFκB-ligand gene expression associated with 
an osteoclastogenesis inhibition. During bone remodelling, resorption cycle is coupled to 
formation through the receptor activator of NFκB (81). Peroxisome proliferator-activated 
receptors (PPAR) have also been recognized as additional targets of phytoestrogen. It can 
trigger PPAR activation and induce divergent effects on adipogenesis and osteogenesis. ER-
mediated effects can be observed at low phytoestrogen concentrations, whereas PPAR-
mediated effects are only apparent at high concentrations (82, 83).  




Typical magnesium body content is around 20 g, 50 to 60% of which is located in the 
bone (84). It is the main intracellular divalent cation and 99% of it is found in the intracellular 
space (84).  It regulates the structure of ribosome, different activating effects of enzymes, 
transport across membranes, synthesis of proteins and nucleic acids, generation and 
transmission of nerve impulses, muscular and cardiac contraction, as well as in oxidative 
phosphorylation. Through the hormonal action of vitamin D, PTH and calcitonin, magnesium 
is essential to the control of calcium and phosphorus metabolism (85). It is also important in 
bone crystal growth and stabilization. A positive correlation between dietary magnesium 
intake and bone density and/or an increased rate of bone loss with dietary magnesium 
reduction has been demonstrated in several epidemiological studies. In humans, magnesium 
deficiency results in impaired PTH secretion and low serum 1,25(OH)2D levels (86, 87). In 
several studies of postmenopausal women with osteoporosis, magnesium deficiency has been 
observed (88). Although several epidemiological studies indicate a positive association 
between magnesium intake and bone mass (89-91), other earlier studies have shown no 
correlation (92, 93).   
Vitamin A is essential in bone remodeling processes. Nuclear receptors for retinoic 
acid exist in both osteoblasts and osteoclasts (94, 95). Studies have shown that both vitamin A 
excess (hypervitaminosis) and deficiency are harmful to bone. In animals, hypervitaminosis A 
causes increased bone resorption, fragility and spontaneous fractures (96). However, vitamin 
A deficiency results in lower osteoclasts number, leading to excessive skeletal deposition in 
the periosteum due to uncontrolled osteoblast activity (97). When consumed within the 
recommended levels, vitamin A is safe and beneficial to bone health (98).  
Sufficient and balanced dietary intake of essential fatty acids (EFAs) has a positive 
effect on bone. Additionally, EFA deficiency has been known to contribute to osteoporosis 
(99). EFAs, which originate from ingested lipids, can be categorized into omega-3 fatty acids 
(ω3FAs) and omega-6 fatty acids (ω6FAs) (100). The relative concentration of ω6FAs and 
ω3FAs in the diet is an important determinant to the skeletal function, as it affects calcium 
metabolism (101). High intake of ω6FAs increased prostaglandin E2 and other cytokines 




(102), which in turn activated osteoclasts and bone resorption (103, 104). In contrast, ω3FAs 
reduced the level of inflammatory cytokines (105). Sufficient intake of ω3FAs also facilitates 
calcium absorption in the intestine, reduce calcium urinary excretion, increase calcium 
skeletal deposition and enhance bone collagen synthesis (101). Overall, a low ω6/3 in the diet 
seems to lower osteoporosis risk and fragility fractures. 
Numerous studies have confirmed a positive relationship between urinary sodium, 
reflecting intake, and urinary calcium (106, 107). As sodium and calcium compete for 
reabsorption at the kidney (108), approximately 20 mg of calcium is excreted per 1 g of 
sodium (108, 109). Hence, it has been speculated that excess sodium intake might decrease 
BMD. So far there are only two studies reporting negative effects of sodium directly on BMD 
(110, 111). The results from other studies did not demonstrate any relationship between 
sodium intake/urinary excretion and BMD, but only showed higher urinary calcium with 
higher urinary sodium (106, 112, 113). The current knowledge about the role of sodium in 
bone health is still insufficient and conflicting (114-116). Heaney concluded in his review that 
with sufficient calcium intakes, there is no deleterious effect of prevailing sodium intakes on 
bone or the calcium economy (108). This is supported by Ilich et al. that determined that 
moderately high sodium with adequate calcium intakes do not result in decreased BMD (117). 
 
2.5.2. Lifestyle 
The data regarding the effects of activity levels (exercise and mechanical stimuli) on 
serum calcium and PTH concentrations are somewhat unclear. The effects may be determined 
by the intensity and duration of the exercise regimen as well as the training status of the 
individual. Exercise-induced acidosis and hence, exercise intensity seem to be responsible for 
the raises in ionized calcium during exercise (118, 119). Short-duration, high-intensity 
exercise elevates ionized calcium with a simultaneous drop in serum PTH concentrations 
(120). On the other hand, during and after prolonged endurance exercise, the higher serum 
ionized calcium concentrations does not always result in lower serum PTH concentrations, 
perhaps due to the elevation in catecholamines. Some studies determined that endurance 




exercise has to last for at least 30 minutes in order to produce a raise in circulating PTH 
concentrations (120-124). Studies regarding the effect of resistance training on serum PTH 
concentrations are contradictory (120, 125). In a meta-analysis, Berard et al. found that 
physical activity have  no  beneficial  effect  on  bone  loss  after menopause (126). 
Chronic alcoholism can cause lower BMD and increase fracture risk due to: 1) 
malnourishment and malabsorption of important nutrients, especially calcium, magnesium 
and zinc; 2) liver disorder, abnormal vitamin D metabolites and parathyroid function; 3) 
toxicity to osteoblasts; and 4) increased tendency to fall leading to increase fracture risk 
(127). Hence, heavy drinkers have higher risk of bone loss (128, 129). However, moderate 
alcohol consumption seems to be beneficial for bone (129-132) supposedly due to the 
stimulation of androstenedione conversion into estrone (133). In postmenopausal women, the 
only source of their estrogen is the aromatization of androgens to estrogens. A study in 
postmenopausal women revealed that women with moderate alcohol consumption had higher 
estradiol levels (133). 
Caffeine was initially thought to merely increase urinary calcium loss and thus 
considered a risk for bone loss. Later, it was found that the correlation between caffeine, 
calcium and bone metabolism is more complex and it probably affects intestinal calcium 
absorption from endogenous sources. Although, there was a negative correlation between 
caffeine intake and calcium intake (134) such that as caffeine (or coffee) consumption 
increased, milk consumption decreased. Caffeine hardly affected urinary calcium excretion or 
total calcium uptake in balance studies (134). However, the association between coffee 
consumption and bone status are inconsistent based on epidemiological data. Some showed 
negative associations between caffeine consumption and bone health (135, 136) and some did 
not (137-140). Like sodium, it seems that the harmful effect of caffeine only becomes evident 
when dietary calcium is insufficient (135, 141, 142). 
  




CHAPTER 3: OSTEOPOROSIS 
 
3.1. Types and Impact of Osteoporosis 
Primary osteoporosis, the most common form of osteoporosis, is not a result of 
another specific disorder. On the other hand, secondary osteoporosis is caused by other 
specific diseases or medications. Primary osteoporosis, or sometimes referred as age-related 
osteoporosis, is mainly found in the elderly as an outcome of the accumulated impact of bone 
loss and structure deterioration that occurs with age (143). Postmenopausal women are 
usually at greater risk, while younger individuals are rarely inflicted by primary osteoporosis. 
Although primary osteoporosis can occur in both sexes, it is two to three times less common 
in men, owing to the fact that women experience two phases of age-related bone loss: 1) a 
rapid phase that begins at menopause and lasts between four to eight years, and 2) a slower 
continuous phase that continues throughout the rest of life (144). On the other hand, men go 
through only the second phase (slow and continuous). Hence, women typically lose more 
bone than men.  
Young adults and even older individuals may suffer from secondary osteoporosis as a 
side effect of another condition or medication. They experience greater levels of bone loss 
than a healthy individual of the same age, gender, and race. The development of osteoporosis 
can be caused or contributed by a wide variety of diseases, medications and toxic agents (145, 
146). Several genetic disorders have been associated with secondary osteoporosis. Disorders 
such as diopathic hypercalciuria and cystic fibrosis were found to be the most common 
causes. In other cases, estrogen or testosterone deficiency caused by Turner’s, Kallman’s or 
Klinefelter’s syndrome, anorexia nervosa, athletic amenorrhea, cancer, or any chronic illness 
that interferes with the onset of puberty may also lead to secondary osteoporosis (144). 
Osteoporosis can also be a side effect of particular medications, including glucocorticoid, 
cyclosporine A, tacrolimus and anticonvulsants (145, 146). 
Bone disease brings a devastating impact on patients and their families. For most 
individuals a fracture may result in a significant drop in physical health and even death 




resulting from fracture complications (147). Fractures may cause pain, height loss as well as 
inability to perform basic daily activities. Besides increasing risk of health complications, 
such as pressure sores, pneumonia and urinary tract infections, fractures may also affect 
patients psychologically by lowering their self-esteem and mood. A fear of suffering another 
fracture from falling may immobilize some patients permanently. However, osteoporosis and 
fractures should no longer be thought of as an unavoidable part of aging. By concentrating on 
fracture prevention and lifestyle changes, such as nutrition and increased physical activity 
discussed in Part A, Section 2.5, combined with early diagnosis and proper treatment that will 
be discussed in the following sections, the damaging impact of osteoporosis can be mitigated, 
if not avoided. 
 
3.2. Pathophysiology  
Osteoporotic fractures are a result of both reduced bone strength and increased rate of 
falls. Although BMD is still the best available non-invasive assessment of bone strength in 
routine clinical practice, there are other skeletal characteristics, such as bone macro- and 
micro-architecture, matrix and mineral composition, degree of mineralization, micro-damage 
accumulation and the rate of bone turnover, that also contribute (148). The bone mass of an 
older individual is a result of the PBM accumulated during early age and also the subsequent 
bone loss. Although genetic factors greatly contribute to PBM, environmental factors in 
intrauterine life, childhood and adolescence also control the genetically determined pattern of 
skeletal growth (25). 
At the cellular level, an imbalance between the activities of osteoclasts and 
osteoblasts results in bone loss. In adults, the skeleton is constantly remodeled in a 
synchronized sequence of bone resorption and formation. When the processes of bone 
resorption and formation are not synchronized, remodeling imbalance will occur. This 
imbalance can be exacerbated by an increase in the initiation rate of new bone remodeling 
cycles (27). 




In postmenopausal women, bone loss may result from estrogen deficiency as well as 
via estrogen-independent age-related mechanisms, such as reduced mechanical loading and 
secondary hyperparathyroidism. Estrogen plays an important role in normal physiological 
remodeling and estrogen deficiency following menopause causes commonly an imbalance in 
remodeling with a considerable increase in bone turnover. This causes a progressive loss of 
trabecular bone, partially due to an increase in osteoclastogenesis. Higher formation of 
osteoclasts is found to be a consequence of increased elaboration of osteoclastogenic 
proinflammatory cytokines, including interleukin-1 and tumour necrosis factor, which are 
negatively controlled by estrogen (149-151). Increased production of transforming growth 
factor β is another direct effect of estrogen in accelerating osteoclast apoptosis (152). 
Osteoclastic bone resorption in vitro and in vivo is regulated mainly by the receptor 
activator of NFκB (RANK), its ligand (RANKL) and the decoy receptor osteoprotegerin 
(153). RANKL is expressed by osteoblasts constitutively on their cell surface. It interacts with 
RANK, which is expressed on osteoclast precursors and promotes its differentiation. On 
mature osteoclasts, this interaction leads to their activation and prolonged survival. 
Osteoprotegerin, primarily secreted by osteoblasts and stromal cells, blocks the interaction of 
RANKL with RANK in vivo and consequently acts as a regulator of bone turnover. Estrogen 
stimulates osteoprotegerin expression in osteoblasts and thus exert its antiresorptive effects on 
bone (154). 
Key novel genes and pathways for osteoblast function and differentiation have been 
discovered. LDL receptor-related protein 5 (LRP5) modulates osteoblast function, and thus 
bone formation. It is expressed on the membrane of the osteoblast between Frizzled and 
Kremen (receptors). Frizzled and LRP5 bind to Wnt, thus activating bone formation. 
Inhibition of bone formation will occur when Wnt inhibitors bind to Kremen and LRP5, 
unabling LRP5 to bind Wnt. Differences in bone density and fracture risk have been linked 
with polymorphisms of LRP5 (155, 156). 
 
 




3.3. Osteoporosis Treatments 
3.3.1. Antiresorptive Agents 
Bisphosphonates inhibit bone resorption leading to reduction of fracture risk. They 
include alendronate, risedronate, ibandronate and zoledronic acid. The direct intracellular 
target of bisphosphonates is the enzyme farnesyl diphosphate synthase in the HMG-CoA 
reductase biosynthetic pathway. Its inhibition reduces protein prenylation, causing 
disturbance of signaling pathways required for bone resorption by osteoclast. Due to its 
affinity to calcium, bisphosphonate molecules accumulate in bones and are taken up by 
osteoclasts. In postmenopausal women with osteoporosis, risedronate has increased BMD and 
reduced vertebral and non-vertebral fracture risks by 41% and 49%, respectively (157). It also 
reduced hip fracture rate by 30% in older women receiving osteoporosis treatment (158). In 
postmenopausal women with low BMD, alendronate has reduced hip fractures by 50% and 
vertebral fractures by 44–50% (159, 160). Ibandronate was found to reduce hip and vertebral 
fracture risk (161, 162). Zoledronic acid reduced vertebral and hip fracture by 70% and 41%, 
respectively (163). When given two weeks after hip fracture, zoledronic acid offers 35% 
relative decrease in recurrent fracture and all-cause mortality (164, 165). In rare occasions, 
bisphosphonates may cause adverse skeletal events, including atypical fragility fractures and 
osteonecrosis, which might be a result of bone remodelling suppression (166, 167). To reduce 
the risk of adverse effects, patients receiving long-term biphosphonate therapy are usually 
given a drug holiday. Since bisphosphonates are incorporated into the bone, they continue to 
exert an antiresorptive effect for a period of time after the discontinuation of the therapy 
(168). 
Selective oestrogen receptor modulators (SERMs) include raloxifene, lasofoxifene 
and bazedoxifene. In a study on postmenopausal women, raloxifene has decreased vertebral 
fracture risk (169). Analyses of a subgroup of women with severe vertebral fractures showed 
a decrease in both new vertebral and non-vertebral fracture risk (170). Bazedoxifene and 
lasofoxifene significantly decreased new vertebral fracture risk in postmenopausal women 
with osteoporosis and non-vertebral fracture risk in subjects with higher fracture risk (171, 




172). The main concern with SERMs treatment is the increased risk of venous 
thromboembolism (VTE).  
Denosumab is a human monoclonal IgG2 antibody directed against RANKL or 
usually called RANKL inhibitor (173). RANKL is a member of the tumour necrosis factor 
family, that is expressed by osteoblasts and its precursors and functions to stimulate 
recruitment and differentiation of osteoclast precursors (174). The effect of RANKL on 
osteoclastogenesis can be inhibited by osteoprotegerin (OPG) that is produced and secreted 
by osteoblasts and its precursors. Denosumab functions like OPG, limiting RANKL activity 
and thus reducing osteoclast numbers and activity. Clinical trials have shown that denosumab 
increased BMD, reduced bone turnover markers and fracture risks in postmenopausal women 
(175-178). Increased risk of nausea, abdominal pain and flatulence have been reported, but no 
increased risk of infections, neoplasms, jaw osteonecrosis or serious atrial fibrillation has 
been observed (178). 
Since bone loss happens rapidly at the start of postmenopausal period as a result of 
oestrogen deficiency, hormone replacement therapy (HRT) seems to be a logical means to 
delay this bone loss. In postmenopausal women, it has been observed that the overall risk of 
osteoporotic fractures dropped by 24% and the risk of both hip and spinal fractures dropped 
by 34% each (179). The BMD of the lumbar spine also increased by 5.1% and bone turnover 
rate decreased. However, the benefits of HRT disappear after withdrawal of treatment (180). 
In addition to that, UK Committee on the Safety of Medicine recommends that HRT should 
not be used as the first-line treatment of osteoporosis, due to the adverse effects such as 
increased risk of stroke, VTE as well as breast cancer (181).  
 
3.1.2. Anabolic Agents 
Recombinant PTH 1-34 and 1-84 enhance bone remodelling by stimulating pre-
osteoblasts maturation into osteoblasts. A clinical trial on postmenopausal women with 
previous vertebral fracture showed a rise in BMD at the lumbar spine and femoral neck in the 
treatment groups. The increase in BMD is quick and of greater magnitude compared to other 




treatments. It is particularly useful to treat patients with high fracture risk or pre-existing 
fragility fractures (182). The main concern is the development of osteosarcoma with long-
term treatment, as seen in rat models receiving high-dose treatment (183). However, this has 
not been reported in human. Due to safety concern and plateau in bone formation after 18 
months of treatment, PTH treatment is limited to a low dose for at most 2 years. Nevertheless, 
owing to its cost, complexity of administration and the lack of data on non-vertebral fracture 
reduction, PTH is not considered as first-line therapy. 
 
3.1.3. Double-Acting Agents 
Strontium ranelate dissociates bone remodeling by reducing bone resorption without 
affecting bone formation. Strontium was found to reduce relative risk of vertebral fractures by 
49% and 41% after 1 year and 3 years, respectively (184). In 3 years, it increased BMD at the 
lumbar spine and the femoral neck by 14.4% and 8.3%, respectively. BMD of the lumbar 
spine, femoral neck and total hip continued to increase up to 8 years (185). In postmenopausal 
women, the strontium group experienced reduction in relative risk of major fragility fractures 
by 19% (186). A subgroup analysis on women aged ≥ 80 years who are at an elevated risk of 
fractures showed an early and sustained reduction of both non-vertebral and vertebral 
fractures following strontium treatment (187). As the change in BMD value may partially be 
caused by accumulation of strontium that attenuates X-ray more strongly than calcium, BMD 
values must be interpreted with caution.  
Side effects of strontium ranelate include transient nausea, diarrhoea and headache. A 
slight rise of VTE has been noted, but no increased incidence in patients treated with 
strontium compared with alendronate (188). Nevertheless, a recent data evaluation from 
clinical studies in postmenopausal women published by the European Medicines Agency’s 
(EMA's) Committee for Medicinal Products for Human Use (CHMP) has revealed a higher 
risk of heart attack with strontium ranelate than with placebo. However, there is no observed 
increase in mortality risk. Considering the other side effects including blood clots and serious 
skin reactions, EMA suggested to restrict the use of strontium ranelate only for treatment of 




severe osteoporosis with high risk of fracture and on patients without any cardiovascular 
problems (16). 
  




CHAPTER 4: METHODS TO STUDY BONE METABOLISM AND BONE HEALTH 
 
4.1. Clinical Techniques 
As mentioned earlier, although BMD assessment has been used as the benchmark for 
diagnosis of osteoporosis, low BMD alone does not necessarily lead to a fracture. Even 
though many clinical trials have shown the usefulness of the diagnostic threshold of a T-score 
< –2.5 as a cut-off for osteoporosis, the clinical use of the term osteopenia (–1 > T-score > –
2.5) is less clear. It is well established that fracture risk increased sharply with decreasing 
BMD, but assessment of fracture risk should take into account all aspects of risk and 
intervention should not be deduced only from BMD. Based on the data gathered by World 
Health Organization (WHO), several osteoporosis risk factors have been identified, including 
fracture history, glucocorticoid use, family fracture history, cigarette smoking, alcoholism and 
low bodyweight (189). Multivariate models combining these risk factors with age and BMD 
allow the prediction of 10-year fracture probability. This will enhance the ability to design 
more targeted and cost effective treatments. 
Biochemical markers of bone turnover in serum and urine have been established and 
used as diagnostic tools. They are non-invasive and relatively inexpensive techniques to 
assess in vivo bone formation and resorption rates. Serum bone-specific alkaline phosphatase 
and the amino-terminal propeptide of type 1 procollagen (bone formation markers) and urine 
or serum telopeptides of collagen crosslinks (bone resorption markers) are widely used. 
However, day-to-day and circadian variability have limited their values. Independent of 
BMD, a correlation between osteoporotic fracture and bone turnover indices in 
postmenopausal women and in elderly women has been shown (190). Elderly women whose 
bone resorption markers exceed the reference range showed an increase in fracture risk by 
about two-fold, after adjustment for BMD. Hence, a combined approach using BMD, clinical 
risk factors and bone turnover markers could enhance fracture prediction (191).  
 
 




4.1.1. Bone Mineral Density 
In clinical settings, BMD measurement by using DXA has widely been used as a tool 
to diagnose osteoporosis, assess fracture risk and therapeutic effects (192). Nevertheless, it 
involves relatively high cost and its availability is limited, particularly in less developed 
countries. Furthermore, the correlations between bone strength and BMD, measured by DXA, 
are found to be between 0.51 and 0.80 (193-196), which means that it accounts for only 50 to 
80% of bone strength. Another technique, quantitative computed tomography (QCT) can 
measure volumetric BMD (mg/cm3). Cancellous bone can be separately measured without 
the interference from the cortical bone and aortic calcification. Lately, quantitative ultrasound 
(QUS) has also emerged as a cheaper and more accessible alternative for identifying 
osteoporosis, evaluating fracture risk and initiating osteoporosis treatment.  
DXA can simultaneously measure the transmission of gamma-rays of two different 
energies which enables it to accommodate the different thicknesses of soft tissue, allowing 
this technique to be used on any part of the body. The sites that are commonly measured 
include lumbar spine, hip, forearm, whole body and skeletal segments. DXA is easy to use, 
yet it has high precision in vivo (197). A value for BMD by DXA 2.5 standard deviation (SD) 
or more below the mean for young adult women (T-score = -2.5) has been defined as a cut-off 
for osteoporosis. Using this criterion, 30% of all postmenopausal women is identified as 
osteoporotic and more than 50% would have suffered from a prior fracture (197). During 
osteoporosis treatment, accurate detection of BMD changes can only be achieved when the 
change is larger than the precision error of the measurement. In practice, changes of this 
magnitude are not likely to be achieved within one year and would require at least three years 
of treatment (182, 184, 198). Besides that, only a small fraction of fracture reduction can be 
explained by BMD changes (199, 200). 
In QCT, a thin transverse slice is scanned through the body. The image is used to 
quantify the volumetric BMD (mg/cm
3
). The correlations between QCT and vertebral body 
compressive strength are approximately 0.72 to 0.74 (201, 202). Besides BMD, QCT can also 
analyze bone geometry (203, 204). The biggest source of measurement error is fat within the 




bone marrow. Fortunately, the accuracy can be improved by using dual energy techniques, 
which carry out scans at two different potentials. Peripheral QCT (pQCT) can be used in a 
peripheral part of the body. It is precise, inexpensive and involving low radiation doses (205). 
In experimental and clinical studies done ex vivo, pQCT variables were shown to correlate 
with biomechanical predictors of fractures and fragility. Hence, it is useful in identifying 
women who are prone to osteoporosis (206, 207). MicroCT has a spatial resolution of 1–100 
µm and can be used to replace the tedious histomorphometry technique. It can also be coupled 
with sophisticated software to render 3D analysis of bone structure (208). Nevertheless, CT 
has some limitations, including the large extent of operator dependence, limited access to 
scanners and lack of a technique to evaluate the proximal femur. These limit its usage in 
clinical practice (208).  
QUS is a recent alternative method for bone mass assessment, measuring bone 
strength, density and elasticity or fragility (209). Being low cost, portable and radiation-free, 
have promoted its usage for osteoporosis assessment and bone fracture risk evaluation. QUS 
devices can be categorized into three groups: 1) trabecular sound transmission which is best 
for measuring the heel and most commonly used in clinical settings; 2) cortical transverse 
transmission which is currently used only in phalanx contact devices; and 3) cortical axial 
transmission which is used in phalanges, the radius and the tibia (197). QUS can differentiate 
patients with osteoporotic fractures from healthy people with the same age (Durosier et al., 
2006; Krieg et al., 2008; Hans and Krieg, 2008). However, there are a few factors that may 
contribute to in vivo measurement errors, which include foot or leg positioning; surrounding 
soft tissue and its thickness, temperature and composition; the properties of the coupling 
medium; and the quality of sound transmission from the coupling medium to the skin. A 
standard or phantom can be used to examine instrument performance and to perform the 








4.1.2. Biochemical Markers 
Bone remodeling rate is an important determinant of bone strength that is not 
measured by BMD tests. Increased bone remodeling rates have been associated with severe 
osteoporosis (211, 212). In fact, high levels of bone turnover markers (BTMs) are correlated 
with an increase in fracture risk (212), while lower bone turnover is associated with 
therapeutic efficacy of anti-resorptive agents. Hence, reliable bone remodeling assessment 
could be useful for predicting fracture risk. Even though the analytical precision for 
measurement of several BTMs has improved with the development of automated assays, their 
large biological variability still complicates their use in the clinical setting (213, 214). The 
biological variability can be categorized into modifiable factors, such as circadian variability 
(215, 216) and food intake (217, 218), and non-modifiable factors, such as disease states, 
medication affecting the skeleton and a recent fracture (219). Collection of paired fasting 
samples at a standard time on different days helps to reduce the variability, but it is 
impractical for everyday clinical practice. 
BTMs can be classified as markers of bone resorption or bone formation, although 
the two processes are typically coupled. During bone resorption, products of type I collagen 
breakdown are generated (amino- or carboxyl-terminal cross-linking telopeptides, pyridinium 
cross-links). They are currently the most widely used bone resorption markers. Matrix 
proteins (osteocalcin), products of post-translational processing of type I collagen molecules 
(procollagen type I N- or C-terminal propeptides) and enzymes (alkaline phosphatase) 
released from osteoblasts during bone matrix synthesis can be used as bone formation 
markers (220).  
 
4.1.2.1. Bone Formation Markers 
Osteocalcin is a bone matrix protein that is synthesized by mature osteoblasts and 
constitutes about 15% of the non-collagenous bone matrix proteins (221). It has calcium-
binding properties that are facilitated by three vitamin K-dependent γ-carboxy glutamic acid 
residues (222). Even though osteocalcin participated in the mineralization process, its exact 




function is still unknown (223). Most of the synthesized osteocalcin is incorporated into the 
skeleton, but a small portion gets into the circulation (224). It is rapidly degraded in serum, 
resulting in detectable osteocalcin fragments together with the full-length molecule (224, 
225). Although osteocalcin is a very good bone formation marker, it has a high circadian and 
biological variability (223) which negatively affects the measurement reproducibility. 
Osteocalcin can be detected by using enzyme-linked immunosorbent assay (ELISA), 
radioimmunoassay (RIA) or a chemiluminesence immunoassay (220). 
Alkaline phosphatase (ALP) is a glycosyl–phosphatidyl–inositol attached to ecto-
enzyme existing on the osteoblast membrane (226). Its exact function is not confirmed, but its 
presence is necessary for bone mineralization (227). Typically, bone and liver isoforms 
contributed to about equal amounts of ALP in serum (228), which can be distinguished by 
heat inactivation (220). However, immunoassays for the bone isoform can provide a better 
assessment of bone-specific ALP, which has greater specificity for osteoblast function (229). 
Nevertheless, in patients with normal liver function, assessment of total ALP assays is good 
enough. 
Procollagen type I N-terminal propeptide (PINP) and procollagen type I C-terminal 
propeptide (PICP) are derived from post-translational cleavage of type I procollagen 
molecules preceding the assembly into fibrils. They get into the circulation and can be used as 
bone formation markers (230). Although skin, tendon, dentin, and cartilage also contribute to 
a small amount of PINP and PICP, they originate mainly from bone (223, 230, 231). This is 
due to the higher turnover rate of skeletal tissues compared to non-skeletal tissues (223). RIA 
or ELISA, and electrochemiluminescence immunoassay can be used to determine serum 
PINP and PICP (232). However, unlike PINP, PICP is broken down by the mannose receptor, 
which is controlled by growth and thyroid hormones. This makes the data interpretation in 
patients with pituitary or thyroid dysfunction complicated (231, 233, 234). Hence, PINP is 
usually preferred over PICP. 
 
 




4.1.2.2. Bone Resorption Markers 
Amino-terminal cross-linking telopeptides of type I collagen (NTX) is a type I 
collagen breakdown product that results from osteoclastic bone resorption. It can be measured 
in either serum or urine. Although serum NTX drops significantly following antiresorptive 
therapies, it is not as sensitive as urinary NTX (235). However, it is still unclear if collagen 
from dietary sources can affect serum NTX levels. On the other hand, measurement of NTX 
in 24-hour urine is less affected by dietary collagen intake and it is able to overcome the 
circadian variability in bone turnover (220, 236).  
Carboxyl-terminal cross-linking telopeptides of type I collagen (CTX) can also be 
determined using ELISA, RIA, and an electrochemiluminescence assay in both serum and 
urine (220, 237). With time, C-terminal telopeptide α1 chain of type I collagen is subjected to 
β-isomerization and racemization (238). Consequently, the ratio of α-CTX to β-CTX, 
representing the breakdown product of newly synthesized and aged collagen, has been 
proposed to assess rapid bone turnover. In patients with Paget’s disease, the α-CTX/β-CTX 
ratio increases as a result of the breakdown of newly synthesized woven bone and decreases 
significantly following bisphosphonate therapy (239). Similarly, in postmenopausal women, 
higher ratio of α-CTX/β-CTX is positively correlated to fracture risk (240). However, inter-
individual variability of the α-CTX/β-CTX ratio is high (220), Hence, further studies are 
required to determine whether this ratio can be used as a better measure than the total CTX. 
Pyridinoline (PYD) and deoxypyridinoline (DPD) are covalent pyridinium cross-
links resulting from collagen breakdown. They are produced during bone resorption, released 
into the circulation and passed into the urine (241, 242). They can be detected by RIA and 
ELISA (220, 223, 242). In addition to bone, collagen cross-links are also present in cartilage, 
vessels, and ligaments. Due to higher turnover rate in bone, most of the circulating and 
urinary PYD comes from bone (223). Unlike PYD, DPD originates almost exclusively from 
bone and dentin (223). Overall, both of them can be used to reliably assess bone resorption. 
Tartrate-resistant acid phosphatase (TRACP5b) is the 5b isoform of acid 
phosphatases. It is expressed in the osteoclast and is the only marker of osteoclast activity. In 




some conditions causing high bone turnover, such as Paget’s disease, bone metastases, 
multiple myeloma and ovariectomization, the level of TRACP5b is normally elevated (243). 
Nevertheless, due to its poor sensitivity in reporting changes in bone turnover resulting from 
anti-resorptive therapy, it is not widely accepted (243, 244). 
 
4.2. Tracer Techniques 
4.2.1. Stable and Radioisotopes to Study Mineral and Trace Element Metabolism 
Both stable and radioactive isotopes can be used to trace mineral metabolism in the 
body. For this purpose, they have to be administered in the forms that are distinguishable 
from their naturally-existing forms. The isotopes, usually called ‘tracer’, can be administered 
either orally or intravenously. For oral administration, the tracer can be incorporated into 
foods either intrinsically (incorporated biosynthetically into a plant or animal) or extrinsically 
(added to the food before ingestion). After administration, tracer appearance in plasma, urine 
and feces can be monitored over several days, weeks or even years depending on its 
characteristics (245). This isotopic technique can be used to assess mineral absorption, 
retention, excretion or even compartment sizes and transfer rates between the different 
mineral compartments in the body. Calcium and strontium isotopes are listed in Table A-1. 
However, not all of them are suitable to be used as a tracer in metabolic studies. 
There are a few advantages in using radioisotope tracers for studying mineral 
metabolism. They can be measured in blood, urine or feces samples by scintillation counting, 
while whole body counting can be used to assess body retention directly by measuring the 
total amount of absorbed tracer in the body. Besides a small natural background radiation, the 
radiotracer is usually the only source of radioactivity in the sample. Hence, a proper 









Table A-1: List of calcium and strontium isotopes with their atomic masses, natural 



























Calcium  Strontium 
34
Ca 34.014  < 0.035 µs 
 73
Sr 72.966  > 25 ms 
35
Ca 35.005  25.7 ms 
 74
Sr 73.956  > 1.5 µs 
36
Ca 35.993  0.100 s 
 75
Sr 74.949  88 ms 
37
Ca 36.986  0.182 s 
 76
Sr 75.942  7.9 s 
38
Ca 37.976  444 ms 
 77
Sr 76.938  9.0 s 
39
Ca 38.971  0.861 s 
 78
Sr 77.932  2.7 m 
40








Sr 78.930  2.1 m 
41
Ca 40.962  1.02 x 10
5
 a  80Sr 79.925  1.77 h 
42






Sr 80.923  22.3 m 
43






Sr 81.918  25.36 d 
44






Sr 82.918  1.350 d 
45
Ca 44.956  162.7 d 
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Ca 45.953  
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Sr 84.913  64.85 d 
47
Ca 46.955  4.536 d 
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Ca 48.956  8.72 m 
 
88





Ca 49.958  14 s 
 89
Sr 88.907  50.6 d 
51
Ca 50.962  10 s 
 90
Sr 89.910  28.9 a 
52
Ca 51.965  4.6 s 
 91
Sr 90.910  9.5 h 
53
Ca 52.970  0.4 s 
 92
Sr 91.911  2.64 h 
54
Ca 53.974  0.1 s 
 93
Sr 92.914  7.4 m 
55
Ca 54.981  22 ms 
 94
Sr 93.915  1.25 m 
56
Ca 55.986  11 ms 
 95
Sr 94.919  25.1 s 
 
    96Sr 95.922  1.06 s 
a
 Taken from a table in IUPAC Technical  
 97
Sr 96.926  0.42 s 
Report (246)  98Sr 97.928  0.65 s 
b
 Taken from a table in CRC Handbook of  
 99
Sr 98.933  0.27 s 
Chemistry and Physics, 94
th
 Edition (247)  100Sr 99.935  0.201 s 
 
    101Sr 100.941  0.115 s 
 
    102Sr 101.943  68 ms 
 
    103Sr 102.949  > 0.3 µs 
 
    104Sr 103.952  > 0.3 µs 
 
    105Sr 104.959  > 0.3 µs 




measuring counting rates can be achieved, resulting in high precision of radioisotope analysis 
(248). Thus, minute amount of tracer, that is unlikely to perturb the system being studied, is 
usually sufficient (245). In the case when two or more radioactive tracers are present in the 
same sample at the same time, contributions of the different isotopes can be distinguished 
separately by repeated counting measurements or by spectrometric measurements. 
Nevertheless, the concern about exposure to ionizing radiation together with the advancement 
in mass spectrometric techniques for analysis of stable isotopes has promoted the use of 
stable-isotope tracers (245). In most cases, stable isotopes can replace radioisotopes in 
research, medicine, and industry (249). 
In nature, there are six naturally occurring calcium stable isotopes. 
40
Ca (96.94%) is 
the most abundant isotope and hence cannot be used as a tracer due to the large quantity of 
40
Ca that will be required. 
44
Ca (2.08%) is the second most abundant isotope of calcium and it 
has been widely used in human studies. However, due to its relatively high natural abundance, 
relatively high doses are required. The high doses of tracer may increase the total element 
intake and perturb the system under investigation. Tracers with very low natural abundances, 
such as 
46
Ca (0.003%), are ideal tracers. However, the high costs of these isotopes as well as 
the challenging measurement can be drawbacks. Other isotopes with relatively low 




Ca (0.14%) and 
48
Ca (0.19%), are better alternatives as 
they are less expensive, less challenging to be measured, and the doses can be kept relatively 
low. Similar principles are used in determining strontium tracers to be used. There are four 
naturally occurring stable strontium isotopes. The most abundant isotope, 
88
Sr (82.58%), 
cannot be used as a tracer due to the large quantity of tracer that will be required. 
87
Sr is a 
radiogenic nuclide produced by a radioactive decay of 
87





Sr (5.6%). The least abundant isotope, 
84
Sr, would be an ideal choice in most 
cases even though it is relatively more expensive. Thermal ionization mass spectrometry 
(TIMS) and inductive coupled plasma mass spectrometry (ICP-MS) are commonly used to 
measure isotope ratios for stable isotope analysis. These techniques will be discussed in Part 
A, Section 7.1.1 and 7.1.2. 




4.2.2. Short-term Kinetics 
After tracer administration, its appearance in plasma or serum, urine and feces can be 
monitored and assessment of mineral absorption, retention, excretion or even compartment 
sizes and transfer rates between the different mineral pools in the body can be performed. 
 
4.2.2.1. Plasma or Serum Isotope Appearance 
The appearance of oral doses of tracer in plasma or serum can be used to estimate its 
bioavailability. It is usually less precise, because of the extra load required to produce an 
increase in the serum level of the element and might lead to major perturbation in its 
homeostasis regulation (250). However, isotopic methods require a much smaller rise in total 
serum content of the element in order to produce detectable changes in serum tracer 
concentration. Hence, the disturbance in the homeostasis regulation can be greatly reduced. In 
order to calculate fractional absorption from the orally administered dose, the dual isotope 
tracer method involving one orally and one intravenously administered isotope, has to be 
used. These isotopes must follow similar kinetics irrespective of route of entry (251). 
Although this method has normally been used with radioisotopes, it could be used with stable 
isotopes as well. This approach allows assessing absorption of minerals, but it is invasive as it 
requires continuous blood sampling and is therefore not preferred. 
 
4.2.2.2. Fecal Excretion 
Absorption of the isotope is calculated as the difference between intake of the isotope 
dose and fecal excretion. This method can measure the luminal disappearance of the isotope 
without correction for endogenous losses, which means, it can only measure apparent 
absorption. Determining the optimum time period for fecal collection is crucial to ensure that 
all non-absorbed isotope is excreted with little or no isotope that has been absorbed and re-
excreted into the gut. The transit time of the tracer varies considerably with diet composition, 
genetic and physiological differences. The colonic passage accounts for the major part of the 
time as intestinal transit is usually less than 24 hour. After several days in the colon, it is 




therefore highly likely that fecal samples which contain most of the non-absorbed isotopes 
will also contain endogenously excreted isotopes (252). In order to overcome this source of 
error, which leads to an underestimation of the absorption, endogenous losses of the element 
have to be measured (251).  
The administration of one isotope allows only the calculation of apparent absorption 
which results in an underestimation of true absorption. True absorption can only be 
determined by intravenous administration of a second isotope. Both tracers have to be 
metabolized in the same way and the same fraction is excreted in the feces. True calcium 
absorption can be calculated from apparent absorption added with the amount of absorbed and 
re-excreted label that is estimated based on the fraction of intravenous label in the feces.  
 
4.2.2.3. Urinary Excretion 
The most widely used method to assess calcium absorption is the dual isotope tracer 
method with urinary monitoring (253). One oral and one intravenous isotopic tracer are 
administered and calcium absorption is assessed based on the relative recovery of the oral and 
intravenous isotopes in urine. Samples of 24-hour urine are collected and the relative fractions 
of the two isotopes are measured. The ratio corresponds to the fraction of absorbed calcium in 
the diet. The molar ratio of the two isotope labels in urine can be calculated from the 
measured isotope ratios based on isotope dilution principles. Calculation techniques are 
described in Part A, Section 7.1.4. True fractional calcium absorption can be calculated from 
the molar ratio of the isotopic labels after correction for dose (254). 
Several variations of this method have been used. They differ in the timing of the 
urine collection and types of isotopes used (stable (255) or radioisotopes (256) or a 
combination of both (257). A collection of urine for at least 24 hour after dosing was 
described in Degrazia et al. (258). This technique was later adopted by Hillman et al. (255), 
Eastell et al. (259), etc. Later on, it was proposed that a spot urine sample that was taken at 
any time between 24 hour and 48 hour after dosing was sufficient to assess calcium 
absorption. However, calcium absorption might be underestimated if the measurement is 




based on samples collected during the first hours after isotope administration when intestinal 
absorption of the oral isotope is incomplete (254).  
In general, the most widely used method to assess true fractional calcium absorption 
is the dual isotope method with 24-hour urine collection. The method has been validated 
against other techniques to assess calcium absorption. It has been demonstrated that the 
assessment of true fractional calcium absorption using a complete 24- hour urine collection is 
well correlated with the data from fecal balance (259), which has been discussed in Section 
4.2.2.2. Abrams et al. (260) also reported that the dual isotope tracer method shows less 
variability than the fecal balance method. The dual isotope tracer method has been shown to 
correlate well with results for the serum isotope appearance technique (261) and whole body 
counting (257). 
 
4.2.2.4. Compartmental Analysis 
Compartmental modeling is the most common approach for mathematical evaluation 
of calcium kinetics data. Physiological processes such as intestinal calcium absorption, 
endogenous calcium losses into feces, renal handling of calcium, bone calcium deposition 
rate, bone calcium resorption rate, body pool sizes and turnover rates of exchangeable 
calcium can be described. The number of samples and the length of the study period influence 
the choice of the compartmental model; i.e. with more samples available and with longer 
monitoring period, a more complex model can be applied to describe the data. 
When using compartmental modeling, a few assumptions have to be made: 1) the 
system is in steady state (pool sizes do not change during the study period); 2) the tracers do 
not perturb the system; 3) rapid and slow exchangeable pools are covered in the sampling 
period; and 4) when the system has been perturbed, e.g. by an intervention, a new steady state 
has to be reached before calcium kinetics can be studied (248). 
To describe tracer kinetics, a single compartment system is the simplest model that 
can be used (see Figure A-4a). The tracer is introduced once and leaves the system with the 
carrier material as a constant fraction of the total amount in the system. Its concentration will 




decrease with time. Two compartment models are more complicated (see Figure A-4b). The 
tracer enters compartment 1, from which it might leave the system or get transferred to 
compartment 2. After the tracer mixes with material in compartment 2, some of it will return 
to compartment 1. At the start, the tracer concentration drops as a non-linear function of time. 
At equilibrium, the concentration follows a straight line in both compartments in a semi 
logarithmic plot (262). In multi-compartment models, tracer concentration will never be the 
same in all compartments (see Figure A-4c). A compartment is in equilibrium with other 
compartments, when the rate of change in tracer concentration becomes the same as for the 












Figure A-4: Schematic illustration of compartment models with their transfer routes (k). (a) 
A single compartment model, (b) a two compartment model, and (c) a three compartment 
model. 
 
A number of compartmental models to describe calcium metabolism have been 
proposed. There are several one compartment models (263, 264), which are no longer used. 
Thereafter, additional compartments have been introduced by Heaney (265), Cohn et al. 
(266), Aubert and Milhaud (267) and Neer et al. (268). Despite varying numbers of 
compartments and individual compartmental sizes, there are no significant differences in total 
pool size and bone mineralization rate between the different models. All models, except 
(a) (b) 
(c) 




Neer’s, pointed that time needed for compartmental equilibration is five days or less. 
However, Neer’s model includes compartments that need 10-20 days to equilibrate, which 
leads to larger total pool size and lower accretion values. 
Compartmental models have also been used to describe long-term calcium 
metabolism. Three compartmental models, which include a central dosing compartment, bone 
surface compartment and deep bone compartment, have been employed by Johnson et al. 
(269), Hillegonds et al. (270), Denk et al. (271), and Sharma et al. (272). Four compartmental 
models, which separate bone compartment into cortical and trabecular bones, have been used 
by Staub et al. (273) and Lee et al. (274). Whereas Hui et al. (275) employed a more 
complicated five compartmental model by splitting the bone compartments into slow, 
medium and fast exchanging compartments. 
 
4.2.3. Long-term Kinetics 
Since long-term kinetic studies using 
41
Ca are of great relevance to the technique used 
in this thesis, this section will be elaborated with greater details to observe how this method 
has evolved and improved throughout the years. 
 
4.2.3.1. 41Ca Studies 
In vivo, bone calcium can be labeled by administration of calcium isotope tracers. 
After administration, tracer that is not incorporated into the skeleton will be slowly excreted 
through urine. After excess tracer has been eliminated from the dosing compartment, tracer 
signal in urine will originate mainly from tracer that has been incorporated into the skeleton. 
Hence, changes in urinary tracer excretion can be used to assess the changes in bone 
metabolism (276). The cost of using calcium stable isotope tracers, would be very high, 
whereas the use of conventional calcium radiotracers is not possible due to ethical 
considerations. A compelling reasonable alternative is 
41
Ca, a very long-living radioisotope 
which requires the use of ultra-trace levels of 
41
Ca using accelerator mass spectrometry 
(AMS) (277) or resonance ionization mass spectrometry (RIMS) (278). The sensitivity of 




conventional mass spectrometric techniques including TIMS or ICP-MS is not high enough. 
Even with the use of high-resolution instruments, they are not capable to suppress the 
neighboring peaks interference on the 
41
Ca signal effectively. To overcome this limitation, the 
dose would have to be increased substantially, which would defeat the purpose of using 
41
Ca 
as a tracer. Although 
41
Ca is a radioisotope, when it is used in combination with AMS or 
RIMS for the analysis, only very small amounts of the tracer have to be administered (276). 
Thus, the health risk is negligible. For comparison, the effective radiation dose that comes 
from the dosing material is about 1/1000 of the dose received from a single chest X-ray scan. 
It is also comparable to the amount of natural radioactivity of 5 kilograms potatoes. 
Due to bone formation and resorption processes, 
41
Ca tracer will be incorporated into 
bone matrix. Tracer that is not incorporated will be gradually excreted in urine. After the 
majority of the tracer left in the body is incorporated in bone matrix, the 
41
Ca signal can be 
used to follow the effect of interventions on bone. Eventually, 
41
Ca will be resorbed from the 
bone matrix and subsequently transferred to plasma. Some of it will be excreted in urine, 
while the rest will be re-incorporated into bone matrix through bone accretion processes. 
These processes determine the changes in the plasma 
41
Ca, which can be monitored through 
the changes in 
41
Ca/Ca isotopic ratio in urine (see Figure A-5).  
To assess changes in bone calcium metabolism as a result of an intervention, the 
kinetics of urinary tracer excretion must be established. Compartmental modeling techniques 
to describe the observed urinary
 41
Ca excretion pattern are widely used for data evaluation. 
The effect of an intervention on bone metabolism can be recognized as changes to the transfer 
rates between different compartments. This can be done by fitting a compartmental model to 
experimental data by using nonlinear mixed effects regression analysis. Data analysis using 
compartmental modeling has been elaborated in Part A, Section 4.2.2.4. and non-
compartmental modeling will be discussed in Part A, Section 4.3.2. 
 





Figure A-5: Basic principle in monitoring changes in bone metabolism using 
41
Ca. Following 
a single isotope administration, the tracer urinary excretion pattern is monitored throughout 
the labeling period. Once tracer that is not incorporated into bone has been washed out from 
the body, all urinary 
41
Ca can be assumed to originate from bone and the labeling curve can 
be used as an index against which changes resulting from an intervention can be measured. 
Figure is taken from Denk et al., 2006 (271) with modifications. 
 
Previous studies have shown that bone calcium can be labeled using 
41
Ca, allowing 
changes in bone calcium metabolism to be assessed at much higher sensitivity compared to 
other established techniques. The first study using 
41
Ca as a long term tracer for monitoring 




Ca were given 
intravenously to mature dogs. Serum levels of the isotopes were measured by AMS. Twenty-
five weeks after dosing, a subgroup of the labeled dogs was given cadmium (Cd) in their 





reported to be resorbed from bones at similar rates. 
Following this study, Johnson et al. (269) conducted another study using 
41
Ca in 
humans. They labeled the skeleton of a premenopausal woman with an intravenous dose of 
41
Ca and monitored its urinary excretion for more than one year. A compartmental modeling 
approach was used to describe the urinary excretion pattern of 
41
Ca. The applied model was a 




sequential three compartmental model consisting of dosing compartment that was proposed to 
describe extracellular fluid, and two bone compartments (exchangeable bone and deep bone). 
The transfer rates between the different calcium pools and the pool sizes were calculated 
based on the urinary excretion data of 
41
Ca over 1000 days. Based on the results of the 
41
Ca 
study, it was found that the two bone compartments consist of about 1.1 kg calcium and the 
extracellular fluid compartment of 1.2 g calcium. This was in good agreement with the 
literature (279) indicating that 
41
Ca is a useful tool to describe calcium kinetics in human. 
During the monitoring period, the
 41
Ca excretion pattern is described very well with the 
proposed model even in a non-controlled study (269). Variations in the 
41
Ca signal around the 
fitted curve might be explained with menstrual cycle phases, changes in diet or exercise. 
In a subsequent study, a continuous feeding protocol was carried out in a 
postmenopausal woman (280). The study involved the administration of 
41
Ca, which was 
divided between three meals a day for two weeks, with spot urine and feces sample collection. 
At day 10 of the feeding period, a standard dual isotope kinetic study using stable isotopes 
was performed which included intravenous 
42
Ca and oral 
44
Ca administration, followed by 24-
hour urine sampling. The results from both protocols were compared and found to be in good 
agreement.  
The next study was conducted in 25 subjects, who received 
41
Ca orally and their 
urinary excretion was followed over 500-600 days (281). It was suggested that the 
41
Ca tracer 
excretion pattern could be best described with a combined power and exponential law, as 
proposed by Norris et al. (282). The mathematical excretion pattern of 
41
Ca was proposed as 
baseline from which perturbations (e.g. due to an intervention) might be measured. In the 
same study, one subject received two therapeutic agents for osteoporosis treatment after 
which 
41
Ca excretion was followed for 400 days. The effectiveness of an alendronate 
intervention in reducing urinary 
41
Ca excretion was compared to raloxifene. Results 
demonstrated that only alendronate and not raloxifene induced a drop in the 
41
Ca signal. In 
this study, bone resorption was also studied in parallel during intervention phase using urinary 
NTX, a conventional biomarker for bone resorption. It was shown that the results from 




biomarkers are much more variable than that of the 
41
Ca signal. Hence, 
41
Ca could be used to 
study individual’s response to therapy and provide an advantage over conventional 
biomarkers technique.  
In a more recent study, 
41
Ca was administered orally to a postmenopausal woman 
followed by collection of urine, blood and saliva samples at different time points over a 
period of two months after dosing (283). It was demonstrated that 
41
Ca could be successfully 
determined in urine, serum and saliva although ratios in the saliva were not similar to blood 
and urine. They also demonstrated that the 
41
Ca/Ca ratio is similar in urine and serum and 
there is similarity between isotopic concentrations in urine and serum. This finding avoids the 




Hillegonds et al. (270) developed a kinetic model of human calcium balance using 
41
Ca. It was predicted that this method was able to detect a 10% change in bone turnover rate 
in the subjects, which would allow close monitoring of patients with altered bone turnover 
associated with various diseases, including osteoporosis, cancer, kidney disorders, arthritis 
and many others. In a subsequent study, the serum 
41
Ca/Ca signal in labeled subjects was 
found to be significantly different between healthy individuals and patients with renal failure 
(284). 
Denk et al. (271) conducted a study using 
41
Ca in postmenopausal women. It was 
found that following isotope administration, it requires 150 to 250 days until tracer 
incorporation into bone matrix reaches the maximum amount. In this study, the urinary 
41
Ca 
excretion pattern was described by a three-compartmental model. Besides describing the 
urinary 
41
Ca excretion pattern, the model can also identify changes in transfer rates between 
the different compartments which allow the effect of an intervention to be evaluated. It was 
concluded that this technique could potentially assess the influence of diet and lifestyle on 
bone calcium metabolism, which is useful in the development of better strategies for 
osteoporosis prevention. They continued to explore the potential of this technique by 
assessing the effect of bisphosphonate interventions on bone health (285). The correlation 




between changes in the 
41
Ca signal during the intervention with changes of PINP as a 
biomarker of bone formation and serum CTX as a resorption marker was observed. This study 
showed that once the skeleton was labeled, 
41
Ca can be used to directly detect changes in 
bone calcium metabolism in response to controlled interventions. As this method is sensitive, 
short-term interventions might be sufficient, ensuring better compliance. 
A study on perimenopausal women was conducted by Hui et al. (275) using 
41
Ca 
tracer. They monitored long-term dynamic bone remodeling balance during the transition 
between premenopausal and menopausal stage, which is useful to achieve early prediction of 
fracture risk for osteoporosis prevention or treatment. Besides providing predictive bone state 
for osteoporosis prevention, dynamic tracking may also be useful for monitoring treatment 
outcomes. 
More recently Lee et al. (274) developed a four-compartmental model for 
41
Ca 
kinetics by fitting urinary 
41
Ca and total bone calcium data in post-menopausal women. The 
estimated bone resorption is in agreement with earlier studies using 
45
Ca. Hence, they 
concluded that if bone loss is constant, the model could be used to estimate bone resorption 
using urinary
 41
Ca signal. The model simulations also verified that changes in urinary 
41
Ca/Ca 
ratio could be used to estimate changes in bone metabolism as a proxy for bone balance. 
Also using a four-compartment model to study 
41
Ca kinetics, Sharma et al. (272) 
evaluated the impact of bisphosphonate intervention and the effect of metabolic bone disease 
such as osteoporosis and on bone remodeling. Moreover, the inclusion of cellular 
accommodation might allow this model to offer a more realistic prediction of disease 
progression. 
Kejun et al. (286) used 
41
Ca to quantitatively analyze and monitor the whole process 
of drug-induced osteoclast skeletal resorption in vitro. The behavior of osteoclast with the 
administration of strontium ranelate, an osteoporosis drug, was studied by using 
41
Ca labeled 
hydroxyapatite to simulate the bone. 
 
 




4.2.3.2. Non-compartmental Analysis 
Besides the compartmental evaluation technique, non-compartmental approaches 
have also been used for long-term kinetics. These include a combination of power and 
exponential function to describe tracer retention or excretion from body. Norris et al. (282) 
was the first to describe such a model, followed by Burkinshaw et al. (287). In general, non-
compartmental models involve an expanding pool, which is described by a power function 
and an exponential function describing bone accretion and resorption. The combination of 
these functions is shown by Eqn. 1. 




  (1) 
 
where A is a factor empirically fitted to the data. The power term (t
-b
) describes the decline of 
the pool specific tracer concentration because of the progressive dilution of tracer by 
increasing quantities of body calcium. The exponential term (e
-kt
) represents the decline of the 
pool specific tracer concentration due to a first order, non-exchanging loss of tracer from the 
pool. 
A range of different non-compartmental and compartmental models exist to describe 
calcium metabolism. Since all models are approximations, the model chosen is the one that 
best describes the data. An important measure of the goodness of the description of the data 
by a model is the coefficient of determination, R
2
, that is calculated from the sum of the 
squares of the distances of the points from the best-fit curve determined by non-linear 
regression. Several other mathematical tools are available to assess the goodness of a model 
used to describe data, which will not be discussed in detail in this overview. The non-
compartmental and compartmental models were originally established with short-term tracer 
studies, conducted over 5-20 days. Important features of bone metabolism such as bone 
remodeling were thus not fully covered as a remodeling cycle takes about 120 days. Even so, 
several more recent studies have shown that these models are also applicable for long-term 
studies. 
  




CHAPTER 5: STRONTIUM METABOLISM 
 
Strontium is a trace element found in ocean water and calcareous rocks (288, 289). It 
is inherently found in present-day diets (290). Since it is a bone-seeking element., 98% of 
strontium in the human body can be found in the skeleton (291). Strontium metabolism is 
closely related to that of calcium due to their chemical similarities. Both strontium and 
calcium ions have a valency of 2+, similar ionic radii, complexing and chelating abilities, 
resulting in products with various solubilities and binding strengths. Their relative binding 
affinities differ among anionic compounds. Generally, in most biological systems, preference 
is given to calcium over strontium. 
The formation of strontium radionuclides as byproducts of nuclear fission and atomic 
bomb detonation has discouraged the study of strontium as a calcium analog in clinical 
research. Earlier investigations on strontium have mainly focused on finding measures to 
reduce the body burden of radiostrontium caused by contamination of the environment and 
food supply. Hence, little has been done to study the metabolism of strontium as well as its 
functional role in the human body. However, animal studies have shown that in many 
physiological processes, such as in muscular contraction and blood clotting, strontium can be 
a substitute for calcium. These processes are triggered by calcium as well as by strontium, but 
to a lesser degree. Hence, strontium metabolism will be discussed here in comparison to 
calcium. 
 
5.1. Physiological Functions 
Calcium is the most abundant mineral element in the body. The majority (~99%) of 
calcium is found in the skeleton and teeth. The remaining calcium exists in soft tissues and 
body fluids, accounting for <1% of total calcium in the body. It is an essential nutrient, not 
only for bone and teeth mineralization, but also for regulating intracellular events in the body.  
Even though strontium is also mainly deposited in bone, the ratio of strontium to calcium 
amount in the skeleton is only 0.00045 (292). In hydroxyapatite, strontium can substitute 




calcium positions (293). It has been suggested that in addition to sharing some chemical and 
physical characteristics, they also exhibit similar contributions in a number of biological 
process (14). Although the response to stimulation seems to be weaker, strontium often 
mimics the actions of calcium (294, 295).  
Calcium provides skeletal rigidity by forming hydroxyapatite [Ca10(OH)2(PO4)6], 
which is deposited in collagen fibrils (296). In return, bone mineral serves as a reservoir for 
calcium (297). Hence, calcium may enter the extracellular fluid either from the intestine or 
bone. However, calcium is needed not only to maintain skeletal structures but also to control 
the cells’ and tissues’ behaviour in respond to environmental changes, including a diet, a 
stimulus or a pathogen (298). Non-skeletal functions of calcium can be categorized into 
structural, such as maintaining intracellular structures, preserving the integrity and 
permeability of biological membranes, defining a few structural features of chromosomes; 
and regulatory, such as regulating enzymes biochemically. Calcium is not only stored in the 
skeleton, but mobilisable calcium is also stored in specialized compartments (endoplasmic 
reticulum) within cells (299). Release of intracellular calcium into the cell cytosol triggers 
cellular events and responses. 
Depending on the cell type, the concentration of intracellular calcium may vary from 
0.02 to 15 mmol/L cell water (298). Most of cellular calcium (>99.9%) is bound within 
organelles and the nucleus. In a resting cell, the concentration of free calcium in the cytosol is 
about 10 000-fold compared to concentration in plasma, causing an electrochemical gradient 
across the cell membrane (299). Even a small increase in the cell membrane permeability or a 
small release of calcium from an internal store can cause a very significant change in 
cytosolic calcium concentration. This will ‘switch on’ metabolic pathways within the cells 
and may even damage it. This electrochemical gradient is maintained by a pump that is 
responsible for counterbalancing the small passive leakage of calcium into the cell.  
Calcium has the ability to trigger events within the cell, which are initiated by a 
primary stimulus, which may be physical (touch or an action potential) or chemical (hormone 
or neurotransmitter). An increase in cytosolic calcium is responsible for muscle contraction 




and vesicular secretion, several cell aggregation (e.g. blood clotting), cell transformation, cell 
division and activation of intermediary metabolism (299). To maintain those vital activities, 
plasma calcium concentrations must be tightly regulated. 
Calcium plays a crucial role in blood coagulation (clotting) (298). The process of clot 
formation involves a cascade of proteolytic reactions that require a series of inactive enzymes 
or clotting factors to be activated, which will subsequently activate another inactive factor. 
The response amplifies each time, which eventually results in the conversion of prothrombin 
to produce thrombin and the production of a fibrin clot. 
Calcium is also essential for the activity of several extracellular digestive enzymes, 
including proteases, phospholipases and nucleases (298). A calcium ion sensing receptor is 
expressed in the gastrointestinal tract, which is believed to play a role in gastric acid 
secretion. 
Calcium plays an essential role in triggering the release of neurotransmitter from 
nerve cells and in muscle contraction (298). For neurological function, calcium selective ion 
channels in the cell membranes open when the membranes are depolarised, leading to an 
influx of calcium and eventually a rise in cytosolic calcium concentration. This results in the 
release of neurotransmitters (e.g. acetylcholine) in nerves. 
For muscular function, calcium regulates the interaction of thick (mainly myosin) 
and thin (mainly actin) filaments in muscle fibers and it plays a vital role in skeletal, heart and 
smooth muscle contraction (298). When the muscle fibre is at rest, a regulatory protein 
complex (troponin and tropomyosin) inhibits the formation of cross-bridge by blocking the 
access to actin cross-bridge binding sites. Calcium ions released from the sarcoplasmic 
reticulum can bind to calcium binding sites on the troponin-binding molecule, resulting in 
conformational change, which eventually allows cross-bridges to form. Such binding results 
in muscular contraction. As calcium is pumped back into the sarcoplasmic reticulum, 
cytosolic calcium concentrations decrease and muscle relaxation occurs following the 
detachment of cross-bridges. As the thin filaments of smooth muscle do not contain troponin, 
the binding of calcium to calmodulin, which has a similar to structure to troponin, happens as 




the intracellular calcium ion concentration increases. This complex results in the 
phosphorylation of myosin, causing myosin cross-bridges to form with actin, which results in 
the muscle contraction. Conversely, dephosphorylation results in muscle relaxation. 
Under normal circumstances, strontium level in the body is much lower than calcium. 
Therefore, it does not interfere in any biological process that involves calcium. However, 
when there is excess of strontium, it may interfere in these processes. Because strontium is 
similar to calcium, it can replace calcium imperfectly in the skeleton as well as other cellular 
compartments. Although many calcium-dependent enzymes, secondary cell messenger 
systems and transporter systems will still function in the presence of strontium in place of 
calcium, changes in the kinetic parameters may take place. Thus, neurotoxic and 
neuromuscular disturbance may be observed as a result of high strontium uptake (300). 
 
5.2. Skeletal Deposition and Release 
In normal individuals, the total body calcium increases from about 20 gram at birth 
(301) to about 1200 g once they reach maturity (127). All the calcium accumulated in the 
process is obtained from dietary sources and deposited in the skeleton in the form of 
hydroxyapatite. Strontium can be incorporated into bone via two mechanisms: surface 
exchange or ionic substitution. However, even when large doses of strontium is administered 
to experimental animals over a long period of time, the total bone strontium is still much 
lower compared to calcium. Theoretically, only one out of ten calcium atoms can be 
substituted by strontium (302). There are three important mechanisms determining the uptake 
and release of bone seeking elements: 1) apposition, resulting in an increase in mineral 
volume; 2) resorption, contributing to the modeling and remodeling of the skeleton together 
with apposition; and 3) surface and diffuse exchange, that occur at all bone surfaces in contact 
with blood and allow bone-seeking elements to enter the entire bone volume. 
On the first day of SrCl2 administration through drinking water, MacDonald et al. 
noticed a rapid drop in the calcium to strontium ratio in rat and mouse femur, which was 
followed by a much slower decrease during the following 6 to 8 weeks (303). It was 




suggested that strontium is incorporated into the skeleton by two mechanisms: 1) an initial 
rapid mode which relies on osteoblastic activity and ionic exchange at the crystal surface in 
new bone; and 2) a second slower mechanism that involves the incorporation of strontium 
into the crystal lattice in old bone (304). It has been demonstrated that incorporation of 
strontium into the bone of strontium-treated monkeys occurred mainly by ionic exchange at 
crystal surfaces, and to a smaller extent by heteroionic substitution into the crystal lattice 
(302). Strontium was dose-dependently taken up by the bone mineral. It was distributed 
heterogeneously in cortical and trabecular bone and in new and old cortical bone, with 
approximately three- to four-fold more strontium in new than in old compact bone, and 2.5-
fold more strontium in new than in old trabecular bone. Strontium incorporation did not 
significantly alter the crystal lattice parameters and the cohesion properties of the mineral 
crystals, which displayed the properties of a “young” bone. 
As reviewed by Comar and Wasserman, calcium was more effectively transported 
than strontium across a biological membrane (305). A few soft tissues from the rat also 
revealed higher uptake of 
45
Ca than of 
85
Sr in vitro, but the discrimination was much less 




Ca ratios were 
reported in rat bone (308). Some discrepancies between results regarding strontium vs. 
calcium discrimination could be due to: 1) differences in strontium and calcium transport 
from blood into bones; 2) differences in the composition of bone interstitial fluid and the 
experimental solution used in vitro; and 3) stronger binding of plasma protein to calcium than 
strontium. In the kidneys and intestine, the preference of biological membranes towards 
calcium has been demonstrated clearly (305), but it is less clear for the transport from blood 
into bone. 
Five different factors affecting the strontium incorporation into the skeleton have 
been identified from animal studies: dose, plasma strontium level, gender, duration of 
treatment and skeletal site. Dose-dependent increase in bone strontium have been verified 
(309). The bone strontium content increased proportionally to the administered dose after four 
and eight weeks of strontium ranelate treatment (35–140 mg Sr2+/kg per day). However, the 




strontium content in bone reached a plateau level at higher dose levels (310). The most likely 
explanation for the non-proportional correlation between strontium dose and bone strontium 
level appears to be the saturation of the gastrointestinal absorption mechanisms (308).  
Intestinal absorption discriminates calcium and strontium, by favoring calcium (311). 
It has been shown in humans that strontium gastrointestinal absorption takes place partially 
via an active transport mechanism that involves a calcium-binding protein (308). Although a 
nonlinear relationship has been shown between the plasma strontium levels and the 
administered dose, there was a linear correlation between plasma concentration and strontium 
incorporation into the bone after oral strontium treatment (34 to 255 mg/kg/day of strontium) 
for 26 weeks (312-314). 
No gender discrimination in strontium concentrations in bone or plasma was shown 
in rats (315). However, after oral strontium ranelate administration, female rats acquired less 
bone strontium than the male rats. However, this difference was less evident in monkeys (313, 
316). Apparently, the higher strontium concentrations found in male rats are caused by higher 
strontium gastrointestinal absorption. So far, no evidence of such gender discrimination has 
been found in humans. 
Incorporation of strontium into bones is also dependent on the length of treatment 
(309, 310). Although from 10 to 25 days of strontium ranelate treatment the strontium content 
in rat femur doubled (310), the increase was less significant from days 28–56. In rat, bone 
strontium content might have approached a plateau level after four weeks of treatment. On the 
other hand, the plasma strontium levels were almost constant after 10 and 29 days of 
treatment (310), which indicates that plasma level had plateaued after 10 days. 
Strontium incorporation into bone also depends upon the skeletal site. The diaphysis 
of the femur always contained less strontium than the lumbar vertebra, which contained less 
strontium than the iliac crest in animal experiments (312-314). Bone mineralization is mainly 
determined by the bone turnover rate (317). The distribution of strontium depends on the 
relative proportions of cortical and trabecular bone in the skeleton. Since bone turnover is 
higher in trabecular than in cortical bone, newly formed bone is more abundant in trabecular 




than in cortical bone (302). In strontium-treated monkeys, the bone strontium content was 
lower in the lumbar vertebra than in the iliac crest (312-314), which can be explained by the 




In many organs, common transport paths for calcium and strontium have been 
described. They compete for intestinal absorption, renal tubular reabsorption, etc. Under 
normal physiological circumstances, discrimination occurs between calcium and strontium for 
the following functions: gastrointestinal absorption, renal excretion, placental transfer, and 
mammary secretion (318). Calcium is transported more easily than strontium whenever there 
is an active transport across those biological membranes (14). 
In the body, the gastrointestinal tract is the main route of entry of strontium. 
Papworth et al. proposed two routes of entry for strontium: carrier- and diffusion-mediated 
(319). The way strontium and calcium are absorbed from the ingesta can partly explain the 
preferential intestinal absorption of calcium over strontium. Two factors in the transcellular 
path of absorption that are involved in calcium transport, the high-affinity calcium-binding 
protein and the plasma membrane ATP-dependent calcium-pump, are parts of the 
discriminatory process (320). Binding of calcium to each of these proteins is considerably 
greater than that of strontium (321, 322). In addition to that, calcium is also transferred across 
the intestinal membrane by a paracellular, diffusional-type process that also appears to give 
preference to calcium over strontium (320). However, some studies showed that strontium is 
absorbed entirely via passive diffusion or paracellular transport (323, 324). In general, 
strontium is not as well absorbed as calcium, the strontium/calcium absorption ratio being 
roughly 0.50 (325). The preferential absorption of calcium might partially be attributed to the 
relatively smaller size of the calcium atom.  
Strontium absorption is greatly dependant on the food matrix. Since the focus of 
earlier research works on strontium was reduction of consumption of radioactive strontium, 




food items are categorized based on the fractional intestinal absorption of the ingested activity 
(f1 value). Hollriegl et al. conducted a study to assess if the f1 value corresponds with the 
actual strontium absorption from food items by using dual-isotope technique (326). They 
found f1 values that ranged between 0.29-0.59 in various food and drink items. This finding 
was independent of age and gender. Strontium intestinal absorption increases under fasting 
conditions and is reduced by the presence of high dietary calcium and phosphate, or chelating 
agents (327, 328). Strontium intestinal absorption also gradually increases during pregnancy 
and lactation. At the end of the lactation period, it reaches a maximal fractional absorption 
(329). The strontium gastrointestinal absorption depends largely on age. It varies between 
10% (in the elderly) to 90% of the dietary intake (in infants) (330). However, within the same 
age group, inter-individual variations have also been observed, which are attributed to the 
actual functional state of the gastrointestinal tract (331). In addition to the gastrointestinal 
pathway, strontium can also be absorbed via the lung and skin (330). 
 
5.3.1. Dietary Factors Enhancing Absorption 
A study in a rat model found a decrease in the quantity of calcium and strontium in 
the feces and an increase in the urinary excretion of these minerals in vitamin D-treated 
animals (332). In this study, it was estimated that in the rachitic rats dosed with calcium and 
strontium orally about 40% of the calcium and 45% of strontium passed through the 
gastrointestinal tract unabsorbed, while in the vitamin D-treated animals only about 15% of 
the calcium and 30% of the strontium passed through unabsorbed. The bones of the vitamin 
D-treated animals also retained a larger proportion of the metal ions than those of the 
untreated rats. If the only action of vitamin D was to promote absorption of calcium from the 
digestive tract, the rachitic animals should retain as much of the injected calcium and 
strontium in the bone as do the vitamin D-treated rats. However, this was not the case; the 
injected animals in a state of healing accumulated nearly twice as much calcium and 
strontium in the bone. In the vitamin D-deficient animals more of the injected calcium and 
strontium were excreted in the urine. This finding has shown that vitamin D has a direct 




action on the mineralization of bone in rachitic animals, besides promoting healing indirectly 
by increasing the absorption of these minerals from the digestive tract. 
Lactose has been reported to improve calcium and strontium absorption in the 
intestine (333-338). However, a few studies have shown little statistically significant 
differences in the absorption and utilization of calcium from lactose-containing dairy products 
and from calcium supplements (339-342). Differences in the physiological state of animals or 
human subjects, including the level of calcium intake, age or maturity, the level of intestinal 
lactase, might have led to controversies (343-346). Although much attention had been given 
to the interrelationship between lactose and calcium metabolism, the mechanism is still not 
confirmed. A popular explanation is based upon the fermentation of the poorly absorbed 
lactose by intestinal bacteria and the subsequent favorable effect of a lowered pH on calcium 
absorption (347). However, many of the sugars that were attacked with difficulty by intestinal 
bacteria also increased calcium retention (347-349). Another theory is that the increased 
glucose and galactose resulting from the hydrolysis of lactose may improve dissolution of 
calcium and eventually enhanced its absorption in the intestine (350). Due to similarities 
between strontium and calcium, the effects of lactose are expected to be similar on these two 
compounds.  
Dietary protein has been shown to increase calcium absorption in the intestine (351). 
One possible mechanism is by improving the secretion of gastric acid, which is needed to 
liberate calcium from the food matrix and allow its absorption (352). Besides that, some 
protein digestion products, like casein, have been shown to directly enhance calcium 
absorption (353, 354). However, the findings on the effect of dietary protein on calcium 
absorption are still contradicting. A study on healthy young women showed reduced intestinal 
calcium absorption in the low-protein-diet group and normal intestinal calcium absorption in 
the high-protein-diet group (355). This was in agreement with earlier studies (356-358). In 
contrast, some studies found no differences in calcium absorption between high- or low-
protein-diet groups (359, 360). These contradictions might be caused by differences in the 
level of dietary calcium intake (361). 





5.3.2. Dietary Factors Inhibiting Absorption 
The results from the studies of the effects of dietary calcium on the absorption of 
ingested radioactive strontium show that calcium significantly affects strontium metabolism 
(362, 363).  Higher dietary level of calcium causes a reduction in strontium absorption 
(Thompson and Palmer, 1960). However, Wasserman et al. pointed out that the increased 
dietary calcium levels caused a decrease in the total radiostrontium retention because calcium 
effective diluted strontium (363). 
Gruden et al. suggested that phosphate acts at two sites in the body; the 
gastrointestinal tract – reducing absorption, and in the kidney – diminishing the strontium and 
calcium excretion in urine (364). They also suggested that it is very likely that the complexing 
of calcium and strontium by phosphates is responsible for this action of phosphates. High 
phosphate diets or phosphate infusions cause a rise in the concentration of inorganic 
phosphates in serum (365, 366) and a fall in plasma total and ultrafiltrable calcium (365, 367). 
This is followed by a simultaneous fall in urinary calcium elimination (365, 367, 368). 
Results from an earlier study show a difference in the phosphate action on calcium and 
strontium metabolism (369). Vojvodic showed that phosphates selectively affect strontium 
absorption, due to the formation of strontium phosphate which is less soluble than those of 
calcium (370). Hence, phosphate seems to discriminate calcium and strontium in favour of 
strontium in the absorption process. 
 
5.4. Excretion 
Strontium is mainly excreted in urine and, to a smaller extent, in feces and sweat. 
Typically, the total clearance in adult varies between 9.4 and 11.7 mL/minute, while the renal 
clearance varies between 4.0 and 5.4 mL/minute (308). Data from a “reference” man have 
described strontium balance as follows: dietary intake (1.9 mg/day), urinary loss (0.34 
mg/day), loss in faeces (1.5 mg/day), loss in sweat (0.02 mg/day) and loss in hair (0.0002 
mg/day) (300). In subjects receiving an intravenous injection of SrCl2, the urinary to faecal 




excretion ratio was observed to be three (331, 371-374). Thus, urine seems to be the major 
excretion route of absorbed strontium. Although strontium and calcium share a common 
tubular transport path in the renal tubules (375), the renal clearance of strontium is around 
three times that of calcium. This is perhaps due to smaller tubular reabsorption, as a result of 
larger size of the strontium atom than that of calcium (376). 
Faecal excretion of strontium indicates the presence of a mechanism to transfer 
absorbed strontium into the gastrointestinal tract, either from the bile or directly from the 
plasma. Singer et al. compared the biliary excretion of calcium and strontium and their 
excretion into different parts of the gastrointestinal tract in a dog model (377). Calcium and 
strontium were excreted into all parts of the tract and roughly 20% more strontium was found 
than calcium. Approximately 75% of excreted strontium and 50% of excreted calcium was 
found in the small intestine. While for the large intestine, the values were about 20% for 
strontium and 40 % for calcium. About 6-9% of the calcium and strontium excreted into the 
tract was assumed to originate from the bile. 
An increase of dietary phosphorus reduced the urinary excretion of calcium and 
strontium. However, it seems to increase the faecal excretion of both elements. The kidney is 
believed to play an important part in the overall discrimination between calcium and 
strontium, and that the discrimination between calcium and strontium in the kidneys may be 
associated with the dietary phosphorus level (369). 
 
5.5. Homeostasis 
Calcium concentration in plasma is tightly regulated between 1.1 and 1.3 mmol/L 
(378). Calcium homeostasis is maintained at three sites: the kidneys, bone and gastrointestinal 
tract (296). Homeostasis is regulated directly or indirectly by PTH, which is one of three 
major calciotropic hormones that are involved in calcium homeostasis besides calcitonin and 
calcitriol (1,25-dihydroxyvitamin D3). Its production and secretion is regulated by plasma 
calcium concentration. A drop in calcium concentration results in PTH secretion to restore 
plasma calcium concentrations. On the other hand, a raise in plasma calcium concentration 




inhibits PTH secretion. Calcitonin is a hormone that acts to reduce plasma calcium, opposing 
the effects of PTH. Calcitriol is an active form of vitamin D. It controls the levels of PTH and 
calcium in the body to prevent low plasma calcium. Hence, high level of vitamin D in the diet 
or supplements might lead to increase plasma calcium. 
Low plasma calcium concentrations will increase neuromuscular excitability (298). If 
it becomes too low, hypocalcaemic tetany may occur. This will cause paraesthesia (itchy, 
tingly skin), laryngeal spasms, respiratory arrest and cardiac arrhythmia, which can be fatal. 
On the other hand, excessive amounts of calcium in plasma will result in hypercalcaemia, 
which can be characterized by anorexia, nausea, vomiting, muscle weakness, itchiness, 
extreme thirst and liquid excretion (298). If not treated, kidney failure may also occur. Since 
the focus of this thesis is on calcium and strontium supplementation and not on deficiency, 
only hypercalcemia will be discussed in this section in more detail,  
Aortic valve calcification (AVC) formation and progression may be affected by several 
factors, including endothelial disease, inflammation, and atherosclerosis (40). In addition, 
calcific valvular and vascular diseases have been suggested to share similar characteristics to 
bone remodelling (379). Hence, it became a concern if supplemental calcium intended to 
improve bone density may result in enhanced aortic valve and vascular calcification. 
The pathophysiology of AVC can be separated into two phases (380). The initial phase 
is characterized by inflammation, deposition of oxidized lipoprotein, and co-localization with 
deposition of calcium (381). It is similar to the early aortic valve lesion pathology and it is 
also a characteristic of atherosclerosis. The advanced phase is characterized primarily by 
calcium ossification (382), which happens at a rate that is dependent on calcification load 
(383). Calcium accumulates faster as the calcium load goes higher (380). Thus, any 
intervention that influences aortic calcium load may have significant clinical implications. 
Vascular calcification may be initiated at two different sites: atherosclerosis at intimal 
location and vascular ossification at medial location (see Figure A-6). Atherosclerosis is 
characterized by a series of events, which include endothelial dysfunction, intimal edema, 
foam cell formation and migration of leukocytes and macrophages culminating in the rupture 




of a plaque followed by thrombus formation (384). Atherosclerotic lesions are normally 
formed in curved arteries and areas closed to ‘junctions’, such as in the opening of carotid 
arteries, lumbar aorta and coronary arteries, in which the blood flow may be hemodynamics. 
Arterial calcification can take place without (medial calcification) or within (neo-intimal 
calcification) atherosclerotic lesions. Medial calcification is most common in the femoral 
arteries (385).  
 
Figure A-6: Clinical effects of arterial calcification. Figure is taken from Nitta, 2011 (386). 
  
Generally, biomineralization only occurs when type I collagen and alkaline 
phosphatase are present in the same tissues. Co-expression of these two proteins is adequate 
to cause ectopic calcification (387). In calcific atherosclerosis, type I collagen and alkaline 
phosphatase co-localize with mineral deposits (388), and are produced by vascular cells in 
vitro (389, 390) whereas in normal artery wall, only type I collagen, but not alkaline 
phosphatase, is present. Crystallization may initiate within extracellular membrane vesicles, 
such as matrix vesicles or apoptotic bodies, which provide a micro environment rich in 
calcium and phosphate and transfer membrane-bound alkaline phosphatase (391). Usually, 
such crystalline matrix vesicles are adjacent to apoptotic cells within atherosclerotic plaques 
(392) and are able to concentrate calcium and phosphate and start new crystal formation 
(393). Nevertheless, medial calcification is often related to elastin, a major component of the 
vascular wall, instead of type I collagen (394). Elastin is present in atherosclerotic plaques 




(395, 396). Elastin fibers or their degradation products may promote early crystal initiation 
(395, 396). Thus, although still related with chondro-osseous conversion of vascular cells and 
the expression of regulatory proteins like osteopontin (397), vascular elastin calcification 
might involve distinctive regulatory pathways not present in bone. 
There are two different hypotheses regarding arterial calcification process (398). The 
presence of osteoblast- and osteoclast-like cells as well as the secretion of several bone-
related proteins in lesions affected by arterial calcification support the hypothesis that arterial 
calcification is an active process (385). Both calcification of complex atherosclerotic plaques 
and medial arterial calcification include many complex bone-synthetic pathways (which are 
similar to skeletal osteogenesis) in the vessel wall, which involves a range of genes and 
proteins that involve in mineral metabolism. Various bone-related proteins, including 
osteonectin, osteopontin, PTH, PTH-related peptide, osteoprotegerin, and bone morphogenic 
protein, are present in atherosclerotic plaques and in sites of medial arterial calcification 
(399). The passive hypothesis is based on the concept that when the threshold for 
physiological calcium phosphate solubility is exceeded, they will physiochemically 
precipitate in areas of advanced tissue degeneration or necrosis within the vascular wall (400). 
In normal condition, mesenchymal stem cells differentiate to adipocytes, osteoblasts, 
chondrocytes, and vascular smooth muscle cells (VSMC). A few conditions, including 
hyperphosphatemia, uremia and hyperglycemia can initiate the transformation of VSMC to a 
chondrocyte or osteoblast-like cells. These osteo/chondrocytic-like VSMC can be calcified 
and collagen and non-collagenous proteins can be laid down in the blood vessels. This 
process is enhanced in a setting of high calcium and phosphorus, and abnormal bone 
remodeling, increasing the risk of vascular calcification. Eventually, calcium and phosphorus 
will be incorporated into matrix vesicles, which will initiate mineralization. This site can be 
further mineralized into hydroxyapatite. However, the presence of the inhibitors present in the 
circulation (fetuin-A) and in the arteries (such as pyrophosphate, matrix Gla protein and 
osteopontin) will decide whether artery calcification occurs or not in the end (17). 




As observed in some studies, an increased risk for cardiovascular events was only 
correlated with the use of calcium supplements, but not consumption of dietary calcium (37-
39). This could be due to the sharp increase in serum calcium which has been detected after 
consumption of calcium supplements but not after consumption of calcium-rich foods (401). 
Some studies have shown a positive correlation between serum calcium levels and vascular 
calcification (402, 403). High serum calcium levels might cause this pathological change by 
affecting calcification modulators such as pyrophosphate and binding to the calcium-sensing 
receptors on VSMC (404). Other studies have reported positive correlations between serum 
calcium levels and some predictive biomarkers of cardiovascular disease, including fasting 
insulin and lipid measures (405, 406) and with myocardial infarction risk (407-409). A close 
relationship was also observed between PTH, a key regulator of calcium metabolism, and 
cardiovascular risk (410, 411). 
Conversely to calcium, strontium is not under homeostatic control, meaning its total 
amount in the body and its level in biological fluids is not maintained by a feedback 
mechanism (14). Nevertheless, this does not eliminate the possibility that strontium levels can 
be influenced by calcium and hormones. In mammals, extracellular fluids have only 
micromolar concentrations of strontium but they have millimolar concentrations of calcium. 
Hence, strontium is unable to compete with calcium, and there is little need for strontium 
specific mechanisms (300). Strontium also appears to be less biologically active than calcium, 
and its toxicity is not pronounced. It is possible that intracellular strontium is more strictly 
regulated than extracellular strontium, but little is known about this. 




CHAPTER 6: STRONTIUM AND BONE HEALTH 
 
6.1. Diagnostic Applications 
6.1.1. Use of Strontium as a Surrogate Marker or Tracer for Calcium 
As there is no long-living gamma-emitting radioisotope of calcium, a substitute is 
required for long-term studies. Because of the chemical similarity of calcium and strontium, 
radioactive strontium has been used earlier as a tracer in calcium metabolic studies. However, 
with the advancement in the area of mass spectrometry, stable strontium isotopes have been 
used in place of radioactive strontium. In general, earlier studies have observed preferential 
absorption of calcium by the intestine as well as re-absorption of calcium by the kidneys. 
However, the preferential absorption and re-absorption are regulated and can be defined by 
certain factors (325, 375, 412, 413). In the skeleton, the discrimination between calcium and 
strontium was negligible and non-measurable (304, 414, 415). Nevertheless, it has to be noted 
that this was derived from short-term studies, which might overlook the discrimination 
between the two elements in the long-term. 




Ca on male subjects and 
developed a three-compartmental model (416). This study has demonstrated that the 
differences in the parameters for both strontium and calcium were small and strontium-
derived values did reflect calcium metabolism quite well during the study period. A series of 
older studies (417-419) and another more recent short-term study using stable isotope (420) 
have confirmed this finding. However, the long-term data required to assess the slow-
exchange rate from bone as well as the difference in the turnover and resorption of strontium 
and calcium were not available. 




Ca administered intravenously to cancer patients 
found that the isotopes were almost equally distributed between bone and soft tissue for the 
first few days after the tracer administration. After four months, the majority of the isotopes 
(99.5%) which were retained by the body were found in bone (421). The net retention of the 
isotopes appears to level off at about 60% for 
45
Ca, and 25% for 
85
Sr, with a steady increase in 








Sr ratio in bone. In a more recent study, Rokita et al. showed that strontium 
passively followed the route of calcium in bone minerals (422). They concluded that 
strontium may be applied as an adequate tracer for studying the mechanism of calcium uptake 
by the skeleton. At selected parts of the skeleton, the in vivo measurements of strontium 
content may be used to determine the rate of the formation of bone minerals. 
A study by Reeve et al. suggested that if there is any differences in the in vivo uptake 
and release by the skeleton of strontium and calcium, they are small and indistinguishable 
without more advanced techniques for their measurement (414, 423). Reeve and Hesp have 
suggested that both calcium and strontium tracers are released from the skeleton by resorption 
and diminution (414). It seems unlikely that osteoclasts discriminate for or against bone 
which they are resorbing because it contains strontium. In addition to that, an in vivo study by 
Marshall et al. suggested that diminution of the two tracers were similar (415). Lastly, if the 
two tracers are resorbed at the same rate, and their rates of accretion are also the same within 
measurable limits, their rate of removal by other processes such as solid state diffusion should 
also be identical. It therefore appears that strontium is an adequate and suitable tracer for the 
study of long term skeleton kinetics provided appropriate measures are taken to allow for the 
differences in the handling of calcium and strontium by tissues other than bone. This has been 
confirmed by a later study by Reeve et al. (304). 
Walser and Robinson (375) examined Sr/Ca relationships in the kidneys and 
developed a mathematical model to establish a correlation between the clearance of these 
cations. In their approach, the rate of reabsorption of calcium and strontium from tubular fluid 
in the nephrons is assumed to be directly correlated to their concentration in that fluid. On the 
basis of that assumption, they came up with the equation (Sru/Srf) = (Cau/Caf)
0.7
, where Sru 
and Cau represent strontium and calcium excreted in urine, and Srf and Caf represent filtered 
strontium and calcium, respectively. The concentration of filterable cations in plasma and the 
glomerular filtration rate are needed for this model. Based on the equation, the reabsorption 
rate of strontium is 0.7 of that of calcium.  




Staub et al. have described a nonlinear compartmental model for strontium based on 
plasma strontium concentration data from postmenopausal women receiving oral doses of 
strontium ranelate twice-daily and after discontinuation of the treatment (424). The model 
was in a good agreement with experimental data at the initial stage, including calcium and 
strontium discrimination, but the experimental evidence was limited. Blumshon et al. also 
indicated that strontium is a useful surrogate for calcium in clinical assessment of the 
absorbability of calcium from dietary sources (412). The preferential absorption of calcium 
over strontium was reported to be around 1.9. Similarly, Milsom et al. determined that the 
strontium absorption test is useful to assess calcium absorption in patients and a preferential 
absorption of calcium over strontium was observed to be a factor of ~1.9 (325).  
Sips et al. has also designed a study to determine calcium intestinal absorption using 
stable strontium (
88





concurrently and assessed the correlation between the intestinal absorption of these two 
tracers. A good correlation between both elements was observed. They also conducted a 
preclinical screening on this technique by testing how vitamin D administration, a potent 
enhancer for calcium intestinal absorption, may affect the absorption of calcium and 
strontium. Based on the results, it was concluded that the ratio between true absorption of 
calcium to strontium remain constant (1.7:1) before and after the vitamin D treatment, which 
validate further the usefulness of this technique under various conditions. The discrimination 
factor, 1.7, was also in agreement to what has been found earlier by Milsom et al. (325) and 
Blumsohn et al. (412). The same technique has been utilized by Zittermann et al. to 
investigate the difference in the calcium intestinal absorption and urinary excretion between 
exercise-trained young men and sex- and age-matched men with sedentary lifestyle (426). 
 
6.1.2.  Use of Strontium to Study Bone Metabolism 
Although short-term studies have shown that strontium can be used as a surrogate 
marker for calcium, its use in the assessment of long-term bone metabolism is still limited to 
qualitative assessment rather than quantitative. Isotope analysis alone is not able to provide a 




true estimate of bone mineralization rate (427). However, it is sufficient for clinical 
applications (304). 
Using radioactive strontium, Bishop et al. found that the cumulative excretion of 
strontium could be categorized into three stages. In stage 1, a fraction containing 
approximately 70% of the administered dose was excreted within the first 20 to 30 days. 
During this stage, kidneys were the major excretion pathway, contributing to about 70% of 
the total excretion. In stage 2, a fraction containing about 15% of the dose was excreted with a 
half-life of approximately 50 days. The tracer was excreted almost equally in both urine and 
faeces. In the last stage, the excretion of the remaining tracer (approximately 15% of the dose) 
was negligible (371). They suggested that these three excretion processes were closely 
associated with the degree of binding between strontium and the calcified tissue. Hence, the 
high excretion rate at the beginning might be caused by the relatively high mobility of 
loosely-bound strontium newly placed in the bone. By monitoring the concentration of the 
radioactive strontium in plasma and urine for the first two days after tracer administration, it 
was observed that about 65% of the administered dose was deposited in the skeleton during 
the first 10 to 12 hours. However, the rate of removal was also fast. At this point, the bone 
strontium might be freely exchangeable with the calcium of the extracellular fluid. Hence, a 
substantial amount of strontium was removed, mainly through the kidneys. The next stage 
represented a tighter binding between strontium and the apatite crystals. Although exchange 
between strontium and calcium still proceeded, it happened at a much lower rate. The last 
stage was attributed to a much tighter binding, most likely resulted from penetration of 
strontium into the crystal lattice, which signified a more ‘permanent’ retention when 
strontium could only be released through bone resorption.  
Strontium isotopes have been used to measure rates of bone deposition in man (417, 
418, 428-431).  Eisenberg and Gordan conducted a study using strontium gluconate on non-
patients and patients with various bone health conditions (419). The results of their study 
indicated that nonradioactive strontium can be used to detect alterations of skeletal 
metabolism in various defined physiological and pathological states. 




Palmer and Karagianes administered 
85
Sr intravenously to beagle dogs to study bone 
mineral replacement after immobilization (432). Radiotracer remaining in the bone was 
measured and the 
85
Sr uptake in the bone of the immobilized leg was shown to be up to 400% 
higher than in the control leg. They also suggested that changes of less than 1% in bone 
mineral could be detected and located by using this technique. They concluded that the 
sensitivity, simplicity and minimal radiation dose associated with this technique points 
towards potential application for use in human. 
McCarthy has performed experiments to examine if the short-term exchange of bone 
mineral could be influenced by perturbation of the energy metabolism of bone cells (433). 






Rb, were simultaneously injected into the 
nutrient artery of the tibia. Following which, a measurement of the tracers’ concentration in 
the venous outflow from the tibia was carried out for five minutes. Such experiment was 
carried before and after the administration of potassium cyanide into the bone. Based on the 




Rb with respect to 
125
I-albumin could be 
calculated. It was observed that net extraction after five minutes of 
85
Sr was significantly 
higher. This result has shown that the metabolic activity of bone cells could significantly 
affect the efflux of ions from exchangeable mineral. 
Shimmins and Smith did a long-term study of 
85
Sr retention in patients with 
osteoporosis and Paget’s disease for periods of up to 160 days (427). Together with the data 
obtained from autoradiography, this finding strongly suggested that the administered tracer 
was exchanging back from both diffusely-labeled fully mineralized bone as well as the 
incompletely-mineralized sites of active bone formation at comparable rates. They suggested 
that during active bone formation, no tracer was permanently deposited on one specific site. 
Additionally, because tracer was deposited in both the fully mineralized and mineralizing 
bone, the relative proportions of isotope in these different bone compartments could not be 
calculated. Hence, the bone mineralization rate could not be estimated by isotope tracer 
studies alone. Nonetheless, these estimates might be useful in clinical practice.  




In the 1970’s a technique for correction of long-term exchange processes in the 
kinetic estimation of whole body bone formation rates using strontium radioisotope was 
developed (423), but it was not adopted elsewhere until late the 1980’s. The researchers did a 
study to evaluate the difference between the whole body bone formation and resorption rates 
measured by kinetic methods and histological indices of bone formation and resorption based 
on in vivo tetracycline labeling of iliac trabecular bone (434). They found slight correlations 
between the results from these two measurements, which could not be explained by the 
methodological uncertainties alone (435). Their other works suggested that a more accurate 
determination of bone formation rates might be achieved through corrections for long-term 
exchange and non- or slow mineralizing osteoid surfaces by kinetic (436) and histological 
(437) methods, respectively.  
To obtain good correlations with histomorphometric data, more recently Eastell (438) 
used 
85
Sr as a surrogate marker for estimating whole body bone formation and to correct for 
long-term exchange processes (434). Since calcium does not have any gamma-emitting 
radioisotope with a half-life that is sufficiently long for this purpose, 
85
Sr seems to be 
adequate to study the long-term handling of calcium by the skeleton (304). The purpose of 
this study was to validate the use of 
85
Sr in osteoporosis studies. They observed a strong 
correlation between the bone-specific marker (Dpd) and long-term exchange parameter. The 
weakest correlation was found with hydroxyproline (a nonspecific marker of bone 
resorption). 
 
6.2. Therapeutic Applications 
In 1952, Shorr and Carter showed after administering a moderate dose of strontium 
lactate that the deposition of calcium in bone was greater than total calcium storage when 
calcium was given without strontium (15). This finding was the first one suggesting that 
strontium could be useful in osteoporosis treatment. In the later years, different types of 
strontium salts have been explored and strontium ranelate became the most heavily studied. It 
was finally approved to be used as an osteoporotic drug. It must be noted, however, the 




bioactive ingredient that plays a role in modifying bone properties is strontium, regardless of 
the form of the salts used in these studies, 
 
6.2.1. Strontium Ranelate 
Several studies have indicated that strontium ranelate has both anti-resorbing as well 
as bone-forming capability. In vitro, strontium ranelate inhibited bone resorption in mouse 
calvaria cultures (439), reduced osteoclast activity in isolated rat cells (440) and suppressed 
the bone-resorbing activity of mouse osteoclasts (439). The amount of osteoclasts in chicken 
bone-marrow cultures treated with calcitriol was also decreased by strontium ranelate (439). 
In short, inhibition of bone resorption in vitro by strontium might partially be a result of 
inhibition of osteoclast activity, but it is not completely stopped. Strontium ranelate also has 
positively affected bone formation in vitro. In an osteogenic model of differentiating mouse 
osteoblastic cells, strontium ranelate increased alkaline phosphatase activity, osteoblast 
differentiation marker and increased collagen synthesis (441). In rat calvaria cell and organ 
cultures, strontium ranelate enhanced the pre-osteoblastic cell replication leading to enhanced 
activity of functional cells and synthesis of bone matrix (442). These effects were not 
reproduced with calcium ranelate and were only specific for strontium ranelate. Several 
mechanisms of action have been suggested for the cellular actions of strontium that are not 
fully established (443). Strontium triggered the calcium-sensing receptor in some cells, 
causing the activation of inositol trisphosphate production and mitogen-activated protein 
kinase signaling (444, 445). In bone cells, other receptors sensitive to strontium might also be 
effective (446). Through activation of the extracellular signal-regulated kinase pathway in 
osteoblasts, strontium also induced cyclooxygenase-2 expression and prostaglandin E2 
production (447). This might be a part of the bone-forming effect of strontium ranelate. 
The anti-resorbing and bone-forming effects of strontium ranelate have also been 
observed in vivo. Strontium improved bone mass in the lumbar vertebra and femur in adult 
rats by increasing trabecular thickness and number and decreasing trabecular separation in the 
metaphysis (448). These indicated that strontium ranelate enhanced bone strength, as shown 




by the mechanical properties of lumbar vertebrae, midshaft humerus and femur, by improving 
bone microarchitecture (448). Plasma alkaline phosphatase activity was also higher in 
strontium-treated rats, pointing to the bone-forming activity of strontium ranelate (448). In 
normal adult mice, strontium ranelate also improved vertebral bone formation, reduced bone 
resorption and subsequently increased bone mass (449). Similarly, in normal adult monkeys, 
strontium ranelate was found to reduce bone resorption and to increase mineralizing surfaces 
(450). The available findings support strontium ranelate’s anti-resorbing and bone-forming 
effects in vivo result in improved bone mass and strength. 
Based on the findings from in vivo studies, strontium ranelate was expected to be 
effective in preventing bone loss in osteoporosis animal models. In ovariectomized rats, 
strontium ranelate prevented trabecular bone loss by decreasing bone resorption, while 
maintaining bone formation (451). In a model of immobilization-induced bone loss, strontium 
ranelate prevented the increase in bone resorption and trabecular bone loss (452). Strontium 
ranelate also increased bone-specific alkaline phosphatase levels in plasma and decreased 
urinary hydroxyproline excretion, pointing to the fact that it has opposite effects on bone 
resorption and bone formation in vivo (452). These findings led to the possible anti-
osteoporotic effects of strontium ranelate in humans.  
The efficacy of strontium ranelate in postmenopausal women with osteoporosis has 
been assessed in several clinical trials. In a double-blind randomized controlled trial, 
osteoporotic women received either strontium ranelate (500 mg, 1 g or 2 g) or placebo 
together with calcium (500 mg) and vitamin D. An annual increase of 7.3% in lumbar 
vertebrae BMD was observed in women treated with 2 g of strontium ranelate (453). 
Although, overestimation of BMD was expected as a result of increased attenuation of X-ray 
by strontium (454), new vertebral fracture prevalence in the second year was reduced by 44% 
in patients treated with 2 g of strontium ranelate compared with the placebo group (453). This 
showed the anti-osteoporotic effects of strontium ranelate. The efficacy of strontium ranelate 
was subsequently assessed in the Spinal Osteoporosis Therapeutic Intervention (SOTI) trial 
and the Treatment of Peripheral Osteoporosis Study (TROPOS). In the SOTI trial, strontium 




ranelate treatment significantly decreased new vertebral and clinical vertebral fracture 
incidences by 40–50% after one and three years (184). Reduced back pain and height loss 
were also observed. Bone alkaline phosphatase levels (bone formation marker) increased by 
8.1%, while telopeptide crosslink levels (bone resorption marker) decreased by 12.2% in 
strontium-treated patients compared with the placebo group, showing the opposite and 
concomitant changes in bone turnover markers. After strontium ranelate treatment for three 
years, no delayed mineralization was observed, which emphasized the safety of strontium 
ranelate on bone mineralization in osteoporotic subjects (184). In the TROPOS trial, the risk 
of non-vertebral fractures was reduced by 16% in the strontium-treated patients throughout 
the three year study (455). The relative risk for major fragility fractures was also reduced by 
19%. In a subgroup of patients with high hip fracture risk, strontium ranelate reduced the risk 
by 36% over a period of three years (455). In general, strontium ranelate was well tolerated. 
The most common adverse effects, such as nausea and diarrhea, disappeared within the first 
three months (184, 455). These trials concluded that strontium ranelate has substantial clinical 
benefits for treating postmenopausal osteoporosis. It is now available in European countries 
as well as some Asian countries, including Singapore, for osteoporosis treatment. 
 
6.2.2. Other Types of Strontium  
6.2.2.1. Citrate 
Strontium ranelate is not indicated for use in Canada or the United States. However, 
other strontium sources, available in pharmacies as nutritional supplements, are promoted to 
improve bone health (456). Daily doses are recommended such that the elemental strontium 
intake is similar to strontium ranelate. Due to the scarcity of data comparing the 
bioavailability of strontium ranelate to other salts, the uptake level of these alternative salts 
remains unknown. Strontium citrate is widely available as an alternative strontium source. 
However, levels of bone strontium achieved after consumption of this salt are not known and 
no direct comparison with strontium ranelate has been conducted in humans. An animal study 
to compare bone strontium levels in rats receiving equivalent strontium amounts in the form 




of strontium citrate and strontium ranelate has been conducted (456). It was found that both 
salts were equally effective to deliver strontium to the bone. These data suggest similar 
pharmacokinetics between strontium ranelate and strontium citrate in the rats. 
 
6.2.2.2. Chloride 
Comparison between strontium ranelate and strontium chloride has been carried out 
in three-month-old ovariectomized rats (457). The study showed that strontium uptake in 
bone of the strontium chloride-treated animals was generally lower than that of strontium 
ranelate. In a rat study, strontium chloride has been shown to decrease the number of active 
osteoclasts while increasing osteoid formation slightly (458). Strontium chloride has also 
been shown not to produce deleterious effects on growth and mineral homeostasis. Strontium 
chloride has been shown to increase bone formation, without causing apparent change in bone 
resorption, and eventually bring about a 10% increase in trabecular bone volume.  
A study by Fisch evaluated the digestive tolerance of strontium ranelate and 
strontium chloride on cynomolgus monkeys (459). Endoscopic examination of the 
oesophagus, the stomach and the first part of the duodenum was done after fasting. Strontium 
ranelate did not induce any toxic effect on the oesophagus, the gastric mucosa and the first 
part of the duodenum. In contrast, acute and superficial damages were observed on all 
animals receiving strontium chloride, including haemorrhagic and erosive lesions. It was 
concluded that oral administration of strontium ranelate is safe for the gastric mucosa while 
strontium chloride induced superficial and reversible lesions. 
 
6.2.2.3. Gluconate 
Skoryna conducted clinical studies to determine strontium and calcium levels in 100 
subjects who were receiving a regular diet that supplied approximately 1 g of calcium to 2 mg 
of strontium a day (460). Strontium gluconate was administered for periods of at least 3 
months to 50 of these patients with various conditions that might be affected by stable 
strontium: metastatic bone carcinoma, cachexia, postmenopausal osteoporosis and hepatic 




cholestasis. No toxic reactions were observed in patients receiving supplemental strontium. 
On the contrary, subjective improvement was reported. Strontification around metastatic 




McCaslin and Janes conducted a long-term study in patients with postmenopausal 
osteoporosis (461). A significant clinical improvement was observed in 84% of the patients 
receiving strontium lactate treatment orally for periods ranging from 3 months to 3 years. A 
study by Warren and Spencer (1971) also provided data on strontium metabolism using 
strontium lactate. Daily oral doses of strontium lactate for periods ranging from 24 to 36 days 
resulted in a positive strontium balance in all subjects. Following a daily intravenous infusion 
of stable strontium (administered as strontium gluconate) for 6 days, patients kept on a low-
calcium diet excreted each day an average of 235 mg of strontium in the urine and 60.2 mg in 
the feces. This study showed that humans can take in considerable amounts of strontium 
without any toxic effects and that not all strontium is tightly bound to the bone crystal lattice, 
as indicated by the high rates of strontium excretion. Once strontium administration is 
stopped, it is replaced by calcium. 
 
6.3. Toxicity 
If calcium intake is low, high amounts of dietary strontium can induce bone changes 
similar to rachitic lesions in experimental animals (462-464). This seems to be caused by 
impaired intestinal absorption of calcium as well as reduced renal production of 1,25-
dihydroxy cholecalciferol. The effects of strontium on intestinal calcium absorption might be 
caused by the common absorption pathway shared by them, which favors calcium. It has been 
proven that calcium-binding protein binds strontium to a lesser degree than calcium (465), 
and that strontium inhibits the kidney 1-hydroxylase, impairing the production of 1,25-(OH)2 
vitamin D3 (466, 467). 




In a study carried out in a region in Turkey, a relationship between strontium 
concentrations in soil and rickets in childhood was observed (468). There was a high 
prevalence of childhood rickets in that region (32% compared with 4.4% nationally among 
children up to 5 years of age). In this region, the children’s diet is based largely on grains 
from strontium-rich soils, which were categorized based on their strontium concentration 
(Group 1 >350 mg/kg; Group 2 <350 mg/kg). The proportion of children with at least one 
rachitic sign and the severity of disease were higher in Group 1. 
Due to the chemical similarity of strontium to calcium, strontium uptake is inevitable. 
Due to the high calcium requirement during growth period, the absorption and retention of 
strontium are significantly higher in children. As a result, children experience a greater 
potential systemic dose from strontium exposures compared to adults  (300). Numerous 
laboratory animal studies have demonstrated abnormal skeletal development in young 
animals subjected to high levels of dietary strontium (469-472). 
Abnormal skeletal development caused by high exposure to strontium has not been 
established in adults. In contrast children as well as young animals show more effective 
strontium absorption from the intestine, which may explain partly why they are more 
sensitive to excessive strontium intake. Rat studies showed that strontium absorption was four 
to eight times higher in weanlings than in adults. It is assumed that the absorbed dose may be 
eight times higher in infants than in adults (473, 474). This age-dependent difference in 
absorption could be partly explained by the duodenal level of vitamin D–dependent calcium-
binding protein, which is much lower in mature rats than in young rats (475). 
Due to their immature skeleton with high bone remodeling rate and strontium’s 
potential to negatively affect bone development, children are particularly vulnerable to excess 
strontium. Besides, impairing intestinal absorption of calcium as well as renal production of 
1,25-dihydroxy cholecalciferol, strontium also binds to hydroxyapatite crystals and possibly 
interfere with the normal crystalline structure of bone in rats (469). In rats, excess strontium 
may also inhibit the normal maturation of chondrocytes in the epiphyseal plates of long bones 
(471). Excess strontium seemingly interferes with the mineralization of complexed acidic 




phospholipids, which is believed to assist in the formation of hydroxyapatite crystals in 
developing bone (476). Consequently, bone will contain an excess of complexed acidic 
phospholipid and it will have a significantly lower ash weight. This finding is in agreement 
with the reduced rate of matrix vesicle degradation found in rachitic cartilage of strontium-
treated rats (477). 
Nevertheless, strontium has been used to treat patients with osteoporosis or other 
skeletal disorders. Typically, the treatments involve administration of “low doses” of 
strontium, in the form of lactate, gluconate, carbonate or ranelate over several years (300). 
Until recently, no adverse effects were reported in studies on osteoporosis patients. However, 
based on an evaluation from clinical studies in postmenopausal women, EMA's CHMP has 
indicated that there is a higher risk of heart attack with strontium ranelate than with placebo. 
However, there is no observed increase in mortality risk. Thus, it was recommended to limit 
the use of strontium ranelate (Protelos®, Osseor®) only for treating patients with severe 
osteoporosis and high fracture risk (16) without any cardiovascular problems. Further 
assessment on this matter has been initiated. 
The finding of cardiovascular events with strontium ranelate treatment is not 
surprising considering the similarities between calcium and strontium. Like calcium, high 
strontium intakes may increase the risks of soft tissue mineralization by formation of poorly 
soluble salts. For therapeutic purpose, strontium ranelate is administered at a dose level (500 
mg/day of strontium) that is comparable to regular calcium supplementation (500-1,000 
mg/day of calcium) which has been suggested to increase the risks of soft tissues calcification 
(35, 38). In addition to that, strontium ranelate is usually taken together with up to 1,000 mg 
of calcium supplement and up to 800 IU of vitamin D (478). Therefore, taking into account 
the calcium intake from dietary sources, the overall strontium and calcium intake may 








6.4. Strontium as an Essential Element? 
Strontium is ubiquitous in nature. The relative abundance of strontium to calcium in 
the earth’s crust is estimated to be 8/1000 (w/w), with some regional variations (14). The 
strontium to calcium ratio in plants could vary between 1.4 and 5.7/1000 (w/w) in England, 
similar to that of soil (480).  
Strontium is not an essential element, but it may promote growth in some plants 
(481). A study showed that strontium levels in water, plaque, and enamel is inversely related 
to caries prevalence in humans (482). In rats, moderate doses of strontium also prevented 
caries (483). In experimental animals and osteoporotic patients, strontium has been given to 
improve bone properties and reduces fracture risk. A certain degree of strontium deficiency 
might be related to osteoporosis, but the data comparing bone strontium in osteoporotic and 
normal subjects are very limited. However, iliac crest biopsies of an osteoporotic rabbit model 
did not show a decrease in bone strontium levels (484). Nevertheless, among the trace metals 
present in human bone, strontium was the only one correlated with improved bone 
compression strength (485). 
Generally, the amount of strontium in regular diets is negligible compared to calcium. 
Based on literature, a regular diet may contain from 0.20 mg/day of strontium to 2.36 mg/day 
of strontium. In Asia, average daily strontium intakes have been assessed in Vietnam (1.3 
mg/day), Philippine (1.1 mg/day), China (2.9 mg/day), Japan (2.3 mg/day), India (1.5 
mg/day), Bangladesh (1.8 mg/day) and Pakistan (2.6 mg/day) (486, 487). In UK and Finland, 
average daily intakes of strontium were estimated to be 1.3 mg/day and 1.9 mg/day (486, 
488), which were comparable with that of Asia. In Germany and Switzerland, the intakes 
were estimated to be between 1.1 to 4.5 mg/day (489, 490). The intake might be boosted by 
the consumption of strontium-rich water. 
Major dietary sources of strontium include cereal (2440 µg/kg), vegetables (530 – 
940 µg/kg), meat and poultry (450 ug/kg), seafood (274 µg/kg), full cream milk (180 to 2800 
μg/L) and water (20 – 60 µg/L) (491, 492). Higher strontium contents in drinking water have 
been reported in several countries in Europe (10.6 – 12,200 µg/L) (493), Riyadh (25.4 – 406.4 




µg/L) (494) and Japan (1.96-4539 µg/L) (495). In Singapore, water is not a relevant strontium 
source due to intensive water processing and infrequent consumption of bottled mineral-rich 
water  
Overall, the strontium dietary intake is lower by two orders of magnitude than the 
therapeutic dose of strontium used in osteoporosis therapy (approximately 500 mg/day of 
strontium in the form of strontium ranelate). Hence, dietary strontium intake is likely to have 
a negligible effect on bone health. 
 
 




CHAPTER 7: METHODOLOGY AND STATISTICS 
 
7.1. Mass Spectrometry 
Calcium absorption and kinetic studies are evaluated based on the determination of 
isotope ratios, usually performed by mass spectrometry, which is based on the principle that 
the different isotopes of an element are physically separated and determined quantitatively 
(496). The element is ionized in the ion source. These ions are then separated by their mass to 
charge ratio either in a magnetic field (magnetic sector mass spectrometry) or by the 
application of radiofrequency and constant voltages applied to four parallel rods (quadrupole 
mass analyzer). Using magnetic sector field technology, ions are accelerated linearly into the 
sector field and deflected due to their mass to charge ratio, which allows simultaneous ion 
beam detection. There are two different types of sector field instruments: single- and double-
focusing mass spectrometers (see Figure A-7). In a single focusing mass spectrometer, an 
initially divergent ion beam with a given value of mass/charge ratio is brought to focus. 
Double focusing mass spectrometers with high resolving power is used for analyses which 
require high resolution measurements. Their principles are identical to those of single 
focusing machines, but they include an electric focusing sector field before separation by the 
magnetic field. In quadrupole mass analyzer, the quadrupole is switched back and forth to 
select ions with a distinct mass to charge ratio (peak hopping). Using this principle, ions are 
filtered and not separated, which does not allow for simultaneous ion intensity measurements. 
In general, quadrupole instruments have lower resolutions and precision compared to 
magnetic sector instruments and are less expensive (497).  
After separation, ions can be detected by different systems. For high ion currents, 
detection with a Faraday cup gives the highest precision. A simultaneously detection of 
separated ion beams in magnetic sector field instruments is possible by using a multi-collector 
array of Faraday cups. Secondary ion multipliers such as dynode multipliers or Daly detectors 
can provide higher sensitivity. Faraday cups and secondary electron multipliers can be used in 
parallel when extremely low isotope ratios have to be measured. 






Figure A-7: Double-focusing sector mass spectrometers with different set ups. (a) A forward 
geometry mass analyzer with electrostatic sector before the magnet and (b) a reverse 
geometry mass analyzer where the magnet precedes the electrostatic sector. Figures are taken 
from Ireland, 2013 (496). 
 
There are many different types of mass spectrometry. However, we will only focus on 
the techniques used in this thesis, namely TIMS, ICP-MS and AMS. 
 
7.1.1. Thermal Ionization Mass Spectrometry (TIMS) 
In TIMS, atomic or molecular ions are formed on the hot surface of a filament. 
Owing to its high precision, accuracy and sensitivity, TIMS has become a reference technique 
for isotope ratio measurements and has been used in geochemistry, nuclear chemistry, in the 
determination of atomic weights and in nutrition sciences to determine isotope ratios in 
enriched biological samples.  




Before the analysis, biological samples have to be purified and the element has to be 
separated from organic matrix. Small amounts (usually in ng to μg) of the isolated sample are 
placed on the evaporation filament consisting of a metal strip made from tantalum or rhenium. 
The ionization process is usually endothermic and thus ionization efficiency increases at 
higher filament temperatures. For most elements, the optimum range for filament temperature 
lies between 800-2000°C (498). During the ionization process, only singly charged ions are 
formed because of the high ionization temperature. Single-, double- or triple-filament 
technique can be used for the evaporation and ionization of samples. If the single-filament 
technique is employed, evaporation and ionization take place on the same filament. For 
elements, which evaporate at relatively low temperatures the double- or triple filament 
technique is preferred as it allows to create an adequate ion beam at higher temperatures, 
allowing the creation of a stable and adequate ion beam (499). At the moment, single- or 









Figure A-8: Commonly used filament assemblies in TIMS. (a) Single-filament, where 
evaporation and ionization take place on the same filament and (b) double-filament, where 
evaporation and ionization take place on two separate filaments. 
 
As electron transfer can occur between the analyte and the filament in both directions, 
both positive and negative ions can be generated. Although positively charged ions are the 
most common, negative ions can be obtained from high electron affinity atoms or molecules 
under thermo-ionization conditions (500, 501). After leaving the ion-source, ions are focused 
with several lenses systems, pass the aperture slit and enter the magnetic sector field, where 
(a) (b) 




they are separated by their mass to charge ratio. The selected ions are detected by Faraday-
cup or secondary electron multipliers (see Figure A-9). Using a single Faraday-cup, a series 
of different masses can be measured in sequence using the “peak jumping method”. The 
disadvantages of this method include being time consuming, having small sample throughput, 
and a reduced internal statistical precision (276). Multi-collector systems consisting of several 
Faraday-cups (up to 9) require wide beam dispersion, but it can improve the precision and 
shorten analysis time compared to single collectors. 
 
 
Figure A-9: Schematic diagram of a TIMS instrument with enhanced abundance sensitivity. 
Ions are form in the ion-source and then focused with several lenses systems, pass the 
aperture slit and enter the magnetic sector field, where they are separated by their mass to 
charge ratio. The selected ions are detected by Faraday cups or secondary electron multipliers. 
Figure is taken from Heumann et al., 1995 (502). 
 
For calcium analysis, a double filament technique is usually used. Usually 5-10 μg of 
a isolated and purified calcium sample is loaded on the evaporation filament as CaNO3 or 
CaCl2. Typical evaporation temperatures are 1200–1500°C. The exact conditions for analysis 
depend on various parameters, such as sample loading technique or filament material. The 
long-term external reproducibility of calcium isotope ratio analysis by TIMS was reported to 
fall between 0.12‰ and 0.4‰ (503). The average precision for 44Ca/40Ca ratio analysis in 
standard reference material (SRM) 915a was reported to be 0.09‰ (504). The precision of 
measurements involving less abundant isotopes, such as 
48
Ca, can be improved by avoiding 




the most abundant isotope, 
40





Ca ratios by multi-collector TIMS (505). 
 
7.1.2. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
Since ICP-MS became commercially available, it has been used in a large number of 
human studies (506). ICP-MS uses an ion source, which operates at high temperatures (3727-
7454˚C) and achieves extremely high ionization efficiency for almost all elements. Compared 
to other sample introduction techniques, liquid solution nebulization is the most frequently 
used and most economical. Typically samples in liquid form are introduced by pneumatic or 
ultrasonic nebulization into the high-energy argon plasma. For direct introduction of analytes 
in solids, laser ablation with a spatial resolution on the micrometer scale (~ 1 μm) can be 
used. It is ideal for micro-sampling on surfaces and in-depth profile analysis. It is very useful 
in some cases, such as in geology for the analysis of rock inclusions (507), in analysis of tree 
rings and biological tissue sections (508, 509) or for other microsurface area samplings in 
material and forensic sciences (510) as well as on valuable archaeological objects. There are 
other types of sample introduction methods (see Figure A-10) that will not be discussed in 
detail. The sample introduction system, such as laser ablation chamber, is coupled directly via 
a connection tube to the ICP torch. In the plasma, the samples are ionized (see Figure A-11). 
The ions are then accelerated into a high vacuum and focused by electrostatic lenses into the 
mass analyzer. For detection, ions have to be transferred from 5000-7000 K to room 
temperature and from atmospheric pressure at sample introduction to high vacuum.  





Figure A-10: Principles of sample introduction in ICP-MS. Liquid solution nebulization is 
the most economical and commonly used technique. However, sample digestion and 
dissolution is required. Laser ablation allows direct access to analytes in solid samples and on 
surfaces. It also provides high spatial resolution. Electrothermal vaporization enables in situ 
sample preparation as well as pre-concentration. Direct introduction of samples in gas form is 
only applicable for volatile compounds. Figure is taken from Ammann, 2007 (511). 
 
In quadrupole instruments (see Figure A-12), photons as well as ions are produced in 
the plasma and have to be removed before entering into the detector. Photons are removed 
with a photon-stop, which is a small metal plate in the center of the ion beam that reflects the 
photons. Positively charged ions are guided around this stop by positively charged cylinder 
lenses and can enter the quadrupole, where they are separated by their mass-to-charge-ratio. 
Due to isobaric interferences, especially when the analyte is present in a complex matrix, the 





Figure A-11: The inductively-coupled plasma source. The figure shows the electrical 
potentials, the vacuum cascade and the distribution of ions and neutral in an ICP-MS. In the 
plasma, the samples are ionized. The ions are then accelerated into a high vacuum and 
focused by electrostatic lenses into the mass analyzer. Figure is taken from Albarede and 
Beard, 2004 (512). 
 
achievable accuracy and precision for isotopic analysis using a quadrupole separation is 
limited. However, due to their relative low costs quadrupole instruments are most commonly 
used. Double-focusing mass analyzes can be used for high precision isotopic analysis as 
isobaric interferences can be efficiently reduced by this technique. 






Figure A-12: Experimental arrangement of quadrupole-based ICP-MS. Photons and ions are 
produced in the plasma. Photons are removed with a photon-stop. Positively charged ions are 
guided by positively charged cylinder lenses and enter the quadrupole, where they are 
separated by their mass-to-charge-ratio. Figure is taken from Becker, 2005 (513). 
 
Mass bias, which greatly influences the measurement accuracy, can be corrected by 
measuring a SRM. However, not all elements have such SRM. When laser ablation sample 
introduction is used, measuring an appropriate SRM that match the sample matrix becomes 
even more crucial. Other factors that may limit the measurement precision of laser ablation 
ICP-MS (LA-ICP-MS) include detector dead time, signal stability (plasma instabilities, 
fluctuation in the laser ablation process and inhomogeneous sample), instrumental 
background, sample contamination, mass drift, counting statistics, and isotopic interferences 
(514, 515). 
The development of multicollector (MC) – ICP-MS has offered new perspectives 
(516). In this technique, the ICP ion source is combined with a sector field mass spectrometer 
and an array of Faraday detectors. MC-ICP-MS allows simultaneous detection of isotopes 
and, hence, cancels out any signal variation due to plasma instabilities as well as 
heterogeneities in the sample. The detection of calcium isotopes by ICP-MS is difficult due to 




interference of an intense argon peak with 
40
Ca at mass-to-charge-ratio of 40. MC-ICP-MS 
instruments cost more than conventional ICP-MS and comparable to TIMS (506). For 
calcium analysis, a measurement repeatability of 0.07% RSD with MC-ICP-MS has been 
reported (517) whereas with the conventional quadrupole ICP-MS a precision of 0.25% RSD 
could be achieved (518). 
 
7.1.3. Accelerator Mass Spectrometry (AMS) 



















I. With the exception of 
3
H 
(half-life: 12.25 years), the half-lives of these radionuclides are in the range of 10
3–107 years 
and they are very rare in nature (519, 520). The main purpose of AMS was to overcome the 
basic limitations of decay-counting and conventional mass spectrometry. In principle, it 




Ca. This is accomplished by accelerating ions of these isotopes. After which, the rare 
isotope is counted individually, while the abundant isotope is measured as an electrical 
current in a Faraday cup (see Figure A-13). 




 is only possible with an 
efficient suppression of molecular and isobaric interferences. This is performed by 
acceleration of the negative secondary ions with a tandem accelerator after making a first 
mass analysis. Within the mass analysis, the main isotope is separated from the rare isotope. 
After that, the remaining negative ions are accelerated to the positive high-voltage terminal of 
the tandem accelerator where they encounter either a thin carbon foil or low-pressure gas. In 
the accelerator terminal, the ions are stripped of electrons and converted to positive ions, and 
further accelerated to ground potential. During this conversion, molecular ions, which would 
be a major source of interference, are destroyed. The higher energy which was gained by 
accelerating the ions is used to suppress isobaric interferences using detection systems, such 
as gas ionization chamber, gas-filled magnet, etc. Another advantage of the higher beam 




energy is that cross sections of scattering processes of residual gas atoms, which can cause a 
background in the detector, are smaller (521). 
The potential of AMS to become a routine research tool is limited due to the small 




Figure A-13: The essential features of an AMS system. Carbon isotopes are used for 
illustration. Ions of these isotopes are accelerated. The rare isotope is then counted 
individually, while the abundant isotope is measured as an electrical current in a Faraday cup. 
Figure is taken from Fifield, 1999 (521). 
 
7.1.4. Isotope Dilution Mass Spectrometry (IDMS) 
IDMS is a microanalytical quantitative technique that can be used to determine the 
concentration of a trace element with high accuracy and precision. This technique requires a 
known quantity of spike, an isotopically enriched solution of an element, to determine the 
unknown amount of the same element in the sample (249). After adding a known amount of 




spike into the sample and equilibrating the spike with the sample, the amount of the element 
of interest in the sample can be calculated using this IDMS equation (see Eqn. 2). 
 




1   Ri,sam
1   Ri,spike
  (2) 
 
In Eqn. (2), nsam is the unknown amount of the element in the sample to be 
determined and nspike is the amount of the spike added to the sample. To calculate the value of 
nsam, isotope ratio measurements of the pure sample, pure spike and a mixture of both, 
represented by Rsam, Rspike and Rmix respectively, are required. These ratios have a common 
reference isotope in the denominator and the enriched isotope is the numerator. ∑Ri,sam and 
∑Ri,spike are the sum of all isotope ratios of the sample and spike, respectively. 
In certain cases, for example to study formation, degradation and inter-conversion 
rates of elemental species, multiple spike technique can be used (522). The multiple spike 
contains a mixture of the species of interest, each one enriched with a different isotope. A 
known amount of spike can be added into the sample and equilibrated with the sample. After 
which, the isotope ratio variation with time can be measured.  
IDMS can provide high acccuracy and high analytical precision, which requires a 
mass spectrometer that is able to measure isotope ratios with high accuracy and precision. 
Once the sample and spike have been equilibrated, quantitative sample handling is not 
required. If there is sample loss during the preparation steps, a proportional amount of spike 
will be lost as well. Hence, the ratio of the element of interest in spike to sample remains 
unchanged. In addition to that, high sensitivity and low detection limits can also be achieved 
(276). 
 
7.2. Statistical Approaches 
7.2.1. One-Way Analysis of Variance (ANOVA) 
A One-Way ANOVA is a statistical technique to test the equality of means of three or 
more groups at one time by using variances (523). There are a few assumptions that have to 




be fulfilled, including: 1) normally or approximately normally distributed populations; 2) 
independent samples; and 3) equal variances of the populations. The null hypothesis is that all 
population means are equal, while the alternative hypothesis is that at least one mean is 
different.  
There are a few elements that need to be calculated. Firstly, the grand mean of a set of 
samples is calculated from the sum of all the data values divided by the total sample size (see 
Eqn. 3).  




However, when the individual data is not available, ANOVA can still be performed if 
the number of samples, the sample means, the sample variances, and the sample sizes are 
known. 
Secondly, the total variation, which is the sum of the squares of the differences of 
each mean with the grand mean, should be calculated (see Eqn. 4). The total variation 
comprises of between group variation (see Eqn. 5) and within group variation (see Eqn. 6).  
                   
  (4) 
                      
  (5) 
                (6) 
In principle, ANOVA compares the ratio of between group variation to within group 
variation. When between group variation is much larger than the variation within each group, 
it indicates that the means are not the same. If the sample means are close to each other, and 
hence the grand mean, between group variation will be small. There are k samples involved 
with one mean for each sample, thus there are k-1 degrees of freedom. The variance due to the 
interaction between the samples is denoted MS (B), Mean Square Between groups, or Sb
2
, 
which is the between group variation divided by its degrees of freedom. Within group 
variation is the variation caused by differences within individual samples. Each sample is 
independent; there is no interaction between samples. Each sample has degrees of freedom 
equal to one less than their sample sizes, and there are k samples. Thus, the total degrees of 




freedom is k less than the total sample size (df = N – k). The variance due to the differences 
within individual samples is denoted MS (W), Mean Square Within groups, or Sw
2
, which is 
the within group variation divided by its degrees of freedom. 
The F test statistic is estimated by dividing the between group variance by the within 
group variance (see Eqn. 7).  




  (7) 
The degrees of freedom for the numerator are the between group degrees of freedom 
(k-1) and the degrees of freedom for the denominator are the within group degrees of freedom 
(N-k). 
If the test statistic is greater than the F critical value with k-1 as the numerator and 
N-k denominator degrees of freedom, the null hypothesis will be rejected, meaning that at 
least one of the means is different (524). Nevertheless, ANOVA does not show where the 
difference lies. Another test, usually called posthoc test, such as the Scheffe' or Tukey test, is 
needed for this purpose. 
 
7.2.2. Mann-Whitney U-test and Kruskal-Wallis-H test 
The Mann-Whitney test is a non-parametric test, which is usually applied as an 
alternative to a Student's t-test if the data are not normally distributed (525). The null 
hypothesis is that two populations’ medians are the same, while the alternative hypothesis is 
that they are different.  
There are a few assumptions that have to be fulfilled (525), including: 1) the 
observations from the two groups are independent of each other; 2) the responses are ordinal; 
3) the distributions of both groups are equal under the null hypothesis; 4) under the alternative 
hypothesis, the probability of an observation from one population is above an observation 
from another population is not equal to 0.5. 
The test involves the calculation of a statistic (U) with a known distribution under the 
null hypothesis. The first step is to sum up the ranks for the observations which come from 




group 1. Where there are tied groups, the rank given is equal to the midpoint of the group. 
The sum of ranks in sample 2 can then be determined, since the sum of all the ranks add up to 
N(N + 1)/2 where N is the total number of observations. U is then calculated by using Eqn. 8 
or Eqn. 9. 
       
        
 
 (8) 
       
        
 
 (9) 
where n1 and n2 are the sample sizes for group 1 and 2, and R1 and R2 are the sums of the 
ranks in group 1 and 2. It does not matter which of the two groups is considered group 1. 
When consulting significance tables, the smallest value of U1 and U2 is chosen.  
For large samples, U is approximately normally distributed and the standardized 
value z can be calculated using Eqn. 10. 
   
    
  
 (10) 
where mU and σU are the mean and standard deviation of U, is approximately a standard 
normal deviate whose significance can be checked in tables of the normal distribution. mU and 
σU are estimated by Eqn. 11 and Eqn. 12, respectively. 
    
    
 
 (11) 
     
             
  
 (12) 
Compared to the Student's t-test, the Mann-Whitney test is more widely applicable. It 
is especially preferred when the data are ordinal, but the spacing between adjacent values is 
not constant. In addition to that, in the presence of outliers, the Mann–Whitney test is more 
robust as it compares the sums of ranks. 
The Kruskal–Wallis test is the non-parametric alternative to one-way ANOVA (526). 
The null hypothesis is that the medians of the population are equal, while the alternative is 
that there is a difference between at least two of them. In one-way ANOVA, the test statistic 
is calculated as the ratio of the treatment sum of squares to the residual sum of squares. The 




Kruskal–Wallis test uses the same approach but instead of the raw data, it uses the ranks of 
the data (526). The test statistic is given in Eqn. 13. 
   
  





            (13) 
where Rj is the total of the ranks for the j
th
 sample, nj is the sample size for the j
th
 sample, k is 
the number of samples, and N is the total sample size, given in Eqn. 14. 
    
 
    (14) 
This is approximately distributed as a χ2 distribution with (k – 1) degrees of freedom. 
If there are ties, the adjusted test statistic is calculated as given in Eqn. 15. 








       
 
 
    (15) 
where rij is the rank for the i
th
 observation in the j
th
 sample, nj is the number of observations in 
the j
th
 sample, and S
2
 is calculated by Eqn. 16. 
    
 
   
      
  
       
 
  
   
 
     (16) 
If the null hypothesis is rejected, a least significant difference can be calculated to 
identify which pairs of treatments differ. If the difference between their mean ranks is bigger 
than the least significant difference (if the inequality in Eqn. 17 is true), treatments i and j are 







        
     







  (17) 
where t is the value from the t distribution for a 5% significance level and N – k degrees of 
freedom. 
 
7.2.3. Monte-Carlo Simulation for Estimation of Measurement Uncertainty 
Monte Carlo uses random numbers as a mean to calculate something from variables 
that are not fully random but follow a  given probability density function. For instance, let X 
be a random variable and A be its expected value (A = E[X]) (527). By generating n 




independent random variables with the same statistical distribution, i.e. probability density 
function, X1, …, Xn, A can be approximated as described by Eqn. 18. 
        
 
 
   
 
    (18) 
The strong law of large numbers states that as n → ∞, Ân → A (528). The Xk and Ân 
are random and might be different each time the program is run. However, the target number, 
A, is not random. 
Besides leading to vast improvements in efficiency and accuracy by simulation of 
experimental processes, Monte Carlo can also be used to assess the order of magnitude of 
statistical errors, which is the main source of error in most Monte Carlo computations. 
Estimates correspond to “error bars”, which are essentially statistical confidence intervals 
(527).  
Assuming X is a scalar random variable and A = E[X] is approximated by Eqn. 19. 
     
 
 
   
 
    (19) 
The central limit theorem (528) states that (see Eqn. 20) 
              (20) 
where σn is the standard deviation of Ân and Z ∼ N(0, 1). A simple calculation shows that 
   
 
  
    where σ2 = var(X) = E[(X − A)2]. σ2 can be estimated using (see Eqn. 21) 
   
   
 
 
         
  
    (21) 
then take (see Eqn. 22) 
     
 
  
   
   (22) 
Monte carlo data is usually reported in the form          . The error bar is the 
interval [Ân -   n, Ân +   n] while multiplication of standard deviations with a factor k[Ân - k  n, 
Ân + k  n] allow to obtain confidence intervals of given statistical probability. The central 
limit theorem shows that use of an expansion factor of k=1 has a confidence of 66% and use 
of k=2  gives a confidence of 95% (528). 




Error propagation analysis to obtain combined measurement uncertainties by using 
the propagation of errors formula requires the computation of derivatives, which can be quite 
complicated for larger models. However, the Monte Carlo approach only requires a program 
for computing f(x,p), where x is an independent variable and p is a set of parameters that fit 
into the model. Previously, this could only be done with advanced computer  programming 
skills. At present, the Monte Carlo approach can even be done with a simple program, such as 
Microsoft Excel (529), that is able to generate random numbers. 
 
7.2.4. Outlier Testing by Regression Analysis 
Outliers are data points that do not follow the pattern of the other data points. They 
can be detected by dedicated algorithms including Dixon’s Q-test and Robust Regression 
Analysis (530), which will be explained in more detail as it was the method of choice for the 
presented work. Dixon’s Q-test can only examine if one (and only one) data point from a 
small set of data can be rejected as an outlier. In this test, a normal distribution of data is 
assumed. If the outlier is just an extreme point drawn from the tail of a normal distribution, 
least squares estimate for regression models, which are highly sensitive to and not robust 
against outliers, may be used. However, if the outlier was caused by non-normal measurement 
error or other violation of standard ordinary least squares assumptions, using non-robust 
regression technique would compromise the validity of the regression results. 
When plotting data that are correlated with each other, the slope bij of a line 
connecting data point (xi, yi) and data point (xj, yj) is given by Eqn. 23. 
      
      
      
 (23) 
Firstly, the median med of the slopes of the n-1 lines that go through data point (xi,yi) 
is estimated. And then the median of the slope medians is calculated for all n data points. 
Consequently, the regression slope breg is obtained as described in Eqn. 24. 
                         (24) 




In order to find the intercept of the regression line for all data pairs areg, for each data 
point yi the intercept ai is calculated (see Eqn. 25), followed by determination of areg (see Eqn. 
26). 
              (25) 
                 (26) 
The regression line for all data can then be calculated by using Eqn. 27. 
                         (27) 
which allows the determination the residual Res for each data point (xi, yi) as the difference 
between its measured value and its value based on the regression line (see Eqn. 28). 
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Osteoporosis is a skeletal disease characterized by low bone mass and micro-
architectural deterioration of bone, causing an increase in bone fragility and vulnerability to 
fracture (2). Apart from affecting quality of life of the individual, economic burdens arising 
from osteoporosis treatment and disability management are becoming significant. This makes 
osteoporosis prevention the preferred strategy for moderating societal impact of osteoporosis 
in the foreseeable future (3). 
A major hurdle in identifying effective strategies to improve or maintain bone health 
is the lack of techniques to assess bone response in human intervention trials at high 
sensitivity (531). Effects of diet and life-style are usually small but become relevant as they 
may accumulate over a life-time. Radiometric techniques for measuring bone mineral density 
(BMD) and content (BMC) are insensitive as they can only measure relative but not 
incremental changes over time, which are rather small as bone turnover is slow. Biomarkers, 
i.e. compounds in blood or urine that can be associated with bone accretion or resorption, are 
much more sensitive but subject to significant intra-individual variation (12, 13). 
Conventional approaches therefore require large subject numbers and/or long intervention 
intervals for reliable detection of changes in bone. 
 Isotopic labeling of bone is a conceptually different approach that is potentially more 
sensitive than existing techniques. After giving a tracer orally or intravenously, the tracer is 
gradually incorporated into bone while tracer not incorporated in bone is washed out from the 
body over time. Once complete, all tracer in urine has its origin in bone and changes in tracer 
excretion in urine should reflect bone balance (see Figure B-1). While this concept is simple 
in theory, it is difficult to put into practice. Conventional calcium radiotracers cannot be used 
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for bone labeling because of health concerns. Stable calcium isotopes are a safe alternative 
but doses and therefore costs would be prohibitively high (ca. 70,000 EUR per person) due to 
the large amounts of natural calcium in the skeleton. These shortcomings have led to the 
suggestion of 
41
Ca as the isotope of choice (277). It is a radioisotope but at a half-life of 
105,000 years it decays very slowly and emission of ionizing radiation per unit time is 
therefore also low. As such, it can be regarded as stable with respect to time scales of 
biomedical tracer studies and human life span. In addition, it is virtually non-existent in 
nature and can be detected with extreme sensitivity by accelerator mass spectrometry (AMS) 
(532, 533). This permits usage of 
41
Ca doses for skeleton labeling that are so small that 
resulting radiation burdens are lower by several orders of magnitudes than burdens arising 
from natural radiation exposure.  
Over the past two decades, technicalities of 
41
Ca labeling of the human skeleton have 
been explored systematically (269, 271, 275, 277, 280, 284, 534, 535). More recently, the 
41
Ca technique was validated against established techniques (BMD, biomarkers) (285) and 
used successfully in a series of clinical trials which demonstrated the sensitivity of  the 
technique (285, 536, 537). Nevertheless, the technique has so far not been used widely 
because of practical restrictions. Only a handful of laboratories worldwide have access to the 
necessary instrumental infrastructure for 
41
Ca analysis. Therefore we have explored strontium 
stable isotopes as alternatives. Strontium is known for a long time to mimic calcium closely at 
the level of absorption and discharge from the body, homeostatic control as well as 
distribution between hard and soft tissues (14). Strontium, however, is less abundant than 
calcium by a factor of approximately 1,000 in the biosphere. This permits the use of strontium 
stable isotopes at a much lower dose as compared to calcium isotopes. Furthermore, isotopic 
analysis of strontium is technically much less demanding and can be conducted using mass 
spectrometric techniques (ICP-MS, TIMS) that are now available at nearly every larger 
hospital or research university in the industrialized world. 
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Figure B-1: Basic principle behind the use of 
41
Ca for monitoring changes in bone 
metabolism. Following single administration of the isotope, the urinary excretion pattern of 
the tracer is followed during the labeling period. Once tracer not incorporated into bone has 
been washed out from the body, all urinary 
41
Ca can be assumed to originate from bone and 
the labeling curve can be used as a fixed index against which changes due to an intervention 
can be measured. Figure is reproduced from Denk et al. 2006 with permission (271).   
 
Concerns regarding uptake of 
90
Sr from nuclear accidents, which is highly radioactive 




Sr, led to many in vivo studies in the 
1950s and 1960s. Technically, these experiments were limited to short-term studies over a 
few days only (320, 538). Here, we compare for the first time ever urinary tracer kinetics and 
bone deposition of strontium and calcium in the long-term with the aim to assess (a) how far 
strontium can be used as a surrogate marker of calcium metabolism (b) if strontium stable 
isotopes can be used similarly to 
41
Ca for labeling the bone matrix for monitoring bone 
calcium balance and (c) if incorporation of strontium and calcium into bone is comparable 
across skeletal sites. Experiments were conducted in a young adult sheep as a model of 
human calcium metabolism as sheep bones are big enough to study spatial distribution of the 
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1.2. Materials and methods 
1.2.1. Test Animal  
The study was conducted in a two-year-old female domestic sheep (East Frisean Milk 
Sheep), which was kept in the experimental animal unit at the animal hospital (Tierspital) of 
the University of Zurich, Switzerland. The sheep originated from a flock raised in normal 
environment in a stable with sheep-run and pasture. The animal had access ad libitum to 
standard feed (hay and concentrate, licking stone) and drinking water. On day 1 of the study, 




Sr. Urine was collected the day 
preceding tracer administration and shortly before dose injection for measurement of calcium 
and strontium baseline isotope ratios. A total of 26 urine samples were obtained after tracer 
administration until the sheep was sacrificed on day 181 to obtain bone samples for analysis 
of tracer content. Intervals between urine samplings were shorter at the beginning and 
increased gradually towards the end to account for a faster urinary tracer clearance in the 
days/weeks following tracer administration. The sheep was kept indoors at a 12h day/night 
cycle for a period of approximately 70 days during winter and early spring before it was 
allowed to roam and graze freely outdoors. On day 28 the sheep received antibiotics for three 
days (Danofloxacin, Carprofen) as well as an intravenous Vitamin B bolus dose (B-Neuron®; 
33.3 mg Vit B1, 33.3 mg Vit B6, 333.3 µg Vit B12) following a minor leg injury. Body weight 
was monitored regularly over the course of the study. The study protocol was reviewed and 
approved by the responsible authority for review and approval of animal studies in Zurich 
(Kantonales Veterinäramt Zürich).       
 
1.2.2. Tracer Preparation and Administration 
The 
41
Ca tracer used in this study came from the same batch of tracer used in earlier 
human studies (e.g. (271, 536, 537) and has been characterized earlier for isotopic and 
elemental composition at the Institute for Reference Materials and Measurements (IRMM), 
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Geel, Belgium (539). The 
41
Ca tracer was administered as CaCl2 with a 
41
Ca isotopic 
abundance of 1.25±0.01 %. For administration, 2.85 kBq (22.6 nmol) 
41
Ca in 1 mL 
physiological saline solution containing 1.8 µmol carrier calcium were mixed with 465 µmol 
86
Sr tracer dissolved in 4 mL saline. Isotopically enriched strontium was obtained from 
Chemgas, Boulogne, France, as SrCO3 with a 
86
Sr isotopic abundance of 96.40±0.04 %. The 
strontium tracer was prepared by dissolution of the carbonate salt in 0.5 M HCl and 
subsequent dilution of the solution with saline. The prepared injection solution was sterile 
filtered before administration and tracer administration was well tolerated by the sheep. 
 
1.2.3. Urine Sampling and Sample Preparation 
Spontaneous void urine samples were collected at dawn before feeding in a cup 
(around 50 mL). Samples were acidified with 1 mL of 0.5 M HCl, shipped to Singapore and 
stored at 4°C in polyethylene bottles until analysis. All analytical work was carried out at the 
National University of Singapore apart from 
41
Ca analysis which was carried out at the 
Institute of Particle Physics at ETH Zurich, Switzerland.  
For calcium and strontium elemental analysis by Atomic Absorption 
Spectrophotometry (AAS), concentrated HNO3 was added to the collected urine until all 
precipitates formed during storage were dissolved (pH < 1). Organic sample matrix was 
removed by microwave-assisted wet digestion of the samples using an Ethos 1 digestion unit 
(Milestone Inc., Sorisole, Italy). Urine aliquots (4-70 mL) were weighed into pre-cleaned 
Teflon vessels, dried and mineralized using a mixture of 8 mL conc. HNO3 and 2 mL 30% 
H2O2 and diluted with water to the optimal concentration range for analysis. All chemicals 
used for sample preparation were of analytical grade unless otherwise noted and only purified 
water was used (Milli-Q-System, Millipore, MA, USA). Acids were cleaned further by sub-
boiling distillation in quartz stills (SAP-902 IR, AHF Analysentechnik, Tuebingen, 
Germany). Only acid washed plastic or teflon containers/labware was used for sample 
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preparation. Sample handling was restricted as far as possible to class 10 metal free fume-
hoods in a class 10,000 clean-room and monitored routinely for analytical blanks.   
For calcium isotopic analysis by accelerator mass spectrometry (AMS),
 
sample 
calcium was separated from 30 g aliquots of urine by oxalate precipitation following 
established procedures (271). In contrast to element analysis, isotopic analysis does not 
require quantitative element separation. In brief, urine samples were filtered using 2.0 µm 
pore size membrane filters (Millex-AP20, Merck Millipore, Darmstadt, Germany). Cooled 
saturated ammonium oxalate solution (40 mL) was added to the cooled urine samples and the 
pH of the filtered urine was adjusted to 10 by adding 25% NH4OH solution. Samples were 
kept for 1.5 h at 70 ˚C and then immersed into an ice bath for at least 2.5 h to precipitate 
calcium oxalate. The precipitate was then separated by centrifugation, washed twice with 
saturated ammonium oxalate solution and once with water. To remove sodium and potassium 
from the sample, the precipitate was dissolved in 200 µL 5 M HNO3 and passed through an 
ion exchange column (AG 50WX-8, Bio-Rad, Switzerland). After washing the column with 
0.08 M HNO3, calcium could be eluted with 5 M HNO3. After neutralization with NH4OH 
solution, the isolated calcium was then precipitated as CaF2 by addition of 40% HF. The 
precipitate was washed twice with water and dried at 100°C overnight and shipped to Zurich 
for AMS analysis. 
For strontium isotopic analysis by thermal ionization mass spectrometry (TIMS), 
strontium was isolated from the sample matrix using a strontium-specific ion exchange resin 
(strontium-specific, Eichrom, Lisle, USA) following standard procedures (540, 541). Before 
use, the resin was soaked in 0.1 M HNO3 (1 hour), rinsed with and dispersed in water and 
loaded into polyethylene columns (Bio-spin, 3 mL; Bio-Rad, California, USA). Columns 
were washed with water and conditioned with 2 mL 8 M HNO3. The sample was loaded onto 
the column in 8 M HNO3. The column was then washed with 10 mL of 8 M HNO3 to remove 
interfering elements including calcium. Strontium was then eluted with 7 mL water. The 
collected eluate was evaporated to dryness and stored in Eppendorf vials for later analysis. 
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1.2.4. Bone Sampling and Sample Preparation 
After 6 months (day 181 post dose), the sheep was sacrificed using a captive bolt 
pistol for numbing and killed by bleeding thereafter. Relevant bones were obtained for 
analysis (tibia, radius, metatarsus, metacarpus and vertebrae). Bones were manually cleaned 
of cartilage and soft tissues, washed with saline and freeze dried. Bones were sliced and 
multiple samples were obtained from each type of bone both from cortical and trabecular 
areas to assess spatial differences in tracers deposition between different type and parts of 
bone. Slicing was done with a diamond band saw (Exakt 310 Macro Band System, Oklahoma, 
USA). Slices were cut into smaller pieces with a manual saw which were then sampled using 
a pair of stainless steel pliers (sample size: ca. 2x2x2 mm, weight: ca. 0.5 mg). 
Bone samples were mineralized by microwave-assisted acid digestion (Ethos 1, 
Milestone) and prepared for elemental analysis by AAS as described before. Calcium and 
strontium were separated and purified using strontium-specific resin for isotopic analysis,. 
Digested samples were loaded in 8 M HNO3 on the columns, calcium was eluted with 8 M 
HNO3 and the eluate was dried down. Isolated calcium was converted to CaF2 for AMS 
analysis as described earlier. Strontium was eluted from the column with water for TIMS 
analysis.  
 
1.2.5. Calcium and Strontium Elemental Analysis by AAS 
Samples were analyzed for calcium and strontium concentration by AAS (AA240 FS, 
Varian Pty. Ltd., Victoria, Australia), using standard addition techniques to control for 
possible matrix effects. Commercial calcium and strontium standards (Titrisol
®
, Merck, 
Darmstadt, Germany) were used for element spiking. Calcium was analyzed using a nitrous 
oxide-acetylene flame with KCl (Scharlau, Barcelona, Spain) as an ionization suppressant at a 
spiked potassium concentration of 2,000 μg/g in the sample solutions. All analyses were 
performed in triplicate with absorbances being measured in integration mode and corrected 
 Part B - Chapter 1: Isotopic labeling of bone for assessment of changes 








for analytical blanks. Analytical accuracy was assessed by processing of a certified reference 
material (SRM1567a, wheat flour; National Institute of Standards and Technology, NIST, 
Gaithersburg, USA). 
Strontium concentrations were measured by graphite furnace AAS (AA240 Zeeman, 
Varian Pty. Ltd., Victoria, Australia). All analyses were performed in triplicate with 
absorbances being measured in height mode and corrected for analytical blanks. Analytical 
accuracy was assessed by analysis of a gravimetrically prepared laboratory standard because 
of a lack of commercially available reference materials certified for strontium concentration.  
 
1.2.6. 41Ca Isotopic Analysis by AMS 




Ca ratio by AMS at the Laboratory of Ion Beam 
Physics, ETH Zurich as described earlier (533). The sample material (CaF2) was mixed with 
silver powder in a ratio of 1:9 (w/w) for improving sample conductivity and ionization 
efficiency. Calcium was extracted from the sample as CaF3
-
 ions (extraction current ≤ 100 




Ca were normalized 












 (539). Limit of 
41






Ca as determined by analysis of blank samples. Analytical blanks from sample 
preparation and/or carry over effects were monitored by identical processing and analysis of 
unlabeled urinary samples collected before tracer administration. Average repeatability (2 




Ca isotope ratio measurements of the same sample were < 5% for 




 and < 10% for isotope ratios higher than 1·10
−9
. A 




Ca isotope ratios 
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1.2.7. 86Sr Isotopic Analysis by TIMS 
Isolated strontium was reconstituted in 2 µL 8 M HNO3 for TIMS analysis. The 
instrument (Triton, Thermo Finnigan, Bremen, Germany) was equipped with an array of 9 
moveable Faraday Cups for simultaneous ion detection and operated in positive ionization 
mode at 10 kV acceleration voltage and 10
11
 Ω resistance. Sample strontium was ionized as 
Sr
+
 ions using a rhenium single filament ion source (filament dimensions: 20 x 0.03 x 0.76 
mm, zone refined rhenium, 99.999% purity; H. Cross, Moonachie, NJ, USA) and tantalum 
pentoxide (Ta2O5) as an ionization enhancer (543). The Ta2O5 activator was prepared by 
adding 2 g of TaCl5  (99.999% purity, Sigma-Aldrich, MO, USA) to a mixture of 1.2 mL of 
conc. HF (48% Ultrapur, Merck, Darmstadt, Germany), 1.2 mL of conc. H3PO4  (85% 
EMSURE® ACS, Merck, Darmstadt, Germany), 20 mL of conc. HNO3 (70%) and 80 mL of 
water (544).  About 2 µL of the Ta2O5-activator suspension was first loaded onto the filament 
and dried down electro-thermally at a current of 0.5 A. Sample strontium was added to the 
loaded activator with a micro-pipette and heated to dryness at a current of 0.5 A. The current 
was then increased to 1.6 A and held there for one minute or until the sample turned brown. 
The heating current was increased finally to dull red glow for about 20 seconds before loading 
into the mass spectrometer. 
For sample ionization, the filament current was increased to 2.0 A at a rate of 0.2 




 had fallen below an intensity of 0.001 V for 








 signal. After automated focusing of the 
ion beam and peak centering, the heating current was increased automatically to 2.5 A at a 
rate of 0.1 A/min and further at a rate of 0.05 A/min to ca. 2.8 A (~1,400 - 1,490°C). Data 




 signal intensity reached 8 V. Data were collected 
during ten blocks comprising of 10 scans each at 16.777 s integration time and 4 s idle time 
per scan. Baseline signal intensities were recorded before each block for 60 s by automated 
defocusing of the ion beam and amplifiers were rotated to control for differences in gain 
between individual amplifiers. Measured strontium isotope ratios of natural standards were 
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Sr isotope ratio of 0.1194 as its 
current consensus value (545, 546). An iterative algorithm was used for normalization of 




Sr isotope of SRM 987 (SrCO3; NIST, 
Gaithersburg, MD) was 0.056460±0.000002 (1SD) for 25 independent sample loadings which 
falls well within its certified range (0.05655±0.00014). 
 
1.2.8. Data Analysis 
Similarities and differences between calcium and strontium metabolism were 
identified via studies of their tracer to tracee ratio, i.e. the number of moles of tracer relative 
to the number of moles of tracee in the sample. As strontium was tested as a surrogate marker 





Ca isotope ratios were converted into 
41
Ca/Ca amount ratios by 
multiplication with 0.96941 as the natural abundance of 
40







Ca in the sample could be assumed to be tracer calcium. This 
is different for 
86





Sr isotope ratios were therefore converted first into amount ratios of 
86
Sr 
tracer to natural strontium in the sample (mole per mole) following isotope dilution principles 
(249). Amount ratios of 
86
Sr tracer to natural calcium (
86
Sr/Ca) were then calculated using the 
calcium to strontium mole ratio in the sample as determined by AAS. The amount ratio of 




Ca) was obtained by dividing the 
86
Sr/Ca amount ratio 
in the sample by its corresponding 
41
Ca/Ca amount ratio. Uncertainties in the 
86





Ca amount ratios were estimated using Monte Carlo techniques (529). Testing of 
data for statistical outliers was done by using Robust Outlier Testing. 
 
1.3. Results 
The sheep tolerated the treatment well and the sheep remained apparently healthy 
over the course of the study apart from the leg injury and did not require any intervention or 
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special treatment. The sheep started to gain weight after the first study month for about six 
weeks and lost some weight again the following six weeks (see Figure B-2). Changes were 
within the normal response range to changes in feed, climate and physical activity.  
 
Figure B-2: Weight chart of the sheep during the study period. Each individual point refers to 
one measurement. 
 
1.3.1. Urinary Tracer Excretion 
The tracee to be traced was calcium for both calcium and strontium tracers. 
Normalization of tracer excretion to natural calcium has the advantage of obtaining a more 
stable tracer signal in urine as it controls for variations in daily calcium excretion and allows 
working with spot urine samples as opposed to 24 hour collections. Denk et al. (2006) 
showed in humans that although urinary calcium excretion of calcium and 
41
Ca excretion 




Ca isotope ratio 
significantly (271). 
As expected, the 
41
Ca signal in urine dropped by three orders of magnitude within the 
first month after tracer administration and fourfold within the following five months (see 
Figure B-3). The pattern of tracer excretion, however, deviated from similar labeling 
experiments in animals and man with a slight increase followed by a decrease of the urinary 
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month. It is well established that excretion of bone seeking tracers can be approximated in 




, where S(t) 
is the tracer signal at time point t post dose and A, B, C and D are parameters describing 
individual differences in tracer excretion (282, 548). Accordingly, deviations from these 
regularities become clearer when urinary 
41
Ca tracer data are plotted against time on a double 




Figure B-3: Changes in urinary 
41
Ca tracer excretion relative to natural calcium against time. 
Each individual point represents a spot urine sample from one particular day. Data are plotted 
on a semi-logarithmic scale. Over the observational period, the 
41
Ca/Ca signal dropped by 
nearly 3 orders of magnitude. Measurement uncertainties are smaller than the symbol size. 
Uncertainties for these and all data presented in the following figures are estimated combined 
measurement uncertainties (95% coverage interval). 
 
excretion in humans from an earlier study (271) is shown in Figure B-4b. A clear deviation 
from a regular excretion pattern could be observed after the first month post dose in the 
studied sheep with an apparent normalization in 
41
Ca tracer excretion about three months 
later, although at a different trajectory. The phase during which the 
41
Ca tracer signal deviated 
from its expected excretion pattern coincides remarkably well with the time point at which the 
sheep has received the antibiotics and B vitamins following a leg injury (day 28) and the 
phase during which the sheep lost and subsequently gained weight which compares well to 
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Figure B-4: Changes in urinary excretion of the 
41
Ca tracer relative to natural calcium against 
time on a double logarithmic scale in the studied sheep (a) and postmenopausal women (b) 
from an earlier human study (data from Denk et al. 2006). Urinary excretion of the 
86
Sr tracer 
relative to natural calcium against time in the studied sheep is shown in Figure B-4c. A clear 
deviation from regular tracer excretion patterns as shown for the human subject was found for 
the studied sheep. Irregularities were stronger for the 
86
Sr tracer than the 
41
Ca tracer. 
Measurement uncertainties are smaller than symbol size. 
 
In agreement with our hypothesis, the 
86
Sr signal followed the 
41
Ca signal in urine 
(see Figure B-5a). Tracer signals were highly correlated (R
2
=0.96) when tracer/tracee ratios 
were plotted against each other on a double logarithmic scale (Figure B-5b). The slope of the 
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tracer dropped nearly exponentially from 12,200,000 shortly after tracer administration to 




Ca tracer ratio showed a deviation 
towards higher values during the same interval when tracer/tracee ratios in urine showed a 
deviating pattern. Remarkably, deviations from the expected regular excretion pattern were 
even stronger for the urinary 
86
Sr/Ca ratio as compared to the 
41
Ca/Ca ratio when data were 
analyzed using a double logarithmic plot (see Figure B-4c). 
  
Figure B-5: Changes in urinary excretion of the 
86
Sr tracer relative to natural calcium against 
time (a) on a semi-logarithmic scale and (b) against the corresponding 
41
Ca/Ca ratio on a 
double logarithmic scale. Each individual point refers to spot urine sample from one 
particular day. Excretion of both tracers was highly correlated during the entire study 
(R
2
=0.96). Measurement uncertainties are smaller than symbol size. 
 
1.3.2. Skeletal Tracer Depositions 
Six month after injection of the 
41
Ca tracer, the tracer was not found to be evenly 
distributed among bone sites. The 
41
Ca/Ca amount ratio between bone samples varied 
approximately by an order of magnitude with no indications for a higher tracer deposition in 
trabecular bone as compared to cortical bone (see Figure B-7). Differences in 
41
Ca/Ca amount 
ratios in bone across the skeleton, however, can be higher at the microscopic level. Bone 
samples subjected to isotopic analysis were relatively large (about 10 mm
3
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measured ratios only represent the mean ratio in the analyzed bone volume. As for urine, the 
86
Sr tracer followed the 
41




Ca amount ratio which 
was found to be identical for most analyzed samples within the measurement uncertainty 
(Figure B-8). For 
41
Ca/Ca amount ratios, analytical uncertainties in tracer/tracee ratios were 







Ca amount ratios, however, were significantly larger (ca. 10% RSD). 
Uncertainties for these ratios are relatively large as measurement uncertainties in strontium 
and calcium isotope ratios as well as the measured calcium and strontium concentrations in 
the sample must be taken into account. Testing of data for statistical outliers revealed that 




Ca amount ratios that were significantly 
lower as compared to other sampling sites (6.84±0.98 x 10
3
).   
 
Figure B-6: Progressive changes in the amount ratio of both tracers in urine over time on a 
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Figure B-7: Amount ratio of 
41
Ca to natural calcium ratio for different bone sites. Each point 
represents the analysis of a bone volume of ca. 10 mm
3
. Bone sites are listed on the left side 
while the type of bone is given on the right side (C: cortical bone, T: trabecular bone; C-T: 
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Sr tracer to 
41
Ca tracer amount ratio for different bone sites and bone types (see 
Figure B-7 for legend). Samples that were found to be statistically different were by Robust 
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Ca technique is based on isotopic labeling of the skeleton using a single dose of 
the isotope. After wash out of tracer not incorporated into bone, changes in urinary tracer 
excretion in response to interventions are supposed to reflect changes in bone mineral 
balance. To evaluate the usefulness of strontium stable isotopes as an alternative marker, we 
need to better understand how far the body discriminates strontium against calcium and to 
what extent this discrimination affects the tracer signal in urine. Discrimination of both 
elements against each other is studied best by comparing the molar ratio of both elements in 
body fluids or tissues. For tracer experiments, such as the presented study, comparisons can 




Ca) or by comparing tracer to tracee 




Sr) relative to the tracee. As strontium 
follows calcium closely and as we are interested in using a strontium isotope as a surrogate 
for the 
41
Ca label, natural calcium and not strontium becomes the tracee. While tracer 
concentration in urine varies significantly within and between days due to fluctuations in 
urinary volume, the tracer to tracee ratio in urine is highly constant and identical to that in 
serum provided no discrimination between tracer and tracee occurs at the level of the kidney. 
Discrimination is negligible between calcium isotopes and does not affect the 
41
Ca/Ca ratio. 




Ca ratio in urine 
equals that of serum within measurement uncertainty. This is not the case for calcium and 
strontium. The kidney alters the 
86
Sr/Ca ratio due to the lower efficiency at which strontium is 
known to be reabsorbed in the renal tubules as well as a stronger binding of calcium than 
strontium to serum proteins (430, 549).  
Walser and Robinson have tried to describe renal discrimination mathematically 
based on studies in dogs and humans (375). The ratio of strontium excreted in urine Sru to the 
amount of strontium filtered by the kidney Srf can be correlated to calcium filtration using the 
equation Sru/Srf = (Cau/Caf)
0.7
. The magnitude of the exponent has been confirmed later 
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tracer amount ratio at the beginning of our study (see Figure B-5a) is more likely to be due to 
initial strontium loading rather than discrimination. To achieve a sufficiently high isotopic 
enrichment in urine over the course of the study, we have administered a dose that exceeded 
the estimated daily dietary strontium intake of the sheep by a factor of 10 to 20. Injected 
strontium amounts to ca. 5% of circulating calcium in serum and was given over a few 
minutes only. This sharp rise in serum levels over a short period of time may have triggered a 
homeostatic response that resulted in preferential discharge of the strontium tracer relative to 
the calcium tracer. Their ratio dropped by a factor of 10 within the first day only. This finding 
indicates that 
84
Sr might be the tracer of choice for such experiments as it is about 20 times 
less abundant than 
86
Sr in nature which we have used in our study. Dose requirements for 
stable isotope tracers drop proportionally to their natural abundance (249).  
While homeostatic mechanisms may explain changes in the tracer ratio in urine very 
early in our study, they fail to explain changes in the following weeks and months. Renal 
excretion and bone deposition as homeostatic mechanisms can be safely expected to be 
effective within hours. After this initial discharge, the urinary tracer signal is dominated in the 
second phase by the continuous release of tracer initially adsorbed at the bone surface. Both 
calcium and strontium are bone seeking elements that can bind reversibly to the outer layer of 
bone by ion exchange mechanisms (551). In the third phase, remaining tracer at the bone 
surface has been incorporated into the bone matrix by osteoblast action. Only then, the 
urinary tracer signal is determined by the amount of tracer resorbed from mineralized bone, 
the fraction that is recaptured by bone or other tissues before renal elimination and, finally, 
the efficiency of tubular reabsorption. Because of the dynamic nature of these changes, it is 
only during the final phase that the urinary tracer signal truly reflects bone mineral balance. In 
humans, it was found that this point is reached when the urinary tracer signal tends to stabilize 
approximately after 150 days after dose administration (271). This was found to occur earlier 
in the studied sheep, i.e after 30-50 days post dosing. Due to the strong changes in the tracer 
ratio during the initial phase (see Figure B-6), strontium is less suitable as a surrogate marker 
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of bone calcium metabolism as found in earlier studies (416, 552, 553). Conclusions might be 
biased when strontium is not given sufficient time to be fully incorporated into the skeleton.  
Discrimination of strontium and calcium during tubular reabsorption clearly affect the 
tracer ratio in urine. However, this phenomenon does not disqualify strontium stable isotopes 
per se from being used as a bone label. Because strontium is a bone-seeking element like 
calcium, it can be safely assumed that virtually all strontium tracer in urine originates from 
mineralized bone after wash-out of loosely bound strontium from the body. As strontium 
tracer in the mineralized matrix is gradually replaced during bone remodeling, strontium 
tracer enters serum and urine steadily. Thus, a strontium tracer signal in urine is obtained that 
correlates qualitatively with bone calcium release as long as renal discrimination or even 
discrimination during strontium release from bone is regular. This results in a steadily falling 
tracer signal that can be used to study the effect of an intervention on bone balance (see 
Figure B-1).  
Following these logics, the observed irregularities in urinary 
41
Ca excretion would 
point to a deviation from steady state kinetics of tracer excretion and an effect on bone 
mineral balance, probably caused by giving the sheep access to the outdoors or in response to 
the treatment of the sheep with antibiotics or B vitamins. Because antibiotics were given 
intravenously and over three days only, an effect on bone is unlikely. This is different for the 
B vitamins which were given once only but at doses exceeding daily recommended intakes by 
a factor of 30 for Vit B1 and Vit B6 and a factor of 100 for Vit B12, respectively. However, 
such interactions have not yet been described in the literature or studied systematically to the 
best of our knowledge and are therefore speculative. Nevertheless, observations are most 
remarkable as they demonstrate the potential of the 
41
Ca labeling technique to detect even 
subtle changes in life-style, drugs or diet on bone. Irregularities in 
41
Ca excretion were 
paralleled by changes in 
86
Sr excretion but disturbances were even stronger. Renal 
discrimination is a possible explanation for the observed differences in response between both 
tracer signals. When strontium is retained less effectively than calcium by the kidneys, 
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proportionally more strontium tracer than calcium tracer is expected to be discharged in urine, 
which we have observed. The question arises now if this attenuating effect is limited to the 
kidneys or if discrimination between tracers also occurs at the level of the bone.  
Tracer to tracee ratios in our study were found to vary by one order of magnitude 
between skeletal sites (see Figure B-7). This is not unexpected as we have administered 
tracers only once at the beginning of the study. Bone seeking elements in serum are more 
likely to be trapped in areas of bone that are actively remodeled. While remodeling occurs at 
isolated sites across the entire skeleton, osteoblastic activity is higher in areas that are 
physically loaded than in areas that are less challenged (554, 555) which would speak for a 
higher tracer uptake by trabecular bone. Furthermore, trabecular bone is supposedly 
remodeled more actively in response to calcium-regulating hormones for maintenance of 
body calcium homeostasis (556). However, we have not observed such a clear trend in our 
study. This can basically be explained by the relatively large size of the analyzed bone 
samples. Unless bone is homogenously labeled, which is unlikely as we have administered 
tracer only once, tracer enrichment of the samples is determined by the number and size of 
actively remodeled sites in the analyzed bone volume at the time of tracer incorporation 
which follows its own statistics. 
Despite significant differences in tracer deposition density we observed a clear and 




Sr tracer deposition across the skeleton of the sheep (see 




Ca ratios were mostly undistinguishable 




Ca ratio of bone (ca. 6,700) was 
significantly lower than that of the dose material (20,200). This can be explained either by a 
preferential discharge of the strontium tracer from the sheep's body during the early phase 
post dosing as discussed earlier or a preferential deposition of calcium over strontium in the 
skeleton as suggested earlier (306, 416, 424, 551, 557). Both mechanisms would have 
reduced the amount of 
86
Sr tracer relative to 
41
Ca tracer in serum available for bone deposition 




Ca ratios at sacrifice were generally lower 
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than ratios in urine which can be explained by a preferential discharge of strontium tracer by 
the kidneys. 
For studying discrimination of strontium and calcium tracer at bone level, our 




Ca ratio which is determined both by isotope ratio analysis of strontium and calcium as 
well as their concentration measurements. Despite this obvious limitation, testing for 




Ca ratio that 
was lower and statistically different from the other 21 bone samples which were statistically 




Ca ratio. Sites were located in the tibia and metacarpus with a 
stronger association with samples containing trabecular bone as opposed to samples that were 
sampled solely from compact bone. Because of the low amount of tracers given relative to 
bone calcium, it can be safely assumed that the amount ratio of both tracers adsorbed initially 
on bone surface and later when entering mineralized bone was very similar, if not identical, 
across all bone sites. If no resorption occurs or if resorption does not discriminate between 
calcium and strontium, the tracer ratio should be constant within measurement uncertainty in 




Ca ratio was not homogenous and 
some samples were clearly depleted in 
86
Sr tracer can be explained by a preferential release of 
strontium over calcium from mineralized bone. Because freshly formed bone matrix is less 
likely to be remodelled within the duration of our study and because of low bone turnover, 
such adulterations became only apparent in selected bone sites. Mechanistically, strontium 
can exchange for calcium in the hydroxyapatite crystal in the crystallized areas of bone but its 
larger ionic radius distorts the crystal lattice. This entails that during recrystallization 
strontium is slowly eliminated from the interior as crystal perfection is achieved. This is 
shown by greater discrimination in favor of calcium in older, larger and less rapidly formed 
crystals (557). As an alternative mechanism, a more effective reabsorption of 
41
Ca tracer than 
86




Ca ratio in serum after tracer release from 
 Part B - Chapter 1: Isotopic labeling of bone for assessment of changes 








bone. Non-excreted tracers are expected to bind to the bone surface again and will be 





From the above it appears that strontium mimics calcium closely enough to identify 
changes in bone calcium balance by monitoring of the strontium tracer signal in urine. 
Because of a discrimination of strontium over calcium during tubular reabsorption and 
possibly bone resorption, the urinary strontium isotopic signal appears to accentuate negative 
changes in bone calcium balance better making it a potentially more sensitive marker than 
41
Ca. Because changes in 
86
Sr tracer excretion are consistently proportional to 
41
Ca tracer 
excretion (see Figure B-5b) we would expect that a change to a more positive bone balance 
would also become more visible for the 
86
Sr tracer than for the 
41
Ca tracer. Unfortunately, we 
were not able to show this in our study as the disturbance in tracer clearance made data 
modeling of steady state kinetics impossible. Modeling would have also revealed more clearly 
to what extent calcium and strontium are discriminated against each other during bone 
accretion and resorption, which is still unclear. Such quantitative information would have also 
been crucial to evaluate to what extent strontium isotopic labeling of the skeleton permits 
quantitative estimation of changes in bone calcium. The latter is of relevance when comparing 
the effect of different interventions on bone.   
 
1.5. Conclusions 
For technical reasons it has not been possible so far to directly compare strontium and 
calcium tracer excretion and bone deposition over the long-term. Here we could show for the 
first time that the mammalian body handles calcium and strontium in a very similar manner 
once it has been incorporated into the bone matrix. Strontium is preferentially discharged in 
urine and possibly released more effectively from bone than calcium but discrimination is 
highly systematic. The high degree of correlation in urinary tracer excretion allows for the use 
of stable strontium isotopes for bone labeling in order to monitor changes in bone calcium 
balance. Observed correlations imply that mathematical corrections can possibly be used to 
 Part B - Chapter 1: Isotopic labeling of bone for assessment of changes 








translate changes in strontium tracer excretion into changes in bone calcium balance once 
comparative data are available from kinetic tracer studies in humans. Our findings also 
indicate that strontium labeling is potentially more sensitive to detect changes in bone than 
calcium isotopic labeling of the skeleton. Taken together, strontium stable isotopes can be 
considered a potential alternative to the 
41
Ca labeling technique, opening up the possibility of 
using this ultrasensitive tool for detection of changes in bone calcium more widely in research 
and perhaps as a diagnostic tool in patient care. Once the skeleton is isotopically labeled, 
tracer excretion is measurable over decades and may permit early identification of progressive 
net bone loss or monitoring of therapeutic success in patients. 
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CHAPTER 2: ISOTOPIC LABELING OF BONE FOR THE ASSESSMENT OF 
CHANGES IN BONE MINERAL BALANCE: EVALUATION OF SPATIAL TRACER 
DISTRIBUTION (
86
Sr) IN MINERALIZED TISSUES  
 
2.1. Introduction 
A persistent loss of bone mass during adulthood results ultimately in a weakening of 
bone structure and an increased fragility of bone later in life. Isotopic labeling of the skeleton 
is an ultra-sensitive technique to assess the effect of drugs, diet or life-style on bone mineral 
balance either for the prevention or the treatment of osteoporosis (285, 536, 537). After giving 
a tracer orally or intravenously, the tracer is gradually incorporated into bone while tracer not 
incorporated in bone is washed out from the body over time. Once washout is complete, all 
tracer excreted in urine originates from bone and changes in excretion patterns are supposed 
to reflect changes in bone mineral balance (see Figure B-9). The most ideal isotope for bone  
 
Figure B-9: Basic principle for monitoring bone metabolism using isotopic tracer. Following 
a single tracer administration, the urinary tracer signal is monitored throughout the labeling 
period. The tracer that is not incorporated into bone will eventually be washed out before the 
end of the labeling period. After which, the urinary tracer signal can be assumed to originate 
mainly from bone. Changes in bone metabolism resulting from an intervention can then be 
measured against the labeling curve, which is assumed to be a fixed index. Figure is taken 
from Denk et al. (271) with modifications. 
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Ca, a semi-stable radiotracer (277). Due to its very long half-life of 105,000 years 
and the extreme sensitivity by which it can be detected using Accelerator Mass Spectrometry 
(AMS), 
41
Ca dose requirements are minimal and effective radiation doses can be kept well 
below levels arising from natural radiation exposure (271).  
While several studies have already demonstrated the high sensitivity of the 
41
Ca 
technique (285, 536, 537), it is unlikely that this technique will become widely available in 
the future. Analysis of 
41
Ca requires highly sophisticated instrumentation that is only 
accessible to a handful of research groups worldwide. We therefore explored strontium stable 
isotopes as a potential alternative. Strontium and calcium are both bone seeking elements that 
follow each other closely in nature due to their highly similar chemical and physiological 
properties. As such, it has already been suggested as a surrogate marker for studying calcium 
metabolism (552, 553). In contrast to 
41
Ca, strontium stable isotopes can be detected using 
much less sophisticated instrumentation (TIMS, ICP-MS) that is more widely available than 
AMS. 
To better understand how far the mammalian body discriminates between strontium 
and calcium over the long-term during bone accretion and resorption and, finally, at the level 




Sr simultaneously to an adult sheep (558). In 
contrast to many studies in the past comparing metabolism of both elements over days or 
weeks only, we followed excretion of both tracers in urine for 6 months before sacrifice to 
study tracer deposition in bone.  In this study we could already confirm that short-term 
handling and long-term handling is different for both elements, that bone deposition and 
urinary excretion of both tracers were highly correlated over six months and that strontium 
tracer is discharged more efficiently than calcium tracer in urine and, possibly, bone. The 
latter makes 
86
Sr labeling more sensitive to detect changes in net bone loss as compared to 
41
Ca. For both tracers, however, the question of spatial distribution in the skeleton at the end 
of the labeling period remains to be answered. Mode and site of tracer deposition affect 
ultimately the urinary tracer signal due to possible differences in bone turnover and release of 
the tracer from the skeleton. In our earlier study we were limited to the analysis of bone 
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biopsies of approximately 10 mm
3
 in size. This has made it impossible to identify if areas of 
bone have been labeled homogenously or in small isolated spots or if tracer has been 
incorporated preferentially in trabecular bone as found in earlier short-term radiotracer 
experiments (306, 422).  
To explore skeletal tracer deposition in our earlier sheep experiment we made use of 
the potential of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), 
an innovative technique that permits elemental as well as isotopic analysis at spatial 
resolution at the µm scale (559, 560). Using this approach we tried (a) to locate the stable 
strontium tracer in bone that has been given 6 months earlier to the sheep at the microscopic 
level; (b) to associate tracer deposition with bone site and type; and (c) to relate the tracer 
deposition with skeletal structures, modeling and remodeling processes. Findings for 
strontium tracer deposition can be directly extrapolated to calcium isotopic labeling. In our 
earlier investigations we could show that deposition of both tracers was highly correlated at 
macroscopic level across all studied skeletal sites.  
 
2.2. Materials and methods 
2.2.1. Animal Study 
The study was conducted in a two-year-old female domestic sheep (East Frisean Milk 
Sheep), which was kept in the experimental animal unit at the animal hospital (Tierspital) of 
the University of Zurich, Switzerland. The sheep was the same as the one described in Part B, 
Chapter 1. Experimental details are described in an earlier publication (558). In brief, the 
sheep was kept for 6 months with free access to standard feed (hay and concentrate, licking 
stone) and drinking water.  On day 1 of the study, the sheep received an intravenous dose of 
2.85 kBq (22.6 nmol) 
41
Ca and 465 µmol of 
86
Sr in 4 mL saline. The study protocol was 
reviewed and approved by the responsible authority for review and approval of animal studies 
in Zurich (Kantonales Veterinäramt Zürich).       
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2.2.2. Bone Sampling and Sample Preparation 
After 6 months (day 181 post dose), the sheep was sacrificed using a captive bolt 
pistol for numbing and killed by bleeding thereafter. The tibia as well as one vertebrae (L4) 
were secured for strontium tracer analysis. Bones were manually cleaned of cartilage and soft 
tissues, washed with saline and freeze dried. Bones were sliced using a diamond band saw 
(Exakt 310 Macro Band System, Oklahoma, USA) and mirroring slices were obtained from 
the proximal and midshaft region of the tibia (see Figures B-10 and B-11) as well as the 
dorsal plane of the obtained vertebrae (see Figure B-12) together with a slice of one of the 
vertebrae's transverse processes. For each sampled region, one of the slices was left intact for 
strontium tracer mapping by LA-ICP-MS while smaller pieces (sample size: ca. 2x2x2 mm, 
weight: ca. 0.5 mg) were obtained mechanically from the mirroring slices for measuring 
86
Sr 
enrichment by TIMS. LA-ICP-MS analysis was conducted at the Division of Analytical 
Chemistry, University of Natural Resources and Life Sciences (BOKU), Vienna, while 
samples were analyzed in parallel by TIMS at NutriTrace@NUS.  
 
2.2.3. 86Sr Isotopic Analysis by LA-ICP-MS 
LA-ICP-MS analyses were carried out using a laser ablation system (NWR-193, 
Electro Scientific Industries Inc., Oregon, USA) interfaced with an ICP-MS equipped with a 
quadrupole mass filter (NexION
TM
 300D, PerkinElmer Inc., Massachusetts, USA). Bone 
slices were transferred without further sample preparation into the laser ablation chamber. 
Instrumental parameters are summarized in Table B-1. Two dimensional distribution of the 
strontium tracer was assessed by ablating and analyzing bone at a spot size of 10-50 µm and 
scanning of the bone area in lines. Ablated material was carried to the ICP-MS for isotopic 
analysis in a helium/argon carrier gas stream. Blank signals in the argon/helium carrier gas 
were assessed by measuring background intensities of the ion signals of interest for at least 
20 s prior to ablation. No elevated analyte signals were found during blank readings. All 
measured values were blank corrected. 
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Table B-1: Instrumental parameters of the laser ablation system interfaced with the ICP-QMS 
for direct analyses of the bone samples. 
Parameters Values 
Laser (New wave ‘UP 193’) 
Ablation mode Line scan 
Wavelength (nm) 193 
Pulse length (ns) 3 - 5 
Repetition rate (Hz) 20 
Spot size (μm) 10 - 50 
Scan speed (µm/s) 25 - 50 
Ar mix gas / make-up gas (L min
−1
) 1 







RF power (W) 1,300 
Auxiliary gas flow (L min
−1
) 1.25 
Plasma gas flow (L min
−1
) 18 
Analog stage voltage (V) -1,712 
Pulse stage voltage (V) 1,050 
Detector Dual 
Autolens On 































Dwell time (ms) 50 
Integration time (ms) 135,000 
 
Isotope ratio measurements by ICP-MS are always biased due to mass dependent 
fractionation of analyte ions arising from mass sensitive transfer of ions from the ion source 
into the mass analyzer. For matrix matched mass bias correction, a non-spiked sheep bone 
sample was used. Ten independent line scans were conducted before analysis of the actual 
bone samples on a given day and a mass bias correction factor was calculated for each of the 
line scans. The average correction factor was calculated from these scans and used to correct 
the following measurements of spiked bones. The ratio of 
86
Sr tracer over natural calcium in 
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the ablated material was calculated for each data point by using established mathematical 
algorithms for isotope dilution mass spectrometry (IDMS) analysis (249). Data presentation 
and image development were done by using SigmaPlot 11.0 (Systat Software Inc., CA, USA) 
and Adobe Photoshop CS5 (Adobe Systems Inc., CA, USA) for enhancement of color 
contrasts. 
 
2.2.4. 86Sr Isotopic Analysis by TIMS 
Samples have been analyzed for bulk strontium isotopic composition using 
Multicollector-TIMS (Triton, Thermo Finnigan, Bremen, Germany). Methodological details 
are described elsewhere (558). In brief, a strontium-specific ion exchange resin (Sr-Spec, 
Eichrom, Lisle, USA) was used to isolate strontium from the sample digests. Isolated 
strontium was ionized as Sr
+
 ions using a rhenium single filament ion source with tantalum 
pentoxide (Ta2O5) as an ionization enhancer. Mass bias correction was done on the measured 




Sr isotope ratio of 0.1194 as its 
current consensus value (545, 546). Normalization of isotope ratios of spiked samples was 
done using an iterative algorithm. Measurements of 25 independent sample loadings of SRM 




Sr isotope ratio of 
0.056460±0.000002 (1SD) which falls well within its certified range (0.05655±0.00014). The 
ratios of 
86
Sr tracer over natural calcium were calculated based on the measured strontium 
isotope ratios and calcium concentrations of the samples using established mathematical 





Sr tracer to natural calcium ratio of the proximal tibia and shaft are 
shown in Figures B-10 and B-11 and of the analyzed L4 vertebrae in Figure B-12. In 
agreement with our earlier findings (558), analysis by LA-ICP-MS and TIMS show both that 
after 6 month of tracer administration the label is not evenly incorporated into bone. 
Macroscopic TIMS data (see Figure B-10d) point to a gradual increase in tracer deposition 
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from the epiphytical area towards the diaphytical area. Microscopic LA-ICP-MS analysis 
reveals clearly that tracer distribution is patchy and highly scattered with preferential 
deposition along the subcortical region in the metaphysis and beneath the growth plate where 
longitudinal growth has most likely occurred. High resolution tracer analysis (see Figures B-
10f and B-10g) shows that the tracer has not been deposited only at the bone surface of 
trabecular cavities but also inside mineralized bone. Outside the areas that showed high tracer 
deposition, tracer could also be detected but at a much lower level. 
The part of the shaft that was analyzed using TIMS covered the area between the 
endosteum and periosteum (see Figure B-11f). Based on TIMS analysis, the 
86
Sr tracer to 
natural calcium ratio of the shaft is very similar to that of epiphytical area. However, LA-ICP-
MS analysis shows that there is a strong preferential deposition of the tracer close to the 
periosteum and there is almost no tracer found in other areas of bone (endosteum and 
mesosteum). This finding could be confirmed by analysis of three other sites of the shaft 
pointing to a radial deposition of the tracer as a sharp line (see Figures B-11c-e). 
The body of the fourth lumbar vertebrae (L4) was also analyzed for its site-specific 
86
Sr tracer to natural calcium ratio by using both LA-ICP-MS and TIMS (see Figure B-12). 
LA-ICP-MS analysis revealed a highly localized deposition of the tracer both in cortical and 
trabecular bones (see Figure B-12d). While some tracer has been incorporated inside the 
corticula and trabecular bone, most tracer was found at the bone surface of trabecular cavities 
similar to the proximal tibia. The transverse process was also analyzed for tracer enrichment 
using TIMS. It shows a much higher enrichment of 
86
Sr as compared to the vertebral body 
(see Figures B-12e and B-12f).  
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Figure B-10: Analysis of the 
tibia of the sheep (a) for 
strontium tracer deposition. 
The sites that were analyzed 
are marked by black boxes. 
Ratio of 
86
Sr tracer over 
calcium were analyzed on the 
two adjacent parts from the 
epiphysis and metaphysis area 
(b) and (c). Samples were 
analyzed for 
86
Sr tracer at the 
marked positions (b) relative 
to calcium by TIMS (d). The 
mirroring slice (c) was 
analyzed by LA-ICP-MS (e) 
for lateral distribution of the 
86
Sr tracer (f and g) according 
to the given color scale which 
codes for 
86
Sr tracer relative to 
calcium at the point of 
analysis. The area shown in 
(f) visualizes data from 
strontium mass spectra 
obtained from ca. 80,000 spot 
ablations. For better 
visualization, spots with 
measured ratios less than 2 x 
10
-5
 have not been colorized. 
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Figure B-11: Analysis of the tibia of the sheep (a) for strontium tracer deposition. Ratio of 
86
Sr tracer over calcium were analyzed on the two adjacent parts from the shaft (b) and (f). 
The sites that were analyzed are marked by black boxes. Samples were analyzed for 
86
Sr 
isotopic tracer at the marked position (f) relative to calcium by TIMS. The mirroring slice (b) 
was analyzed by LA-ICP-MS for lateral distribution of the 
86
Sr tracer according to the given 
color scale which codes for 
86
Sr tracer relative to calcium at the points of analysis (c), (d) and 
(e). For better visualization, spots with measured ratios less than 2 x 10
-5
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Figure B-12: Analysis of the lumbar vertebrae 4 (L4) of the sheep (a) for strontium tracer deposition. Ratio of 
86
Sr tracer over calcium were analyzed on the 
two adjacent parts from the vertebrae body (b) and (e) and on the transverse process of the vertebrae (f). The sites that were analyzed are marked by black 
boxes. Samples were analyzed for 
86
Sr tracer at the marked positions (e) and (f) relative to calcium by TIMS. The mirroring slice (b) was analyzed by LA-
ICP-MS (c) for lateral distribution of the 
86
Sr tracer (d) according to the given color scale which codes for 
86
Sr tracer over calcium at the point of analysis. For 
better visualization, spots with measured ratios less than 2 x 10
-5
 have not been colorized. 
86Sr Tracer 
/Ca-nat:  
0.39 x 10-5 
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For isotopic labeling of the skeleton, an isotopic tracer is given once either orally or 
intravenously. Short-term studies using radiotracers have shown that osteons undergoing 
remodeling can take up considerable quantities of tracer rapidly. Osteons which are not 
completely mineralized take up smaller quantities as mineralization is slowing down. The rest 
of the bone takes up the tracer uniformly through adsorption processes (561). 
When administering an isotopic tracer of calcium or strontium, tracer recovery in 
urine is determined by washout of tracer from plasma within the first hours following tracer 
administration. In the second phase, tracer initially adsorbed on the bone surface by ion 
exchange is mobilized and excreted. Only in the third phase, the tracer signal in urine is 
dominated by release of tracer from the mineralized bone matrix into circulation. From there 
it may also re-enter bone in a second cycle either following surface deposition or by direct 
osteoblast uptake at bone areas that are currently remineralized. In agreement with these 
mechanisms, a fast exchanging pool (bone surface) and a slowly exchanging pool 
(mineralized bone) could be identified by modeling long-term 
41
Ca kinetics in earlier studies 
(271). These models showed that it takes approximately 120-150 days in humans until the 
tracer signal in urine is dominated by tracer resorption from bone (271). This compares to 
approximately 60 days in the studied sheep (558). Our observational period of 180 days has 
therefore been sufficiently long to ensure labeling of the bone matrix itself as the basis for 
identifying changes in bone mineral balance as the information of interest. 
Earlier studies have demonstrated that the 
41
Ca/Ca signal in urine and serum cannot 
be distinguished experimentally following 
41
Ca adminsitration (283). This allows modeling of 
serum tracer kinetics based on the kinetics of urinary tracer excretion (271). Typical models 
include serum calcium, a fast exchanging calcium pool probably reflecting calcium bound to 
bone by adsorption and a slow exchanging pool which probably reflects calcium in 
mineralized tissue (see Figure B-13). Modeling therefore considers that most but not all tracer 
recovered in urine comes from mineralized bone. Furthermore, a single slow exchanging pool 
as in Figure B-13 does not discriminate between more and less active bone sites in terms of 
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remodeling rate but all bone from which tracer release is slow. Modeling of tracer kinetics 
delivers therefore quantitative information on calcium uptake (k2) and release (k3) from 
mineralized bone (C3) per unit time, i.e. net bone calcium balance and turnover. 
Pharmacokinetic analysis of tracer data, however, requires more frequent measurements of 
urinary tracer excretion during the labeling phase and during interventions. 
 
Figure B-13: Three-compartmental model describing 
41
Ca tracer kinetics. The administrated 
tracer will first enter the central compartment (C1), from which it will be transferred to a fast 
exchanging pool (C2), which is presumably representing loosely bound calcium, and 
eventually to a slowly exchanging pool (C3), which is presumably representing calcium in 
mineralized tissue.  
 
In accordance with our current understanding of mechanisms of bone strontium 
uptake we observed a localized deposition of the tracer in the studied bone samples, shown by 
tracer deposition in clusters (see Figures B-10 to B-12). In the proximal tibia and the analyzed 
vertebrae, the tracer was deposited in hot spots that compare well in size to the dimensions of 
an average basic multi-cellular unit (BMU) (see Figures B-10 and B-12). BMUs are groups of 
tightly packed osteoclasts/osteoblasts at which bone remodeling occurs and are approximately 
200 µm in diameter in sheep (562). Ratios of 
86
Sr to natural calcium in these hotspots could 
be as high as 12x10
-4
 exceeding ratios in surrounding tissues by more than an order of 
magnitude. After 6 months of administration, 
86
Sr tracer could be found in both trabecular and 
corticular bone. In trabecular spaces, tracer was mostly not adsorbed at the surface as a thin 
layer but laid down deeper into bone as it can be expected to result from osteoblastic 
deposition (see Figures B-10 and B-12). The same holds for corticular bone where tracer was 
laid down in individual osteons (see Figure B-11). Most of the other bone areas were also 
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reached by the tracer but at a much lower concentration amounting to a molar ratio of 
approximately 1-2 x 10
-5
 of tracer to natural calcium. There were only approximately 23% of 
the bone areas with tracer to natural calcium ratio that was below the detectable limit. 
This is in agreement with basic remodeling mechanisms. It can be assumed that 
strontium tracer has been taken up primarily by BMUs that were in the bone forming phase 
within hours of tracer administration. At this time, circulating tracer concentration was 
order(s) of magnitude higher in plasma than in the days and weeks to follow which resulted in 
the observed patchy tracer distribution. The less tracer is in circulation, the less tracer is 
available for BMU uptake. Tracer not bound initially by BMUs was loosely adsorbed on bone 
surface across the skeleton from where it could re-enter circulation with time although at 
much lower plasma concentration than before. In consequence, much less tracer became 
available to BMUs than in the early phase of the study which explains the patchy tracer 
distribution with spots of high tracer enrichment as observed.  
In newly formed bone, strontium is incorporated via heteroionic substitutions into the 
crystals as well as adsorption and exchanges at the surface of crystals (563). In older bone, 
strontium is incorporated mainly via adsorption and exchanges. Hence, clearance of strontium 
is likely to be higher in old than in new bone. Gradually, more tracer will be incorporated into 
bone and less will be bound at the bone surface, leaving more tracer in newly formed bone. In 
the metaphysis, rich with newly formed bone, high tracer deposition was observed along the 
sides of the growth plate, but not directly on it. The growth plate mainly consists of resting 
and proliferating cartilage zones, which do not take up tracer. The sections that take up tracer 
in a diffuse fashion are the hypertrophic cartilage beginning of the first or second row of cells 
where provisional calcification occurs as well as the metaphyseal bone trabeculae (564). 
Compared to the area above the growth plate, higher tracer deposition was observed beneath 
the growth plate. This indicates that there was a longitudinal growth of the tibia during the 
study period. This is in agreement with the finding from a short-term radiotracer study in 10-
week-old rabbits that showed high level of calcium tracer beneath the growth plate while the 
plate itself was almost free of radioactivity (565). 
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Tracer was deposited in the bone matrix as a result of growth and bone remodeling 
with the latter being regulated mainly by mechanical force (555). Therefore, higher tracer 
enrichment can be expected in areas with elevated mechanical load. In the tibia sample, 
increased tracer deposition has been observed in the epiphysis and metaphysis, compared to 
the diaphysis. This can be explained by the fact that the epiphysis and metaphysis regions 
experience higher load from weight bearing. In addition to that, the epiphysis and metaphysis 
regions are richer in trabecular bone which undergoes remodeling more frequently and, thus, 
more new bone tissue. In contrast, the diaphyseal region contains mainly cortical bone which 
is less frequently remodeled as well as older bone tissue (302). Corresponding to this, lower 
tracer deposition was found in the cortical bone surrounding the epiphysis and metaphysis 
regions, compared to the trabecular bone inside (see Figure B-10). In the vertebrae, elevated 
mechanical loading also resulted in higher tracer deposition in the transverse process (see 
Figure B-12). The mechanical loading results from the muscles being attached to the 
transverse process (566).  
The sheep model used in this study was still experiencing bone growth. Increasing 
mechanical demands can be expected to activate modeling and eventually promote radial 
bone growth. While undergoing radial bone growth, periosteal bone balance is mildly 
positive, whereas endosteal bone balance is mildly negative (18). Hence, the amount of tracer 
found in the mesosteal and endosteal surfaces was negligible and the tracer was deposited 
exclusively in the periosteum. This indicates that there was very little bone remodeling 
happening in the other areas of the shaft. Several short-term animal studies found that calcium 
radioisotope was distributed over the entire diaphyseal cortex (564, 567, 568). Nevertheless, it 
is important to note that short-term studies might observe only the initial adsorption of 
strontium onto the crystal surface, which does not differentiate mesosteum from endosteum 
and periosteum where bone modeling actually occurs.  
Findings from the cortical bone in the diaphysis region of the sheep must be 
interpreted with caution. Cortical bone of the long bones of large fast-growing animals, such 
as sheep, typically contains plexiform bone which is uncommon in humans (569). Plexiform 
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bone has a similar structure to laminar bone with a denser vascularization system and a 
‘‘brick wall’’ appearance. Cortical bone of a mature sheep’s long bone also consists of 
Haversian bone and Haversian systems, but they are very scattered on the periosteum and 
become denser towards the endosteal surface. In contrast to sheep, humans’ cortical bone 
contains almost exclusively Haversian bone and systems due to the higher load associated 
with bipedalism and the resulting increase in remodeling rate of the lower limbs. 
 
2.5. Conclusions  
Our study shows that isotopic labeling of the skeleton by single administration of an 
isotopic tracer does not reach all bone. Tracer is preferentially deposited in young bone as 
well as areas undergoing growth or more frequent remodeling due to a higher mechanical 
load. This must be considered when extrapolating changes in urinary tracer excretion to 
changes in bone mineral balance as illustrated in Figure B-9. Firstly, tracer recovered in urine 
can either originate from bone surface where it was bound loosely by ion exchange 
mechanisms or from mineralized bone from where it was released by osteoclastic resorption. 
Secondly, the urinary tracer signal is dominated by tracer release/uptake from bone areas that 
undergo remodeling more frequently. Accordingly, measurable deviations in tracer excretion 
from its original excretion pattern cannot be more than a qualitative index for changes in bone 
mineral balance in response to changes in lifestyle, diet or pharmacological treatment.     
Based on our findings and known physiological similarities between calcium and 
strontium we can conclude that strontium stable isotopes can be used for bone labeling to 
identify changes in bone mineral balance similar to 
41
Ca but with some restrictions. As for 
41
Ca, modeling of urinary tracer excretion is the preferred approach to estimate absolute 
changes in bone calcium balance in response to interventions. The human body, however, 
discriminates between calcium and strontium during tubular reabsorption and possibly during 
uptake and release by the skeleton as shown in the first part of this study (558). This lets us 
conclude that strontium stable isotopes cannot replace 
41
Ca for measuring bone calcium 
uptake, release and turnover in absolute terms but that they can be useful for qualitative 
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assessments. In principle, strontium stable isotopes can be detected similar to 
41
Ca over 
decades in urine following a single oral or intravenous administration of the tracer. When 
being given to individuals in their late 30s or early 40s, regular monitoring of urinary tracer 
excretion would permit detection of accelerated bone loss or to qualitatively assess response 
of bone to pharmacological interventions or changes in lifestyle or diet. Because of the high 
sensitivity and specificity of the bone labeling approach, changes in bone could be detected 
probably earlier and thus faster as compared to conventional techniques at costs that are 
comparable or even lower than for radiological measurements of bone mineral density. 
Instruments that permit strontium isotopic analysis in urine such as inductively coupled 
plasma mass spectrometry (ICP-MS) are already widely available at university hospitals or 
commercial clinical laboratories.  
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CHAPTER 3: UPTAKE AND DEPOSITION OF STRONTIUM IN BONE AND SOFT 
TISSUES: A DOSE-RESPONSE STUDY IN RATS  
 
3.1. Introduction 
Osteoporosis is a disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in 
fracture risk (570).  Due to the high morbidity associated with osteoporotic fractures as well 
as their crippling nature (571-573), availability of safe and effective interventions for 
osteoporosis prevention and treatment is critical. 
Shorr and Carter suggested as early as in the 1950s that strontium might be useful in 
the treatment of osteoporosis after giving  moderate doses of strontium lactate to osteoporotic 
patients (15). Strontium ranelate was suggested later as a more suitable strontium salt due to 
its pharmacological and chemical characteristics and was finally approved as an osteoporotic 
drug in recent years (574). Strontium ranelate is composed of two atoms of stable strontium 
and ranelic acid as the carrier anion. Strontium was found to act as a dual-action agent by 
reducing bone resorption and enhancing bone formation simultaneously (575). Efficiency of 
the drug to reduce fracture risks and increasing bone strength has been demonstrated in 
humans (455, 574, 576) as well as laboratory animals (443, 448, 575, 577, 578). 
Strontium, like calcium, is a bone seeking element. As such ca. 98% of strontium in 
the body is found in bones (291). Strontium and calcium share similar physiological pathways 
and mechanisms of tubular transport (300) with some differences resulting from the larger 
size of the Sr
2+
 ion (14). Excretion of Sr
2+









 can exchange imperfectly for Ca
2+
 in the 
bone and other cellular compartments (300) and is supposed not to greatly interfere in 
physiological processes at therapeutic dose level (14, 300). However, uptake of one will be 
affected by the presence of the other due to competitive mechanisms (14). While being used 
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as a potent osteoporotic drug, strontium is not alien to the human body. A normal diet 
contains 2-4 mg Sr
2+
 per day which comes mostly from vegetables and cereals.  
Calcium is the most abundant mineral in bone and an insufficient supply through diet 
results inevitably in bone loss (296). Calcium concentration in extracellular fluids is tightly 
regulated. Nonetheless, excess calcium in serum results in hypercalcemia. Calcium functions 
as a sodium-channel blocker and inhibits depolarization of nerve and muscle fibers. As such, 
hypercalcemia decreases neuromuscular excitability and gastrointestinal contractility (579). 
Furthermore, it can cause arrhythmias and ventricular fibrillation by increasing excitability of 
the cardiovascular system (580). In kidney, excess calcium decreases its concentrating ability 
and damages renal tubules and can lead to mineral deposits. Calcium can form insoluble salts 
with phosphates and oxalates in soft tissues (44, 581). Calcification risks are higher in 
patients with compromised kidney function (404, 582) and those who obtain calcium from 
supplements (38, 39, 583). The latter has led the US Institute of Medicine to lower the 
Tolerable Upper Level of Intake (UL) for calcium for adults aged 51 years-old and above 
from 2,500 mg/day to 2,000 mg/day in 2010 (479). Since strontium behaves similarly to 
calcium and strontium intake from strontium ranelate by osteoporosis patients is comparable 
to the calcium content of common supplements (ca. 500 mg), strontium treatment may cause 
the same health problems as high levels of calcium supplementation. 
Strontium levels in extracellular fluids are not as tightly regulated as for calcium and 
high strontium intakes may therefore lead to high serum concentrations (14). Because 
strontium behaves similar to calcium in the body, elevated serum strontium concentrations 
may cause effects similar to those observed in hypercalcemia. Persistently high strontium 
intakes can also cause strontium rickets, a condition known to make bone brittle. The 
mechanism by which excess strontium can cause an adverse effect on bone calcification is not 
yet confirmed. Due to the larger size of the strontium ion, hydroxyapatite crystals 
preferentially bind calcium than strontium. However, at high concentrations, strontium may 
replace calcium by heteroionic exchange (584). A mild distortion of the crystal lattice 
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followed by impaired crystal growth and increased dissolution of mineralized bone may lead 
to lower bone mineral density (585). 
A recent evaluation of data from clinical studies in post-menopausal women by the 
European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use 
(CHMP) showed a higher risk of heart attack with strontium ranelate than with placebo, with 
no observed increase in mortality risk. Taking other known side effects of the drug such as 
blood clots and serious skin reactions into consideration, it has been recommended to restrict 
the use of strontium ranelate (Protelos®, Osseor®) to the treatment of severe osteoporosis in 
postmenopausal women and males at high risk of fracture (16) not suffering from heart or 
circulatory problems. An in-depth evaluation has been initiated.   
The aim of this study was to investigate the possible risks associated with high 
strontium intakes, in particular strontium deposition in soft tissues (heart, kidney and lungs), 
as well as their effects on turnover and biomechanical properties of bone. Experiments were 
conducted in adult rats which were fed two different dose levels of strontium through their 
drinking water. In contrast to earlier studies, animals were sacrificed by hyper-perfusion to 
study strontium deposition in bones and soft tissues. Hyper-perfusion minimizes risks of 
artifacts arising from incomplete blood removal from tissues. Strontium and calcium are 
extra-cellular ions. Their concentrations inside cells are lower by four orders of magnitude as 
compared to extracellular fluids, including blood. Strontium and calcium concentrations were 
determined by isotope dilution mass spectrometry as a reference method for delivering 
element concentrations in biological samples at highest accuracy (586). Spatial distribution of 
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3.2. Materials and methods 
3.2.1. Test Animals and Sampling Procedures 
Adult male Wistar rats (ex-breeders, 6-8 month old at study onset) were chosen as 
models in this study. Studies were conducted in male and not ovariectomized female rats to 
assess risks of high strontium intakes uncoupled from pathological conditions. Forty rats with 
an initial weight ranging from 550 to 700 g were randomly divided into four groups (baseline 
group, control group, low Sr dose group, high Sr dose group). The low dose group received 
0.2% Sr (w/w) and the high dose group 1% Sr (w/w) in the drinking water while no Sr was 
added to the water given to the control group. The baseline group was sacrificed at study 
onset to identify changes associated with aging and immobilization during the study period 
alone. The rats had access to a standard pelleted rodent diet (Harlen Teklad, Madison, 
Wisconsin) and prepared aqueous strontium solutions ad libitum. Strontium lactate (food 
grade, Dr. Paul Lohmann, Emmerthal, Germany) containing 24% (w/w) Sr
 
was used for the 
preparation of drinking water which was adjusted to a pH of 5.4±0.2. Weight, water and feed 
consumption were monitored closely over 12 weeks. Rats were kept under conditions of 
controlled temperature and a 12 hour light-dark regimen in the vivarium at the Centre for Life 
Sciences (CeLS), NUS. The experimental protocol was approved by the NUS Institutional 
Animal Care and Use Committee (IACUC). 
After a period of 12 weeks, the rats were sacrificed by hyper-perfusion with 
heparinized Ringer's solution to effectively remove blood in the sampled organs. The rats 
were anaesthetized using a mixture of ketamine (0.75 mg/kg rats’ body weight) and xylazine 
(10 mg/kg rats’ body weight). A cut was made from the abdomen to the chest cavity. A 
needle was then inserted 1 cm into the left ventricle of the rat’s heart to perfuse tissues and 
organs with Ringer’s solution (ca. 2 L per rat) without the use of a pump or by applying 
pressure. Fluid was drained through the right atrium where a small cut was made. Ringer’s 
solution was self-prepared from salts of analytical grade quality. Organs were collected after 
perfusion and cleaned with analytical grade phosphate-buffered saline (PBS; Ultrapure, 1st 
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Base, Singapore). Bone samples were wrapped with gauze soaked in PBS solution. All 
samples were stored at -20˚C until further analysis. 
 
3.2.2. Calcium and Strontium Concentration in Tissue Samples 
Strontium and calcium concentrations in freeze dried samples were determined by 
IDMS as described elsewhere (558). Isotopically enriched strontium and calcium were both 
obtained from Chemgas, Boulogne, France, in carbonate form with a 
86
Sr isotopic abundance 
of 95.32±0.83 % and a 
44
Ca isotopic abundance of 98.841±0.079 %, respectively. Both tracers 
were prepared by dissolution of the carbonate salts in 0.5 M HCl. Samples and suitable 
amounts of strontium and calcium tracer were weighed into pre-cleaned Teflon vessels, dried 
and mineralized in a microwave digester (Ethos 1, Milestone Inc., Sorisole, Italy) using a 
mixture of 8 ml conc. HNO3 and 2 ml 30% H2O2. All chemicals used were of analytical grade 
unless otherwise noted and only purified water was used (Milli-Q-System, Millipore, MA, 
USA). Acids were cleaned further by sub-boiling distillation in quartz stills (SAP-902 IR, 
AHF Analysentechnik, Tuebingen, Germany). Only acid washed plastic or teflon 
containers/labware were used for sample preparation. Sample handling was restricted as far as 
possible to class 10 metal free laminar flow hoods in a class 10,000 clean-room and was 
monitored routinely for analytical blanks. 
Strontium was isolated for isotopic analysis by thermal ionization mass spectrometry 
(TIMS) analysis from the sample digests by column chromatrography using a strontium-
specific ion exchange resin (Sr-spec, Eichrom, Lisle, USA). Sample strontium was ionized as 
Sr
2+
 ions using a rhenium single filament ion source and tantalum pentoxide (Ta2O5) as an 
ionization enhancer (558). Measured strontium isotope ratios were corrected for mass bias by 




Sr isotope ratio of 0.1194 as its current consensus value 
(545, 546). An iterative algorithm was used for normalization of isotope ratios of spiked 




Sr isotope of SRM 987 (SrCO3; NIST, Gaithersburg, MD) was 
0.056460±0.000002 (1SD) for 25 independent sample loadings which falls well within its 
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certified range (0.05655±0.00014). Eluted fractions from the strontium columns containing 
calcium were dried down and calcium was separated from other matrix elements by ion-
exchange chromatography. Sample calcium was ionized as Ca
2+
 ions using a rhenium double 
filament ion source and isotope ratios measured by TIMS (558). Measured calcium isotope 




Ca isotope ratio of 
0.3104 as its current consensus value (587). Isotope ratios were normalized using an 





Ca isotope of SRM 915b (CaCO3; NIST, Gaithersburg, MD) was 
0.064613±0.000007 for five independent sample loadings which falls well within the range of 
the current best measurements accepted by IUPAC of 0.0648±0.0009 (587). Measured 
calcium and strontium isotope ratios of the spiked samples were converted into calcium and 
strontium concentrations using established mathematical algorithms for IDMS analysis (249). 
Differences in element concentrations between the different groups were identified by 
ANOVA test at 95% confidence level. 
 
3.2.3. Calcium and Strontium Distribution in Bone Samples 
To study spatial distribution of calcium and strontium by PIXE analysis, bone 
samples were oven dried and embedded in epoxy resin using standard procedures 
recommended by the manufacturer (EpoFix Kit, Struers Inc., OH, USA). Sections were cut to 
expose the area near the region of interest using a low speed diamond saw (Isomet, Buehler, 
IL, USA) under constant water irrigation. Sample heating and tissue damage was minimized 
by maintaining the cutting rate below 150 rpm. After cutting, samples were re-embedded and 
the surface to be analyzed was grinded (TegraPol-11, Struers Inc.). Final surface preparation 
was done by diamond polishing (3 µm and 1 µm grain size, Struers Inc.). Thin slices (< 0.5 
mm thickness) for Particle Induced X-ray Emission (PIXE) and Rutherford Backscattering 
Spectrometry (RBS) analyses were finally cut from the polished resin block by using a low 
speed diamond saw under similar conditions. 
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PIXE and RBS analyses were conducted at the nuclear microscopy facility at the 
Physics Department, National University of Singapore (588). The instruments were operated 
with a 2.1 MeV proton beam focused to a spot size of approximately 1 m2 and with an 
average beam current of 250 pA. The two measurements can be carried out simultaneously 
for mapping and measurement of the major, minor and trace elements concentrations in 
biological samples. Since the bone samples are rich in calcium, the area of interest was 
selected using the calcium images provided by PIXE. Quantitative results were determined by 
using RBS and PIXE; RBS provided the information on matrix composition and incident 
charge, while PIXE measured the concentrations of the elements from sodium upwards in the 
periodic table. X-ray spectra were collected using a lithium-drifted silicon X-ray detector 
placed at 90˚ to the beam axis and fitted with a filter consisting of 50 micron aluminium and 
250 micron of Kapton. This filter is specially designed to reduce the calcium and potassium 
X-ray intensity to 0.01%, in order to improve the detection of trace amount of strontium in the 
samples. Initial scans (area: 4mm  4mm) were carried out on each sample to map the 
calcium and strontium distributions. Strontium rich areas were identified, and subsequent 
scans with higher spatial resolution were carried out. The data was collected and recorded in 
listmode files, so that offline analysis was possible using the GUPIX code (589) to extract 
quantitative strontium and calcium concentrations. 
 
3.2.4. Mechanical Testing 
Three-point bending tests were based on the method suggested by Stürmer (590) and 
conducted as described in an earlier publication (591) using the instrumentation at the 
Department of Bioengineering, NUS (Instron 5848, Norwood, MA, USA). Tibia samples 
were thawed overnight at 4˚C. Bones were kept moist with PBS until mounting on a jig with 
an aluminum base. The proximal tibia was fixed by a notch on the base of the jig while the 
distal part remained unfixed to allow the bone to extend along the diaphyseal axis. The stamp 
was connected to the micro tester by an aluminum stem. The distance between the proximal 
Part B - Chapter 3: Uptake and deposition of strontium in bone and soft tissues: A dose-




end of the tibia (with epiphysis removed) and the center of the roller stamp was set to 3 mm to 
achieve a consistent loading scenario between different samples. Before the test, the stamp 
was driven down slowly to the metaphysis of the tibia until the initial loading of 0.25 N was 
reached. After a final visual check of the correct tibia position, the breaking test was initiated. 
Maximum load, maximum stress and flexural modulus were recorded directly using the 
instrument's software (Merlin, Series IX). Yield load which divides the elastic from the plastic 
region was determined by the offset method. Stiffness and failure load were determined from 
the load-deformation curve, where stiffness is obtained from the slope of the elastic region 
and fracture load as the point at which the bone breaks. ANOVA test was used to compare 
averages of biomechanical parameters between groups at 95% confidence level. 
 
3.2.5. Biomarkers of Bone Turnover 
Blood (500 μL) was collected from the lateral tail vein after overnight fasting of the 
rats at the beginning of the study (week 0) and shortly before sacrifice (week 12). Serum was 
separated by centrifugation and stored at −20 °C until analysis. Serum levels of bone 
formation markers, procollagen type 1 N-terminal propeptide (P1NP), and bone resorption 
markers, C-terminal cross-linked telopeptides of type I collagen (CTX), were measured in 
duplicate in the control, standard and serum samples by enzyme-linked immunosorbent assay 
(Immunodiagnostic Systems Ltd, UK). Average values of P1NP and CTX concentration of 
the serum samples from the different groups were compared using ANOVA test at a 
confidence level of 95%. 
 
3.3. Results 
3.3.1. Treatment Tolerability 
The rats tolerated the treatment well and remained apparently healthy over the course 
of the study. They did not require any intervention or special treatment. However, one rat 
from the control group died due to natural causes one day before study completion which did 
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not allow perfusion/sampling of organs. The rats from all groups gained weight steadily from 
the start until the end of the study (initial weight = 603±22 g; final weight = 684±21 g; refer 
to Appendix II, Table II-1), with no significant difference in the final weight between groups 
(p=0.29). Their feed consumption remained relatively constant throughout the study period 
(average consumption: 26±1 g/day; refer to Appendix II, Table II-4) with no significant 
difference between groups (p=0.24). Water consumption increased slightly with time (average 
consumption: 33±7 g/day; refer to Appendix II, Table II-2) with significant differences 
between the groups (p<0.01). The control group generally consumed more water throughout 
the study and the high dose group consumed less than the low dose group, respectively. Total 
strontium intake in the low dose group was 98±15 mg/kg/day and 383±36 mg/kg/day in the 
high dose group, respectively (refer to Appendix II, Table II-3).  
 
3.3.2. Strontium Absorption and Uptake 
Strontium lactate given with the drinking water increased the concentration of 
strontium in the serum in a dose dependent manner (see Figure B-14a). Serum strontium 
concentrations were about four times higher in the high dose group (35.6±3.8 µg/g) than in 
the low dose group (9.3±2.8 µg/g). This compares well to the nearly fourfold higher strontium 
intake of the high dose group as compared to the low dose group. Relative to the 
baseline/control group, oral administration of strontium increased its serum concentration 
about 100 times in the low dose group and about 400 times in the high dose group. 
A dose-dependent increase of strontium was also observed in the skeleton (see Figure 
B-14b). Strontium concentrations in the right tibia of the baseline and control groups were 
very similar at 0.0300±0.0015 mg/g and 0.0270±0.0017 mg/g, respectively. Strontium 
administration increased strontium concentration in bone 90-fold to 2.56±0.92 mg/g in the 
low dose group and 280-fold to 8.0±2.3 mg/g in the high dose group, respectively. While the 
increase in strontium content relative to the baseline/control group was comparable for bone 
and serum (90-fold increase versus 100-fold increase), the increase in strontium content 
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between the strontium supplemented groups was significantly low for bone than serum (three-
fold increase versus four-fold increase). 
Strontium was distributed across the studied skeletal sites with some areas having 
higher strontium deposition (see Figures B-15 and B-16). In the femoral head and neck region 
of the treatment groups, more strontium was incorporated into trabecular bone compared to 
the cortical shell. Trabecular bone itself was scattered with strontium-rich areas (see Figures 
B-15b-3 and B-15c-3). The Sr/Ca ratio at the strontium-richest area was as high as 0.074 in 
the low dose group and 0.257 in the high dose group, respectively. In the mid-shaft region, 
strontium was incorporated mainly as a band close to the periosteum in the treatment groups 
(see Figures B-16a-3 and B-16b-3). In the high dose group, the strontium level was also 
elevated in the endosteum (see Figures B-16b-3 and B-16b-5), but it remained at the baseline 
level in the mesosteum (see Figures B-16a-3 and B-16b-3). In addition to that, cavities with 
lower calcium density were observed which appear to be surrounded by a strontium rich 
mineral phase.  
Unlike strontium, calcium distribution in both groups was almost homogenous across 
the studied bone samples, both in the epiphysis and diaphysis (see Figures B-15a-b and B-
16a-b), with a slight decrease in calcium concentration in areas with particularly high 
strontium enrichment (see Figure B-17). Some exceptions were observed in the mid-shaft 
region of the high dose group (see Figure B-16b). In sections without high strontium 
enrichment (blue areas in Figures B-15b-c and B-16a-b), the Sr/Ca ratio was approximately 
0.0036-0.0070 in the low group and 0.0089-0.017 in the high dose group. This value was 
about 10-20 times lower than that for the Sr/Ca ratio in the strontium-richest area in the low 
dose group and about 15-30 times lower as found for the high dose group. In the control 
group, the Sr/Ca ratio was significantly lower (ca. 0.00012-0.00014). This shows that 
strontium was incorporated nearly homogenously into most parts of the skeleton (see Figures 
B-15a-b and B-16a-b) with the exception of few ‘hot spots’ showing a significantly higher 
strontium enrichment (see Figure B-17). 
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Figure B-14: Strontium concentration in serum samples (a) and bones (b) of the different 
study groups. The baseline group was sacrificed at the beginning of the study. The control 
group was sacrificed after 3 month, but did not receive any additional strontium in the 
drinking water. Average strontium intake from the drinking water was 98±15 mg/kg/day for 
the low dose group and 383±36 mg/kg/day for the high dose group. Each bar represents the 
mean strontium concentration (±1 SD) as measured in a given group (n=9 for control group, 
n=10 for baseline, low dose and high dose group).  
 
In general, a dose dependent increase of strontium concentration was observed in all 
soft tissues (see Figure B-18b) while calcium concentrations were relatively similar across 
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tissues were found to be statistically significant, yet moderately, increased in the low dose 
group as compared to the control group for the studied tissues. In contrast, increases in 
strontium concentration were substantial for the high dose group and clearly disproportionate 
to the increase in strontium intake and serum strontium concentration between groups. 
Differences in strontium concentration between the low dose and the high dose group were 
the highest for the kidneys (15x) followed by lungs (6x) and heart (5x). However, due to the 
much higher calcium content of bone, differences in combined calcium and strontium 
concentration of organs were statistically insignificant between study groups except for the 
kidneys (see Figure B-19). 
  
3.3.3. Strontium Effects on Bone Mechanical Properties 
The flexural modulus and stiffness of the control group were significantly lower than 
that of the low dose group (p<0.05) (see Figures B-20c and B-20d). Differences in parameters 
between the high dose group and the other groups were insignificant. 


























































Figure B-15: PIXE scans of femoral heads of (a) low Sr dose group and (b) high Sr dose group. The measured values were corrected for filter factors and 
expressed in logarithmic scale. 
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Figure B-16: PIXE scans of mid-shaft femurs: (a) low Sr dose group and (b) high Sr dose 
group. The measured values were corrected for filter factors and expressed in logarithmic 
scale. 
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Figure B-17: Correlation between calcium and strontium concentration in the bone samples 
from the control, low Sr dose and high Sr dose groups. The background readings from the 
area with no elevated strontium deposition (represented with hollow markers) are scattered at 
the lower side of the chart. The readings from the area with high strontium deposition 
(represented with solid markers) are scattered at the middle and upper side of the chart. 
 
3.3.4. Strontium Effects on Bone Biomarkers 
Serum concentration of CTX as a biomarker of bone resorption was not significantly 
different between the different groups (see Figure B-21a). For P1NP as a biomarker of bone 
formation, serum concentrations for the baseline group were significantly higher compared to 
all other groups (p<0.05; see Figure B-21b). However, no significant difference was observed 
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Figure B-18: Concentrations of calcium (a) and strontium (b) in the kidneys, hearts and lungs 
as measured in the different study groups. Symbols indicate statistically significant 
differences between groups (p=0.05): *significantly different from control group; 
†significantly different from low dose group (n=9 for control group, n=10 for low dose and 
high dose group). Each bar represents the mean strontium concentration (±1 SD) as measured 
in a given group. A dose dependent increase of strontium concentration was observed in all 
soft tissues, while calcium concentrations were relatively similar across groups. Strontium 
concentrations in soft tissues were found to be insignificantly increased in the low dose group 
as compared to the control group. In contrast, increases in strontium concentration were 
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Figure B-19: Total amounts of calcium and srontium in the kidneys, hearts and lungs of rats 
as measured in the different study groups. Symbols indicate statistically significant 
differences between groups (p=0.05): *significantly different from control group; 
†significantly different from low dose group (n=9 for control group, n=10 for low dose and 
high dose group). Each bar represents the mean strontium concentration (±1 SD) as measured 
in a given group. Differences in combined calcium and strontium concentration of organs 
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Figure B-20: Mechanical properties of collected bone samples. Symbols indicate statistically 
significant differences between groups (p=0.05): *significantly different from baseline group; 
†significantly different from control group. Each bar represents the mean value (±1 SD) as 
measured in a given group. The flexural modulus and stiffness of the control group were 
significantly lower than that of the low dose group. Differences in parameters between the 
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Figure B-21: Serum concentration of bone resorption (a) and formation (b) markers in the 
studied groups. Symbols indicate statistically significant differences between groups 
(p=0.05): *significantly different from baseline group. Each bar represents the mean 
concentration (±1 SD) as measured in a given group. No significant difference in the serum 
concentration of CTX as a biomarker of bone resorption, was observed. For P1NP as a 
biomarker of bone accretion, serum concentrations for the baseline group were significantly 
higher compared to all other groups. 
 
3.4. Discussion 
In the present study we observed dose-dependent differences in serum strontium 
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Marie (310) and Ammann et al. (448) who also found that strontium concentrations in serum 
stabilized after 3 month of strontium administration. The ratio of serum strontium in the high 
dose group to the low dose group is approximately 4 in our study (see Figure B-14a) and is 
equal to the ratio of the intake of strontium from their drinking water. This indicates no 
suppression of strontium absorption at higher intakes.  
Previous studies have shown that strontium exposure in rats receiving 625 mg/kg/day 
of strontium ranelate for 44 weeks (equivalent to 213 mg/kg/day of elemental strontium) was 
comparable to that of humans receiving 500 mg of strontium per day in the form of strontium 
ranelate as preventive treatment for 52 weeks (592). Serum strontium concentrations in 
humans after 1 year of strontium treatment were 12.4±5.9 μg/ml in CL3-032 (593), 11.2±5.9 
μg/ml in TROPOS (455) and 10.2±6.7 μg/ml in SOTI (184) as the available phase 3 trials for 
the drug. This compares well to a serum strontium concentration of 9.3±2.8 μg/ml in the rats 
in the low dose group in our study that received only 98±15 mg/kg/day of strontium in form 
of strontium lactate, i.e. more than half times less than in comparable studies using strontium 
ranelate as the strontium source. After 52 weeks of strontium ranelate treatment at 625 
mg/kg/day (equivalent to 213 mg/kg/day of elemental strontium), serum strontium level in 
ovariectomized rats was only elevated to 9.0±2.3 µg/ml in the study by Bain et al. (594). 
However, direct comparisons between studies are difficult due to differences in age, gender 
and ovariectomization status of the rats. 
Lactate and lactic acid were found in earlier studies to enhance the bioavailability of 
calcium. In absence of comparable studies, the same may hold true for strontium. Both 
elements share the same pathways of absorption and excretion. Calcium from calcium lactate 
was found to be better absorbed than calcium gluconate in two human studies (595, 596). In 
another study in rats, calcium lactate was found to have a greater bone-stimulating activity 
than calcium carbonate and citrate (597). It has been suggested that lactate and/or lactic acid 
binds to calcium in the intestine and increases its solubility at intestinal pH (598, 599). Lactic 
acid also regulates release of the gastric moiety from the stomach to the small intestine (600) 
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which may also affect calcium absorption (601). In contrast to these findings, Tsugawa et al. 
(602) observed no significant difference between the bioavailability of calcium lactate and 
carbonate in rats.  
Similar to serum, we have also observed a dose-dependent increase in strontium 
concentration in the skeleton. A three-fold higher strontium content of bone was observed in 
the high dose group relative to the lower dose group. This compares to a factor of four for the 
concentration of strontium in serum and feed. Strontium content of rat femur also increased in 
an earlier study in a dose-dependent manner up to 255 mg/kg/day of strontium in the feed but 
the relative increase was less from 93.5 to 255 mg/kg/day than from 0 to 93.5 mg/kg/day 
(310).  
For the studied soft tissues we found clear indications of strontium accumulation with 
increasing strontium dosage. Strontium treatment increased strontium concentration in tissues 
for the low dose group by a factor of 7 to 27 relative to the control group. At a factor of 78 to 
164, the increase in strontium concentrations in the high dose group was much more 
substantial and clearly disproportionate to the increase in strontium intake and serum 
strontium concentration between groups. Nevertheless, strontium is still overall a trace 
element and risks of tissue mineralization should be considered together with calcium. In the 
low dose group, there was no significant increase in its combined strontium and calcium 
content. However, it could be observed in the kidney in the high dose group. This can be 
problematic as oxalates and phosphates are present in the kidney and they can form poorly 
soluble salts both with calcium and strontium. Excess strontium supplementation, however, 
appears to be of less concern for the heart than for the kidney in terms of tissue 
mineralization. There was no significant increase in the total amounts of calcium and 
strontium in heart even at the higher dose. Calcium data for the lungs has been excluded from 
discussion due to the markedly higher levels of calcium in the control group as compared to 
the treatment groups and the poor consistency of the results. This was due to the difficulty in 
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properly perfusing capillary blood vessels in the lungs. Remaining blood may have introduced 
sufficient amounts of calcium and strontium to artificially inflate results. 
Substantial strontium accumulation in the kidney and heart of the treatment group as 
compared to the control was also observed in the earlier rat study by Skoryna (460). The 
treatment group received strontium in drinking water for 12 weeks at a dose (0.34% SrCl2 
w/w) that was similar to the low dose in this study. Their findings are in agreement with ours. 
The changes in calcium levels were insignificant. As a result, the amount of total calcium and 
strontium were relatively unaffected. On the other hand, Aranyosiova et al. (603) who fed 400 
mg/kg/day of strontium to a group of rats for five weeks did not observe any strontium 
deposition in soft tissues at all. This could be explained by their lower measurement 
sensitivity as they quantified strontium by mass spectrometric imaging and not chemical 
analysis. 
Based on our findings, we suggest that there is a maximum capacity for bone mineral 
uptake from circulation above which excess calcium or strontium will remain in circulation 
and increases risks of tissue mineralization. This could explain why disproportionately more 
strontium was deposited in organs in the high dose group as compared to the low dose group 
while less strontium was deposited in bone. Serum strontium concentration between treatment 
groups differed four-fold and was proportional to strontium intake. In contrast, organ 
strontium concentration was higher by a factor of 5-15 for the high dose group while bone 
strontium concentration increased by a factor of three only. In general, bone can bind cations 
including strontium in the calcification process, by later heteroionic exchange against calcium 
in the hydroxyapatite crystal or by ionic exchange at the surface of mineralized bone (293). 
Kinetic tracer studies in humans point conclusively to calcium pools that differ in the rate by 
which they exchange calcium with the serum calcium pool (269, 271, 424, 534). It has been 
suggested that the fast exchanging pool comprises mainly of loosely bound calcium while the 
slow exchanging pool is supposed to represent mineralized bone. Fast exchange of calcium in 
serum and bone is pivotal for maintaining calcium homeostasis. Bone accretion and 
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resorption are processes that are much too slow to respond to the bodies’ immediate needs. 
Capacities of bone surface to remove calcium and strontium from circulation by ion 
exchange, however, are naturally limited. 
 Besides deposition in bone, risks of tissue mineralization by high strontium intakes 
might also be mitigated by the competition of strontium and calcium for transfer across 
biological membranes and, thus, organ uptake. Previous studies showed that although serum 
strontium concentration increased parallel to oral intake, serum calcium level remained 
unchanged in the range of 90.3 – 102.1 µg/ml (460, 604). There was a similar finding for 
organs in our study. Strontium exposure did not decrease tissue calcium content. In agreement 
with our finding, Skoryna (460) showed that although the amount of strontium in the kidney 
and heart had increased when the rats were fed with strontium, there was no corresponding 
decrease in the amount of calcium. Hence, strontium does not appear to replace calcium even 
when it is present at higher levels. 
In earlier strontium supplementation studies in animal and human models, calcium 
concentration in bone at the end of the experiment did not differ between groups (291, 302, 
563, 605). This shows that strontium uptake by the skeleton does not deplete bone calcium. Li 
et al. showed in bone biopsies of osteoporosis patients treated with strontium ranelate for 3 
years that most of the ingested strontium was absorbed on the bone crystal surface while only 
a limited amount of strontium replaced calcium in hydroxyapatite crystals (563).  
PIXE analysis in our study revealed that calcium and strontium were deposited nearly 
homogenously across all bone sites with certain areas having high strontium deposition. 
Calcium concentration in the mid-cortical region was higher than in the endosteum and 
periosteum, in general. In the treatment groups, strontium concentration was highest in the 
periosteum followed by the endosteum while the mid-cortical was lowest. This is in 
agreement with an earlier study by Li et al. and Boivin et al. in bone biopsies of patients 
treated with strontium ranelate (563, 606). Higher strontium concentration in endosteum and 
periosteum illustrated that therapeutic strontium tends to concentrate in areas where new bone 
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is actively formed. This is in good agreement with several studies in ovariectomized monkeys 
and osteoporotic women treated with the drug which also showed that more strontium enters 
new bone than old bone in therapeutic regimens (302, 607-609). 
 Elemental mapping by PIXE also showed that at certain areas in the skeleton, the 
strontium to calcium ratio can go up to 0.074 in the low dose group and up to 0.257 in the 
high dose group. Although Boivin et al. found that only 1 in 10 calcium can be replaced by 
strontium, our finding shows that when the amount of strontium given to the rats is high 
enough, more strontium can enter and be deposited in the skeleton regardless of the amount of 
calcium present (302). However, a depletion of calcium in the shaft can be observed in the 
endosteum of the mid diaphysis in the high   dose group. In contrast to the mid diaphysis of 
the low dose group that has a fully calcified surface, some cavities can be observed in that of 
the high dose group (see Figure B-16). The cavities were surrounded by high strontium 
deposition. This observation could be related to strontium rachitis. In several studies, chronic 
exposure to high strontium doses caused several skeletal abnormalities, including calcification 
defects, a lower mineral content and bone density, etc (300). 
Growing strontium rachitic or mineralization defects could explain the finding that 
strontium improved mechanical bone properties only in the low dose group, i.e. the group in 
which serum strontium concentrations were induced similar to humans undergoing strontium 
ranelate therapy. In comparison to the control group, the low dose group showed significantly 
higher flexural modulus and stiffness. For the high dose group, no significant differences 
relative to the control and the low dose group were observed (see Figure B-20). In agreement 
with our findings, previous studies in rats revealed that a threshold exists (strontium content 
in diet < 0.4% w/w) up to which an increased dietary strontium intake increases bone 
formation rate as well as trabecular bone density (610, 611). At higher intakes, strontium can 
potentially disturb bone mineralization (466, 471). Previous studies showed that the action of 
strontium involves the dissociation of bone formation and resorption, rebalancing bone 
remodeling towards formation (612, 613). This mode of action has been verified in animal 
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studies as well as clinical trials (614). In our study, no significant difference was observed in 
the serum concentration of CTX as a bone resorption marker between treatment groups and 
the control group (see Figure B-21a). Similar findings were reported by Ma et al., who also 
found no indications for a change in bone resorption rate in ovariectomized rats after 3 
months of strontium ranelate therapy (615). The significant decrease in serum P1NP 
concentration we have observed in the control, low dose and high dose groups compared to 
the baseline group could potentially be the result of prolonged immobilization of the rats in 
their cages. Lack of physical activity is well-known to negatively affect bone health in 
animals and man (616). However, the relatively small sample size in our study must be 
considered when comparing biomarker data in our study with previous observations. A recent 
human study by Chavassieux et al. (2013) has confirmed that strontium ranelate has a mild 
negative effect on bone formation and insignificant effect on bone resorption (617). However, 
clinical trials have provided strong evidence for the effectiveness of strontium ranelate in 
fracture prevention. Hence, it is likely that strontium ranelate works physically, rather than 
biologically, to offer this fracture prevention capability. 
 
3.5. Conclusion 
Several studies in animals and humans have demonstrated the potential of strontium 
salts to positively affect bone health. This refers in particular to strontium ranelate, the only 
strontium drug approved so far for osteoporosis treatment. A positive effect on bone could 
also be confirmed in our study in the low dose group which exhibited strontium 
concentrations in serum comparable to those observed in patients undergoing strontium 
therapy. 
Concerns have been raised recently by the European Medicines Agency regarding the 
safety of strontium ranelate treatment. Restrictions to its use have been recommended to 
mitigate higher risk for heart attacks observed in patients undergoing strontium therapy. As 
for calcium supplementation, high strontium intakes may exacerbate risks of tissue 
Part B - Chapter 3: Uptake and deposition of strontium in bone and soft tissues: A dose-




mineralization and artherosclerosis by formation of poorly soluble strontium salts. 
Disproportionate changes in bone and soft tissue content relative to strontium levels in feed 
and serum let us hypothesize that a threshold level may exist from which strontium is taken 
up less efficiently by bone and risks for tissue accumulation were increasing. The same may 
hold true for calcium due to their physiological and chemical similarity.  
Strontium ranelate is used at a dose level (500 mg/day of strontium) that is 
comparable to regular calcium supplementation which has been suggested to increase risks of 
soft tissues calcification. On top of that, strontium ranelate treatment is recommended to be 
administered together with up to 1,000 mg of calcium and 400 IU or 800 IU of vitamin D 
depending on the patients’ needs (478). The combined strontium and calcium intake may 
approach or even exceed the tolerable upper intake level of 2,000 mg calcium per day (IOM, 
2010). This would point to a reconsideration of dosage levels for strontium therapy and/or 
practices of concomitant intake of calcium supplements. 
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CHAPTER 4: AGE-DEPENDENT DIFFERENCES IN CALCIUM AND 
MAGNESIUM INTAKE IN SINGAPOREAN CHINESE WOMEN 
 
4.1. Introduction 
Osteoporosis is a skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone causing an increase in bone fragility and vulnerability 
to fractures (2). Postmenopausal women and the older population are at an elevated risk of 
developing osteoporosis (8, 618). With growing life expectancy (1), osteoporosis is on the 
rise (9, 619). Effective strategies are needed for its prevention and treatment not only to 
alleviate individual burden but also dampen economic impact on public health systems in the 
coming decades (5). 
Calcium is the most abundant cation in the human body, of which 99% is bound in 
the skeleton as hydroxyapatite crystals. The remaining calcium is contained in the 
extracellular fluid, blood, and soft tissues. Besides its structural role, bone functions as a 
reservoir of calcium which is readily available to fulfill its roles in multiple physiologic and 
biochemical processes including neuromuscular functioning, blood coagulation, cell 
permeability, enzyme activation and hormone secretion (32). Negative calcium balance 
inevitably results in bone loss and a lowered structural stability of bone in the long-term 
(620). Generally accepted strategies to reduce osteoporosis risks at advanced age include 
maximization of peak bone mass during childhood and puberty and to minimize net calcium 
losses during adulthood. Hence, a sufficient dietary calcium supply throughout life together 
with vitamin D for facilitating its absorption is widely considered a major pillar of 
osteoporosis prevention (621-623).  
Besides calcium, magnesium is also believed to play a role in bone health, yet its 
actual role in bone metabolism is poorly understood. Normal magnesium body content is 
around 20-30 g. About half of it is located in bone where it is mostly present as a surface 
constituent of the hydroxyapatite crystal (84). Because bone undergoes continuous 
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remodeling, an adequate supply of magnesium as well as other nutrients important to bone is 
needed to support bone formation. Studies have shown that magnesium deficiency could 
affect bone growth, osteoblastic and osteoclastic activity, as well as induce osteopenia and 
bone fragility. It may also alter calcium metabolism by affecting calciotropic hormones (624). 
Furthermore, it is necessary for activation of more than 300 enzyme systems making it an 
essential nutrient in a plethora of physiological processes. An insufficient magnesium supply 
has been associated with an increased risk for diabetes mellitus type 2, hypertension and 
atherosclerosis but findings are still inconclusive (625-628).  
Singapore is an example of an Asian country that has experienced significant changes 
in lifestyle including dietary habits in response to rapid socioeconomic developments. This is 
evident, in particular, in the younger generation which is presumably more westernized and 
more open to other ethnic cuisines in the local, highly multi-cultural context than the older 
generation. In this study we tried to assess (1) differences in dietary habits between the 
younger and older generation in Singapore and how they affect their calcium and magnesium 
intakes; (2) the adequacy of the mineral intakes with reference to current requirements; and 
(3) the contribution of food fortification and dietary supplements to calcium and magnesium 
intake. An integral part of the project was the development of an in-house database for 
calcium and magnesium content of local foods and the design and validation of a strategy for 
assessment of calcium and magnesium intake in the Singaporean context. In parallel, we have 
estimated dietary intake of strontium, a bone seeking element that is known to reduce fracture 




Two groups of Singaporean women of Chinese descent, aged 18-30 years-old (n=94) 
and ≥ 55 years-old (n=75), were recruited from the local population. The survey was limited 
to women as the group at higher risk of contracting osteoporosis and to ethnic Chinese as the 
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dominant ethnic group (74.2%) (630). Subjects were balanced for their highest educational 
degree in each group according to recent demographic data (630). Educational level is a major 
determinant of socioeconomic status and known to influence dietary habits (631, 632). 
General health status and dietary habits were assessed through a guided questionnaire. 
Subjects who had major dietary changes over the past six months and/or had to restrict their 
diet were excluded from the study. Vegetarians were not purposely excluded but there were 
none in both subject groups. Vegetarianism is not widely practiced among Singaporeans of 
Chinese descent. Written informed consent was obtained from all subjects and the protocol 
was approved by the Institutional Review Board of the National University of Singapore. 
 
4.2.2. In-house Calcium and Magnesium Database 
The in-house database covers calcium and magnesium contents from over 2,700 
entries of food and drink items that were considered relevant to the Singaporean context (see 
Appendix). Data were compiled mainly from six food composition tables: Food Composition 
Guide Singapore (633), McCance and Widdowson's The Composition of Foods (5
th
 Ed) 
(634), Pacific Islands Food Composition Tables (635), ASEAN Food Composition Tables 
(636), Thai Food Composition Tables (637) and Food Composition and Nutrition Labels (6
th
 
Ed) (638). Additional information on calcium content of some food and drinks were also 
obtained from food labels, Singapore Food Facts (639) and the United States Department of 
Agriculture (USDA) National Database for Standard Reference (640). For highly relevant 
food items that are known to have a high mineral content and/or are frequently consumed by 
the majority of the studied population group, content was determined in-house by Flame 
Atomic Absorption Spectroscopy (F-AAS). After data compilation, food items were 
categorized into groups based on their calcium contents and their expected consumption 
frequency. The nine major food groups were: staple foods and carbohydrate sources; 
vegetables and vegetable products; meat, poultry, eggs and their products; fish, seafood and 
their products; soybean products; topping, sauces and condiments; fruits; dessert and snacks; 
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and dairy products. Under each main group, food items were grouped further and each sub-
group was assigned a standard portion size and a calcium and magnesium content, 
respectively. Assigned values were rounded to only one or two significant figure(s). Mineral 
contents can vary by more than 50% between batches for the same food items for most foods. 
Assigned values were based primarily on concentrations determined in-house (if available), 
followed by those reported in food composition tables or in the scientific literature and, lastly, 
food labels. If different brands of the same product showed highly variable calcium contents, 
assignments were brand specific and were based on mineral contents as indicated on the food 
label. Standard portion sizes for main food items were determined based on information 
obtained from food composition tables, food packaging labels and weighing of food items 
purchased from food vendors. In the process of developing the database, the composite dishes 
and the spices and additives used as ingredients, especially those rich in calcium, were given 
extra consideration. 
 
4.2.3. Assessment of Mineral Intake 
Mineral intake was assessed in this survey by three-day food records. Subjects were 
briefed both orally (in English or Mandarin) and in writing about the study. They were also 
provided with two samples of completed food records and a set of picture aids to help them 
estimate portion sizes. During the study periods (two weekdays and one weekend), subjects 
were asked to write down all the food and drinks directly after consumption including portion 
sizes, brands and methods of preparation. For composite meals they were asked to write down 
major food items in the dish. Portion sizes were standardized for recording in terms of 
measurable units e.g. number of rice bowls, number of tablespoons, etc. In addition, subjects 
were asked to write down any nutritional supplements including brand names and number of 
pills/tablets they have consumed during the recording period. Food Records were analyzed 
using the developed in-house database for mineral content. Average values for individual 
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mineral intake were obtained by weighting of data obtained on two weekdays and 
Saturday/Sunday at a 5/2 ratio. 
A duplicate diet study was conducted for method validation. Subjects (n=24) were 
asked to collect all foods and drinks they consume in duplicate for any two weekdays and one 
Saturday or Sunday and to complete food records on each of the three days in parallel. 
Calcium and magnesium content of the duplicate diet samples was analyzed (measured daily 
intake) using F-AAS as well as estimated using the in-house database. For evaluation, 
estimated and measured mineral contents were plotted against each other. Slope of the 
regression line and goodness of fit (R
2
) was used to assess accuracy of estimates for mineral 
intake in population assessment. Strontium intake was estimated by analysing collected 
duplicate diets for strontium content by Graphite Furnace Atomic Absorption Spectroscopy 
(GF-AAS). Assessment of strontium intake through the collected food records was not 
possible as data on strontium content of foods in the literature are scarce and insufficient for 
the intended purpose. 
 
4.2.4. Sample Analysis 
Sampled foods as well as the collected duplicate diets was analyzed for calcium and 
magnesium content by F-AAS (AA240 FS, Varian Pty. Ltd., Victoria, Australia) and for 
strontium content by Graphite Furnace AAS (GF-AAS, AA240 Zeeman, Varian Pty. Ltd., 
Victoria, Australia). For sub-sampling, solid samples were blended with a standard food 
blender after adding a measured amount of Millipore water (Milli-Q-System) and 
homogenised using a laboratory blender (SilentCrusher M; Heidolph Instruments GmbH & 
Co. KG, Kelheim, Germany). Drink samples were stirred until they were mixed well or 
homogenized when they contained solids. Three aliquots were taken from each sample. 
Samples were mineralized by microwave-assisted wet digestion using an Ethos 1 digestion 
unit (Milestone Inc., Sorisole, Italy). Homogenized samples were weighed into pre-cleaned 
Teflon vessels, mineralized using a mixture of 8 ml concentrated nitric acid, HNO3 and 2 ml 
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30% hydrogen peroxide (Merck, Darmstadt, Germany) and diluted with water after digestion 
to the optimal concentration range for analysis. All chemicals used for sample preparation 
were of analytical grade. Only ultrapure water was used (Milli-Q-System, Millipore, MA, 
USA) and acids were cleaned further by surface distillation. Element concentrations were 
measured by external calibration using commercial standards (Titrisol
®
, Merck, Darmstadt, 
Germany). Calcium and strontium were analyzed with KCl (Scharlau, Barcelona, Spain) as an 
ionization suppressant at a spiked K concentration of 2,000 μg/g in the sample solutions.  
The F-AAS was equipped with a 10 mA calcium hollow cathode lamp and was 
operated at a slit width of 0.5 nm and a wavelength of 422.7 nm. A nitrous oxide-acetylene 
flame was used for the determination of calcium. The same system equipped with a 4 mA 
magnesium hollow cathode lamp operated at a slit width of 0.5 nm and a wavelength of 285.2 
nm was used for the determination of magnesium with an air-acetylene flame. The GF-AAS 
was equipped with a 10 mA strontium hollow cathode lamp and was operated at a slit width 
of 0.5 nm and a wavelength of 460.7nm. High purity argon gas (Soxal, Singapore) was used 
to flush the graphite tube. All readings were performed in triplicate in integration mode for 
FAAS and height mode for GF-AAS to determine absorbances and corrected for analytical 
blanks. For calcium and magnesium, analytical accuracy was assessed by processing a 
certified reference material (SRM1567a, wheat flour; National Institute of Standards and 
Technology, NIST, Gaithersburg, USA). For strontium, analytical accuracy was assessed by 
analysis of a gravimetrically prepared laboratory standard because of a lack of commercially 
available reference materials certified for strontium concentration. 
 
4.2.5. Statistical Analysis 
Testing for distribution was done by Kolmogorov-Smirnov and Shapiro-Wilk test. 
Since calcium and magnesium intake data were not normally distributed, Mann-Whitney U-
test was used to perform non-parametric comparison of mineral intakes between subject 
groups. Mann-Whitney U-test and Kruskal-Wallis-H test were used to compare mineral 
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intakes of subjects which were categorized by socio-economic and health factors as well as 
dietary habits to assess for any possible confounders. Factors assessed using Mann-Whitney 
U-test included whether the participant had any diagnosed health condition (including 
hypertension, diabetes, chronic disease(s), etc.). Factors assessed using Kruskal-Wallis H-test 
included: (1) highest educational degree, (2) body mass index (BMI) and (3) physical activity 
level. Mann-Whitney U-test was also used to compare the mineral intakes of subjects from 
each individual food group. 
 
4.3. Results 
4.3.1. Subject Characteristics 
Average age was 24±3 years for the younger subjects and 63±8 years for the older 
subjects. Table B-2 shows the subject characteristics assessed including highest educational 
degree, body mass index (BMI), location where most meals are taken (at home/outside), level 
of physical activity, diagnosed health conditions and calcium and/or magnesium supplement 
consumption. Factors which were found to be statistically associated with and therefore might 
have confounding effects on mineral intakes were location where most meals were taken 
(food stalls/restaurants versus home) for magnesium and supplement consumption for both 
calcium and magnesium. 
Subject characteristics were within expectations for the Singaporean context. 
Virtually all young Singaporeans have a Diploma or University Degree while the majority of 
the older population has joined the workforce after secondary school. Average BMI was 
higher in the older (23.1 ± 3.6) than in the younger women (20.2 ± 2.6) with more of the 
younger subjects below cut-offs for underweight (26%) and more of the elderly women above 
cut-offs for overweight (43%) when applying current WHO recommended for BMI 
classification for Asian populations (641). Physical activity level of the younger and the older 
women was comparable with about 1/3 in both groups following a sedentary lifestyle. While 
most of the younger women (91%) had no diagnosed health condition, about 2/3 of the older   
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Table B-2: Subject groups’ characteristics.  
Age Group 18 – 30 Years Old ≥ 55 Years Old Overall 
 n 94 75 169 
Average age 24 ± 3 years 63 ± 8 years 41 ± 21 years 
       
Highest educational degree (n) 
    No formal   
    qualification 
0 0 % 18 24 % 18 12 % 
    Primary school 0 0 % 9 12 % 9 6 % 
    Secondary school 0 0 % 33 44 % 33 22 % 
    Diploma course 33 35 % 11 15 % 44 25 % 
    University degree 61 65 % 4 5 % 65 35 % 
       
BMI (n)       
    <18.5 kg/m
2
 24 26 % 1 1 % 25 13.5 % 
    18.5-23.0 kg/m
2
 55 58 % 44 59 % 99 58.5 % 
    >23.0 kg/m
2
 15 16 % 30 40 % 45 28 % 
       
Physical activity level (n)* 
    None 31 33 % 22 29 % 53 31 % 
    Category 1 28 30 % 29 39 % 57 34.5 % 
    Category 2 15 16 % 7 9 % 22 12.5 % 
    Category 3 20 21 % 17 23 % 37 22 % 
       
Diagnosed health condition (n)      
    None 86 91 % 28 37 % 114 64 % 
    Yes 8 9 % 47 63 % 55 36 % 
       
Meals taken mostly at (n) 
    Home 29 31 % 45 60 % 74 45.5 % 
    Outside 65 69 % 30 40 % 95 54.5 % 
       
Ca / Mg supplements       
     Ca 4 4 % 14 19 % 18 11.5 % 
     Mg 0 0 % 0 0 % 0 0 % 
     Ca + Mg 7 8 % 11 15 % 18 11.5 % 
     None 83 88 % 50 66 % 133 77 % 
 
*Physical activity level.  
None:             sedentary lifestyle 
Category 1:  ca. 20 minutes of moderate-intensity physical activity 5 days per week or 10 minutes of 
vigorous-intensity physical activity 3 days per week or equivalent. 
Category 2:  ca. 30 minutes of moderate-intensity physical activity 5 days per week or 20 minutes of 
vigorous-intensity physical activity 3 days per week or equivalent. 
Category 3:  ca. 45 minutes or more of moderate-intensity physical activity five days per week or 30 
minutes or more of vigorous-intensity physical activity 3 days per week or equivalent. 
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women were found to be diagnosed with a disease. In agreement with common Singaporean 
habits, most meals (69%) were taken by the younger women outside at public places while 
60% of the older women reported to prepare and eat their meals mostly at home. 
Consumption of calcium or magnesium supplements was more common in the older subject 
group (43%) as compared to the younger women (14%). In general, calcium supplements 
were found to be more commonly consumed than magnesium supplements. 
 
4.3.2. Method Validation 
Figure B-22 shows the results of the duplicate diet study. At a slope of correlation 
lines close to 1.00, measured and estimated average intakes were found to agree remarkably 
well over the 3-day study period for both elements. Residuals were 18±86 mg/day for calcium 
and 2±37 mg/day for magnesium. This translates to a 95% confidence interval of ±18% for 
estimated calcium content and ±5% for estimated magnesium content of the duplicate diet on 
an individual basis. 
 
4.3.3. Survey 
Average calcium intake was found to be lower for the younger women (483±24 
mg/day) than for the women aged 55 and above (653±47 mg/day). The same was observed 
for magnesium intake which was 188±7 mg/day for the younger women and 225±11 mg/day 
for the older women. Differences (Mann-Whitney U-test) between age groups were highly 
significant both for calcium (p=0.024) and magnesium (p=0.007). Distribution of mineral 
intakes is shown in Figure B-23. The majority of women did not meet the estimated average 
requirements (EAR) for calcium and magnesium as suggested by the US Institute of Medicine 
(479) and adopted by WHO for this age group. Average calcium intake of the younger 
women in our survey was 317 mg/day below the current EAR of 800 mg for adults aged 19 - 
50 years, while that of the older women was 347 mg/day below the current EAR of 1,000 mg 
for adults aged ≥ 51 years. The estimated average magnesium intake of 188±7 mg/day for the 
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younger women and 225±11 mg/day for the older women in our study are noticeably lower 
than the current EAR of 255 mg/day for women aged 19 - 30 years and 265 mg/day for 
























Figure B-22: Correlation between mineral contents as measured in 3-day duplicate diet 
collections and as estimated using parallel 3-day food records for calcium (Figure B-22a) and 
magnesium (Figure B-22b) in 24 subjects. Best fit-lines were forced through the origin. 
Slopes close to 1.00 demonstrate that 3-day food records in combination with an in-house 
database for calcium and magnesium content of local foods can be used to accurately estimate 
mineral intake of population groups in the Singaporean context. Absolute residuals for 
calcium (Figure B-22c) and magnesium (Figure B-22d) are also presented as residual plots. 
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Figure B-24 shows the contribution of non-fortified food and beverages to the average 
daily calcium and magnesium intake of both age groups. Among food items/groups, major 
contributors to calcium intake were vegetables, staple foods/carbohydrates and meat products 
in both groups in that particular order. Together, they accounted for ca. 50% of calcium intake 
from foods. The contribution from vegetables to calcium and magnesium intakes in both 
subject groups was comparable (p=0.107 and 0.124, respectively). However, there were 
statistically significant, yet negligible, differences in the contributions from other food 
groups, such as staple foods/carbohydrates (p<0.01), meat products (p<0.01) and dairy 
products (p<0.01).  Among the beverages, major sources of calcium were milk and milk 
products which contributed approximately as much as staple foods/carbohydrates to overall 
calcium intake. For magnesium, staple foods/carbohydrates contributed ca. one third of 
magnesium intake from foods with the other two thirds of magnesium coming from the other 








Figure B-23: Distribution of dietary calcium (Figure B-24a) and magnesium (Figure B-24b) 
intake of female Chinese Singaporeans aged 18 - 30 years old (■) and ≥ 55 years old (□). The 
average calcium intake for the group aged 18 - 30 years old and that for the group aged ≥ 55 
years old were 483±24 and 653±47 mg/day, respectively. Average magnesium intake for the 
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intake from foods. There were significant differences in the contributions from unfortified 
beverages, such as milk (p=0.015), milk products (0.019), as well as coffee and tea (p<0.01) 
to calcium and magnesium intakes in both subject groups. 
Figure B-25 shows the contribution of fortified foods and supplements to overall 
calcium and magnesium intake. While intake of calcium from non-fortified foods was 
comparable for both age groups (p=0.94), intake of calcium from non-fortified beverages 
(p=0.009) and magnesium from non-fortified foods (p=0.001) and beverages (p=0.035) were 
significantly different. Fortified foods and beverages and supplements contributed to a much 
larger extent to calcium intake of the older women as compared to the younger women in our 
study (p=0.011 and 0.001, respectively). For magnesium, intake from fortified foods and 
beverages did not contribute to the age-dependent differences (p=0.640), but intake from 
supplements contributed significantly (p=0.040). Observed age dependent differences in 
calcium intake of Singapore Chinese women can thus be attributed primarily to a higher 
proportion of fortified foods and beverages in the diet of the older generation, such as milk 
powder (p<0.01), and their higher supplement intake. For magnesium, the observed age 
dependent differences in intake can be attributed to a higher supplement intake and 




We have hypothesized that mineral intake may differ between older and younger 
Singaporean women of Chinese descent. Because identification of general age related 
differences in dietary preferences has not been the subject of this survey, we could focus on 
the accurate assessment of mineral intake for method optimization. This is still challenging in 
a multi-ethnic society such as Singapore and the openness of Singaporeans to cross culinary 
borders. Major difficulties arise from the diversity of food ingredients used, the variety of 
composite meals and processed foods as well as the common habit of Singaporeans to enjoy   
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Figure B-24: Contribution of individual non-fortified food items (Figure B-24a and B-24b) 
and beverages (Figure B-24c and B-24d) to daily average calcium (Figure B-24a and B-24c) 
and magnesium (Figure B-24b and B-24d) intake of age groups 18 - 30 years old and ≥ 55 
years old. Dashed lines (------) show no significant difference in the contribution of the 
respective food group to daily average mineral intake of the two subject groups. Thin 
(────) and thick (       ) lines show significant difference in the contribution of the 
respective food group to daily average mineral intake of the two subject groups (p<0.05 and 
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Figure B-25: Breakdown of non-fortified foods, non-fortified beverages, calcium- and 
magnesium-fortified foods and beverages, and calcium/magnesium supplements and their 
contributions to daily average calcium (Figure B-25a) and magnesium (Figure B-25b) intake 
of age groups 18 - 30 years old and ≥ 55 years old. Dotted arrows show no significant 
difference in the contribution of the respective food group to daily average mineral intake of 
the two subject groups. Dashed lines (------) show no significant difference in the contribution 
of the respective food group to daily average mineral intake of the two subject groups. Thin 
(────) and thick (        ) lines show significant difference in the contribution of the 
respective food group to daily average mineral intake of the two subject groups (p<0.05 and 
p<0.01, respectively). 
 
food outside at food stalls and restaurants rather than cooking at home. A recent market 
survey showed that about 90% of Singaporeans ate at food courts and food stalls at an 
average of 16 times per month and 82% of consumers ate at an average of seven times a 
month at fast-food outlets and five times monthly at restaurants (642). 
Initially we attempted to assess mineral intake through a validated food frequency 
questionnaire (FFQ) but this approach turned out to result in a significant overestimation of 
food intake. The developed FFQ was rather complex as it had to consider relevant Southern 
Chinese, Southeast Asian, Indian and Western dishes and drinks which are all equally 
available across the country. It is well established that an overly complex FFQ tends to 
diminish data quality as it may lead to over-reporting of food intake (643, 644). Instead, we 
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consumption make food records less suitable to estimate nutrient intake in the individual but 
they are useful to assess nutrient intakes of population groups as intended in this survey (643, 
644). Under the typical assumption that records reflect actual food intake on the assessment 
day, the mean of a single-day intake for a group is equal to the mean of the usual intake 
distribution (645). To increase study power, we have used 3-day food records as this allows a 
better control of bias due to day-to-day variations in food intake of the individual subject and, 
thus, the entire population group.  
Conversion of food intake data into mineral intake was another difficulty we had to 
address. With a few exceptions such as eggs and farmed sea-fish, all food sold in Singapore is 
imported either from neighboring countries or elsewhere in order to satisfy the diverse 
demands of Singapore's multi-ethnic and multi-national population. We have therefore 
compiled data both from Asian and non-Asian databases. As our survey was nutrient specific, 
we could reduce the complexity of the database substantially by grouping relevant foods 
according to their calcium and magnesium content and assigning estimates for average 
mineral content of portion sizes typical for the local context. Groupings were done based on 
the assumption that variability in nutrient content for a given food is at least ±50%, i.e. a food 
item with a reported calcium content of 100 mg calcium per serving cannot be differentiated 
from a food item with a reported content of 200 mg calcium per serving. Seasonal variations, 
genotype, production method, water content, geographic origin and highly variable losses 
during food preparation, to name a few out of many possible factors that can affect food 
mineral content substantially (646). As can be seen from Figures B-22a and B-22b, this 
approach yielded a very good agreement between estimates of calcium and magnesium 
content and actual mineral contents as measured in the collected duplicate diets. Confidence 
intervals (95%) were relatively small and allowed the statistical resolution of differences in 
estimated mineral intake between both subject groups larger than 59 mg for calcium and 13 
mg for magnesium.  
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Nutrient requirements differ between individuals. As such, the EAR value represents 
an estimate of the median of the amount of nutrient that is required by a population to satisfy 
physiological needs. Nutrient supply of a population is therefore sufficient if not more than 
50% of individuals show a nutrient intake that is below their EAR. In the present study we 
found that the calcium intake of 80% of Singaporean women was below their current EAR of 
1,000 mg calcium per day while frequency was even higher at 91% for the younger women. 
The low calcium intake of the younger women (483±24 mg/day) and the older women 
(653±47 mg/day) in our study agree well with observations in other Asian populations. 
Estimated calcium intake of females was found to be in the range of 390 - 570 mg per day in 
Hongkong (616, 647, 648), 640±240 mg/day in Taiwan (649) and 230 - 724 mg/day in 
mainland China with regional differences (616, 650). In Japan, a trend towards a lower 
calcium intake by younger women has also been observed. In the Japanese National 
Nutritional Survey (1999), it was found that calcium intake by women aged 20-29 years-old 
(497±242 mg/day) was generally lower than that of women aged 50-59 years-old (606±280 
mg/day), 60-69 years-old (610±283 mg/day) and 70-79 years-old (570±275 mg/day) (651). 
Similar to calcium, we observed a suboptimal supply of Singaporean Chinese women with 
magnesium. At an estimated magnesium intake of 188±7 mg/day, 71% of the older women 
did not meet their current EAR while magnesium intake of 84% of the younger women 
(225±11 mg/day) was lower than their EAR. This compares to estimates of magnesium intake 
of women aged 35 to 64 years of 333±3 mg per day in Tianjin, China (652), 306±130 mg per 
day in women aged 31 to 50 years from Jiangsu province, China (653) and 214 - 318 mg per 
day in various regions in mainland China (650). 
The rather low calcium intake of most women in the study can be explained, at least 
partly, by the rather low intake of milk and dairy products. Together they account for less 
than 10% of total dietary calcium intake in both age groups with milk intake being higher in 
younger women and tea/coffee consumption in older women. About one third of dietary 
calcium was found to come from vegetables, staple foods (primarily rice and noodles) and 
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meat at similar proportions. This is in good agreement with other studies in Chinese 
populations which showed consistently that milk and dairy products contribute little to total 
calcium intake and that vegetables are a more relevant source of calcium (654-656). In 
Caucasian populations, milk and dairy products account for up to two-thirds while vegetables 
contribute to less than 5% of total calcium intake from food sources (657, 658). Tofu is a 
more relevant source of calcium than milk and dairy products in the traditional Asian diet 
(659). Gypsum (CaSO4·H2O) or CaCl2 are commonly used in tofu production to precipitate 
protein from soy milk which is rather low in native calcium content similar to soy beans. 
While tofu was found to be a major dietary source of calcium in China and Hongkong (650, 
654, 660), we found that it is of little relevance in the Singaporean context (<5% of total 
calcium intake), irrespective of age group. We also found that whole dried small fish (ikan 
bilis), shrimp or shrimp paste (belachan) as common condiments of high calcium content in 
Southeast-Asian dishes were not significant sources of calcium in the studied population 
group.   
Sources of magnesium in the diet and their proportional contribution to total 
magnesium intake were mostly similar to calcium in our study. Exceptions were staple foods 
which contributed proportionally more and vegetables which contributed less to total dietary 
intake of magnesium in comparison to calcium. The suboptimal magnesium intake we have 
observed in both age groups can be attributed to the rather low intake of whole grain products 
as a major source of magnesium in the human diet (650). Polished rice and noodles prepared 
from low extraction wheat flour appear to remain the more popular choice among 
Singaporeans despite attempts of local authorities to promote consumption of whole grain 
products. Other than that, magnesium is found in green leafy vegetables, legumes, nuts, seeds, 
fish and hard water (26). Although most fluid intake of Singaporeans comes from tap water, it 
is a minor source of magnesium in the local context. Due to extensive cleaning procedures 
which include reversed osmosis, local tap water is very low in minerals including calcium and 
magnesium. 
Part B - Chapter 4: Age-dependent differences in calcium and magnesium intake in 




Dietary intake of strontium as estimated by duplicate diet analysis was much lower 
than for calcium and magnesium. The estimated strontium intake was 1.03±0.08 mg strontium 
per day in this study, which is within published range (0.20 to 2.36 mg) (486, 487). This 
finding is also in agreement with findings other South-East Asia countries, including Vietnam 
(1.3 mg/day) and Philippine (1.1 mg/day) (486). In UK and Finland, the average daily intakes 
of strontium were estimated to be 1.3 mg/day and 1.9 mg/day (486, 488), which were 
comparable with the strontium intake in South-East Asia. In Germany and Switzerland, the 
strontium intake could reach an even higher value and it was estimated to be between 1.1 to 
4.5 mg/day (489, 490). There are a few major dietary sources of strontium, including cereal 
(2,440 µg/kg), vegetables (530 – 940 µg/kg), full cream milk (180 to 2,800 μg/L), meat and 
poultry (450 ug/kg), seafood (274 µg/kg), water (20 – 60 µg/L) (491, 492). Higher strontium 
content in water have been reported in Europe (10.6 – 12,200 µg/L) (493), Riyadh (25.4 – 
406.4 µg/L) (494) and Japan (1.96 - 4539 µg/L) (495). As with magnesium, water is not a 
relevant strontium source in Singapore due to intensive water processing and infrequent 
consumption of bottled, mineral rich natural waters. Contents of strontium and calcium of the 
duplicate diets were correlated, which was not unexpected. Both elements follow each other 
in water, soil and foods due to their similar chemical properties (14). Overall, the strontium 
content of the Singaporean diet was found to be lower by two orders of magnitude than the 
therapeutic dose of strontium used in osteoporosis treatment (ca. 500 mg strontium per day in 
the form of strontium ranelate). As such, native strontium in the Singaporean diet has 
supposedly a negligible effect on bone. 
When looking at mineral intake from non-fortified foods and beverages alone, we 
found no statistically significant difference in intake for calcium between both age groups, but 
we found significant difference in intake for magnesium. Sources of both minerals in the diet 
were also relatively similar for both age groups. The differences that need to be highlighted 
were higher consumption of dairy products, such as cheeses and milk by the younger group of 
females, resulting in higher contribution to calcium and magnesium intake. This finding is not 
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surprising considering higher acceptance of Westernized food items by the younger 
generation. While consumption of coffee and tea, typical traditional Chinese beverages, was 
higher in the older subject group. This is different when taking calcium and magnesium intake 
from fortified food products as well as supplements into account. In fact, age dependent 
differences in total calcium and magnesium intake that we have observed in this study can be 
mostly attributed to calcium and magnesium intake from these non-traditional sources. 
Mineral intake from supplements and fortified food products was higher by a factor of three 
for calcium and by a factor of two for magnesium in the older women as compared to the 
younger women. Dietary supplements are very popular in Singapore. On average, every 
family that consumes health supplements spends US$120 per month and it was estimated that 
in 2010 Singaporeans spent US$260 million on supplements (661). Furthermore, 
Singaporeans are relatively well informed on health consequences of calcium deficiency in 
older woman through the mass media and advertisement campaigns by manufacturers of 
foods and dietary supplements (642). Age related differences in the intake of supplements and 
fortified foods can be explained by income gaps between generations and that older women 
are usually more concerned with their bone health than younger women. Furthermore, the 
older generation tends to prepare food more often themselves. This makes them more likely to 
consume fortified food products such as fortified breads, instant beverages and milk powder 
which are typically prepared and consumed at home. A trend toward higher use of 
supplements among older age groups was also observed by Mangano et al. (662) and Bailey 
et al. (663) in non-Asian populations. Contribution of supplements and fortified foods to 
magnesium intake was much lower in comparison. This can be explained by a greater 
awareness of calcium as a limiting nutrient in the Asian diet and maintenance of bone health. 
In our study, we found that supplemental magnesium has only been consumed as part of 
multi-vitamin and mineral supplements. Communication with regards to health impacts of a 
suboptimal magnesium intake remains difficult as it cannot be associated easily with a 
particular disease such as calcium or iron (664). Being much less studied than other nutrients 
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despite its multitude of functions it is often considered as the "forgotten mineral" in our diet 
(665). 
Our study demonstrates that a suboptimal calcium and magnesium intake from the 
diet as commonly observed in Asians of Chinese descent can easily be boosted by the use of 
dietary supplements and fortified food products. Such a strategy, however, is not without risk. 
Supplements can close the gap between dietary intake and physiological needs. Increasing 
mineral intake beyond this threshold level has no additional health benefits. This may explain, 
at least in part, unequivocal findings regarding the effect of calcium supplementation with or 
without Vitamin D on reduction of fracture risk (666, 667). Increasing mineral intake beyond 
this threshold can be more harmful than useful. Excessive calcium intake may result in 
vascular and soft tissue calcification, in particular of heart and kidneys, and may increase 
risks for developing cardiovascular disease (37-39, 404). This increasing body of evidence 
has resulted recently in the lowering of the Tolerable Upper Level of Intake (UL) for calcium 
by the US Institute of Medicine from 2,500 mg per day to 2,000 mg per day for males and 
females 51 years and above (479). The current UL, i.e. the regular Ca intake from which 
harmful effects of calcium are increasing, is difficult to reach through diet. It can be reached, 
however, by excessive intake of calcium supplements. A recent epidemiological study points 
to calcium supplementation rather than dietary calcium intake as a concern (39). Consumption 
of calcium fortified food products is less problematic as fortification levels of food products 
are commonly not associated with any harmful effect when looked at in isolation. They can 
be of concern, however, when calcium fortified foods are given preference over unfortified 
foods and taken in combination with the aim to maximize bone health.  
Because of reasonable grounds for doubting the safety of calcium supplements, in 
particular in the older generation, the question arises if supplementation should be 
recommended to correct low calcium and magnesium intakes in Chinese Singaporeans. This 
refers in particular to the younger generation for which we have observed a very low calcium 
intake that amounted, on average, to less than two-third of the EAR. While the role of calcium 
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nutrition and calcium supplementation in fracture prevention in the elderly remains debatable, 
the importance of calcium nutrition in the first three decades of life is largely unquestioned. A 
sufficient calcium supply during growth is pivotal to reach the genetically pre-determined 
peak bone mass to delay the onset of osteoporosis later in life (26). Further studies are 
necessary to elucidate if calcium intakes during childhood and puberty are as low as for the 
young women in our study and not only confined to Singaporean women of Chinese descent. 
With a greater openness of the younger generation to consume milk and dairy products 
despite a deep penetration of lactose intolerance in Chinese Asians, there is some untapped 
potential to increase calcium intake by the younger generation without relying on 
supplements.     
Our study has shown that calcium and magnesium intake of Singaporean Chinese 
women is well below the current EAR. However, it remains open if low mineral intakes are 
actually a true concern and have, finally, an impact on fracture risk. Our knowledge on 
calcium requirements is based largely on studies in Caucasian populations. Ethnic differences 
have already been identified for Africans while studies are still scarce for Asian populations. 
Recent absorption studies using stable calcium isotopes showed that calcium absorption in 
Chinese is apparently more efficient than in Caucasians (668, 669). A more recent study 
points to lower calcium requirements of Asian than White US children (670). No such studies 
exist for magnesium. Differences in calcium requirements may explain the Asian paradox. 
Despite a much lower dietary calcium intake as compared to Caucasians, age corrected 
fracture incidence is significantly lower in Asian populations than in the West (671). Until 
actual mineral requirements of Asian populations are known, it will be difficult to make 
evidence based recommendations to Singaporeans and other Asian populations regarding 
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Osteoporosis is a skeletal disease characterized by low bone mass and micro-
architectural deterioration of bone, resulting in an increase in bone fragility and vulnerability 
to fracture. Besides affecting the quality of life, osteoporosis treatment and management 
cause considerable economic burdens. The main challenge in recognizing effective strategies 
to maintain and improve bone health is the absence of techniques that are sensitive enough to 
evaluate the skeletal response to interventions. The commonly used techniques, measurement 
of BMD and biomarkers, are either insensitive or subjected to significant intra-individual 
variation.  
On the other hand, isotopic labeling of bone is able to serve as an ultra-sensitive tool to 
detect changes in bone metabolism, which allows the assessment of short-term and soft 
interventions, such as diet and lifestyle changes. Technically, either stable or radioisotopes of 
calcium can be used for isotopic labeling. However, due to health concerns, conventional 
radiotracers are no longer used. Although stable isotopes are safe, the doses required, and 
consequently the costs involved, would be very high.  Alternatively, there is a very long-
living radiotracer (
41
Ca), that is safe to use and only required in a minute amount. 
Nevertheless, its technically challenging analysis has hindered its use in routine applications.  
The similarities between strontium and calcium have pointed to the possibility of using 
strontium stable isotopes as a surrogate marker for calcium in bone metabolism studies. 
Strontium, like calcium, is a bone seeking element. It has similar chemical properties and 
passively follows calcium in the body. However, it requires much less sophisticated 
instrumentation for isotopic analysis.  
The first aim of this thesis was to explore the potential of strontium stable isotopes as a 
diagnostic tool to study bone mineral metabolism. The first study described in this thesis (Part 
B, Chapter 1) has shown that once calcium and strontium have been incorporated into the 
bone matrix, the body handles them in a very similar manner. Although strontium is 
preferentially discharged in urine and possibly released more effectively from bone than 




calcium, the discrimination follows certain correlations, allowing the use of strontium stable 
isotopes for bone labelling in order to monitor changes in bone calcium balance. This implies 
that once comparative data are available from kinetic tracer studies in humans, mathematical 
corrections can possibly be used to translate changes in strontium tracer excretion into 
changes in bone calcium balance. Up to now, several human studies have used only 
41
Ca for 
skeletal labelling to monitor changes in bone calcium balance 
The second study described in this thesis (Part B, Chapter 2) has revealed some 
setbacks of using strontium stable isotopes to study bone mineral metabolism. It has been 
shown in this study that isotopic labelling of the skeleton by single administration of an 
isotopic tracer does not reach all bone. Tracer is preferentially deposited in young as well as 
areas undergoing growth or more frequent remodelling due to a higher mechanical load. 
Tracer recovered in urine can either originate from bone surface where it was bound loosely 
by ion exchange mechanisms or from mineralized bone from where it was released by 
osteoclastic resorption. However, the urinary tracer signal is dominated by tracer 
release/uptake from bone areas that undergo remodeling more frequently. Accordingly, 
measurable deviations in tracer excretion from its original excretion pattern cannot be more 
than a qualitative index for changes in bone mineral balance in response to changes in 
lifestyle, diet or pharmacological treatment. This applies to all tracers administered for the 
purpose of skeletal labeling. Quantitative evaluations are still possible but they require more 
complex kinetic modeling of tracer data which can be used to differentiate changes in flux 
rates for slow exchanging and fast exchanging bone pools as opposed to measuring 
differences in urinary tracer excretion alone. 
Similar to 
41
Ca, strontium stable isotopes can be detected over decades in urine 
following a single oral or intravenous administration of the tracer. When being given to 
individuals in their late 30s or early 40s, regular monitoring of urinary tracer excretion would 
permit detection of accelerated bone loss or to qualitatively assess response of bone to 
pharmacological interventions or changes in lifestyle or diet. Because of the high sensitivity 
and specificity of the bone labeling approach, changes in bone could be detected probably 




earlier and thus faster as compared to conventional techniques at costs that are comparable or 
even lower than for radiological measurements of bone mineral density. This technique can 
also be used as an ultra-sensitive tool to evaluate the skeletal response to interventions, 
including those short-term and soft interventions. Instruments that permit strontium isotopic 
analysis in urine such as ICP-MS are already widely available at university hospitals or 
commercial clinical laboratories. Hence, this technique can overcome not only the 
insensitivity of the conventional techniques, like BMD and biomarker measurement, but the 
technical challenges of using calcium isotopes. 
Strontium has also played a role as a therapeutic agent for osteoporosis prevention and 
treatment. Since the 1950s, strontium has been suggested to be useful for osteoporosis 
treatment. A few decades later, strontium ranelate has finally been approved as an 
osteoporotic drug. In principle, strontium ranelate increases bone formation and decreases 
bone resorption. It also improves bone biomechanical properties including bone strength 
(672). While strontium binding to human plasma proteins is low (approximately 25%), it has 
a high affinity for bone tissue (672). The manufacturer of the drug has claimed that strontium 
does not accumulate in non-calcified tissues (672). However, a recent data evaluation from 
clinical studies by the European Medicines Agency’s Committee for Medicinal Products for 
Human Use showed a higher risk of heart attack in strontium ranelate group than with 
placebo, with no observed increase in mortality risk. 
The second aim of this thesis was to investigate the role of strontium as a therapeutic 
substance to improve bone health, together with its side effects on soft tissues. The third study 
described in this thesis (Part B, Chapter 3) has confirmed a positive effect of strontium 
ranelate on bone although less clearly as opposed to other studies, probably due to sample 
size restrictions. It has also showed that the absorption of strontium lactate based on the 
strontium level in the serum samples was comparable if not higher than for other types of 
strontium salts, including strontium ranelate shown by earlier studies (594). However, a direct 
comparison and a solid conclusion on this matter could not be drawn due to the differences in 
the experimental set ups (strain and age of rats, study duration, sample size etc.).  




Based on the concerns raised by the European Medicines Agency regarding the safety 
of strontium ranelate treatment, restrictions to its use have been recommended to mitigate 
higher risk for cardiovascular events observed in patients undergoing strontium therapy. In 
principle, this would be consistent with the fact that strontium and calcium show similar 
physiological behavior. As for calcium supplementation, high strontium intakes may 
exacerbate risks of tissue mineralization and atherosclerosis by formation of poorly soluble 
strontium salts. Disproportionate changes in bone and soft tissue content relative to strontium 
levels in feed and serum let us hypothesize that a threshold level may exist on from which 
strontium is taken up less efficiently by bone and risks for tissue accumulation are increasing.  
In clinical settings, strontium ranelate is used at a dose level (500 mg/day of strontium) 
that is comparable to regular calcium supplementation which has been suggested to increase 
risks of soft tissues calcification. On top of that, strontium ranelate treatment is recommended 
to be administered together with up to 1,000 mg of calcium and 400 IU or 800 IU of vitamin 
D depending on the patients’ needs. The combined strontium and calcium intake may 
approach or even exceed the tolerable upper intake level of 2,000 mg per day which is the 
current upper limit for dietary intake of the US DRI for calcium. This would point to a 
reconsideration of practices of concomitant intake of calcium supplements and/or dosage 
levels for strontium therapy. 
Although strontium is used as a therapeutic agent for osteoporosis, it is not a foreign 
element to human. In fact, it can be found in many types of regular foods and beverages. The 
third aim of this thesis was to assess the intake of strontium, as a dietary component with 
potential positive effects on bone, in a group of Singaporean Chinese. The last study 
described in this thesis (Part B, Chapter 4) showed that the estimated strontium intake was 
1.03±0.08 mg strontium per day. It also showed that contents of strontium and calcium of the 
duplicate diets were correlated, which was expected. Overall, the strontium content of the 
Singaporean diet was found to be lower by two orders of magnitude than the therapeutic dose 
of strontium used in osteoporosis treatment (ca. 500 mg strontium per day in the form of 




strontium ranelate). As such, intake of strontium from the Singaporean diet has supposedly a 
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Table I-1: Changes in urinary 41Ca tracer excretion relative to natural calcium against time. 
The spot urine samples from the sheep were collected over 181 days. The 41Ca/40Ca 
measurements (n(41Ca)/n(40Ca)) were obtained from single measurements by using AMS with 
relative measurement uncertainty of 5% (coverage factor (k) = 1). The amount ratios of 41Ca 
tracer over natural calcium (n(41Catracer)/n(Canat)) were calculated based on the isotopic 









[1] [2] [3] [4] 
0.25 186509 178862 5.25 
0.5 106635 102263 5.01 
1 52321 50176 4.70 
2 22780 21846 4.34 
3 12132 11635 4.07 
5 6023 5776 3.76 
15 1512 1450 3.16 
19 1510 1448 3.16 
28 857 822 2.91 
34 746 716 2.85 
41 778 746 2.87 
50 710 681 2.83 
62 776 744 2.87 
89 622 597 2.78 
117 460 441 2.64 
132 354 339 2.53 
156 241 231 2.36 
169 245 235 2.37 
171 274 263 2.42 
172 259 248 2.40 
174 282 270 2.43 
181 241 231 2.36 
 
a  Amount ratio of 41Ca tracer to natural calcium was calculated by multiplying the measured amount 
ratio of 41Ca tracer to 40Ca in the sample (column [2]) with the natural isotopic abundance of 40Ca 
of 0.959. 
b  Log of amount ratio of 41Ca tracer to natural calcium was calculated by logarithmizing the amount 
ratio of 41Ca tracer to natural calcium (column [3]). 
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Table I-2: Changes in urinary 86Sr tracer excretion relative to natural calcium against time. The spot urine samples from the sheep were collected over 181 
days. The 86Sr/88Sr measurements (n(86Sr)/n(88Sr)) were obtained from triplicate measurements by TIMS. The amount ratios of 86Sr tracer over natural 
strontium (n(86Srtracer)/n(Srnat)) were calculated following IDMS principles. Natural strontium and calcium concentrations (c(Srnat) and c(Canat)) were obtained 
from triplicate measurements by AAS. 86Sr tracer concentration (c(86Srtracer)) and amount ratio of 86Sr tracer to natural calcium (n(86Srtracer)/n(Canat)) were 
calculated based on the amount ratio of 86Sr tracer to natural strontium, the concentration of natural strontium and the concentration of natural calcium. 














[1] [2] [3] [4] [5] [6] [7] [8] 
0.25 11.180585 12.8422 6.17 x 10-8 7.92 x 10-7 3.63 x 10-7 2.18 3.38 x 10-1 
0.5 6.208150 6.1047 1.55 x 10-8 9.47 x 10-8 5.93 x 10-7 1.60 x 10-1 -7.96 x 10-1 
2 1.125028 0.8849 3.61 x 10-9 3.19 x 10-9 1.69 x 10-7 1.89 x 10-2 -1.72 
5 0.347933 0.1974 2.08 x 10-9 4.10 x 10-10 1.42 x 10-7 2.89 x 10-3 -2.54 
19 0.173447 0.0465 2.81 x 10-9 1.31 x 10-10 4.98 x 10-7 2.62 x 10-4 -3.58 
34 0.147021 0.0238 3.45 x 10-9 8.21 x 10-11 1.28 x 10-6 6.40 x 10-5 -4.19 
41 0.144499 0.0216 4.95 x 10-9 1.07 x 10-10 2.36 x 10-6 4.54 x 10-5 -4.34 
50 0.142047 0.0195 2.92 x 10-9 5.69 x 10-11 6.08 x 10-7 9.36 x 10-5 -4.03 
62 0.130075 0.0092 1.06 x 10-9 9.75 x 10-12 1.71 x 10-7 5.71 x 10-5 -4.24 
75 0.138143 0.0162 3.69 x 10-9 5.96 x 10-11 4.63 x 10-7 1.29 x 10-4 -3.89 
103 0.130043 0.0092 3.73 x 10-10 3.43 x 10-12 2.70 x 10-8 1.27 x 10-4 -3.90 
117 0.140274 0.0180 1.48 x 10-9 2.65 x 10-11 1.64 x 10-7 1.62 x 10-4 -3.79 
132 0.127098 0.0067 1.75 x 10-9 1.16 x 10-11 4.20 x 10-7 2.77 x 10-5 -4.56 
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145 0.126190 0.0059 7.72 x 10-10 4.54 x 10-12 4.73 x 10-8 9.59 x 10-5 -4.02 
156 0.125975 0.0057 1.47 x 10-9 8.34 x 10-12 6.15 x 10-7 1.36 x 10-5 -4.87 
172 0.124040 0.0040 2.69 x 10-9 1.08 x 10-11 1.24 x 10-6 8.74 x 10-6 -5.06 
181 0.122916 0.0031 3.25 x 10-9 9.94 x 10-12 1.58 x 10-6 6.28 x 10-6 -5.20 
 
a Amount ratio of 86Sr tracer to natural strontium was calculated based on IDMS prinicples (Eqn. 2). 
b 86Sr tracer concentration in the sample was calculated by multiplying the amount ratio of 86Sr tracer to natural strontium (column [3]) with the concentration of natural 
strontium (column [4]). 
c Amount ratio of 86Sr tracer to natural calcium was calculated by dividing 86Sr tracer concentration in the sample (column [5]) with the natural calcium concentration 
(column [6]). 
d Log of amount ratio of 86Sr tracer to natural calcium was calculated by logarithmizing the amount ratio of 86Sr tracer to natural calcium (column [7]).  
Appendix I: Supplementary data for isotopic labeling of bone for assessment of changes in bone calcium balance: A comparative study in sheep using 




Table I-3: Changes in ratio of 86Sr to 41Ca urinary tracer excretion against time. The spot urine samples from the sheep were collected over 181 days. The 
concentrations of 86Sr tracer in the samples (c(86Srtracer)) were calculated in Table I-2. The amount ratios of 41Ca tracer to natural calcium (n(41Catracer)/n(Canat)) 
were calculated in Table I-1. Natural calcium concentrations (c(Canat)) were obtained from triplicate measurements using AAS. 41Ca tracer concentration in 
the sample (c(41Catracer)) and amount ratio of 86Sr tracer to 41Ca tracer (n(86Srtracer)/n(41Catracer)) were calculated based on the amount ratio of 41Ca tracer to 














[1] [2] [3] [4] [5] [6] [7] 
0.25 7.92 x 10-7 178862 3.63 x 10-7 6.50 x 10-14 1.22 x 107 7.09 
0.5 9.47 x 10-8 102263 5.93 x 10-7 6.06 x 10-14 1.56 x 106 6.19 
2 3.19 x 10-9 21846 1.69 x 10-7 3.68 x 10-15 8.66 x 105 5.94 
5 4.10 x 10-10 5776 1.42 x 10-7 8.20 x 10-16 5.00 x 105 5.70 
19 1.31 x 10-10 1448 4.98 x 10-7 7.21 x 10-16 1.81 x 105 5.26 
34 8.21 x 10-11 716 1.28 x 10-7 9.17 x 10-16 8.95 x 104 4.95 
41 1.07 x 10-10 746 2.36 x 10-6 1.76 x 10-15 6.08 x 104 4.78 
50 5.69 x 10-11 681 6.08 x 10-7 4.14 x 10-16 1.37 x 105 5.14 
62 9.75 x 10-12 744 1.71 x 10-7 1.27 x 10-16 7.67 x 104 4.88 
117 2.65 x 10-11 441 1.64 x 10-7 7.23 x 10-17 3.67 x 105 5.56 
132 1.16 x 10-11 339 4.20 x 10-7 1.43 x 10-16 8.16 x 104 4.91 
156 8.34 x 10-12 231 6.15 x 10-7 1.42 x 10-16 5.87 x 104 4.77 
172 1.08 x 10-11 248 1.24 x 10-6 3.08 x 10-16 3.52 x 104 4.55 
181 9.94 x 10-12 231 1.58 x 10-6 3.66 x 10-16 2.71 x 104 4.43 
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a 41Ca tracer concentration in the sample was calculated by multiplying the amount ratio of 41Ca tracer to natural calcium (column [3]) with the 
concentration of natural calcium (column [4]). 
b Amount ratio of 86Sr tracer to 41Ca tracer was calculated by dividing 86Sr tracer concentration in the sample (column [2]) with 41Ca tracer concentration in 
the sample (column [5]). 
c Log of amount ratio of 86Sr tracer to 41Ca tracer was calculated by logarithmizing the amount ratio of 86Sr tracer to 41Ca tracer (column [6]).  
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Table I-4: Strontium isotopic ratio and strontium and calcium elemental contents in urine samples. The spot urine samples from the sheep were collected over 
181 days. The 86Sr/88Sr measurements (n(86Sr)/n(88Sr)) were obtained from triplicate measurements by TIMS. Natural strontium and calcium concentrations 
(c(Srnat) and c(Canat)) were obtained from triplicate measurements using AAS. This table shows the individual measurements, average and %RSD for each 
spot urine sample. 
 
Day 
n(86Sr) /n(88Sr)  c(Srnat)  c(Canat) 

















 6.25 x 10-8 
6.17 x 10-8 4.91% 
 3.76 x 10-7 
3.63 x 10-7 3.00% 11.18187  5.83 x 10-8  3.59 x 10-7 




 1.60 x 10-8 
1.55 x 10-8 4.27% 
 5.88 x 10-7 
5.93 x 10-7 0.79% 6.20818  1.82 x 10-8  5.94 x 10-7 




 3.60 x 10-9 
3.61 x 10-9 0.14% 
 1.80 x 10-7 
1.69 x 10-7 9.40% 1.12528  4.16 x 10-9  1.57 x 10-7 




 2.04 x 10-9 
2.08 x 10-9 1.68% 
 1.44 x 10-7 
1.42 x 10-7 2.88% 0.34792  2.10 x 10-9  1.37 x 10-7 




 2.67 x 10-9 
2.81 x 10-9 4.25% 
 4.87 x 10-7 
4.98 x 10-7 2.00% 0.17344  2.85 x 10-9  5.07 x 10-7 
0.17346  2.90 x 10-9  5.00 x 10-7 
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c(Srnat)  c(Canat) 















 2.86 x 10-9 
3.45 x 10-9 5.76% 
 1.34 x 10-6 
1.28 x 10-6 4.49% 0.14701  3.59 x 10-9  1.28 x 10-6 






5.30 x 10-9 
4.95 x 10-9 0.83% 
 2.38 x 10-6 
2.36 x 10-6 2.46% 0.14450 0.001% 4.98 x 10-9  2.29 x 10-6 






2.78 x 10-9 
2.92 x 10-9 4.50% 
 5.83 x 10-7 
6.08 x 10-7 4.99% 0.14204 2.93 x 10-9  6.42 x 10-7 






1.02 x 10-9 
1.06 x 10-9 3.79% 
 1.80 x 10-7 
1.71 x 10-7 4.97% 0.13007 0.002% 1.10 x 10-9  1.68 x 10-7 






3.75 x 10-9 
3.69 x 10-9 5.25% 
 4.74 x 10-7 
4.63 x 10-7 3.31% 0.13814 0.003% 3.85 x 10-9  4.46 x 10-7 
0.13815  3.48 x 10-9  4.69 x 10-7 
103 0.13004 0.13004  
 
3.73 x 10-10 3.73 x 10-10 
 
 2.70 x 10-8 2.70 x 10-8 
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c(Srnat)  c(Canat) 
















1.50 x 10-9 
1.48 x 10-9 3.02% 
 1.64 x 10-7 
1.64 x 10-7 1.42% 0.14028 
 
1.42 x 10-9  1.66 x 10-7 
0.14027 
 





1.67 x 10-9 
1.75 x 10-9 5.00% 
 4.13 x 10-7 
4.20 x 10-7 1.53% 0.12710 
 
1.72 x 10-9  4.26 x 10-7 
0.12710 
 
1.84 x 10-9  4.21 x 10-7 
145 0.12619 0.12619  
 
7.72 x 10-10 7.72 x 10-10 
 







1.48 x 10-9 
1.47 x 10-9 4.08% 
 6.01 x 10-7 
6.15 x 10-7 3.58% 0.12599 0.013% 1.51 x 10-9  6.03 x 10-7 






2.61 x 10-9 
2.69 x 10-9 3.02% 
 1.28 x 10-6 
1.24 x 10-6 2.71% 0.12400 0.055% 2.70 x 10-9  1.23 x 10-6 






2.39 x 10-9 
3.25 x 10-9 11.72% 
 1.55 x 10-6 
1.58 x 10-6 2.53% 0.12464 2.443% 2.98 x 10-9  1.57 x 10-6 
0.12466  3.52 x 10-9  1.63 x 10-6 
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Table I-5: Amount ratio of 41Ca tracer relative to natural calcium for different bone sites. The 41Ca/40Ca measurements (n(41Ca)/n(40Ca)) were obtained from 
single measurements using AMS with relative measurement uncertainty of 5% (coverage factor (k) = 1). The ratios of 41Ca tracer over natural calcium 
(n(41Catracer)/n(Canat)) were calculated based on the isotopic abundance of 40Ca. Column numbers are indicated in square brackets. 
 
Sample Bone Typea Bone Site 
n(41Ca)/n(40Ca) n(41Catracer)/n(Canat) 
(10-12 mol/mol) (10-12 mol/mol)b (mol/mol) 
[1] [2] [3] [4] [5] [6] 
Tibia 
C T A2 a 228 219 2.19 x 10-10 
T T A2 b 270 259 2.59 x 10-10 
C T A2 c 368 353 3.53 x 10-10 
C TH 185 177 1.77 x 10-10 
C T P2 e 748 718 7.18 x 10-10 
T T P2 c 474 454 4.54 x 10-10 
T T P2 b 190 182 1.82 x 10-10 
T-C T P2 a 252 242 2.42 x 10-10 
      
Metacarpus 
T-C MC A2 a 181 174 1.74 x 10-10 
C MC A2 b 151 145 1.45 x 10-10 
C MC E 116 111 1.11 x 10-10 
T MC J3 a 332 318 3.18 x 10-10 
C-T MC J3 b 359 344 3.44 x 10-10 
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Table I-5 (cont’d): 41Ca tracer relative to natural calcium for different bone sites. 
 
Sample Bone Typea Bone Site 
n(41Ca)/n(40Ca) n(41Catracer)/n(Canat) 
(10-12 mol/mol) (10-12 mol/mol)b (mol/mol) 
Metatarsus 
T-C MT A2 a 223 214 2.14 x 10-10 
C MT A2 b 351 336 3.36 x 10-10 
C MT E 305 293 2.93 x 10-10 
C-T MT J3 b 254 244 2.44 x 10-10 
      
Radius 
T-C R A3 a 195 187 1.87 x 10-10 
T R A3 b 188 181 1.81 x 10-10 
T R A3 c 628 602 6.02 x 10-10 
T R A3 d 700 671 6.71 x 10-10 
T-C R A3 e 781 749 7.49 x 10-10 
C R H 224 214 2.14 x 10-10 
C R K 223 214 2.14 x 10-10 
T R N 176 169 1.69 x 10-10 
      
Vertebrae 
C-T V B 659 632 6.32 x 10-10 
C V F a 254 244 2.44 x 10-10 
T V F b 212 204 2.04 x 10-10 
 
a C refers to cortical bone. T refers to trabecular bone. C-T refers to a mix of cortical and trabecular bone, dominated by the cortical portion. T-C refers to a mix of 
trabecular and cortical bone, dominated by the trabecular portion. 
b  Amount ratio of 41Ca tracer to natural calcium was calculated by multiplying the measured amount ratio of 41Ca tracer to 40Ca in the sample (column [4]) with the natural 
isotopic abundance of 40Ca of 0.959.  
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Table I-6: 86Sr tracer relative to 41Ca tracer for different bone sites. The 86Sr/88Sr measurements (86Sr/88Sr) were obtained from single measurements by using 
TIMS with relative measurement uncertainty of 10 ppm (k=1). The amount ratios of 86Sr tracer over natural strontium (n(86Srtracer)/n(Srnat)) were calculated 
following IDMS principles. Natural strontium and calcium concentrations (c(Srnat) and c(Canat)) were obtained from triplicate measurements using AAS. The 
amount ratio of 41Ca tracer to natural calcium (n(41Catracer)/n(Canat)) was calculated in Table I-5. 86Sr tracer concentration (c(86Srtracer)), 41Ca tracer 
concentration (c(41Catracer)) and amount ratio of 86Sr tracer to 41Ca tracer in the sample (n(86Srtracer)/n(41Catracer)) were calculated based on the amount ratio of 
86Sr tracer to natural strontium, the concentration of natural strontium, the amount ratio of 41Ca tracer to natural calcium and the concentration of natural 
























[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 
Tibia 
 
C T A2 a 0.126871 0.0065 1.28 x 10-6 8.26 x 10-9 2.19 x 10-10 6.05 x 10-3 1.33 x 10-12 6.24 x 103 
C T A2 c 0.132086 0.0109 1.37 x 10-6 1.50 x 10-8 3.53 x 10-10 5.72 x 10-3 2.02 x 10-12 7.43 x 103 
C TH 0.124877 0.0047 1.58 x 10-6 7.50 x 10-9 1.77 x 10-10 6.60 x 10-3 1.17 x 10-12 6.42 x 103 
C T P2 e 0.145326 0.0223 1.45 x 10-6 3.23 x 10-8 7.18 x 10-10 6.15 x 10-3 4.41 x 10-12 7.33 x 103 
T T P2 c 0.131061 0.0101 9.81 x 10-7 9.87 x 10-9 4.54 x 10-10 4.66 x 10-3 2.12 x 10-12 4.66 x 103 
T T P2 b 0.125590 0.0054 1.10 x 10-6 5.89 x 10-9 1.82 x 10-10 4.93 x 10-3 8.97 x 10-12 6.56 x 103 
T-C T P2 a 0.124243 0.0042 1.02 x 10-6 4.30 x 10-9 2.42 x 10-10 4.46 x 10-3 1.08 x 10-12 4.00 x 103 
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T-C MC A2 a 0.124959 0.0048 1.13 x 10-6 5.45 x 10-9 1.74 x 10-10 5.78 x 10-3 1.00 x 10-12 5.43 x 103 
C MC A2 b 0.124407 0.0043 1.47 x 10-6 6.37 x 10-9 1.45 x 10-10 6.19 x 10-3 8.95 x 10-13 7.12 x 103 
C MC E 0.123102 0.0032 1.42 x 10-6 4.57 x 10-9 1.11 x 10-10 7.00 x 10-3 7.79 x 10-13 5.86 x 103 
T MC J3 a 0.131057 0.0101 1.16 x 10-6 1.17 x 10-8 3.18 x 10-10 5.31 x 10-3 1.69 x 10-12 6.92 x 103 
C-T MC J3 b 0.132145 0.0110 1.48 x 10-6 1.63 x 10-8 3.44 x 10-10 6.41 x 10-3 2.21 x 10-12 7.38 x 103 
           
Meta-
tarsus 
T-C MT A2 a 0.123382 0.0035 1.13 x 10-6 3.92 x 10-9 2.14 x 10-10 5.22 x 10-3 1.12 x 10-12 3.50 x 103 
C MT E 0.129610 0.0088 1.14 x 10-6 1.01 x 10-8 2.93 x 10-10 6.09 x 10-3 1.78 x 10-12 5.66 x 103 
C-T MT J3 b 0.122080 0.0023 1.26 x 10-6 2.96 x 10-9 2.44 x 10-10 6.38 x 10-3 1.55 x 10-12 1.90 x 103 
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T-C R A3 a 0.125862 0.0056 1.15 x 10-6 6.44 x 10-9 1.87 x 10-10 5.17 x 10-3 9.65 x 10-13 6.67 x 103 
T R A3 b 0.125178 0.0050 1.39 x 10-6 6.94 x 10-9 1.81 x 10-10 5.08 x 10-3 9.18 x 10-13 7.56 x 103 
T R A3 c 0.144344 0.0215 1.08 x 10-6 2.31 x 10-8 6.02 x 10-10 5.10 x 10-3 3.07 x 10-12 7.53 x 103 
T R A3 d 0.146565 0.0234 1.38 x 10-6 3.22 x 10-8 6.71 x 10-10 5.21 x 10-3 3.50 x 10-12 9.21 x 103 
T-C R A3 e 0.149815 0.0262 1.42 x 10-6 3.72 x 10-8 7.49 x 10-10 5.72 x 10-3 4.28 x 10-12 8.69 x 103 
C R H 0.126619 0.0062 1.42 x 10-6 8.84 x 10-9 2.14 x 10-10 6.66 x 10-3 1.43 x 10-12 6.19 x 103 
C R K 0.126930 0.0065 1.47 x 10-6 9.56 x 10-9 2.14 x 10-10 5.94 x 10-3 1.27 x 10-12 7.52 x 103 
T R N 0.124787 0.0047 9.68 x 10-7 4.52 x 10-9 1.69 x 10-10 4.71 x 10-3 7.96 x 10-13 5.68 x 103 
 
a C refers to cortical bone. T refers to trabecular bone. C-T refers to a mix of cortical and trabecular bone, dominated by the cortical portion. T-C refers to a mix of 
trabecular and cortical bone, dominated by the trabecular portion. 
b 86Sr tracer concentration in the sample was calculated by multiplying the amount ratio of 86Sr tracer to natural strontium (column [5]) with the concentration of natural 
strontium (column [6]). 
c 41Ca tracer concentration in the sample was calculated by multiplying the amount ratio of 41Ca tracer to natural calcium (column [8]) with the concentration of natural 
calcium (column [9]). 
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Table II-1: Rats’ body weights. The body weight of each rat was monitored weekly 
throughout the study period. Numbers in the table header indicate individual rats (n=10) in 
each of the groups. 
Day 
Body Weight (gram) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
Control Group 
1 580 624 608 670 642 640 613 577 654 615 622 30 
4 580 626 604 669 638 642 614 585 660 619 624 29 
11 590 637 619 694 637 671 633 602 686 634 640 34 
18 601 650 628 696 646 670 631 594 694 632 644 35 
25 602 669 626 707 653 684 641 607 706 644 654 37 
31 603 675 637 714 658 683 651 611 716 638 659 39 
38 614 699 645 714 670 694 654 626 729 648 669 38 
45 618 707 657 735 678 710 669 643 752 653 682 43 
54 628 720 659 740 690 714 679 652 760 663 691 42 
60 634 733 663 741 698 721 677 654 769 669 696 44 
66 640 743 670 750 701 732 685 666 782 675 704 45 
73 642 758 677 756 700 723 681 669 781 672 706 46 
83 642 758 673 756 690 728 681 673 - 674 697 41 
Mean 613 691 644 719 669 693 655 627 728 649 669 39 
 
Low Dose Group 
4 653 597 582 668 586 591 615 668 618 571 615 36 
11 655 604 576 669 582 606 616 681 622 574 619 38 
28 676 631 594 706 606 625 620 712 602 580 635 47 
32 674 629 593 701 615 626 626 711 630 581 639 43 
39 674 644 595 710 615 634 629 721 644 583 645 45 
47 683 645 600 711 604 645 638 730 651 593 650 46 
56 695 649 601 728 614 655 652 744 664 594 660 51 
60 693 658 596 727 618 658 650 742 663 596 660 50 
67 705 668 597 734 624 672 656 741 663 588 665 52 
76 716 688 603 734 610 683 668 750 668 600 672 54 
83 715 687 612 750 623 691 662 761 677 596 677 56 
Mean 678 635 590 702 604 633 634 713 640 584 641 44 
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Table II-1 (cont’d): Rats’ body weights. 
 
Day 
Body Weight (gram) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
High Dose Group 
0 623 728 702 697 694 613 690 692 655 659 675 37 
6 623 724 692 695 690 608 684 692 648 663 672 36 
13 629 736 688 713 684 611 689 678 636 669 673 39 
20 630 754 698 719 698 618 695 689 648 695 684 41 
28 640 764 703 734 713 617 705 677 651 702 691 45 
34 644 770 695 736 706 615 714 688 660 710 694 45 
41 650 781 702 740 715 611 735 689 665 716 700 49 
56 666 788 700 761 724 601 749 698 667 737 709 55 
62 668 787 702 768 730 608 754 673 679 744 711 55 
69 649 800 707 758 733 608 750 590 675 755 703 70 
77 650 821 710 767 744 608 742 566 660 764 703 80 
83 628 792 708 757 733 604 735 578 652 767 695 75 
Mean 643 770 700 736 712 611 720 668 659 711 693 47 




Table II-2: Rats’ drinking water consumption. The amount of water consumed by each rat was monitored regularly (2-3 times weekly) and average daily 
water consumption was calculated. Empty cells show that no reading was taken on those days and the average was based on the following monitoring periods. 
Numbers in the table header indicate individual rats (n=10) in each of the groups. 
Day 
Average Amount of Water Consumed (gram/day)   
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
Control Group   
0 20.3 19.6 23.6 26.9 19.0 30.5 22.9 21.5 25.3 24.4 23.4 3.6 
1 16.8 23.8 21.2 22.3 17.8 25.0 24.0 25.2 26.8 28.4 23.1 3.7 
4 20.9 26.2 24.6 23.6 21.5 26.4 22.5 26.9 29.9 33.1 25.6 3.8 
5 24.6 30.3 32.5 35.7 20.7 39.9 33.5 46.2 50.4 46.1 36.0 9.7 
8 31.1 32.0 32.4 31.6 30.7 54.2 37.2 39.2 43.9 47.7 43.6 4.3 
11 33.2 33.9 35.9 34.7 37.2 43.4 40.7 33.0 49.0 51.3 39.23 6.7 
13 - - - - - - - 44.7 39.7 56.1 46.8 8.4 
18 35.5 35.0 31.2 33.9 33.2 40.1 45.5 41.7 45.4 54.2 39.6 7.2 
25 31.5 33.1 32.2 33.4 36.1 41.8 42.1 42.4 40.5 54.0 38.7 6.9 
32 36.2 40.8 33.8 30.3 38.4 45.7 51.3 34.2 49.7 57.1 41.8 8.8 
36 35.1 36.4 37.8 32.6 36.3 45.3 56.5 35.4 46.7 58.5 42.1 9.3 
39 34.5 36.9 34.2 36.4 37.5 47.9 45.5 38.3 44.9 58.7 41.5 7.7 
43 34.4 30.1 31.3 40.7 32.5 42.2 43.1 37.1 42.7 61.9 39.6 9.2 
46 42.5 36.1 36.6 42.6 37.3 45.2 45.9 54.2 49.8 61.7 45.2 8.2 
49 40.6 33.8 30.9 32.4 31.8 48.0 37.6 43.3 42.1 63.4 40.4 9.9 




Table II-2 (cont’d): Rats’ drinking water consumption. 
 
Day 
Average Amount of Water Consumed (gram/day) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
53 36.5 32.3 36.3 34.3 31.9 47.3 41.5 37.1 42.2 62.9 40.2 9.3 
56 37.3 29.4 34.1 30.5 31.1 41.4 36.5 37.3 41.2 53.4 37.2 7.1 
61 34.5 32.0 33.9 30.0 28.3 28.5 36.8 32.3 41.7 40.4 33.8 4.6 
63 36.8 32.1 28.7 30.6 31.1 38.8 38.6 33.7 41.4 42.0 35.4 4.7 
67 32.0 34.3 29.4 32.8 28.2 39.3 49.9 36.0 37.7 56.4 37.6 9.0 
71 38.2 31.5 31.8 31.7 23.9 46.2 43.9 44.0 42.4 57.5 39.1 9.7 
74 37.3 30.7 32.2 31.0 23.5 47.7 45.3 40.8 37.6 56.6 38.3 9.7 
78 36.8 33.9 31.7 29.1 25.6 49.7 49.6 38.5 - 52.5 38.6 9.8 
           
  
Low Dose Group 
         
  
0 22.3 39.4 30.4 36.8 29.5 28.0 27.7 31.5 26.2 23.3 29.5 5.4 
4 23.3 34.9 28.9 35.4 29.9 29.5 27.0 28.2 26.3 23.0 28.6 4.2 
8 25.3 33.8 29.6 37.1 31.1 33.2 25.7 33.2 29.1 22.3 30.0 4.6 
11 26.8 35.2 30.1 34.2 33.0 26.5 25.6 33.9 29.9 22.3 29.7 4.3 
15 26.7 39.5 33.5 45.4 39.1 26.2 23.4 32.8 34.3 24.1 32.5 7.4 
20 26.9 35.1 33.3 40.2 40.2 29.4 25.4 35.3 36.3 26.6 32.9 5.5 
22 - - - - - - - 32.7 33.9 28.1 31.6 3.1 
25 18.7 42.0 39.5 37.8 41.8 42.3 49.3 41.4 28.7 29.9 37.1 8.9 




Table II-2 (cont’d): Rats’ drinking water consumption. 
 
Day 
Average Amount of Water Consumed (gram/day) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
28 20.0 23.8 22.2 46.6 29.7 17.9 17.9 41.6 14.9 27.3 26.2 10.5 
32 26.4 36.4 30.1 37.9 35.8 27.5 26.6 32.9 43.3 27.6 32.5 5.8 
35 23.3 38.2 31.8 43.5 41.5 28.4 24.0 38.0 38.7 25.7 33.3 7.6 
39 27.4 39.9 32.7 41.9 38.1 24.7 26.0 39.8 43.1 26.4 34.0 7.3 
42 27.8 41.8 33.9 41.0 34.2 27.6 25.7 42.6 36.8 22.8 33.4 7.2 
47 28.2 43.5 31.7 42.6 32.0 27.7 25.0 34.8 44.4 26.0 33.6 7.5 
49 32.2 38.2 35.9 37.8 32.1 26.9 26.6 37.0 36.8 25.2 32.9 5.1 
53 29.8 39.7 32.7 44.5 36.0 28.4 27.8 37.0 34.0 25.3 33.5 6.0 
56 24.9 34.4 28.0 42.7 35.3 24.0 24.0 30.4 34.0 26.7 30.4 6.1 
60 26.9 38.0 31.3 48.2 32.9 29.4 25.8 34.2 34.5 27.4 32.9 6.6 
63 27.1 38.2 30.4 36.7 32.8 27.9 25.1 30.3 31.1 24.0 30.4 4.6 
67 28.5 37.3 26.8 29.6 36.0 29.6 24.6 38.0 36.4 25.9 31.3 5.1 
70 28.0 37.0 29.8 36.6 34.7 27.6 25.2 31.8 31.6 24.7 30.7 4.4 
76 22.8 33.5 33.7 36.5 34.9 26.2 23.8 31.8 33.9 23.2 30.0 5.4 
81 26.2 38.7 33.1 41.4 33.6 26.9 22.3 26.8 34.0 21.4 30.4 6.7 
           
  
High Dose Group 
         
  
0 19.3 19.0 16.0 24.9 18.5 17.5 20.3 21.3 18.7 19.5 19.5 2.4 




Table II-2 (cont’d): Rats’ drinking water consumption. 
 
Day 
Average Amount of Water Consumed (gram/day) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
3 19.3 26.9 22.3 25.5 30.2 23.1 25.9 24.5 19.5 26.0 24.3 3.4 
6 19.1 28.9 24.4 28.7 24.0 24.3 27.6 22.2 19.4 26.8 24.5 3.5 
13 19.5 30.6 28.1 28.7 23.3 26.8 25.5 25.3 22.7 28.8 25.9 3.4 
20 20.7 31.6 28.4 31.2 25.5 26.1 28.7 24.3 23.4 27.0 26.7 3.4 
28 21.6 29.1 26.6 31.4 21.5 17.0 26.4 23.5 24.3 29.1 25.1 4.3 
34 20.9 31.5 27.7 30.0 22.4 25.3 27.1 23.7 26.2 26.7 26.1 3.3 
37 21.4 33.2 28.3 28.8 25.4 23.1 31.1 23.9 25.2 26.7 26.7 3.7 
40 21.2 34.0 30.5 31.7 25.1 26.0 28.7 26.9 26.9 29.0 28.0 3.6 
44 21.1 35.2 30.4 30.3 26.3 25.3 25.8 27.9 26.8 28.5 27.7 3.8 
49 21.5 34.6 31.0 34.5 26.6 20.9 29.4 27.9 27.8 36.8 29.1 5.3 
54 30.3 24.8 28.3 37.5 21.5 13.6 9.5 16.9 30.6 26.8 24.0 8.6 
57 25.3 36.5 39.2 26.5 29.2 36.3 35.9 49.5 27.6 29.0 33.5 7.5 
61 23.6 36.7 35.0 31.9 26.3 29.9 28.5 11.2 28.6 30.7 28.2 7.1 
64 15.5 30.1 31.8 28.8 24.6 27.0 23.1 5.4 28.1 28.5 24.3 8.1 
68 20.2 38.6 31.3 30.3 26.2 29.3 27.5 7.6 28.7 29.7 27.0 8.2 
71 18.3 38.5 33.1 33.9 23.8 29.0 25.2 16.8 22.7 28.8 27.0 7.0 
76 20.1 42.8 36.8 33.1 25.5 29.1 28.8 20.5 29.7 34.4 30.1 7.1 
78 17.8 33.2 35.3 30.8 24.6 28.1 27.0 25.6 27.0 30.8 28.0 5.0 
83 19.7 49.9 23.5 28.9 23.7 25.0 31.6 26.7 22.5 30.0 28.2 8.5 




Table II-3: Rats’ strontium intake from drinking water. The amount of strontium intake for each rat was estimated based on the strontium concentration in 
the drinking water and the amount of water consumed. The total amount of strontium intake was added up at the end of the study and the average daily intake 
was calculated. Empty cells show that no reading was taken on those days and the total amount of intake was based on the following monitoring periods. 





Total Amount of Strontium Intake (mg)   
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
Low Dose Group 
         
  
0 0.2 179 315 243 294 236 224 222 252 209 187   
4 0.2 186 279 231 283 239 236 216 225 210 184   
8 0.2 152 202 177 223 187 199 154 199 175 134   
11 0.2 214 281 241 273 264 212 205 271 240 178   
15 0.2 266 395 334.86 454 391 262 234 328 343 241   
20 0.2 269 351 333 402 402 293 254 141 145 106   
22 0.2 - - - - - - - 196 203 169   
25 0.2 112 252 237 227 251 254 296 248 172 179   
28 0.2 160 190 178 373 238 143 143 333 120 218   
32 0.2 159 219 181 228 215 165 160 198 260 165   
35 0.2 187 305 255 348 332 227 192 304 309 206   
39 0.2 164 240 196 252 229 148 156 239 259 158   
42 0.2 278 418 339 410 342 276 257 426 368 228   
47 0.2 113 174 127 171 128 111 100 139 178 104   









Total Amount of Strontium Intake (mg)  
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
49 0.2 258 306 287 302 257 215 213 296 295 201   
53 0.2 179 238 196 267 216 170 167 222 204 152   
56 0.2 199 275 224 342 282 192 192 243 272 214   
60 0.2 161 228 188 289 197 176 155 205 207 165   
63 0.2 217 305 243 294 263 223 201 242 249 192   
67 0.2 171 224 161 178 216 178 148 228 218 155   
70 0.2 336 443 357 439 416 331 303 382 379 296   
76 0.2 228 335 337 365 349 262 239 318 339 232   
81 0.2 157 232 199 249 201 161 134 161 204 128   




4344 6209 5262 6661 5849 4659 4337 5798 5557 4192   
Average / day 52 734 63 79 70 56 52 69 66 50   
Average / kg / day 76 116 106 113 115 88 82 97 103 86 98 15 
            
  
High Dose Group   
0 1 578 569 481 746 554 525 610 639 560 586   
3 1 579 807 670 766 906 694 777 734 585 780   
6 1 1338 2020 1709 2007 1683 1698 1928 1554 1357 1873   









Total Amount of Strontium Intake (mg) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
13 1 1368 2141 1968 2006 1630 1873 1784 1771 1592 2019   
20 1 1654 2530 2270 2498 2036 2087 2295 1943 1873 2158   
28 1 1297 1745 1594 1883 1291 1022 1581 1410 1460 1746   
34 1 836 1259 1106 1200 894 1011 1085 947 1048 1066   
37 1 642 997 850 862 761 694 933 717 756 801   
40 1 847 1359 1219 1267 1003 1039 1150 1076 1074 1159   
44 1 1053 1758 1518 1514 1316 1263 1290 1394 1338 1426   
49 1 1077 1730 1551 1724 1330 1047 1472 1397 1389 1841   
54 1 909 743 848 1126 645 407 285 508 918 804   
57 1 1011 1462 1568 1059 1168 1453 1434 1981 1106 1158   
61 1 706 1101 1051 956 790 896 854 336 858 921   
64 1 619 1202 1272 1153 986 1081 924 214 1124 1139   
68 1 606 1159 937 910 786 880 826 229 861 890   
71 1 916 1926 1656 1696 1192 1449 1260 838 1134 1442   
76 1 403 856 736 663 511 582 576 411 593 688   
78 1 710 1329 1410 1233 983 1123 1079 1025 1080 1233   
83 1 197 499 235 289 237 250 316 267 225 300   
  









Total Amount of Strontium Intake (mg) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
Total 17345 27190 24651 25555 20699 21073 22456 19391 20930 24030   
Average / day 207 324 294 304 246 251 267 231 249 286   
Average / kg / day 321 421 419 414 346 411 371 345 378 402 382.79 35.91 




Table II-4: Rats’ feed consumption. The feed intake for each rat was monitored regularly. The total amount of feed intake was added up at the end of the 
study and the average daily intake was calculated. Empty cells show that no reading was taken on those days and the average was based on the following 
monitoring periods. Numbers in the table header indicate individual rats (n=10) in each of the groups. 
Day 
Average Feed Intake (g/day) 
  
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
Control Group 
          
1 24 29 26 29 21 27 25 26 31 26 26 3 
4 24 27 26 31 22 29 24 32 31 26 27 3 
11 27 31 29 33 25 34 27 21 34 29 29 4 
18 25 31 27 31 25 31 26 26 33 27 28 3 
32 25 31 27 31 27 30 25 27 32 27 28 2 
56 26 30 27 29 25 30 25 27 - 28 27 2 
Average 25 30 27 30 25 30 25 27 31 27 28 2 
             Low Dose Group 
          
4 23 30 30 26 25 27 25 27 25 23 26 2 
15 26 29 24 29 28 28 27 30 26 24 27 2 
49 27 30 23 27 28 27 26 29 26 24 27 2 
 
83 - 25 18 - - - - - - - - - 
 
Average 25 28 24 26 26 26 25 27 25 23 26 2 
 
               




Table II-4 (cont’d): Rats’ feed consumption. 
Day 
Average Feed Intake (g/day) 
1 2 3 4 5 6 7 8 9 10 Mean ± SD 
High Dose Group 
          
0 26 29 25 29 27 24 29 28 29 35 28 3 
6 23 29 24 26 23 23 28 23 21 32 25 3 
13 23 30 24 28 26 23 28 25 23 33 26 3 
23 25 31 25 30 26 21 29 25 24 32 27 4 
55 24 29 26 29 26 23 27 14 23 33 25 5 
77 - - - - - - - - - 32 32 - 
83 - 38 - 29 - - - - - 38 35 - 
84 - - - - - - 31 - - 35 33 - 
Average 24 30 25 29 26 22 28 21 24 33 26 4 
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Table II-5: Strontium concentration in rat serum samples. The serum samples were collected 
one day before the sacrifice. Strontium spike (n(Srspike)) was added into the sample for 
quantification. The 86Sr/88Sr measurements (n(86Sr)/n(88Sr)) were obtained from single 
measurements using TIMS (relative measurement uncertainty of ~10 ppm, k=1). Number of 
moles strontium in the sample (n(Srsample)) was calculated following IDMS principles. 
Concentration of strontium in the sample (c(Srsample)) was calculated based on the number of 
moles strontium in the sample and the mass of the serum sample (mserum). Column numbers 
are indicated in square brackets. 
 







[1] [2] [3] [4] [5] [6] 
Baseline      1 0.20549 0.00527 13.80674 0.00020 0.084 
2 0.20886 0.00530 13.59199 0.00021 0.086 
3 0.20301 0.00524 13.14927 0.00022 0.094 
4 0.20943 0.00526 13.54903 0.00021 0.086 
5 0.19944 0.00524 13.19258 0.00022 0.095 
6 0.20214 0.00528 13.21627 0.00022 0.094 
7 0.20640 0.00522 13.36808 0.00021 0.089 
8 0.20611 0.00528 12.71088 0.00024 0.100 
9 0.20415 0.00528 13.61613 0.00020 0.087 
10 0.20080 0.00534 13.68012 0.00020 0.089 
Average     0.091 
SD     0.005 
%RSD     6% 
      
Control Group 
    
1 0.19581 0.00512 13.68779 0.00020 0.087 
2 0.20131 0.00517 13.77199 0.00019 0.085 
3 0.20482 0.00522 13.65571 0.00020 0.086 
4 0.20000 0.00518 13.81659 0.00019 0.085 
5 0.20087 0.00525 13.83975 0.00020 0.085 
6 0.20463 0.00527 13.67686 0.00020 0.086 
7 0.20890 0.00526 13.58284 0.00020 0.086 
8 0.20768 0.00523 13.13229 0.00022 0.092 
10 0.20092 0.00523 13.67553 0.00020 0.087 
Average     0.086 
SD     0.002 
%RSD     3% 
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Table II-5 (cont’d): Strontium concentration in rat serum samples. 









Low Dose Group 
    
1 0.10312 0.00517 0.73594 0.00938 8.0 
2 0.10281 0.00518 0.62337 0.01156 9.9 
3 0.10462 0.00518 0.56206 0.01320 11.1 
4 0.10708 0.00519 0.47979 0.01630 13.3 
5 0.10227 0.00512 0.73857 0.00925 7.9 
6 0.10184 0.00523 0.70176 0.01008 8.7 
7 0.10179 0.00524 0.94650 0.00703 6.1 
8 0.10428 0.00527 0.68408 0.01047 8.8 
9 0.09909 0.00533 0.49901 0.01587 14.0 
10 0.105 0.00511 0.99273 0.00648 5.4 
Average     9.3 
SD     2.8 
%RSD     30% 
     
High Dose Group 
    
1 0.09976 0.00509 0.25909 0.04160 36.5 
2 0.10429 0.00523 0.23784 0.05049 42.4 
3 0.09968 0.00520 0.25582 0.04355 38.3 
4 0.10894 0.00523 0.24860 0.04625 37.2 
5 0.10108 0.00521 0.26217 0.04169 36.1 
6 0.10158 0.00508 0.28470 0.03503 30.2 
7 0.09093 0.00523 0.29053 0.03484 33.6 
8 0.10142 0.00517 0.29287 0.03401 29.4 
9 0.10508 0.00518 0.25664 0.04314 36.0 
10 0.10229 0.00518 0.25987 0.04214 36.1 
Average     35.6 
SD     3.8 
%RSD     11% 
 
a Number of moles of strontium in the sample was calculated following IDMS principles (Eqn. 2). 
b Concentration of strontium in the sample was calculated by multiplying the number of mol of 
strontium in the sample (column [5]) with the standard atomic weight of strontium in the sample 
(87.61681) and dividing it by the mass of the serum (column [2]). 
  




Table II-6: Strontium concentration in rat bone samples. After being subjected to three-point bending measurement, the whole right tibia was weighed and 
subjected to microwave-assisted acid digestion. The digest was evaporated and a portion of it was used for strontium analysis. Strontium spike (n(Srspike)) was 
added and equilibrated with the strontium from the sample (n(Srsample)). The 86Sr/88Sr measurements (n(86Sr)/n(88Sr)) were obtained from single measurements 
using TIMS (relative measurement uncertainty of ~10 ppm, k=1). Number of moles strontium in the sample (n(Srsample)) was calculated following IDMS 
principles. Concentration of strontium in the sample (c(Srbone)) was calculated based on the number of moles strontium in the sample, the total mass of digest 
(mdigest), the dilution factor (mtotal/mdilute), the mass of the sample used for measurement (manalyze) and the mass of the bone sample (mbone). Column numbers are 

























[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 
Baseline 
           
1 0.66138 4.99794 
  
0.25226 0.50612 0.00589 0.69937 0.0114 3.95 19.8 29.9 
2 0.72278 5.00551 
  
0.25006 0.50108 0.00583 0.62560 0.0130 4.54 22.7 31.4 
3 0.76378 4.99660 
  
0.25478 0.50085 0.00582 0.65501 0.0122 4.20 21.0 27.5 
4 0.71218 5.00341 
  
0.25622 0.50069 0.00582 0.60958 0.0134 4.57 22.9 32.1 
5 0.82414 5.01645 
  
0.26300 0.50948 0.00592 0.59821 0.0139 4.64 23.3 28.3 
6 0.66256 5.00003 
  
0.25858 0.50185 0.00584 0.65557 0.0122 4.14 20.7 31.3 
7 0.66734 4.99332 
  
0.25353 0.50879 0.00592 0.70952 0.0112 3.89 19.4 29.1 
8 0.70748 5.00039 
  
0.24967 0.50127 0.00583 0.64396 0.0125 4.38 21.9 31.0 
9 0.66412 5.01405 
  
0.26119 0.50347 0.00585 0.67797 0.0118 3.95 19.8 29.8 
10 0.73086 5.43505 
  
0.25492 0.49901 0.00580 0.67656 0.0117 4.02 21.8 29.9 
Average            30.0 
SD            1.5 
%RSD            4.9% 
  






























           
1 0.6448 5.00598 
  
0.12901 0.50346 0.00585 1.42237 0.00489 3.32 16.6 25.8 
2 0.6812 5.00086 
  
0.13908 0.50016 0.00582 1.16036 0.00615 3.87 19.4 28.4 
3 0.6913 5.14605 
  
0.13450 0.50208 0.00584 1.26331 0.00559 3.64 18.7 27.1 
4 0.7517 4.92476 
  
0.13240 0.50096 0.00583 1.30824 0.00536 3.55 17.5 23.2 
5 0.7474 5.08199 
  
0.13192 0.50132 0.00583 1.22871 0.00576 3.83 19.5 26.0 
6 0.7179 4.98104 
  
0.12854 0.50082 0.00582 1.20166 0.00591 4.03 20.1 28.0 
7 0.7418 5.09413 
  
0.13113 0.49978 0.00581 1.17088 0.00608 4.06 20.7 27.9 
8 0.6562 5.08588 
  
0.13090 0.50324 0.00585 1.27593 0.00554 3.71 18.9 28.7 
9 0.7024 5.04293 
  
0.13477 0.50002 0.00581 1.24283 0.00567 3.69 18.6 26.5 
10 0.7388 4.97617 
  
0.13028 0.57532 0.00669 1.27092 0.00636 4.28 21.3 28.8 
Average            27.0 
SD            1.7 
%RSD            6.4% 
  
  





























Low Dose Group 
          
1 0.7086 5.81047 0.21389 50.00389 0.20009 0.50580 0.00588 2.18475 0.00300 307 1783 2516 
2 0.7087 5.79609 0.20461 50.00289 0.20153 0.50391 0.00586 1.31620 0.00535 569 3295 4650 
3 0.5627 5.59289 0.20883 50.00122 0.20844 0.50039 0.00582 2.67360 0.00235 236 1321 2347 
4 0.7100 5.72480 0.20174 50.02046 0.20256 0.49945 0.00581 1.89745 0.00348 373 2138 3011 
5 0.6571 5.69569 0.20720 50.01701 0.20226 0.49960 0.00581 2.91632 0.00212 221 1260 1918 
6 0.6721 5.74194 0.20036 50.00645 0.20045 0.49891 0.00580 2.18460 0.00296 323 1852 2756 
7 0.6638 5.81372 0.20467 49.99905 0.20112 0.50148 0.00583 3.41162 0.00176 188 1091 1644 
8 0.7912 5.91495 0.20811 50.00426 0.19939 0.50181 0.00584 2.09564 0.00312 329 1949 2463 
9 0.6469 5.82604 0.20972 49.99530 0.20041 0.50499 0.00587 2.07865 0.00317 330 1925 2975 
10 0.7042 5.82727 0.20622 50.01032 0.20006 0.50801 0.00591 3.87486 0.00153 163 948 1346 
Average            2563 
SD            917 
%RSD            36% 
  
  





























High Dose Group 
          
1 0.6816 5.00052 0.10644 49.99925 0.10426 0.50431 0.00586 2.44647 0.00262 1035 5176 7593 
2 0.7602 5.00477 0.10387 50.00827 0.10630 0.49815 0.00579 1.79681 0.00370 1467 7343 9659 
3 0.7797 4.98981 0.11358 50.00671 0.10027 0.51351 0.00597 1.76343 0.00389 1498 7476 9588 
4 0.7640 5.00734 0.10725 49.99820 0.10715 0.50754 0.00590 1.77923 0.00381 1452 7272 9518 
5 0.7732 5.00713 0.11379 50.00749 0.10011 0.49852 0.00580 1.96195 0.00334 1286 6441 8330 
6 0.7372 4.99425 0.10209 50.00363 0.10203 0.50137 0.00583 3.69183 0.00160 674 3368 4569 
7 0.7062 4.99972 0.10886 49.99795 0.10202 0.50062 0.00582 1.86156 0.00357 1407 7035 9962 
8 0.7818 4.00774 0.10631 50.01851 0.10008 0.50137 0.00583 3.21890 0.00189 778 3119 3990 
9 0.7047 5.02209 0.10208 50.00205 0.10026 0.49963 0.00581 3.03912 0.00202 863 4333 6148 
10 0.6961 5.01058 0.10158 50.00150 0.10021 0.50037 0.00582 1.98200 0.00332 1428 7154 10277 
Average            7963 
SD            2313 
%RSD            29% 
  
a Number of moles of strontium in the sample was calculated following IDMS principles (Eqn. 2). 
b Concentration of strontium in the sample was calculated by multiplying the number of moles of strontium in the sample (column [10]) with the standard atomic weight of 
strontium in the sample (87.61681) and dividing it by the mass of the bone digest used for strontium analysis (column [6]). 
c Amount of strontium in the sample was calculated by multiplying the concentration of strontium in the sample (column [11]) with the dilution factor. 
d The concentration of strontium in the sample was calculated by dividing the amount of strontium in the sample (column [12]) with the mass of the sample (column [2]). 
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Table II-7: Strontium to calcium amount ratio (Sr/Ca) of bone samples obtained from PIXE. 
Mid-shaft femur and femoral head of rats from control, low dose and high dose groups were 
analyzed to study the distribution of strontium in cortical and trabecular bone. Background 
areas were those areas with no increase of strontium deposition, whereas strontium rich areas 














Control - Mid-shaft Femur 
 
Control - Femoral Head 
    
Background 








    
           
Low Dose - Mid-shaft Femur 
      
Background 
   
Sr Rich Area 








    
           
High Dose - Mid-shaft Femur 
      
Background 
   
Sr Rich Area-1 
 












           
Low Dose - Femoral Head 
       
Background 
   
Sr Rich Area 








    
           
High Dose - Femoral Head 
       
Background 
   
Sr Rich Area-1 
 













a Relative measurement uncertainty (k=1).  
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Table II-8: Bone mechanical properties. Maximum load (Max. Load), maximum stress (Max. 
Stress) and flexure modulus (Flex. Modulus) were obtained directly from the three-point 

















     
1 85 2176 61791 146 37 72.3 
2 92 2355 46182 79 68 78.5 
3 71 1797 50383 101 59 65.9 
4 74 1872 72098 186 45 69.4 
5 105 2677 57296 180 86 88.2 
6 70 1780 58371 101 59 63.0 
7 86 2188 70130 151 64 80.9 
8 73 1851 65555 161 40 63.0 
9 83 2118 87515 207 70 71.4 
10 77 1962 48888 105 64 70.0 
Average 82 2078 61821 142 59 72.3 
SD 11 286 12578 43 15 8.1 
%RSD 14% 14% 20% 31% 25% 11% 
       
Control Group 
     
1 65.9 1679 58282 134 43.4 65.2 
2 70.9 1804 32587 0.00 0.00 0.00 
3 60.3 1534 61406 0.00 0.00 0.00 
4 72.5 1846 52478 105 60.4 72.5 
5 79.2 2015 70035 179 50.9 75.1 
6 85.0 2164 64515 156 65.7 82.4 
7 84.8 2159 42973 165 65.0 81.6 
8 67.5 1719 48855 108 53.1 64.3 
9 66.7 1699 73706 186 53.3 65.0 
10 66.6 1695 47239 88 63.1 59.5 
Average 71.9 1831 55208 140 56.8 70.7 
SD 8.4 214 12777 37 7.9 8.5 
%RSD 12% 12% 23% 26% 14% 12% 
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Low Dose Group 
    
1 84.6 2155 78750 190 61.5 83.9 
2 86.2 
  
163 64.2 71.8 
3 73.4 1869 77413 177 62.9 71.8 
4 86.7 2209 97084 250 56.3 82.9 
5 91.0 2317 32986 172 77.7 80.4 
6 79.7 2030 79001 187 53.0 79.3 
7 94.1 2396 70526 169 65.3 91.9 
8 78.6 2002 101023 206 62.5 75.3 
10 84.0 2139 75367 203 67.6 74.9 
Average 84.3 2139 76519 191 63.5 79.1 
SD 6.4 172 20590 26 7.0 6.5 
%RSD 7.5% 8.0% 27% 14% 11% 8.2% 
       
High Dose Group 
    
1 69 1769 81620 178 48 66 
2 56 1435 57502 134 35 41 
3 76 1926 48931 112 57 74 
4 133 3385 73060 168 110 128 
5 85 2165 67547 152 65 82 
6 74 1893 52101 112 57 68 
7 79 2014 84578 157 55 79 
8 54 1381 41702 84 39 54 
9 84 2133 85705 206 63 77 
10 85 2172 78067 177 58 84 
Average 80 2027 67081 148 59 75 
SD 22 553 16023 37 21 23 
%RSD 27% 27% 24% 25% 35% 30% 
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Table II-9: Serum biomarkers for bone resorption (CTX) and bone formation (P1NP). Serum 
samples were collected one day before the sacrifice. The levels of these biomarkers were 
determined by using ELISA kits and calculated based on UV-vis absorption against a 







Baseline   
1 19.5 1.50 
2 22.9 1.25 
3 33.8 2.00 
4 22.9 1.40 
5 15.3 1.35 
6 35.2 0.75 
7 27.0 1.25 
8 24.1 1.00 
9 23.5 1.00 
10 29.3 1.20 
Average 25.4 1.27 
SD 6.1 0.34 
%RSD 24% 27% 
   
Control Group   
1 10.7 0.20 
2 27.9 0.25 
3 8.3 0.30 
4 24.5 0.40 
5 20.3 0.50 
6 19.2 0.00 
7 19.6 0.50 
8 27.8 0.25 
10 8.9 0.25 
Average 18.6 0.39 
SD 7.6 0.33 
%RSD 41% 84% 
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Low Dose Group   
1 32.3 0.30 
2 24.2 0.25 
3 13.5 0.20 
4 11.5 0.40 
5 11.3 0.00 
6 16.7 0.00 
7 14.8 0.25 
8 13.7 0.50 
9 17.6 0.00 
10 31.7 0.00 
Average 18.7 0.19 
SD 7.9 0.18 
%RSD 42% 97% 
   
High Dose Group   
1 11.5 0.00 
2 12.8 0.00 
3 15.5 0.00 
4 12.3 0.25 
5 36.4 0.00 
6 22.2 0.00 
7 18.1 0.00 
8 13.3 0.00 
9 35.3 0.00 
10 20.2 0.40 
Average 19.8 0.07 
SD 9.1 0.15 
%RSD 46% 220% 
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Table II-10: Strontium concentration in rat soft tissues. Freeze-dried organs from the rats 
were weighed and digested using microwave-assisted acid digestion. A known amount of 
strontium spike (n(Srspike)) was added to each sample for quantification. Measurements of 
86Sr/88Sr (n(86Sr)/n(8Sr)) were obtained from single measurements using TIMS (relative 
measurement uncertainty of ~10 ppm, k=1). Measured amount of strontium in the sample 
(n(Srsample)) was calculated following IDMS principles and corrected for strontium blank 
contribution (corr. n(Srsample)), including the blank contribution from the calcium spike 
(n(Srblank)). Concentration of strontium in the sample (c(Srsample)) was calculated based on the 
corrected measured amount of strontium in the sample and the mass of the organ (morgan). 






















[1] [2] [3] [4] [5] [6] [7] [8] 
 
Kidney 
      
Control Group 
      
1 0.3478 0.00176 0.31659 0.01016 0.00764 0.00251 0.632 
2 0.3931 0.00177 0.31664 0.01022 0.00766 0.00255 0.568 
3 0.3458 0.00178 0.31841 0.01018 0.00767 0.00250 0.634 
4 0.3847 0.00178 0.31708 0.01026 0.00769 0.00257 0.584 
5 0.3150 0.00178 0.32195 0.00100 0.00765 0.00234 0.651 
6 0.4692 0.00174 0.31244 0.01028 0.00765 0.00262 0.489 
7 0.3484 0.00189 0.34083 0.00973 0.00765 0.00207 0.520 
8 0.3861 0.00175 0.31443 0.01025 0.00768 0.00257 0.583 
9 0.5755 0.00174 0.29701 0.01115 0.00747 0.00368 0.560 
10 0.4762 0.00176 0.32463 0.00977 0.00761 0.00216 0.397 
Average       0.562 
SD       0.077 
%RSD       14% 
        Low Dose Group 
      
1 0.3297 0.00347 0.41934 0.01311 0.00010 0.01301 3.457 
2 0.4230 0.00351 0.28375 0.02433 0.00010 0.02423 5.018 
3 0.2905 0.00343 0.34556 0.01727 0.00010 0.01716 5.177 
4 0.3876 0.00349 0.26942 0.02657 0.00010 0.02647 5.983 
5 0.4209 0.00364 0.29139 0.02411 0.00010 0.02400 4.997 
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6 0.3987 0.00353 0.39439 0.01459 0.00011 0.01449 3.183 
7 0.3304 0.00354 0.58310 0.00860 0.00010 0.00849 2.252 
8 0.3975 0.00355 0.39068 0.01485 0.00010 0.01475 3.251 
9 0.3735 0.00342 0.44928 0.01175 0.00010 0.01165 2.733 
10 0.3234 0.00344 0.74299 0.00618 0.00010 0.00607 1.645 
Average       3.8 
SD       1.4 
%RSD       38% 
       
High Dose Group 
      
1 0.3151 0.00174 0.12411 0.42514 0.00774 0.41739 116.060 
2 0.3555 0.00176 0.12478 0.37595 0.00757 0.36837 90.789 
3 0.3263 0.00174 0.12639 0.28625 0.00762 0.27862 74.814 
4 0.3433 0.00177 0.12832 0.22745 0.00764 0.21980 56.097 
5 0.3280 0.00175 0.12661 0.27918 0.00761 0.27157 72.543 
6 0.3105 0.00175 0.14438 0.08062 0.00763 0.07298 20.593 
7 0.4037 0.00176 0.13063 0.17990 0.00765 0.17224 37.382 
8 0.3322 0.00179 0.13675 0.11841 0.00762 0.11078 29.217 
9 0.3214 0.00180 0.13221 0.16097 0.00762 0.15334 41.803 
10 0.3846 0.00179 0.13916 0.10389 0.00764 0.09625 21.926 
Average       56 
SD       32 
%RSD       57% 
        
 
Heart 
      
Control Group 
      
1 0.3290 0.00357 0.63945 0.00772 0.00761 0.00010 0.027 
2 0.3380 0.00358 0.63526 0.00780 0.00756 0.00023 0.059 
3 0.3337 0.00354 0.63018 0.00780 0.00768 0.00012 0.030 
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4 0.3507 0.00355 0.63660 0.00772 0.00759 0.00012 0.030 
5 0.2835 0.00354 0.63952 0.00766 0.00758 0.00007 0.022 
6 0.3502 0.00372 0.65300 0.00784 0.00759 0.00024 0.060 
8 0.3427 0.00361 0.63003 0.00795 0.00768 0.00027 0.069 
9 0.4128 0.00357 0.62289 0.00798 0.00761 0.00036 0.077 
10 0.3595 0.00356 0.63978 0.00769 0.00760 0.00008 0.020 
Average       0.044 
SD       0.022 
%RSD       50% 
        
Low Dose Group 
      
1 0.3054 0.00345 1.88906 0.00208 0.00010 0.00198 0.567 
2 0.3823 0.00346 1.49688 0.00272 0.00010 0.00262 0.600 
3 0.2787 0.00341 1.22766 0.00338 0.00010 0.00328 1.030 
4 0.3308 0.00346 1.78194 0.00223 0.00010 0.00213 0.564 
5 0.3708 0.00345 1.87898 0.00209 0.00010 0.00199 0.471 
6 0.3058 0.00346 2.75734 0.00135 0.00010 0.00124 0.356 
7 0.3142 0.00339 3.22564 0.00110 0.00010 0.00100 0.278 
8 0.3443 0.00345 1.45860 0.00280 0.00010 0.00269 0.686 
9 0.3061 0.00341 1.61373 0.00246 0.00010 0.00236 0.675 
10 0.2984 0.00349 1.95627 0.00202 0.00010 0.00192 0.563 
Average       0.58 
SD       0.21 
%RSD       35% 
        
High Dose Group 
      
1 0.3151 0.00357 0.30237 0.02223 0.00771 0.01452 4.036 
2 0.3555 0.00358 0.23798 0.03448 0.00760 0.02687 6.623 
3 0.3263 0.00359 0.23146 0.03665 0.00760 0.02905 7.800 
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4 0.3433 0.00358 0.30383 0.02217 0.00760 0.01456 3.715 
5 0.2997 0.00360 0.29740 0.02306 0.00764 0.01541 4.504 
6 0.2720 0.00359 0.43290 0.01297 0.00764 0.00533 1.718 
7 0.3902 0.00362 0.35893 0.01718 0.00767 0.00950 2.133 
8 0.2846 0.00354 0.41519 0.01359 0.00758 0.00600 1.848 
9 0.2956 0.00351 0.27966 0.02504 0.00754 0.01749 5.184 
10 0.3686 0.00352 0.39286 0.01461 0.00762 0.00699 1.661 
Average       3.9 
SD       2.2 
%RSD       55% 
        
 
Lungs 
      
Control Group 
      
1 0.2894 0.00355 0.61242 0.00811 0.00761 0.00049 0.149 
2 0.3191 0.00354 0.60880 0.00815 0.00758 0.00056 0.154 
3 0.3062 0.00355 0.62277 0.00794 0.00758 0.00035 0.099 
4 0.3164 0.00357 0.61091 0.00818 0.00763 0.00054 0.150 
5 0.2991 0.00358 0.60780 0.00826 0.00765 0.00060 0.177 
6 0.3169 0.00362 0.61591 0.00821 0.00769 0.00051 0.142 
7 0.3268 0.00360 0.59639 0.00850 0.00773 0.00077 0.206 
8 0.2934 0.00361 0.60796 0.00833 0.00767 0.00065 0.195 
9 0.4891 0.00359 0.61245 0.00820 0.00766 0.00054 0.096 
10 0.2942 0.00361 0.61559 0.00819 0.00764 0.00054 0.161 
Average       0.153 
SD       0.036 
%RSD       23% 
        
Low Dose Group 
      
1 0.3276 0.00346 0.37669 0.01530 0.00010 0.01520 4.093 
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2 0.3185 0.00348 0.35744 0.01664 0.00010 0.01653 4.576 
3 0.2740 0.00354 0.31572 0.02057 0.00010 0.02046 6.577 
4 0.3092 0.00350 0.40905 0.01371 0.00010 0.01361 3.886 
5 0.3052 0.00347 0.36007 0.01639 0.00010 0.01629 4.707 
6 0.2958 0.00344 0.36801 0.01571 0.00010 0.01561 4.653 
7 0.3244 0.00345 0.45016 0.01181 0.00010 0.01170 3.189 
8 0.5031 0.00357 0.27815 0.02564 0.00010 0.02553 4.465 
9 0.2804 0.00350 0.38206 0.01514 0.00010 0.01504 4.732 
10 0.2898 0.00351 0.77403 0.00600 0.00010 0.00590 1.813 
Average       4.3 
SD       1.2 
%RSD       29% 
       
High Dose Group 
     
1 0.2698 0.00361 0.16619 0.08855 0.00782 0.08072 26.213 
2 0.3201 0.00359 0.15705 0.10946 0.00762 0.10184 27.874 
3 0.3184 0.00361 0.14696 0.15036 0.00773 0.14262 39.246 
4 0.3087 0.00360 0.15250 0.12467 0.00771 0.11695 33.194 
5 0.2884 0.00362 0.14929 0.13901 0.00765 0.13136 39.906 
6 0.2609 0.00360 0.19259 0.05635 0.00775 0.04859 16.317 
7 0.3270 0.00362 0.18890 0.05968 0.00772 0.05196 13.922 
8 0.2994 0.00352 0.17203 0.07678 0.00770 0.06907 20.214 
9 0.2878 0.00364 0.15881 0.10589 0.00771 0.09818 29.889 
10 0.3083 0.00363 0.20512 0.04850 0.00779 0.04071 11.569 
Average       26 
SD       10 
%RSD       39% 
 
a Number of moles of strontium in the sample was calculated following IDMS principles (Eqn. 2). 
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b Blank contribution of strontium from calcium spike was calculated based on the amount of 44Ca 
spike added (refer to Table II-11) and the concentration was quantified in separate measurements. 
c Corrected number of moles of strontium in the sample was calculated by subtracting the blank 
contribution of strontium from calcium spike (column [6]) from the total number of moles of 
strontium in the sample (column [5]). 
d The concentration of strontium in the sample was calculated by multiplying the corrected number 
of moles of strontium in the sample (column [7]) with the standard atomic weight of strontium in 
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Table II-11: Calcium concentration in soft tissues. Freeze-dried left kidney, heart and lungs 
from the rats were weighed and digested using microwave-assisted acid digestion. A known 
amount of calcium spike (nspike) was added to each sample for quantification. The 
measurements of 44Ca/42Ca ((44Ca/42Ca)measured) were obtained from single measurements by 
using TIMS (relative measurement uncertainty of ~10 ppm, k=1). The measured amount of 
calcium in the sample (nsample) was calculated based on IDMS equation and corrected for 
calcium blank contribution (Ca in sample - blank corrected). The concentration of calcium in 
the sample (conc. of Ca in sample) was calculated based on the corrected measured amount of 





























   
1 0.3478 4.50712 4.00954 1.604 63.89 183.7 
2 0.3931 4.51955 3.38036 1.935 77.15 196.3 
3 0.3458 4.52509 4.46053 1.433 57.04 165.0 
4 0.3847 4.53359 3.96935 1.631 64.98 168.9 
5 0.3150 4.51955 3.92342 1.647 65.60 208.3 
6 0.4692 4.51249 2.48157 2.688 107.34 228.8 
7 0.3484 4.51293 4.77623 1.326 52.73 151.4 
8 0.3861 4.52903 3.25067 2.023 80.65 208.9 
10 0.4762 4.48557 3.14854 2.073 82.67 173.6 
Average      187 
SD      25 
%RSD      13% 
   
 
   
Low Dose Group 
 
 
   
1 0.3297 2.27391 2.63001 1.274 50.63 153.6 
2 0.4230 2.29706 1.82628 1.892 75.43 178.3 
3 0.2905 2.27618 2.43710 1.382 54.99 189.3 
4 0.3876 2.28435 2.06055 1.657 66.00 170.3 
5 0.4209 2.27800 1.87722 1.823 72.65 172.6 
6 0.3987 2.31295 2.10089 1.644 65.47 164.2 
7 0.3304 2.26983 2.05993 1.647 65.60 198.5 
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8 0.3975 2.26756 1.77124 1.929 76.91 193.5 
9 0.3735 2.26983 2.28265 1.478 58.81 157.4 
10 0.3234 2.25667 2.01021 1.680 66.93 207.0 
Average      178 
SD      18 
%RSD      10% 
       
High Dose Group 
 
 
   
1 0.3486 4.56363 3.98578 1.635 65.11 186.8 
2 0.4294 4.46474 2.99403 2.178 86.87 202.3 
3 0.3285 4.49246 2.99281 2.192 87.45 266.2 
4 0.4088 4.50614 3.49987 1.859 74.08 181.2 
5 0.3280 4.48548 3.26092 1.996 79.60 242.7 
6 0.3105 4.50059 4.93545 1.275 50.70 163.3 
7 0.4037 4.51463 2.89166 2.285 91.19 225.9 
8 0.3322 4.49577 3.90127 1.649 65.66 197.7 
9 0.3214 4.49532 3.31914 1.963 78.27 243.5 
10 0.3846 4.50363 4.17768 1.533 61.02 158.7 
Average      207 
SD      36 
%RSD      18% 
   
 









   
1 0.3290 4.49049 7.13907 0.838 33.18 100.9 
2 0.3380 4.46063 6.98533 0.854 33.81 100.0 
3 0.3337 4.52795 6.32771 0.971 38.49 115.4 
4 0.3507 4.47824 6.76054 0.890 35.26 100.6 
5 0.2835 4.47109 7.34713 0.807 31.94 112.7 
6 0.3502 4.47878 5.25519 1.184 47.02 134.3 
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7 0.3026 4.65044 7.32213 0.843 33.37 110.3 
8 0.3427 4.52840 6.86686 0.884 35.02 102.2 
10 0.3595 4.48522 6.41681 0.946 37.52 104.4 
Average      109 
SD      11 
%RSD      10% 
       
Low Dose Group      
1 0.3054 2.28290 4.36158 0.741 29.30 95.94 
2 0.3823 2.25803 3.84769 0.841 33.28 87.04 
3 0.2787 2.24673 4.35662 0.730 28.86 103.56 
4 0.3308 2.27342 4.24438 0.760 30.07 90.91 
5 0.3708 2.25562 3.46783 0.940 37.25 100.45 
6 0.3058 2.23965 3.83433 0.837 33.13 108.35 
7 0.3142 2.22476 4.02070 0.790 31.23 99.41 
8 0.3443 2.22780 3.59108 0.894 35.41 102.84 
9 0.3061 2.25930 3.66213 0.888 35.15 114.83 
10 0.2984 2.23642 3.83633 0.835 33.06 110.82 
Average      101.4 
SD      8.7 
%RSD      9% 
   
 
   
High Dose Group      
1 0.3151 4.54771 7.32109 0.824 32.63 103.6 
2 0.3555 4.48388 6.28132 0.969 38.44 108.1 
3 0.3263 4.48003 6.53652 0.925 36.68 112.4 
4 0.3433 4.48531 6.65904 0.907 35.94 104.7 
5 0.2997 4.50819 7.53240 0.791 31.27 104.4 
6 0.2720 4.50346 8.08244 0.727 28.73 105.6 
7 0.3902 4.52652 6.70597 0.908 35.98 92.2 
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8 0.2846 4.47234 7.86516 0.746 29.47 103.6 
9 0.2956 4.44713 4.94743 1.257 49.96 169.0 
10 0.3686 4.49299 6.35422 0.959 38.01 103.1 
Average      111 
SD      21 
%RSD      19% 
       




   
1 0.2894 4.49049 1.62885 4.172 166.82 576.4 
2 0.3191 4.47046 1.41313 4.823 192.87 604.4 
3 0.3062 4.47180 1.84162 3.652 145.94 476.6 
4 0.3164 4.50131 1.48026 4.625 184.95 584.5 
5 0.2991 4.51231 9.13761 7.698 308.12 1030.2 
6 0.3169 4.53627 1.63852 4.189 167.47 528.5 
7 0.3268 4.55746 8.21281 8.702 348.34 1065.9 
8 0.2934 4.52259 1.18674 5.861 234.49 799.2 
10 0.2942 4.50855 1.08611 6.413 256.61 872.2 
Average      726 
SD      222 
%RSD      31% 
   
 
   
Low Dose Group      
1 0.3276 2.26847 0.73946 4.840 193.57 590.9 
2 0.3185 2.24487 0.86848 4.041 161.54 507.1 
3 0.2740 2.28753 1.17444 2.997 119.71 436.9 
4 0.3092 2.24850 0.92281 3.796 151.75 490.8 
5 0.3052 2.25031 0.66920 5.338 213.52 699.6 
6 0.2958 2.21945 0.74984 4.666 186.59 630.8 
7 0.3244 2.25712 0.72895 4.889 195.55 602.8 
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8 0.5031 2.26665 0.51132 7.170 286.94 570.4 
9 0.2804 2.24124 0.69517 5.106 204.21 728.2 
10 0.2898 2.27482 1.10493 3.178 126.95 438.0 
Average      570 
SD      101 
%RSD      18% 
       
High Dose Group      
1 0.2698 4.61379 1.75203 3.971 158.72 588.3 
2 0.3201 4.49174 2.23443 2.991 119.45 373.2 
3 0.3184 4.55817 1.44301 4.810 192.38 604.2 
4 0.3087 4.54718 1.39504 4.972 198.87 644.2 
5 0.2884 4.51114 1.63979 4.162 166.41 577.0 
6 0.2609 4.57114 1.95103 3.512 140.36 538.0 
7 0.3270 4.55031 2.29848 2.940 117.44 359.1 
8 0.2994 4.53904 1.56167 4.409 176.28 588.8 
9 0.2878 4.54646 1.29170 5.390 215.61 749.2 
10 0.3083 4.59242 2.17850 3.141 125.47 407.0 
Average      543 
SD      126 
%RSD      23% 
 
a Number of moles of calcium in the sample was calculated following IDMS principles (Eqn. 2). 
b Blank contribution of calcium was quantified in separate measurements. 
c Corrected amount of calcium in the sample was calculated by subtracting the blank contribution of 
calcium from the total amount of calcium in the sample, which was calculated by multiplying the 
number of moles of calcium in the sample (column [5]) with the standard atomic weight of 
calcium in the sample (40.078). 
d The concentration of calcium in the sample was calculated by dividing the corrected amount of 




Supplementary Data for Age-
Dependent Differences in Calcium 
and Magnesium Intake in 
Singaporean Chinese Women 
(Part B, Chapter 4) 
 
Appendix III: Supplementary data for age-dependent differences in calcium and magnesium 




Table III-1: Assigned calcium and magnesium content for food items. The assigned calcium 
and magnesium contents are estimated with reference to the calcium contents from FAAS 














Staple foods/ carbohydrate 
sources  
 
Rice 1 rice-bowl (200g) 15 4.0 
Glutinous rice 1 serving (100g) 15 4.0 
Porridge 1 bowl (500g) 5.0 1.5 
Noodles 1 serving (200g) 10 13 
Pau 1 item (100g) 30 25 





Breakfast cereals (non-fortified) 1 serving (35g) 30 A.T.B. 
White bread, loaf 2 slices (57g) 170 27 
Milk bread, loaf 2 slices (57g) 300 27 
Wholemeal, grains and other 
flavoured loaves 
2 slices (60g) 120 64 




Cream roll (non-fortified) 1 item (60g) 40 27 
Other breads, buns, Indian 
breads, burger (without cheese) 
1 item (60g) 50 27 
Other breads, buns, Indian 
breads, burger (with cheese) 
1 item (60g) 120 27 
Pasta (non cheese-based sauce) 1 serving (160g) 10 10 
Pasta (cheese-based sauce) 1 serving (160g) 110 10 
Parmesan cheese 1 tablespoon (4g) 1120 43 
Pizza 1 slice (75g) 110 13 
Western Baked Rice 1 serving (200g) 50 5.0 
Potato and potato based 
products, without cheese 
1 serving (50-100g) 15 20 
Potato and potato based 
products, with cheese 
1 serving (100g) 130 20 
 
*A.T.B.: according to brand/label. 
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Vegetable and vegetable 
products  
 
Spinach 1 serving (70g) 150 35 
Chye Sim 1 serving (70g) 100 15 
Kale/ Kai lan 1 serving (70g) 110 35 
Watercress, Cassava leaves 1 serving (70g) 130 15 
Other dark green leafy 
vegetables 
1 serving (70g) 70 15 
Dark green leafy vegetables, 
general 
1 serving (70g) 100 25 
Other vegetables, vegetable 
products and legumes 
1 serving (70g) 30 60 
   
 
 
Meat, Poultry, Seafood, Egg 
 
 
Canned sardines 1 fish (70g) 300 50 
Canned mackerel 1 fish (70g) 190 40 
Unagi, Stingray, other fishes 
eaten with bones 
1 serving (70g) 130 25 
Deep fried prawn eaten with 
shell 
1 serving (70g) 750 55 
Crab 1 serving (70g) 130 40 
Frog leg, Beef stomach 1 serving (40g) 100 12 
Other meats, fishes (not eaten 
with bones),seafood, egg and 
their products 
1 serving (70g) 30 40 






Firm tofu (taukwa) 1/2 square (70g) 190 50 
Soft tofu 1/3 block (100g) 60 32 
Egg tofu 1 serving (60g) 25 14 
Tempeh I serving (30g) 80 60 
Mock/ Vegetarian meat 
(beancurd or gluten) 
1 serving (70g) 20 60 
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Sauces, Toppings, Condiments 
 
 
Ikan bilis 1 tablespoon (4g) 900 240 
Anchovy, canned 1 fish (4g) 180 240 
Silver fish 1 tablespoon (4g) 500 240 
Mermaid fish 1 serving (5g) 2150 240 
Small dried prawn 1 tablespoon (4g) 500 240 
Dried shrimp 1 tablespoon (1g) 2000 240 
Chinchalok 1 tablespoon (10g) 600 - 
Belacan, cooked with dish 1 serving (5g) 1600 - 
Sambal belacan 1 tablespoon (20g) 150 - 
Indian curry 1/2 rice-bowl (100g) 30 15 
Soup, milk-based  1 rice-bowl (200g) 100  
Soup, Laksa lemak 1 rice-bowl (200g) 46 15 
Gravy, Mee rebus 1 rice-bowl (200g) 42 15 
Soup, Mee Siam 1 rice-bowl (200g) 20 15 






Fruits, fresh 1 serving (120g) 20 15 
Dried 1 serving (60g) 50 40 
Preserved, processed 1 serving (60g) 15 15 






Black sesame paste, hawker 1 bowl (400g) 60 - 
Black sesame paste, instant 1 sachet (30g) 200 - 
Glutionous rice ball (tangyuen), 
sesame filling 
3 pieces (60g) 90 - 
Other desserts 1 bowl (380g) 15 20 
   
 
 
Other desserts and snacks 
 
 
Snacks and desserts 1 serving (60g) 45 25 
Almond nuts 2 tablespoons (20g) 220 180 
Pistachio nut, Walnut 2 tablespoons (20g) 90 180 
Other nuts 2 tablespoons (20g) 40 180 
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Dairy-based ice cream, mousse, 
custard 
1 serving (100g) 180 15 
Milk chocolate 6 small blocks (25g) 160 70 
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Table III-2: Calcium and magnesium contents in food products with assigned calcium and 
magnesium contents according to brand/labels. 
 







Breakfast Cereal  K Special Original Bran flakes 667 16 
(calcium enriched) Nestle Fitnesse 600 60 
 
Nestle Fitnesse and fruit 560 60 
 
Nestle Cornflakes 600 25 
 
Nestle Honey Goldflakes 500 25 
 
Nestle Snow flakes 440 25 
 
Nestle Cookie Crisp 420 73 
 
Nestle Milo  360 73 
 
Nestle Clusters 267 73 
 
Nestle Duo Coco 267 73 
 
Nestle Koko Crunch 256 73 
 
Nestle Trix 260 73 
 
Nestle Honey Stars 240 25 
 
Kellogg's Coco Pops 580 25 
 
Kellogg's Balls 175 25 
 
Kellogg's Coco Chex 175 45 
 




F&N Alive Bixies, wildberry 343 114 
  
  
Cream roll  Sunshine Butter roll 185 27 
(calcium enriched) Sunshine Chocolate cream roll 205 27 
 
Sunshine Coffee cream roll 206 27 
 
Sunshine Peanut cream roll 216 27 
 
Sunshine Strawberry cream roll 233 27 
 
Sunshine Apple cream roll 233 27 
 
Sunshine Blueberry cream roll 214 27 
 
Sunshine Vanilla cream roll 951 27 
 
Sunshine Butter sugar cream roll 691 27 
  
  
Cheese Slices Kraft 800 30 
 
Chesdale 1193 30 
 
Cowhead 618 30 
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Table III-2 (cont’d): Calcium and magnesium contents in food products with assigned 
calcium and magnesium contents according to brand/labels. 
 







 President 367 30 
 Valumetric 450 30 
 Lemnos 625 30 
 SCS 695 30 
    
Cheese Spreads Chesdale 1265 30 
 
Laughing Cow 250 30 
 
President 434 30 
   
 
Yogurt Marigold 168 15 
 
Meiji 132 15 
 
Dutch Lady 175 15 
 
Dairy Farmers 180 15 
 
Yoplait 173 15 
 
F & N 106 15 




Appendix III: Supplementary data for age-dependent differences in calcium and magnesium 




Table III-3: Assigned calcium and magnesium content for items in liquid beverage 
categories. The assigned calcium and magnesium contents are estimated with reference to the 
calcium and magnesium contents from FAAS analysis, food composition tables and labels. 
  














1 cup (200 mL) 
 
1.0 0.0 




    








Coffee, brewed (café outlet) 1 cup (300 mL) 2.0 5.0 
Coffee, brewed, with milk (café outlet) 1 cup (300 mL) 70 5.0 
Canned coffee, without milk 1 can (240 mL) 2.0 5.0 
Canned coffee, with milk 1 can (240 mL) 40 5.0 
    
Tea, brewed (homemade/ coffee shop) 
Tea  
1 cup (200 mL) 
 
1.0 5.0 
Tea, brewed, without milk (café outlet) 1 cup (300 mL) 1.0 5.0 
Tea, brewed, with milk (café outlet) 1 cup (300 mL) 60 5.0 
    
Milo, ready-to-drink 
Malt beverage 1 can/packet  
(240 mL) 
60 23 
    
Soya bean milk, ready-to-drink 
Soya bean milk  




Soya bean milk, commercially 
available, unfortified 
1 cup (200 mL) 10 20 
Soya bean milk, commercially 
available, fortified 
1 cup (200 mL) 80 10 
    
Milk, unfortified 
Milk 
1 cup (200 mL) 120 13 
Milk, fortified 1 cup (200 mL) 160 15 
Milk, concentrated, Anlene 
1 packet (125 
mL) 
520 60 
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1 tablespoon (15 
mL) 
250 26 
    
Milk shake 
Milk products  
1 cup (300 mL) 
 
120 11 
Bandong 1 cup (200 mL) 20 - 
Yoghurt drinks 1 cup (200 mL) 50 11 
Probiotic drinks 1 cup (75 mL) 40 5.0 
    
Fruit juice, freshly prepared 
Fruit juices  
1 cup (200 mL) 
 
3.0 9.0 
Syrup / cordial 
1 tablespoon (15 
mL) 
6.0 17 
Fruit juice, processed 1 cup (200 mL) 10 9.0 
    
Carbonated drinks 
Soft drinks  
1 cup (200 mL) 
 
2.0 1.0 
Non-carbonated drinks 1 cup (200 mL) 1.0 0 
Isotonic drinks 1 cup (200 mL) 1.0 5.2 
Energy drinks 1 can (250 mL) 5.0 - 
    
Beer 
Alcoholic drinks  




1 portion (120 
mL) 
7.0 7.5 
Spirit 1 glass (250 mL) 1.0 0.12 









Grass jelly drink 1 cup (200 mL) 8.0 3.0 
Herbal tea, brewed 1 cup (200 mL) 2.0 - 
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Table III-4: Assigned calcium and magnesium content for items in powdered beverage 
categories. The assigned calcium and magnesium contents are estimated with reference to the 
calcium and magnesium contents from FAAS analysis, food composition tables and labels. 
 
 












Coffee, instant, powder 
Coffee  
2 tablespoons (30g) 
 
140 15 
Coffee, 3-in-1, powder 1 sachet (30g) 15 15 
    
Tea, instant, powder 
Tea 
1 sachet (30 g) 10 15 
Tea, 3-in-1, powder 1 sachet (30 g) 200 15 
    
Milo, powder 
Malt beverages and instant cereals  





Milo, 3-in-1, powder 1 sachet (30 g) 450 125 
Horlicks, powder 2 tablespoons (30g) 1800 50 
Horlicks, 3-in-1, powder 1 sachet (30 g) 1800 - 
Ovaltine, powder 2 tablespoons (30 g) 800 108 
Ovaltine, 3-in-1, powder 1 sachet (30 g) 1200 - 
Hot chocolate, powder 2 tablespoons (30 g) 40 483 
Cereal, powder 2 tablespoons (30 g) 400 104 








    
Soya bean milk powder 
Soya bean milk  
1 sachet (30 g) 
610 30 
    
Milk powder, unfortified 
Milk  




Milk powder, fortified 2 tablespoons (30 g) 1500 
A.T.B. 
(75-160) 
    
Creamer, powder 
Creamer  
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Table III-5: Calcium and magnesium contents in beverage products with assigned calcium 
and magnesium contents according to brand/labels. 
 













Mineral water Volvic Natural Mineral Water 1.2 0.8 
 
Danone Aqua Mountain Spring Water 1.6 1.0 
 
Polar Natural Mineral Water 1.8 0.4 
 
Pere Ocean Natural Mineral Water 3.0 0.1 
 
Ice Mountain Pure Drinking Water 3.4 0.7 
 
Evian Mineral Water 8.0 2.6 
 
Voda Voda 7.4 1.4 
 
Ron88 Elite Mini 0.87 0.29 
 
Team Alkaline Drinking water 1.4 0.074 
 
Aquarin Natural Mineral Water 5.4 2.1 
 
Vittel Natural Mineral Water 9.3 2.0 
 




Virga Pure Tasmanian Water 0.30 0.07 
 
Fiji Natural Artesian Water 1.7 1.3 
 
Maniva Mineral Water 4.0 0.5 
 
Glinter Mineral Water - - 
 
Ice Berg Mineral Water 3.0 2.4 
 
Spritzer Natural Mineral Water 4.6 0.5 
 
Acqua Panna Natural Mineral Water 3.3 0.7 
 
San Benedetto Natural Mineral Water 4.8 2.9 
 
First Choice French Spring Water 5.8 2.4 
 
First Choice Natural Mineral Water 0.095 0.006 
 
Perrier Natural Mineral Water - - 
 
BreadTalk, pure mineralised water 0.16 0.016 




Highland Spring Sparkling Spring Water 4.1 1.2 
 
Gerolsteiner Sparkling Mineral Water 14 4.9 
 
San Benedetto Sparkling Mineral Water 4.8 2.9 
 
Apollinaris Classic Sparkling Mineral Water 9.0 12 
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Table III-5 (cont’d): Calcium and magnesium contents in beverage products with assigned 
calcium and magnesium contents according to brand/labels. 
 
    














San Pellegrino Sparkling Natural Mineral 
Water 
18 5.4 
 Perrier Sparkling Mineral Water, lime - - 
 Perrier Sparkling Mineral Water, lemon - - 
    
 Powdered drinks  
Cereal, 3-in-1, 
powder 
Nestle Nesvita 3-in-1 cereal drink 210 - 
 Super Cereal, 3 in 1 0 - 
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Table III-6: Data from a duplicate diet study for validation of a method to estimate calcium 
intake from 3-day weighted food records. Measured calcium intake was determined based on 
the analysis of duplicate diet samples collected using AAS. Estimated calcium intake was 
calculated based on the assigned calcium contents in the in-house database (Table III-1 – III-
5) and the reported amount of food consumed in the 3-day food record. 
Subject 
No. 




Food Drinks Total 
 
Food Drinks Total 
1 1090 96 1186 
 
1033 117 1150 
2 158 7 165 
 
178 6 184 
3 298 12 309 
 
365 23 388 
4 173 15 187 
 
192 12 204 
5 939 36 975 
 
876 36 912 
6 168 23 192 
 
211 24 235 
7 264 26 290 
 
290 76 366 
8 334 17 352 
 
365 24 389 
9 408 126 534 
 
382 222 604 
10 621 108 729 
 
555 140 694 
11 381 44 425 
 
165 53 218 
12 336 177 513 
 
350 152 503 
13 186 21 207 
 
243 16 259 
14 276 48 325 
 
371 131 502 
15 162 21 183 
 
215 14 229 
16 618 110 728 
 
664 178 841 
17 332 220 551 
 
344 102 446 
18 166 248 414 
 
213 176 389 
19 1075 67 1142 
 
869 135 1004 
20 349 488 837 
 
555 382 936 
21 487 93 579 
 
472 212 684 
22 237 165 402 
 
301 108 409 
23 148 189 337 
 
241 158 399 
24 180 55 235 
 
171 126 297 
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Table III-7: Data from a duplicate diet study for validation of a method to estimate 
magnesium intake from 3-day weighted food records. Measured magnesium intake was 
determined based on the analysis of duplicate diet samples collected using AAS. Estimated 
magnesium intake was calculated based on the assigned magnesium contents in the in-house 
database (Table III-1 – III-5) and the reported amount of food consumed in the 3-day food 
record. 
No. 
Magnesium Intake (mg/day) 
Measured  Estimated 
Food Drinks Total  Food Drinks Total 
1 186 12 198  190 6 196 
2 143 0 143  100 2 101 
3 162 9 170  181 27 208 
4 129 5 135  120 5 125 
5 129 7 136  145 10 155 
6 375 23 398  395 26 420 
7 189 58 246  174 44 218 
8 202 37 239  194 42 236 
9 153 22 176  173 10 183 
10 161 19 180  184 30 214 
11 111 2 113  142 6 148 
12 76 11 86  88 19 107 
13 123 15 138  116 45 161 
14 200 50 250  192 34 225 
15 151 3 154  155 20 174 
16 138 44 182  168 33 201 
17 66 42 107  91 29 120 
18 121 0 122  122 1 123 
19 302 0 302  246 1 247 
20 250 17 267  270 26 296 
21 195 79 274  186 66 253 
22 167 2 169  117 11 128 
23 330 15 344  196 27 223 
24 107 7 114  135 7 143 
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Table III-8: Total calcium and magnesium dietary intake by female aged ≥ 55 years-old. The 
average calcium and magnesium intake was calculated based on the assigned calcium and 
magnesium contents in the in-house database (Table III-1 – III-5) and the reported amount of 
food consumed in the 3-day food record. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
1 208 128 
2 1052 396 
3 364 182 
4 431 147 
5 333 111 
6 507 166 
7 268 148 
8 456 163 
9 940 484 
10 2397 487 
11 574 213 
12 477 223 
13 1116 521 
14 1109 308 
15 467 208 
16 200 125 
17 418 292 
18 876 297 
19 932 276 
20 468 210 
21 342 152 
22 483 230 
23 1422 296 
24 639 270 
25 633 193 
26 429 183 
27 1134 381 
28 420 254 
29 837 152 
30 370 192 
31 569 312 
32 331 194 
33 245 178 
34 312 203 
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Table III-8 (cont’d): Total calcium and magnesium dietary intake by female aged ≥ 55 years-
old. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
35 349 160 
36 615 202 
37 1228 281 
38 499 220 
39 679 179 
40 1387 598 
41 916 264 
42 3136 230 
43 1020 244 
44 1101 209 
45 583 175 
46 1436 172 
47 1229 289 
48 758 322 
49 721 197 
50 788 259 
51 1378 169 
52 982 302 
53 875 204 
54 650 177 
55 436 244 
56 225 99 
57 358 182 
58 407 181 
59 1313 394 
60 184 69 
61 311 178 
62 247 95 
63 454 137 
64 409 187 
65 358 269 
66 206 106 
67 1131 218 
68 621 161 
69 306 175 
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Table III-8 (cont’d): Total calcium and magnesium dietary intake by female aged ≥ 55 years-
old. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
70 279 133 
71 274 154 
72 371 181 
73 997 185 
74 473 161 
75 329 224 
Mean 653 225 
SD 407 98 
SE 47 11 
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Table III-9: Total calcium and magnesium dietary intake by female aged 18-30 years-old. The 
average calcium and magnesium intake was calculated based on the assigned calcium and 
magnesium contents in the in-house database (Table III-1 – III-5) and the reported amount of 
food consumed in the 3-day food record. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
1 243 92 
2 193 80 
3 265 125 
4 579 339 
5 540 261 
6 379 163 
7 1035 185 
8 343 90 
9 506 164 
10 431 144 
11 406 109 
12 192 85 
13 288 113 
14 234 119 
15 446 337 
16 446 346 
17 1127 231 
18 1582 296 
19 586 190 
20 380 167 
21 452 213 
22 539 149 
23 281 151 
24 355 147 
25 332 133 
26 863 193 
27 689 161 
28 418 150 
29 380 189 
30 433 174 
31 525 302 
32 510 203 
33 439 334 
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Table III-9 (cont’d): Total calcium and magnesium dietary intake by female aged 18-30 
years-old. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
34 542 169 
35 532 213 
36 365 215 
37 633 197 
38 539 210 
39 782 241 
40 543 310 
41 504 194 
42 477 171 
43 365 351 
44 541 217 
45 314 128 
46 291 141 
47 449 161 
48 332 175 
49 801 208 
50 426 185 
51 506 252 
52 626 320 
53 1028 205 
54 354 165 
55 570 177 
56 350 165 
57 373 186 
58 670 257 
59 215 106 
60 453 127 
61 249 128 
62 416 158 
63 335 184 
64 684 240 
65 327 158 
66 513 201 
67 644 294 
68 179 102 
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Table III-9 (cont’d): Total calcium and magnesium dietary intake by female aged 18-30 
years-old. 
 
Subject No. Average Calcium Intake (mg/day) Average Magnesium Intake (mg/day) 
69 378 142 
70 253 148 
71 168 96 
72 434 147 
73 445 216 
74 389 217 
75 224 106 
76 738 228 
77 786 311 
78 390 191 
79 477 129 
80 275 163 
81 393 159 
82 317 150 
83 548 212 
84 498 142 
85 392 242 
86 200 144 
87 362 137 
88 837 192 
89 329 155 
90 655 186 
91 711 164 
92 1037 288 
93 539 174 
94 309 149 
Mean 483 187.6 
SD 230 65 
SE 24 6.7 
 
 




Table III-10: Example of calcium and magnesium assessment table. The serving sizes, calcium and magnesium contents were based on the in-house database 
(Table III-1-III-5). The numbers of servings were based on the 3-day food record collected from the study participants. Total daily intake was calculated by 
summing up the individual’s mineral intake in a day. Total weekly intake was estimated by assigning different weightage for the total daily intake (2.5 for 
each weekday and 2 for weekend) and summing them up. The average daily intake was calculated by dividing the total weekly intake by seven. 
No. Food / Beverage 
Serving 
size Food 


































A FOOD             
               
1 Staple foods             
a White rice 200 7 4  0 0 1.5 21 12 1 14 8 
  Brown rice 200 14 49  0 0  0 0  0 0 
  Glutinous rice 100 7 4  0 0  0 0  0 0 
  Porridge 500 5 1.5  0 0  0 0  0 0 
b Pau (steamed bun) 100 30 25  0 0  0 0  0 0 
c Loaf bread             
  White bread 57 170 27  0 0  0 0  0 0 
  Milk bread 57 341 27  0 0  0 0  0 0 
  Wholemeal  bread 60 170 64  0 0  0 0  0 0 
  Gardenia Enriched White 57 139 27  0 0  0 0  0 0 
  Gardenia High Fibre White 57 153 27  0 0  0 0  0 0 
  Gardenia Wholemeal 60 167 64  0 0  0 0  0 0 
  Gardenia Fruit & Nut 60 199 64  0 0  0 0  0 0 
  Gardenia Banana Walnut 60 128 64  0 0  0 0  0 0 
  Gardenia Cranberry Fruity Loaf 60 170 27  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Bonjour Wholemeal 60 103 64  0 0  0 0  0 0 
  Bonjour Raisin Loaf 40 75 27  0 0  0 0  0 0 
  Bonjour Grain Loaf with Flax Seed 57 160 64  0 0  0 0  0 0 
  Fairprice Enriched White 57 180 27  0 0  0 0  0 0 
  Fairprice Wholemeal 53 192 64  0 0  0 0  0 0 
  Sure Value White 57 196 27  0 0  0 0  0 0 
  Sunshine Enriched Soft White 57 220 27  0 0  0 0  0 0 
  Sunshine Fruit & Grain 80 166 64  0 0  0 0  0 0 
  Sunshine Softmeal 57 116 64  0 0  0 0  0 0 
  Sunshine Milk Toast 57 370 27  0 0  0 0  0 0 
  Top one Enriched White 57 273 27  0 0  0 0  0 0 
  Top one Wholemeal 60 158 64  0 0  0 0  0 0 
  Top one High Fiber 53 272 27  0 0  0 0  0 0 
  7-11 Quickbites Wholemeal 53 192 64  0 0  0 0  0 0 
d Cream-filled bread roll 65 205 27  0 0  0 0  0 0 
  Other breads & buns 60 50 27 1 30 16  0 0  0 0 
  Other breads & buns w/ cheese 60 120 27  0 0  0 0  0 0 
  Other breads & buns wholemeal 60 50 64  0 0  0 0  0 0 
e Noodles (egg, rice vermicelli, mungbean) 200 10 13  0 0  0 0 0.2 4 5 
  Noodles with milk 200 60 33  0 0  0 0  0 0 
f Pasta 160 10 10 1.5 24 24  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Pasta, cream-based 160 110 10  0 0  0 0  0 0 
g Potato (whole, salad, mashed, fries) 100 15 20 1 15 20  0 0  0 0 
  Hash brown 50 24 20  0 0 1 12 10  0 0 
  Yam 100 30 20  0 0  0 0  0 0 
h Breakfast cereal             
  Whole-wheat 35 48 115  0 0  0 0  0 0 
  Nestle Koko Krunch Duo 35 266 73  0 0  0 0  0 0 
  Nestle Koko Krunch 35 200 73  0 0  0 0  0 0 
  Nestle Honey Stars 35 267 25  0 0  0 0  0 0 
  Nestle Corn Flakes 35 600 25  0 0  0 0  0 0 
  Nestle Milo 35 360 73  0 0  0 0  0 0 
  Kelloggs Corn Flakes 35 16 25  0 0  0 0  0 0 
  Kelloggs Special K 35 16 54  0 0  0 0  0 0 
  Kelloggs Coco Chex 35 175 45  0 0  0 0  0 0 
  Weetabix 35 16 73  0 0  0 0  0 0 
  Quaker Oatmeal 35 80 130  0 0  0 0  0 0 
  Vita Quaker 3-in-1 Oat Cereal 19 1000 130  0 0  0 0  0 0 
  Organic Instant Baby Oats 35 57 130  0 0  0 0  0 0 
  Uncle Toby's Muesli Bar 31 16 50  0 0  0 0  0 0 
  F&N Alive Light 'n' Tasty - Triple Berry 35 500 73  0 0  0 0  0 0 
  Alpen Light Prebiotic Mixed Cereal Bar 21 16 38  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Fairprice 3in1 Instant Cereal 35 16 73  0 0  0 0  0 0 
  Post Blueberries Cereal 55 36 47          
  Post Great Grains Raisins, Dates & Pecans 35 16 111  0 0  0 0  0 0 
  Post Honey Bunches of Oats with Almonds 35            
  Nature Valley Roasted Almond Bar 35 91 180  0 0  0 0  0 0 
  Suiss cereal bar 23 16 73  0 0  0 0  0 0 
  Rolled oats 35 16 130  0 0  0 0  0 0 
              
  Ca-fortified 35 507   0 0  0 0  0 0 
  Non Ca-fortified 35 16   0 0  0 0  0 0 
  Wheat 35 38 73  0 0  0 0  0 0 
  Corn meal 35 16 25  0 0  0 0  0 0 
  Rice 35 18 38  0 0  0 0  0 0 
  Muesli 35 40 50  0 0  0 0  0 0 
  Oat 35 16 130  0 0  0 0  0 0 
  Bran 35 50 210  0 0  0 0  0 0 
               
              
              
              
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































2 Vegetables             
a Kale 70 110 35  0 0  0 0  0 0 
  Spinach, amaranth 70 150 35  0 0  0 0  0 0 
  Chye sim 70 100 15  0 0 0.3 23 3.5  0 0 
  Watercress, cassava leaves 70 130 15  0 0  0 0  0 0 
  All other green leafy veg 70 100 15 0.3 18 2.6  0 0  0 0 
b Okra 70 80 60  0 0  0 0  0 0 
  Beans 40 30 60  0 0  0 0  0 0 
  All other non-leafy veg 70 30 12  0 0  0 0  0 0 
               
3 Meat & meat pdts             
a Chicken, pork, beef, mutton 70 30 20 1.5 32 21 2 42 28 1.3 28 19 
b Egg 60 60 15  0 0  0 0  0 0 
               
4 Seafood             
a Anchovy 4 900 240  0 0  0 0  0 0 
  Silverfish 4 500 240  0 0  0 0  0 0 
  Dried baby prawn 4 500 240  0 0  0 0  0 0 
  Dried baby shrimp 4 2000 240  0 0  0 0  0 0 
  Dried scallop 4 77 40  0 0  0 0  0 0 
b Indian mackerel 40 130 40  0 0  0 0  0 0 
  Eel (unagi), salmon 70 130 25  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Sardine 70 280 50  0 0  0 0  0 0 
  Prawn with shell 70 750 55  0 0  0 0  0 0 
  Crab 70 130 40  0 0  0 0  0 0 
c Other fish, seafood & pdts 70 30 40  0 0  0 0 1 21 28 
               
5 Snacks & desserts             
a Tart, kuey 60 35 25  0 0  0 0  0 0 
b Puff 90 30 25 1 27 23  0 0  0 0 
c Muffin, cake, pastry, pancake 60 45 25 0.5 14 7.5  0 0  0 0 
d Biscuits, cookies 30 50 30  0 0  0 0  0 0 
e Almond nuts 20 220 180  0 0  0 0  0 0 
  Pistachio nuts and walnuts 20 90 180  0 0  0 0  0 0 
  All other nuts 20 40 180  0 0  0 0  0 0 
f Seeds 40 30 350  0 0  0 0  0 0 
g Chips, crackers 30 80 25  0 0  0 0  0 0 
h Milk chocolate 25 160 70  0 0  0 0  0 0 
i Dried seaweed     0 0  0 0  0 0 
  Tao Kae Noi 20 80 135  0 0  0 0  0 0 
  Other brands 20 400 350  0 0  0 0  0 0 
j Jelly, pudding, dessert soup/paste 380 15 20  0 0  0 0  0 0 
               
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































6 Soy or vegetarian products             
a Egg tofu 60 25 14  0 0  0 0  0 0 
  Soft tofu, bean curd dessert 100 60 32  0 0  0 0  0 0 
  Firm tofu (tau kwa) 70 190 50  0 0  0 0 0.5 67 18 
  Chinese tofu 70 60 28  0 0  0 0  0 0 
  Tofu (exact type unknown) 70 60 25  0 0  0 0  0 0 
b Tempeh 30 80 60  0 0  0 0 0.5 12 9 
c Mock meat 70 20 60  0 0  0 0  0 0 
               
7 Fruits             
  Fresh fruit 120 20 15  0 0  0 0  0 0 
  Dried fruit 60 50 40  0 0  0 0  0 0 
  Preserved fruit 120 15 15  0 0  0 0  0 0 
               
8 Dairy pdts             
a Cheese slice 20 700 30  0 0  0 0  0 0 
  Fairprice cheese slice 20 510 30  0 0  0 0  0 0 
  Fairprice Reduced Fat cheese slice 20 510 30  0 0  0 0  0 0 
  Chesdale Original cheese slice 20 1193 30  0 0  0 0  0 0 
  Kraft Singles Hi-Cal 20 800 30  0 0  0 0  0 0 
  SCS Reduced Fat cheese slice 20 880 30  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Cheese spread (Laughing cow, creamy) 15 600 30  0 0  0 0  0 0 
  Cheese cube (Laughing cow) 5 290 30  0 0  0 0  0 0 
  Cheddar cheese 25 700 30  0 0  0 0  0 0 
  Parmesan cheese 20 1120 43 0.5 112 4.3  0 0  0 0 
  Cottage cheese 25 70 10  0 0  0 0  0 0 
  Mozzarella cheese (President) 20 300 30  0 0  0 0  0 0 
b Yogurt 150 140 15  0 0  0 0  0 0 
  Meiji (flavoured) 150 131.7 15  0 0  0 0  0 0 
  F&N (flavoured) 135 106 15  0 0  0 0  0 0 
  Emmi (flavoured) 100 90 15  0 0  0 0  0 0 
  Marigold (non-fat) 125 183 15  0 0  0 0  0 0 
c Dairy based ice cream 100 180 15  0 0  0 0 0.8 144 12 
               
8 Others             
  Curry, mee siam gravy 200 30 15  0 0  0 0  0 0 
               
9 Supplements (1 pill = 100 g)             
  Cetrum Multivitamin & Multimineral 100 200 100  0 0  0 0  0 0 
  GNC Women's Ultra Mega Bone Density 100 250 62.5  0 0  0 0  0 0 
  GNC Calcimate Plus 800 100 200 15  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  GNC Country Life Liquid Multi-vitamin & Multi-complex 100 50 50          
  21st Century Hair, Skin & Nails (Advanced Formula) 100 70 20  0 0  0 0  0 0 
  Total Swiss Fit Solution (Cell Mineral) 6.7 4050 2000  0 0  0 0  0 0 
  Nature's Farm Calcium Citramate 100 400 50  0 0  0 0  0 0 
  Dr Hagiwara Barleygreen 6 583 200  0 0  0 0  0 0 
  Suncal Calcium with Vitamin D 100 450 0  0 0  0 0  0 0 
  Caltrate 600+D Plus Minerals 100 600 50  0 0  0 0  0 0 
  Caltrate 600+D  100 600 0  0 0  0 0  0 0 
  Brands Calcium Plus 100 600 0  0 0  0 0  0 0 
  Berroca (with zinc, magnesim and calcium) 100 100 100  0 0  0 0  0 0 
  CD-R Redoxon (calcium-d) 100 250 0  0 0  0 0  0 0 
  CNI Ester-C Plus (with calcium) 100 50 0  0 0  0 0  0 0 
  Scott's Emulsion Cod Liver Oil 100 414 0  0 0  0 0  0 0 
  Multivitamin (brand unknown) 100 250 100  0 0  0 0  0 0 
  Nature's Way Total Calcium Plus 100 600 0  0 0  0 0  0 0 
  Calcium pill (prescribed) 100 300 0  0 0  0 0  0 0 
  GNC Multivitamis for Teens 100 100 50  0 0  0 0  0 0 
  Guardian calcium 100 180 0  0 0  0 0  0 0 
  Equate-Women's Multivitamin 100 450 50  0 0  0 0  0 0 
  Minibee Pollen Tablet 100 41 0.17  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Ocen Health Multivitamins and minerals 100 162 100  0 0  0 0  0 0 
  Vitahealth multivitamin 100 162 100  0 0  0 0  0 0 
               
B BEVERAGES             
               
1 Water             
  Tap water 200 1 0 11 22 0 10.5 21 0 9 18 0 
  Polar Natural Mineral Water 500 3 1.8  0 0  0 0  0 0 
  Ice Mountain Pure Drinking Water 500 3.4 0.7  0 0  0 0  0 0 
  Evian 500 8 2.6          
  Dasani 500 0 0          
               
2 Coffee & Tea             
a Coffee with milk, canned 240 40 5  0 0  0 0  0 0 
  Coffee without milk, canned 240 2 5  0 0  0 0  0 0 
b Tea with milk, brewed 200 31 5  0 0  0 0  0 0 
  Tea without milk, brewed 200 1 5  0 0  0 0  0 0 
  Coffee with milk, brewed 200 70 5  0 0  0 0  0 0 
  Coffee without milk, brewed 200 2 5  0 0  0 0  0 0 
c Coffee, 3-in-1, powder 30 15 15  0 0  0 0  0 0 
  White coffee, powder 30 24 15  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Tea, 3-in-1, powder 30 200 15  0 0  0 0  0 0 
               
3 Instant beverages             
  Milo, powder 30 500 125.3  0 0  0 0  0 0 
  Milo, 3-in-1, powder 30 450 125.3  0 0  0 0  0 0 
  Milo, 3-in-1, easy cool 26 577 150          
  Ovaltine, chocolate flavour, 3-in-1 powder 30 1175 207          
  Horlicks 28 1800 50  0 0  0 0  0 0 
  Chocolate drink 30 40 130  0 0  0 0  0 0 
  Tehh tarik (pulled tea), powder 25 128 15  0 0  0 0  0 0 
  Jing Huangbao Wheat Germ Soybean Phosphatide 10 125 59  0 0  0 0  0 0 
  Nestle Nestum Original 250 390 29  0 0  0 0  0 0 
  Nestle Nesvita 3 in 1 cereal drink 26 210 73  0 0  0 0  0 0 
  Greenmax Black Sesame Cereal 30 240 350  0 0  0 0  0 0 
  Infocafe Ginseng Cereal Drink 35            
               
4 Milk & milk pdts             
a Milk, unfortified 200 120 13  0 0  0 0  0 0 
  Marigold HL Original/Banana/Strawberry/Chocolate 200 127 15  0 0  0 0  0 0 
  Magnolia UHT Fresh 250 125 15  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































  Magnolia High Ca Low Fat 250 175 15  0 0  0 0  0 0 
  Meiji Fresh Original 200 109 15  0 0  0 0  0 0 
  Meiji Fresh Strawberry 200 107 15  0 0  0 0  0 0 
  Meiji Fresh Coffee 200 98 15  0 0  0 0  0 0 
  Meiji Fresh Cocoa 200 106 15  0 0  0 0  0 0 
  Meiji Fresh Low Fat 200 122 15  0 0  0 0  0 0 
  F&N Daisy UHT Fresh 250 120 15  0 0  0 0  0 0 
  F&N Daisy High Calcium 200 150 15  0 0  0 0  0 0 
  Anlene Concentrate High Calcim Low Fat 125 520 60  0 0  0 0  0 0 
  Greenfields Low Fat 250 163.2 14.4  0 0  0 0  0 0 
  Meadow Fresh NZ Low Fat 200 150 15  0 0  0 0  0 0 
  Farmhouse Fresh 200 120 15  0 0  0 0  0 0 
  Farmhouse Low Fat 200 110 15  0 0  0 0  0 0 
b Condensed milk 15 250 28  0 0  0 0  0 0 
  Evaporated milk 15 250 26  0 0  0 0  0 0 
  Carnation Low Fat Evaporated Milk 15 250 26  0 0  0 0  0 0 
c Milk powder 30 970 100  0 0  0 0  0 0 
  Nestle Nesvita Omega Plus 31 1600 100  0 0  0 0  0 0 
  Fernleaf Full Cream  32 850 87  0 0  0 0  0 0 
  Anlene Gold High Calcium 51+ 30 2000 160  0 0  0 0  0 0 
  Anlene Milk powder 19-50 30 1670 160  0 0  0 0  0 0 
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































d Yogurt drink (Marigold) 250 67 11  0 0  0 0  0 0 
  F&N Magnolia Yoghurt Smoothie, Strawberry with Nata De Coco 200 68 11  0   0   0  
e Milkshake 200 120 11  0 0  0 0  0 0 
f Cultured milk 100 40 5  0 0  0 0  0 0 
g Nestle Coffeemate Coffee Creamer 5 6 0  0 0  0 0  0 0 
               
5 Soy pdts             
  Fortified soy milk 200 80 10  0 0  0 0  0 0 
  Vitasoy (fortified soy milk) 375 67 10  0 0  0 0  0 0 
  Sobe Fresh Soya Milk (Pasteurised), Trim 200 68 10  0 0  0 0  0 0 
  Marigold Hi Cal low Sugar 200 180 23          
  Fresh soy milk 200 10 20  0 0  0 0  0 0 
  Packaged soy milk/drink 200 10 10  0 0  0 0  0 0 
               
6 Fruit juice             
  Fresh 200 3 9  0 0  0 0  0 0 
  Processed 200 10 9  0 0  0 0  0 0 
               
              
 
 




Table III-10 (cont’d): Example of calcium and magnesium assessment table. 
No. Food / Beverage 
Serving 
size Food 


































7 Canned/packet beverages             
  Carbonated soft drink 330 2 1 1.6 10 5  0 0  0 0 
  Non-carbonated soft drink 330 1 0  0 0  0 0  0 0 
  Isotonic drink 330 5 5.2  0 0  0 0  0 0 
  Nestle Milo 240 60 23  0 0  0 0  0 0 
               
8 Alcoholic drinks             
  Beer 330 5 7.7  0 0  0 0  0 0 
  Wine 120 7 7.5  0 0  0 0  0 0 
  Spirit 250 1 0.12  0 0  0 0  0 0 
               
9 Others             
  Honey 15 7 2  0 0  0 0  0 0 
  Grass jelly 200 8 3  0 0  0 0  0 0 
               
      Total intake 
(mg/day) 
 303 123  119 53  307 98 
               
      Total intake 
(mg/week) 
    1670 639    
             
      Ave intake 
(mg/day) 
    239 91    
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Assessment of Intake of Calcium and Magnesium 
by Female Singapore Residents 
PARTICIPANT’S PARTICULARS 
*Please delete where applicable 











Date of Birth: _________________________ (DD/MM/YYYY) 
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  GENERAL INFORMATION 
Marital Status: *Single/Married/Separated/Divorced/Widowed 
Country of birth: *Singapore/Others: _________________________ (please specify) 
Race:  □ Chinese  □ Caucasian  □ Others: ________________ 
Cultural Background:   □ Chinese  □ Others: ________________ 
Diet:  □ Vegetarian  □ Halal   □ No restriction   
□ Others: _______________ 
Religion:  □ Buddhist or Taoist □ Christian □ Catholic □ Muslim □ 
Hindu   □Others: _______________ 
Citizenship:  □ Singapore Citizen □ Singapore Permanent Resident  
□ Others: _______________ 
Number of Years Resided in Singapore: ____ 
Highest Education Qualification Attained:  □ No Qualification □ Primary School 
□ Secondary School □ Technical Education □ Diploma Course □ University Degree 
/higher 
Income Range (Individual or Family):   □ 0 - <$1000  □ $1000 - $2000
  
□ $2000 - $3000 □ $3000 - $4000 □ >$4000 
Occupation/Field of Work or Study: 
_____________________________________________________ 
Location/Region of Stay in 
Singapore:___________________________________________________ 
 
   HEALTH STATUS 
Height (m): _______    Weight (kg): _______ 
Body Mass Index (to be completed by interviewer) 
For Chinese:   □ 18.5 – 22.9  □ <18.5 or >22.9 
For Caucasian:  □ 18.5 – 24.9  □ <18.5 or >24.9 
Which of these best describes your physical activity status: 
□ 45 minutes of moderate-intensity physical activity 5 days per week or 30 minutes of 
vigorous-intensity physical activity 3 days per week or equivalent 
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□ 30 minutes of moderate-intensity physical activity 5 days per week or 20 minutes of 
vigorous-intensity physical activity 3 days per week or equivalent 
□ 20 minutes of moderate-intensity physical activity 5 days per week or 10 minutes of 
vigorous-intensity physical activity 3 days per week or equivalent  
□ None 
 
How many standard drinks of alcohol do you consume on average per day? Standard drink 
= 1 glass of beer, 1 glass of wine, 1 shot of spirits or one small bottle of wine cooler/alco-
pops   
Number of drinks _______   
 
Are you pregnant or lactating at the moment? 
□ Yes  □ No 
Have you been diagnosed with any bone-, kidney-, thyroid- or liver-related disease(s)? 
□ Yes  □ No 
If yes, please 
specify:____________________________________________________________ 
Have you been diagnosed with hypertension? 
  □ Yes  □ No 
Have you been diagnosed with diabetes? 
□ Yes  □ No 
Are you suffering from gastrointestinal disorders or any metabolic disease? 
□ Yes  □ No 
If yes, please 
specify:________________________________________________________ 
Are you suffering from any chronic disease? 
□ Yes  □ No 
If yes, please 
specify:________________________________________________________ 
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Are you taking any medication regularly except oral contraceptives? 
□ Yes  □ No 
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Have you changed your diet (e.g. eating less, consuming less meat, etc) in the past 1 
month/ 
6 months / 2 years / 5 years? 
□ No   □ Yes, 1 month   □ Yes, 6 months 
□ Yes, 2 years  □ Yes, 5 years 
 





Please tick the boxes of which meals are regularly taken: 
 Weekdays Saturdays Sundays 
Breakfast    
Lunch    
Dinner    
Supper    
 
What type of breakfast do you usually eat? 
□ Cereals (e.g. cereals, oat) 
□ Western without cereals (e.g. bread, pasta, potato) 
□ Asian, Chinese (e.g. rice, noodles, steamed bun/包) 
Where do you usually get your meals from? 
Breakfast:  □ Home □ Outside (e.g. school canteen, hawker, restaurant) 
Lunch:   □ Home □ Outside (e.g. school canteen, hawker, restaurant) 
Dinner:  □ Home □ Outside (e.g. school canteen, hawker, restaurant) 
Supper:  □ Home □ Outside (e.g. school canteen, hawker, restaurant) 
How many portions of snacks or desserts on average do you eat per day? 
□ 0  □ 1-2  □ 3 or more (please specify:          ) 
How would you consider your appetite/portion sizes in relation to others? 
□ Small/less □ Medium/normal □ Large/add/extra 
Are you taking any dietary supplements? 
□ Yes  □ No 
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Food Record Sheet 饮食记录 
  Please record down all food & beverages consumed in 24 hours in detail 请记下您在这24小时所吃和喝的食品和饮料 
    Name 姓名: 
  Age 
年龄: 
   Day and date 日期: Weekday 1 工作日 1 / Weekday 2 工作日 2 / Weekend 周末 (please indicate as appropriate) 
    Time 
时间 Food & Beverage Item 食品和饮料 Description 描述 Amount consumed (in servings) 份量 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
   
Version 1 
   
Date of revision: 15th December 2011 
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(1) STAPLE FOODS / CARBOHYDRATE SOURCES 
Rice, glutinous rice, and porridge 1 serving 
(200 gr or 500 
gr for porridge) 
    
Noodles 1 serving  
(200 gr) 
    
With milk added to soup,  
eg. fish soup noodles 
1 serving  
(40 mL) 
    
Pau / bao 1 serving  
(100 gr) 
    
Breakfast cereals (calcium enriched)  






    
Types of milk taken with breakfast cereals 
Unfortified with calcium 1 cup (200 mL)     
Calcium fortified 1 cup (200 mL)     
Calcium fortified soybean milk 1 cup (200 mL)     
Breakfast cereals (others)  1 serving 
(35 gr) 
    
Types of milk taken with breakfast cereals 
Unfortified with calcium 1 cup (200 mL)     
Calcium fortified 1 cup (200 mL)     
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Bread (loaf)      
White bread 1 serving  
(2 slices) 
    
Milk bread 1 serving  
(2 slices) 
    
Wholemeal bread, grain bread, 
other flavoured loaves 
1 serving  
(2 slices) 
    
Indian breads      
Without cheese 1 serving 
(120 gr) 
    
With cheese 1 serving 
(120 gr) 
    
Other breads, buns, burger      
Cream-filled rolls   1 serving 
(65 gr) 
    
Without cheese 1 serving 
(60 gr) 
    
With cheese 1 serving 
(60 gr) 
    
Pasta (dairy-based sauce)  1 serving      
With parmesan cheese topping 1 tablespoon 
(4 gr) 
    
Pasta (non dairy-based sauce) 1 serving 
(160 gr) 
    
With parmesan cheese topping 1 tablespoon 
(4 gr) 
    
Pizza, western baked rice 1 serving  
(160 gr) 
    
With parmesan cheese topping 1 tablespoon 
(4 gr) 
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Potato and potato based products       
Without cheese 1 serving 
(100 gr) 
    
With cheese 1 serving 
(100 gr) 
    
(2) SIDE DISHES 
Vegetables, vegetable products  
Dark leafy green vegetables 1 serving 
(70 gr) 
    
Other vegetables, vegetable 
products and legumes 
1 serving 
(70 gr) 
    
Meat, poultry, fish, seafood and their products 
Canned sardines 1 serving 
(70 gr) 
    
Canned mackerel  1 serving 
(70 gr) 
    
Canned salmon (with bones) 1 serving 
(70 gr) 
    




    
Deep fried prawn eaten with shell 1 serving 
(70 gr) 
    
Crab and soft-shell crab 1 serving 
(70 gr) 
    
Frog leg 1 serving 
(40 gr) 
    
Beef tripe 1 serving 
(40 gr) 
    
Chicken, duck, pork, beef, veal, 
mutton, chevron, other fish and 
fish products (without bones), 
other seafood, turkey, and eggs 
1 serving 
(70 gr) 
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Tofu (soft) 
eg. silken tofu, chinese tofu 
1 serving 
(100 gr) 
    
Tempeh 1 serving 
(30 gr) 
    
Mock / vegetarian  meat (beancurd 
or gluten) 
1 serving  
(70 gr) 
    
(3) TOPPING, SAUCES, AND CONDIMENTS 
Dried anchovy (ikan bilis) 1 tablespoon 
(4 gr) 
    
Canned anchovy 1 tablespoon 
(4 gr) 
    
Silver fish 1 tablespoon 
(4 gr) 
    
Mermaid fish 1 serving 
(5 gr) 
    
Dried baby prawn 1 tablespoon 
(4 gr) 
    
Dried baby shrimp 1 tablespoon 
(1 gr) 
    
Sambal belacan 1 tablespoon 
(20 gr) 
    




    
Belacan dishes  
(eg. stingray, kangkung, rojak) 
1 serving 
(5 gr of 
belacan) 
    
Indian Curry 1 serving 
(100 gr) 
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Gravy/ Soup      
Laksa Lemak 
 Drink all 
 Drink half 
 Drink a little only 
1 serving 
(100 gr) 
    
Mee Rebus 
 Drink all 
 Drink half 
 Drink a little only 
1 serving 
(100 gr) 
    
Mee Siam 
 Drink all 
 Drink half 
 Drink a little only 
1 serving 
(100 gr) 
    
(4) FRUITS 
Fresh fruits 1 serving 
(120 gr) 
    
Canned fruits and dried fruits 1 serving 
(60 gr) 
    
(5) DESSERTS AND SNACKS 
Desserts in ‘soup’      
Black sesame paste (hawker) 1 serving  
(400 gr) 
    
Black sesame paste (instant) 1 sachet     




    
Others (eg. tauhuay, green bean 
soup, red bean soup, ice kacang) 
1 serving 
(400 gr) 
    
Dried seaweed (snack) 1 serving  
(20 gr) 
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Seaweed strands (ready to eat) 1 serving 
(60 gr) 
    
Other seaweed containing dishes 
e.g. soup, sushi 
1 serving     
Nuts      
Almond nut 1 serving 
(20 gr) 
    
Pistachio nut and walnut 1 serving 
(20 gr) 
    
Others 1 serving 
(20 gr) 
    
Biscuits, pastries, cakes and other 
snacks 
e.g. croissants, danish, pies, puff, 
samosas, muffin, pudding, eclairs and 
sweet puff, tart, crispie cakes, getuk, 
dodol, waffles, chips, popcorn, seeds 
1 serving      
(6) DAIRY PRODUCTS      
Cheeses (excluding those recorded previously together with staple foods) 
Cheese slices 




    
Cheese spreads 1 serving 
(15 gr) 
    
Other cheeses  
e.g. Swiss, Edam, Brie, Feta, 
Roquefort 
Please indicate type and 
brand:_______________________ 
1 serving  
(25 gr) 
    
Yoghurts 
Please indicate type and brand :  
1 serving  
(160 gr or 
around 1 small 
cup) 
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Dairy-based ice cream, Mousse and 
Custard 
e.g. gelato,  kulfi (Indian ice-cream) 




    
Milk chocolate  
Chocolate brand(s): _______________ 
________________________________ 
________________________________ 
1 serving  





   

























































- spinach  
  
One serving of 
non-leafy 
vegetable  
- lady’s finger  
(70 gram) 





One serving of 
non-leafy 
vegetable  
- bean sprout  
(70 gram) 





One serving of 
meat – chicken  
(70 gram) 
Beef tripe 
One serving of beef 
tripe (40 gram) 




















One serving of 
firm tofu (half a 
cube / 70 gram) 
One serving of firm 
tofu (70 gram) 
Firm tofu 




















One serving of soft 
tofu (100 gram) 
Soft tofu 
One serving of 
soft tofu (1/3 tub 
/ 100 gram) 




One serving of 
tempeh (30 gram) 
One serving of 
tempeh (30 gram) 
Tempeh 




















One serving of 
dried anchovy  
(1 tbsp / 4 gram) Dried anchovy 
One serving of 
silver fish  
(1 tbsp / 4 gram) Silver fish 




















One serving of 
mermaid fish  
(5 gram) 
One serving of 
dried baby prawn  
(1 tbsp / 4 gram) Dried baby prawn 




















One serving of 
dried baby shrimp  
(1 tbsp / 4 gram) Dried baby shrimp 
One serving of chin 
cha lok  
(1 tbsp / 10 gram) Chin cha lok 
























One serving of black 
sesame paste 
(400 gram) 




One serving of 
milk chocolate 
(6 blocks /  
25 gram) 





200 mL packet 250 mL 
 
330 mL can 500 mL 
 
 1 L packet 1.5 L bottle 
